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General introduction 
Chapter 1 
12 
Annually, almost 17 million people suffer a stroke worldwide, making stroke the second leading 
cause of death.1,2 Many stroke-survivors remain dependent in their daily living, have cognitive 
deficits, and need institutional care.3,4 Stroke therefore poses a tremendous burden on patients, 
family, caregivers, and society.1,5 As a consequence of the ageing population this burden is 
expected to increase further over the next decades.6 Previous efforts to prevent and treat stroke 
have been fruitful resulting in reductions in both incidence (12%) and mortality (37%) over the 
last two decades.2,7,8 However, stroke remains a serious health problem. This means that 
prevention and treatment need further improvement. In my thesis I will focus on emerging risk 
factors and markers of stroke, which may be a first step towards a better prevention. 
 
The key to prevention is answering the question why some people will suffer a stroke whilst 
others do not. This is challenging, since most strokes are unannounced first-ever events.7 
Suddenly, patients experience weakness, sensory loss, blindness and/or language disorders, as 
a consequence of an obstructed or ruptured artery in the brain.9 Despite this rapid start, 
increasing evidence suggests that pathologic changes leading up to stroke are present years 
in advance. For instance, consider the most common etiologies of ischemic stroke, specifically 
cardioembolism, large vessel disease, and small vessel disease.10 Each of these appears to have 
a long preclinical phase, characterized by decrease in cardiac function, accumulation of 
atherosclerotic plaques, or arteriolosclerosis.11-13 Imaging techniques12-14 and laboratory tests15 
detecting these preclinical changes earlier in time are emerging. Knowing how such preclinical 
changes relate to stroke may further unravel the pathophysiology of stroke. This knowledge 
will aid in the identification of people at high risk of stroke and who may stand to benefit from 
targeted therapies. This is therefore an essential first step before a better prediction and 
prevention of stroke can be achieved. 
 
Another approach to reduce the burden of stroke is to prevent its common and invalidating 
consequences, e.g. recurrent stroke, dementia, and death.16-19 Due to the implementation of 
stroke units, intravenous thrombolysis and intra-arterial thrombectomy, and better secondary 
prevention, an increasing number of people now survives the acute phase of stroke and is at 
risk of these consequences.2,8,20-22 Recurrent stroke, post-stroke dementia and post-stroke 
mortality often have a vascular etiology and seem to benefit from secondary prevention.23-25 
However, as described in the previous paragraph, vascular pathology has a long accumulation 
time and is a major risk factor for the stroke itself. Part of the prognosis after stroke may 
therefore already be determined by pre-stroke cardiovascular risk factors. An important 
consideration here is that most studies on stroke prognosis recruit participants at time of stroke 
and therefore cannot measure pre-stroke values.17,26-30 Post-stroke values may not be very 
representative of pre-stroke values due to reverse causality, i.e. levels of risk factors can change 
due to the stroke.31-33 Yet, knowing the influence of pre-stroke factors is highly relevant, since a 
large influence implies that intensive cardiovascular risk factor management implemented 
after stroke may start too late.34  
 
General introduction 
13 
Against this background, the aim of my thesis was twofold. First, to detect early risk factors or 
markers for stroke, mainly related to the cardiovascular system. Second, to detect pre-stroke 
risk factors of consequences after stroke. A population-based study is required to detect such 
early markers, since it collects information on risk factors prior to the stroke. Studies in my thesis 
were therefore embedded within the Rotterdam Study, a population-based study that aims to 
study the occurrence and determinants of age-related diseases in the general population.35 
The Rotterdam Study started in 1990, with 7,983 participants aged 55 years and over. It was 
expanded twice; in 2000 a total of 3,011 participants aged 55 years and over were added, and 
in 2006 another 3,932 participants aged 45 and over joined. All participants resided in 
Ommoord, a suburb of Rotterdam, the Netherlands.  
 
The outline of this thesis is as follows:  
Chapters 2, 3, 4 discuss determinants of stroke. Chapter 2 focuses on determinants of heart 
disease, with an emphasis on the relation between subclinical cardiac dysfunction and stroke. 
Subclinical cardiac dysfunction was measured by echocardiography (Chapter 2.1) and N-
terminal pro-B-type natriuretic peptide (NT-proBNP), a laboratory value reflecting cardiac 
ventricular wall stress (Chapter 2.2).36,37  
Chapter 3 includes determinants of large and small vessel disease. Chapter 3.1 describes 
the relation between intracranial carotid artery atherosclerosis, a marker of large vessel disease, 
and the risk of stroke. In Chapter 3.2, I examined how vasomotor reactivity, another potential 
marker of large vessel disease, affects the risk of mortality independent of stroke. Chapter 3.3 
describes the association between microbleeds, a marker of small vessel disease, and the risk 
of stroke. Hypothesizing that markers may interact in their risk of stroke, I examined in Chapter 
3.4 the interaction between retinal vessel diameter, a marker of small vessel disease, and 
cerebral blood flow for their association with stroke. In Chapter 3.5, I focused on hypertension, 
which is the most important modifiable vascular risk factor of stroke, as the risk of stroke may 
be further influenced by long-term trajectories of hypertension.  
Some non-cardiovascular disorders also seem to have an impact on the cardiovascular 
system. This has for instance been suggested for COPD and anxiety.38,39 Chapter 4 therefore 
describes the relation of COPD (Chapter 4.1) and anxiety (Chapter 4.2) with stroke.  
Chapter 5 is dedicated to problems occurring after stroke. In Chapter 5.1, I describe the 
difference in recognition between left- and right-sided strokes. Chapter 5.2 and 5.3 
respectively focus on the effect of pre-stroke cardiovascular risk factors in relation to the risk of 
mortality and recurrent stroke and dementia after stroke. In Chapter 5.4, I explain how high 
education or cognitive reserve might protect against dementia. 
Finally, in Chapter 6, I summarize my main findings, discuss the methodological 
considerations and give suggestions for further research within the field of stroke. 
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Abstract 
 
Background and purpose 
Clinical cardiac disease has often been associated with stroke and dementia. However, the 
association between subclinical cardiac dysfunction and these major neurological diseases is 
unknown. We investigated the association between cardiac function and the risk of stroke and 
dementia in elderly free of clinical cardiac disease. Additionally, we investigated the relation 
between cardiac function and MRI markers of subclinical cerebrovascular disease. 
 
Methods 
This study was conducted within the population-based Rotterdam Study. A total of 3,291 
participants (60.8% female, age-range 58-98 years) free of coronary heart disease, heart failure, 
atrial fibrillation, stroke, and dementia, underwent echocardiography in 2002-2005 to measure 
cardiac function. Follow-up finished in 2012. In 2005-2006, a random subset of 577 stroke-free 
people without dementia underwent brain MRI on which infarcts and white matter lesion 
volume were assessed.  
 
Results 
During 21,785 person-years of follow-up, 164 people suffered a stroke and during 19,462 
person-years of follow-up, 208 people developed dementia. Measures of better diastolic 
function, such as higher E/A-ratio, were associated with a lower risk of stroke (HR 0.82, 95% CI 
0.69; 0.98) and dementia (HR 0.82, 95% CI 0.70; 0.96). Better systolic function, measured as 
higher fractional shortening, was only associated with a lower risk of stroke (HR 0.84, 95% CI 
0.72; 0.98). Better diastolic function was related to a lower prevalence of silent infarcts on MRI, 
especially lacunar infarcts. 
 
Conclusions 
In elderly free of clinical cardiac disease, worse diastolic function is associated with clinical 
stroke, dementia, and silent infarcts on MRI, whereas worse systolic function is related only to 
clinical stroke. These findings can form the basis for future research on the utility of cardiac 
function as potential intervention target for prevention of neurological diseases. 
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Introduction 
 
Stroke and dementia are major neurological diseases in the elderly.1,2 Cardiovascular risk factors 
play a role in the etiology of both stroke and dementia, including Alzheimer disease (AD).1,3 
Additionally, clinical cardiac diseases, such as heart failure,4,5 atrial fibrillation,6,7 and coronary 
heart disease8,9 have been associated with stroke, dementia, AD, and subclinical 
cerebrovascular damage, such as silent infarcts10 and white matter lesions.11 Cerebrovascular 
damage accumulates slowly before manifesting as clinical event, and silent brain infarcts and 
white matter lesions indicate an increased risk of stroke and dementia.12-14 
On the one hand, shared etiology might explain the link between cardiac and neurological 
diseases. On the other hand, cardiac disease might be causally related to stroke and dementia 
via thrombus formation or hypoperfusion.  
In the general elderly population, cardiac function is often impaired in the absence of 
clinical cardiac disease.15-17 Subclinical cardiac dysfunction has been associated with an 
increased risk of clinical cardiac events and mortality.17-19 However, the longitudinal association 
between subclinical cardiac dysfunction and major neurological outcomes remains unclear. 
Relating echocardiographic markers of subclinical cardiac dysfunction to stroke and dementia 
is important for possible preventive strategies.  
We investigated whether cardiac function is associated with the risk of stroke and dementia 
in people without clinical cardiac disease. Additionally, we investigated whether cardiac 
function is related to MRI markers of subclinical cerebrovascular disease.  
 
Materials and methods 
 
Setting and study population 
This study was embedded within the Rotterdam Study, a prospective population-based cohort 
study among people aged 55 years and older residing in Ommoord, a district of Rotterdam, 
the Netherlands.20 The study started in 1990 with 7,983 participants and was extended in 2000 
with 3,011 people. Follow-up examinations take place every 3 to 4 years.20  
For the current study, data on echocardiography were collected in 2002-2005, because 
echocardiography was only introduced in this round. During this period 3,550 participants of 
the original cohort attended their fourth examination round and 2,486 participants of the 
cohort expansion attended their second examination round. Of these participants, 5,395 
actually visited the study center and 5,287 underwent echocardiography. Missing 
echocardiograms were primarily caused by absence of echocardiographers and were random. 
We excluded participants who had a poor quality echocardiogram (n=233) or missed 
measurements on the echocardiogram (n=483). Participants with prevalent heart failure, 
coronary heart disease, atrial fibrillation, stroke, or dementia (n=765), or missing data on these 
diseases (n=515) were also excluded. Consequently, 3,291 participants were eligible for 
analysis. Because MRI-scanning was implemented in 2005,21 only a random subset of 593 non-
demented, stroke-free people had available brain MRI, of which 577 had good quality MRI data. 
For analyses with white matter lesions, cortical infarcts (n=6) were excluded, as tissue loss and 
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gliosis surrounding cortical infarcts may cause unreliable segmentations. MRI-scanning was 
performed on average 1.0 (standard deviation (SD) ±0.4) years after echocardiography. The 
Rotterdam Study has been approved by the medical ethics committee according to the 
Population Study Act Rotterdam Study and written informed consent was obtained. 
 
Echocardiography 
Transthoracic echocardiograms were performed by 4 trained echocardiographers using 
commercially available systems (AU3 Partner, Esaote Biomedica, Hallbergmoos, Germany, with 
a 3.5/2.5MHz transducer, n=1,289; or Acuson Cypress, Siemens, Mountain View, USA, with a 
3V2c transducer, n=2,002). 
To assess diastolic function, transmitral filling velocities were recorded by pulsed wave 
Doppler in the apical 4-chamber view. The sample volume was placed in the mitral valve orifice 
near the tips of the leaflets. The early filling velocity occurring with mitral valve opening is the 
peak E velocity. Peak A velocity is the velocity occurring with contraction of the atrium.22 
Doppler peak E and peak A velocities were averaged over 3 cycles. Doppler peak E velocity was 
divided by Doppler peak A velocity to calculate E/A-ratio. The time between the peak E wave 
and the upper deceleration slope extrapolated to the zero baseline is the early mitral valve 
deceleration time. Left ventricular diastolic function was categorized,18 using cut-off points as 
described.16,22 Diastolic function was classified as normal (E/A-ratio 0.75-1.50 and deceleration 
time 150-280ms), impaired relaxation (E/A-ratio <0.75 and deceleration time >280ms), or 
restrictive (E/A-ratio >1.50 and deceleration time <150ms). If only one abnormal criterion was 
fulfilled, diastolic function was classified as indeterminate instead of normal.18 
To assess systolic function, we measured left ventricular end-systolic dimension (LVESD) 
and left ventricular end diastolic dimension (LVEDD) in the parasternal long axis view using M-
mode with 2D guidance as described previously.15,18 Fractional shortening was calculated as 
(LVEDD-LVESD)/LVEDD*100%. Qualitative global systolic function was assessed from the 2D 
echocardiogram in 4 categories: normal, fair, moderate, and poor. Inter-reader and intra-reader 
variability of the echocardiography measurements were good.18 
 
Assessment of stroke 
At baseline, history of stroke was assessed using home interviews and confirmed by reviewing 
medical records. Participants were then continuously followed up for stroke through automatic 
linkage of general practitioners’ medical records with the study database. Furthermore, general 
practitioners’ medical records of participants who moved out of the Ommoord district and 
nursing home physicians’ medical records were checked on a regular basis.23 Of all potential 
strokes, information from general practitioners and hospital discharge letters were collected 
and reviewed by research physicians. An experienced neurologist verified the stroke diagnoses. 
Strokes were subclassified into ischemic or hemorrhagic based on neuroimaging reports. A 
stroke was classified as unspecified if lacking neuroimaging.24 Follow-up was complete until 
January 1st, 2012 for 92.7% of potential person-years.  
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Assessment of dementia 
We used a three-step protocol to screen for dementia at baseline and follow-up examinations. 
First, participants underwent the Mini-Mental State Examination (MMSE) and the Geriatric 
Mental Schedule (GMS) organic level. Second, screen-positives (MMSE<26 or GMS organic 
level>0) underwent an examination and informant interview with the Cambridge Examination 
for Mental Disorders in the Elderly (CAMDEX). Third, participants suspected of dementia 
underwent further neuropsychological testing if necessary. Additionally, all participants were 
continuously monitored for dementia linking the study database to digitized medical records 
from general practitioners and the Regional Institute for Outpatient Mental Health Care. When 
clinical neuroimaging was required and available, it was used for decision making on the 
diagnosis. The final diagnosis was determined by a consensus panel, led by a neurologist, in 
accordance with international criteria.25,26 Follow-up for incident dementia was complete until 
January 1st, 2012, for 97.9% of potential person-years.27 
 
Brain MRI 
Scans were performed on a 1.5T MRI scanner (General Electric Healthcare, Milwaukee, USA) and 
reviewed by trained research physicians, who were blinded to clinical data. We used fluid-
attenuated inversion recovery (FLAIR), proton density weighted, and T1-weighted sequences 
to identify infarcts. Focal lesions of ≥3mm and <15mm in size with identical signal 
characteristics as cerebrospinal fluid, and (when located supratentorially) a hyperintense rim 
on the FLAIR were classified as lacunar infarcts. Infarcts showing involvement of grey matter 
were classified as cortical infarcts. Because all people undergoing MRI were free of clinical 
stroke, all infarcts are silent infarcts. White matter lesions were segmented based on the FLAIR 
using an automated processing algorithm and voxels were summed to yield total white matter 
lesion volume in milliliters.21  
 
Covariates 
Covariates were measured during the same examination round as the echocardiography 
(2002-2005). Details on assessment of anthropometrics, cardiovascular risk factors (blood 
pressure, total cholesterol, high-density lipoprotein (HDL) cholesterol, diabetes mellitus, 
smoking), and medication use have been described.28 Heart failure, coronary heart disease 
(defined as myocardial infarction or coronary revascularization procedure), and atrial fibrillation 
were assessed through active follow-up and adjudicated using standardized definitions.23 
MMSE was performed at the research center. Information on apolipoprotein E (APOE)-
genotype, coded as one or two ε4 alleles, was obtained using PCR on coded DNA samples.  
 
Statistical analyses 
We examined the association of cardiac function with stroke and dementia using Cox 
proportional hazards models. Follow-up started at the echocardiography date. We censored 
participants at date of stroke in analyses with stroke and at date of dementia diagnosis in 
analyses with dementia. Participants were additionally censored at date of death, date of loss 
to follow-up, or the end of the study period, defined as the last date of follow-up or January 1st, 
2Chapter 2.1 
22 
gliosis surrounding cortical infarcts may cause unreliable segmentations. MRI-scanning was 
performed on average 1.0 (standard deviation (SD) ±0.4) years after echocardiography. The 
Rotterdam Study has been approved by the medical ethics committee according to the 
Population Study Act Rotterdam Study and written informed consent was obtained. 
 
Echocardiography 
Transthoracic echocardiograms were performed by 4 trained echocardiographers using 
commercially available systems (AU3 Partner, Esaote Biomedica, Hallbergmoos, Germany, with 
a 3.5/2.5MHz transducer, n=1,289; or Acuson Cypress, Siemens, Mountain View, USA, with a 
3V2c transducer, n=2,002). 
To assess diastolic function, transmitral filling velocities were recorded by pulsed wave 
Doppler in the apical 4-chamber view. The sample volume was placed in the mitral valve orifice 
near the tips of the leaflets. The early filling velocity occurring with mitral valve opening is the 
peak E velocity. Peak A velocity is the velocity occurring with contraction of the atrium.22 
Doppler peak E and peak A velocities were averaged over 3 cycles. Doppler peak E velocity was 
divided by Doppler peak A velocity to calculate E/A-ratio. The time between the peak E wave 
and the upper deceleration slope extrapolated to the zero baseline is the early mitral valve 
deceleration time. Left ventricular diastolic function was categorized,18 using cut-off points as 
described.16,22 Diastolic function was classified as normal (E/A-ratio 0.75-1.50 and deceleration 
time 150-280ms), impaired relaxation (E/A-ratio <0.75 and deceleration time >280ms), or 
restrictive (E/A-ratio >1.50 and deceleration time <150ms). If only one abnormal criterion was 
fulfilled, diastolic function was classified as indeterminate instead of normal.18 
To assess systolic function, we measured left ventricular end-systolic dimension (LVESD) 
and left ventricular end diastolic dimension (LVEDD) in the parasternal long axis view using M-
mode with 2D guidance as described previously.15,18 Fractional shortening was calculated as 
(LVEDD-LVESD)/LVEDD*100%. Qualitative global systolic function was assessed from the 2D 
echocardiogram in 4 categories: normal, fair, moderate, and poor. Inter-reader and intra-reader 
variability of the echocardiography measurements were good.18 
 
Assessment of stroke 
At baseline, history of stroke was assessed using home interviews and confirmed by reviewing 
medical records. Participants were then continuously followed up for stroke through automatic 
linkage of general practitioners’ medical records with the study database. Furthermore, general 
practitioners’ medical records of participants who moved out of the Ommoord district and 
nursing home physicians’ medical records were checked on a regular basis.23 Of all potential 
strokes, information from general practitioners and hospital discharge letters were collected 
and reviewed by research physicians. An experienced neurologist verified the stroke diagnoses. 
Strokes were subclassified into ischemic or hemorrhagic based on neuroimaging reports. A 
stroke was classified as unspecified if lacking neuroimaging.24 Follow-up was complete until 
January 1st, 2012 for 92.7% of potential person-years.  
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Assessment of dementia 
We used a three-step protocol to screen for dementia at baseline and follow-up examinations. 
First, participants underwent the Mini-Mental State Examination (MMSE) and the Geriatric 
Mental Schedule (GMS) organic level. Second, screen-positives (MMSE<26 or GMS organic 
level>0) underwent an examination and informant interview with the Cambridge Examination 
for Mental Disorders in the Elderly (CAMDEX). Third, participants suspected of dementia 
underwent further neuropsychological testing if necessary. Additionally, all participants were 
continuously monitored for dementia linking the study database to digitized medical records 
from general practitioners and the Regional Institute for Outpatient Mental Health Care. When 
clinical neuroimaging was required and available, it was used for decision making on the 
diagnosis. The final diagnosis was determined by a consensus panel, led by a neurologist, in 
accordance with international criteria.25,26 Follow-up for incident dementia was complete until 
January 1st, 2012, for 97.9% of potential person-years.27 
 
Brain MRI 
Scans were performed on a 1.5T MRI scanner (General Electric Healthcare, Milwaukee, USA) and 
reviewed by trained research physicians, who were blinded to clinical data. We used fluid-
attenuated inversion recovery (FLAIR), proton density weighted, and T1-weighted sequences 
to identify infarcts. Focal lesions of ≥3mm and <15mm in size with identical signal 
characteristics as cerebrospinal fluid, and (when located supratentorially) a hyperintense rim 
on the FLAIR were classified as lacunar infarcts. Infarcts showing involvement of grey matter 
were classified as cortical infarcts. Because all people undergoing MRI were free of clinical 
stroke, all infarcts are silent infarcts. White matter lesions were segmented based on the FLAIR 
using an automated processing algorithm and voxels were summed to yield total white matter 
lesion volume in milliliters.21  
 
Covariates 
Covariates were measured during the same examination round as the echocardiography 
(2002-2005). Details on assessment of anthropometrics, cardiovascular risk factors (blood 
pressure, total cholesterol, high-density lipoprotein (HDL) cholesterol, diabetes mellitus, 
smoking), and medication use have been described.28 Heart failure, coronary heart disease 
(defined as myocardial infarction or coronary revascularization procedure), and atrial fibrillation 
were assessed through active follow-up and adjudicated using standardized definitions.23 
MMSE was performed at the research center. Information on apolipoprotein E (APOE)-
genotype, coded as one or two ε4 alleles, was obtained using PCR on coded DNA samples.  
 
Statistical analyses 
We examined the association of cardiac function with stroke and dementia using Cox 
proportional hazards models. Follow-up started at the echocardiography date. We censored 
participants at date of stroke in analyses with stroke and at date of dementia diagnosis in 
analyses with dementia. Participants were additionally censored at date of death, date of loss 
to follow-up, or the end of the study period, defined as the last date of follow-up or January 1st, 
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2012, whichever came first. We conducted a sensitivity analysis censoring for both stroke and 
dementia concomitantly in every analysis. We used linear and logistic regression models to 
investigate the associations of cardiac function with silent infarcts and white matter lesions. 
White matter lesion volume, mitral valve inflow deceleration time, and E/A-ratio were natural 
log transformed because of skewed distributions to the right. Fractional shortening was square 
transformed because of a skewed distribution to the left. Continuous echocardiographic 
variables were entered per SD increase into the models. Qualitative systolic function and 
diastolic function were entered categorically into the models. Only 10 participants had diastolic 
dysfunction with a restrictive pattern: therefore we combined diastolic dysfunction with 
impaired relaxation or a restrictive pattern for the analysis. Only 16 participants had poor left 
ventricular systolic function, which we therefore combined with moderate systolic function. In 
sensitivity analyses, we excluded participants (n=66) with moderate or poor systolic function 
to determine whether associations remained similar in people with a normal left ventricular 
function. The basic model (model I) was adjusted for age, sex, and type of ultrasonography 
system. The extended model (model II) was additionally adjusted for cardiovascular risk factors, 
and for MMSE-score and APOE-ε4 status in dementia analyses only. To further adjust for residual 
confounding by shared etiology, we repeated the analyses adjusting for cardiovascular risk 
factors and MMSE-score as assessed at the examination round prior (1997-2001) to our 
baseline. All analyses with white matter lesion volume were also adjusted for intracranial 
volume.  
We explored potential effect modification by sex, age (stratified at median), blood pressure 
(stratified at median), and medication use by using interaction terms. 
Missing data on covariates (less than 3.6%) were imputed using multiple imputations. 
Analyses were repeated for ischemic stroke and AD. 
Analyses were done using IBM SPSS Statistics version 20.0 (IBM Corp., Armonk, USA).  
 
Results 
 
Baseline characteristics are presented in Table 1. Mean age (±SD) was 71.4 (±7.1) years and 
60.8% was female. During a mean follow-up of 6.6 (±1.8) years, 164 strokes occurred, of which 
117 were ischemic. During a mean follow-up of 5.9 (±1.5) years, 208 people developed 
dementia, of which 171 were AD. 
Several measures of diastolic function were associated with the risk of stroke, including 
mitral valve inflow peak A (hazard ratio (HR) per SD increase 1.27 (95% confidence interval (CI) 
1.08; 1.48)), E/A-ratio (HR 0.82 (0.69; 0.98)), and mitral valve inflow deceleration time (HR 1.22 
(1.05; 1.41)), independently of cardiovascular risk factors. Results were similar for ischemic 
stroke. For systolic function, fractional shortening (HR 0.84 (0.72; 0.98)) and moderate or poor 
qualitative systolic function (HR 2.56 (1.21; 5.43)) were associated with the risk of stroke, 
independently of cardiovascular risk factors. Results attenuated slightly when we investigated 
ischemic stroke (Table 2).  
Worse diastolic function was also related to an increased risk of dementia through mitral 
valve inflow peak E (HR 0.85 (0.75; 0.96)), E/A-ratio (HR 0.82 (0.70; 0.96)), mitral valve inflow 
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deceleration time (HR 1.16 (1.02; 1.33)), and impaired relaxation or restrictive pattern (HR 1.78 
(1.08; 2.95)). Results were similar for AD. We did not find any associations between 
measurements of systolic function and the risk of dementia or AD (Table 3).  
Results were similar after censoring for both stroke and dementia concomitantly or after 
excluding 66 people with moderate or poor left ventricular systolic function (results not 
shown). 
Associations were also similar after adjusting for cardiovascular risk factors and MMSE-score 
assessed at the examination round prior to our baseline (Supplementary Table I and II). 
We did not find a consistent pattern of effect modification by age, sex, blood pressure, or 
medication use, which was further hampered by smaller sample sizes in the respective strata. 
The only potential interaction was observed between sex and mitral valve inflow peak E for 
stroke (HR 0.71 (0.53; 0.94) in men and 1.27 (1.07; 1.51) in women). For dementia, we found 
potential interactions between sex and mitral valve deceleration time (HR 1.46 (1.16; 1.84) in 
men and 1.05 (0.89; 1.23) in women) and age and mitral valve deceleration time (HR 1.93 (1.25; 
2.99) for <70.4 years and 1.11 (0.96; 1.27) for >70.4 years). However, such interactions were not 
observed for other parameters related to diastolic function, which might point towards 
spurious associations. 
Of 577 persons with MRI-data, 37 had a silent infarct, of whom 31 a lacunar infarct. Median 
white matter lesion volume was 3.42 ml (interquartile range 2.17-6.43). Mitral valve inflow 
deceleration time and E/A-ratio were associated with silent infarcts, especially lacunar infarcts 
(Table 4). A moderate or poor systolic function was associated with a higher prevalence of silent 
infarcts, but this group only consisted of 4 participants resulting in wide CIs (Table 4). We found 
no associations of cardiac function with white matter lesion volume. 
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2012, whichever came first. We conducted a sensitivity analysis censoring for both stroke and 
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deceleration time (HR 1.16 (1.02; 1.33)), and impaired relaxation or restrictive pattern (HR 1.78 
(1.08; 2.95)). Results were similar for AD. We did not find any associations between 
measurements of systolic function and the risk of dementia or AD (Table 3).  
Results were similar after censoring for both stroke and dementia concomitantly or after 
excluding 66 people with moderate or poor left ventricular systolic function (results not 
shown). 
Associations were also similar after adjusting for cardiovascular risk factors and MMSE-score 
assessed at the examination round prior to our baseline (Supplementary Table I and II). 
We did not find a consistent pattern of effect modification by age, sex, blood pressure, or 
medication use, which was further hampered by smaller sample sizes in the respective strata. 
The only potential interaction was observed between sex and mitral valve inflow peak E for 
stroke (HR 0.71 (0.53; 0.94) in men and 1.27 (1.07; 1.51) in women). For dementia, we found 
potential interactions between sex and mitral valve deceleration time (HR 1.46 (1.16; 1.84) in 
men and 1.05 (0.89; 1.23) in women) and age and mitral valve deceleration time (HR 1.93 (1.25; 
2.99) for <70.4 years and 1.11 (0.96; 1.27) for >70.4 years). However, such interactions were not 
observed for other parameters related to diastolic function, which might point towards 
spurious associations. 
Of 577 persons with MRI-data, 37 had a silent infarct, of whom 31 a lacunar infarct. Median 
white matter lesion volume was 3.42 ml (interquartile range 2.17-6.43). Mitral valve inflow 
deceleration time and E/A-ratio were associated with silent infarcts, especially lacunar infarcts 
(Table 4). A moderate or poor systolic function was associated with a higher prevalence of silent 
infarcts, but this group only consisted of 4 participants resulting in wide CIs (Table 4). We found 
no associations of cardiac function with white matter lesion volume. 
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Table 1. Baseline characteristics 
 At risk 
 N=3,291 
Demographics  
Age, years 71.4 (7.1) 
Female  2,001 (60.8%) 
MMSE score, points  27.6 (2.1) 
Cardiovascular risk factors  
Systolic blood pressure, mm Hg 150 (21) 
Diastolic blood pressure, mm Hg 80 (11) 
Use of blood pressure-lowering medication 1,002 (30.8%) 
Heart rate, b/min 69 (10) 
Total cholesterol, mmol/L 5.7 (0.9) 
HDL-cholesterol, mmol/L 1.5 (0.4) 
Lipid-lowering medication 559 (17.2%) 
Diabetes mellitus 434 (13.2%) 
Smoking   
Past 1,692 (52.6%) 
Current 509 (15.8%) 
Body mass index 27.4 (3.9) 
APOE-ε4 carrier  850 (26.8%) 
Measures of diastolic function  
Mitral valve inflow peak E, m/s 0.65 (0.15) 
Mitral valve inflow peak A, m/s 0.77 (0.17) 
Mitral valve inflow deceleration time, msa 208 (184-240) 
E/A-ratioa 0.83 (0.71-1.00) 
Qualitatively assessed diastolic function  
Normal  2,027 (61.6%) 
Indeterminate 1,110 (33.7%) 
Impaired relaxation  144 (4.4%) 
Restrictive pattern 10 (0.3%) 
Measures of systolic function  
Fractional shortening, %a 40.4 (35.6-44.0) 
Qualitatively assessed systolic function  
Normal 2,102 (63.9%) 
Fair 1,123 (34.1%) 
Moderate 50 (1.5%) 
Poor 16 (0.5%) 
Abbreviations: N = number of persons included in study; HDL = high-density lipoprotein; MMSE = Mini-mental 
state examination; APOE = apolipoprotein E. 
Data are presented as mean (standard deviations) or counts (percentages).  
a Median and inter-quartile range because of skewed distribution 
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deceleration time (HR 1.16 (1.02; 1.33)), and impaired relaxation or restrictive pattern (HR 1.78 
(1.08; 2.95)). Results were similar for AD. We did not find any associations between 
measurements of systolic function and the risk of dementia or AD (Table 3).  
Results were similar after censoring for both stroke and dementia concomitantly or after 
excluding 66 people with moderate or poor left ventricular systolic function (results not 
shown). 
Associations were also similar after adjusting for cardiovascular risk factors and MMSE-score 
assessed at the examination round prior to our baseline (Supplementary Table I and II). 
We did not find a consistent pattern of effect modification by age, sex, blood pressure, or 
medication use, which was further hampered by smaller sample sizes in the respective strata. 
The only potential interaction was observed between sex and mitral valve inflow peak E for 
stroke (HR 0.71 (0.53; 0.94) in men and 1.27 (1.07; 1.51) in women). For dementia, we found 
potential interactions between sex and mitral valve deceleration time (HR 1.46 (1.16; 1.84) in 
men and 1.05 (0.89; 1.23) in women) and age and mitral valve deceleration time (HR 1.93 (1.25; 
2.99) for <70.4 years and 1.11 (0.96; 1.27) for >70.4 years). However, such interactions were not 
observed for other parameters related to diastolic function, which might point towards 
spurious associations. 
Of 577 persons with MRI-data, 37 had a silent infarct, of whom 31 a lacunar infarct. Median 
white matter lesion volume was 3.42 ml (interquartile range 2.17-6.43). Mitral valve inflow 
deceleration time and E/A-ratio were associated with silent infarcts, especially lacunar infarcts 
(Table 4). A moderate or poor systolic function was associated with a higher prevalence of silent 
infarcts, but this group only consisted of 4 participants resulting in wide CIs (Table 4). We found 
no associations of cardiac function with white matter lesion volume. 
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5 
deceleration time (HR 1.16 (1.02; 1.33)), and impaired relaxation or restrictive pattern (HR 1.78 
(1.08; 2.95)). Results were similar for AD. We did not find any associations between 
measurements of systolic function and the risk of dementia or AD (Table 3).  
Results were similar after censoring for both stroke and dementia concomitantly or after 
excluding 66 people with moderate or poor left ventricular systolic function (results not 
shown). 
Associations were also similar after adjusting for cardiovascular risk factors and MMSE-score 
assessed at the examination round prior to our baseline (Supplementary Table I and II). 
We did not find a consistent pattern of effect modification by age, s x, blood pressure, or 
medication use, which was further hampered by smaller sample sizes in the respective strata. 
The only potential interaction was observed between sex and mitral valve inflow peak E for 
stroke (HR 0.71 (0.53; 0.94) in men and 1.27 (1.07; 1.51) in women). For dementia, we found 
potential interactions between sex and mitral valve deceleration time (HR 1.46 (1.16; 1.84) in 
men and 1.05 (0.89; 1.23) in women) and age and mitral valve deceleration time (HR 1.93 (1.25; 
2.99) for <70.4 years and 1.1  (0.96; 1.27) for >70.4 years). However, such interactions were not 
observed for other parameters related to diastolic function, which might point towards 
spurious associations. 
Of 577 persons with MRI-data, 37 had a silent infarct, of whom 31 a lacunar infarct. M dian 
white matter lesion volume was 3.42 ml (interquartile range 2.17-6.43). Mitral valve inflow 
deceleration time and E/A-ratio were associated with silent infarcts, especially lacunar infarcts 
(Table 4). A moderate or poor systolic function was associated with a higher prevalence of silent 
infarcts, but this group only consisted of 4 participants resulting in wide CIs (Table 4). We found 
no associations of cardiac function with white matter lesion volume. 
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2012, whichever came first. We conducted a sensitivity analysis censoring for both stroke and 
dementia concomitantly in every analysis. We used linear and logistic regressi n models to 
investigate the associations of cardiac function with silent infarcts and white matter lesions. 
White matter lesion volume, mitral valve inflow deceleration time, and E/A-ratio were natural 
log transformed because of skewed distributions to the right. Fractional shortening was square 
transformed because of a skewed distribution to the left. Continuous echocardiographic 
variables were entered per SD increase into the models. Qualitative systolic function and 
diastolic function were entered categorically into the models. Only 10 participants had diastolic 
dysfunction with a restrictive pattern: therefore we combined diastolic dysfunction with 
impaired relaxation or a restrictive pattern for the analysis. Only 16 participants had poor left 
ventricular systolic function, which we therefore combined with moderate systolic function. In 
sensitivity analyses, we excluded participants (n=66) with moderate or poor systolic function 
to determine whether associations remained similar in people with a normal left ventricular 
function. The basic model (model I) was adjusted for age, sex, and type of ultrasonography 
system. The extended model (model II) was additionally adjusted for cardiovascu ar risk factors, 
and for MMSE-score and APOE-ε4 status in dementia analyses only. To further adjust for residual 
confounding by shared etiology, we repeated the analyses adjusting for cardiovascular risk 
factors and MMSE-score as assessed at the examination round prior (1997-2001) to our 
baseline. All analyses with white matter lesion volume were also adjusted for intracranial 
volume.  
We explored potential effect modification by sex, age (stratified at median), b ood pressure 
(stratified at median), and medication use by using interaction terms. 
Missing data on covariates (less than 3.6%) were imputed using multiple imputations. 
Analyses were repeated for ischemic stroke and AD. 
Analyses were done using IBM SPSS Statistics version 20.0 (IBM Corp., Armonk, USA).  
 
Results 
 
Baseline characteristics are presented in Table 1. Mean age (±SD) was 71.4 (±7.1) years and 
60.8% was female. During a mean follow-up of 6.6 (±1.8) years, 164 strokes occurred, of which 
117 were ischemic. During a mean follow-up of 5.9 (±1.5) years, 208 pe ple developed 
de entia, of which 171 w re AD. 
Several measures of diastolic function were associated with the risk of stroke, including 
mitral valve inflow peak A (hazard ratio (HR) per SD increase 1.27 (95% confidence i terval (CI) 
1.08; 1.48)), E/A-ratio (HR 0.82 (0.69; 0.98)), and mitral valve inflow deceleratio  ime (HR 1.22 
(1.05; 1.41)), independently of cardiovascular risk factors. Results were similar for ischemic 
stroke. For systolic function, fractional shortening (HR 0.84 (0.72; 0.98)) and moderate or poor 
qualitative systolic function (HR 2.56 (1.21; 5.43)) we e associated with the risk of stroke, 
independently of cardiovascular risk factors. Results attenuated slightly when we investigated 
ischemic stroke (Table 2).  
Worse diastolic function was also related to an increased risk of dementia through mitral 
valve inflow peak E (HR 0.85 (0.75; 0.96)), E/A-ratio (HR 0.82 (0.70; 0.96)), mitral valve inflow 
Subclinical cardiac dysfunction increases the risk of stroke and dementia 
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deceleration time (HR 1.16 (1.02; 1.33)), and impaired relaxation or restrictive pattern (HR 1.78 
(1.08; 2.95)). Results were similar for AD. We did not find any associations between 
measurements of systolic function and the risk of dementia or AD (Table 3).  
Results were similar after censoring for both stroke and dementia concomitantly or after 
excluding 66 people with moderate or poor left ventricular systolic function (results not 
shown). 
Associations were also similar after adjusting for cardiovascular risk factors and MMSE-score 
assessed at the examination round prior to our baseline (Supplementary Table I and II). 
We did not find a consistent pattern of effect modification by age, sex, blood pressure, or 
medication use, which was further hampered by smaller sample sizes in the respec ive strata. 
The only potential interaction was observ d between sex and mitral valve inflow peak E for 
stroke (HR 0.71 (0.53; 0.94) in men and 1.27 (1.07; 1.51) in women). For dementia, we found 
potential interactions between sex and mitral valve deceleration time (HR 1.46 (1.16; 1.84) in 
me  and 1.05 (0.89; 1.23) in women) and age and mitral valve deceleration time (HR 1.93 (1.25; 
2.99) for <70.4 years and 1.11 (0.96; 1.27) for >70.4 years). However, such interactions were not 
observed for other parameters related to diastolic function, which might point towards 
spurious associations. 
Of 577 persons with MRI-data, 37 had a silent infarct, of whom 31 a lacunar infarct. Median 
white matter lesion volume was 3.42 ml (interquartile range 2.17-6.43). Mitral valve inflow 
deceleration time and E/A-ratio were associated with silent infarcts, especially lacunar infarcts 
(Table 4). A moderate or poor systolic function was associated with a higher prevalence of silent 
infarcts, but this group only consisted of 4 participants resulting in wide CIs (Table 4). We found 
no associations of cardiac function with white matter lesion volume. 
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2012, whichever came first. We conducted a sensitivity analysis censoring for both stroke and 
dementia concomitantly in every analysis. We used linear and logistic regressi n models to 
investigate the associations of cardiac function with silent infarcts and white matter lesions. 
White matter lesion volume, mitral valve inflow deceleration time, and E/A-ratio were natural 
log transformed because of skewed distributions to the right. Fractional shortening was square 
transformed because of a skewed distribution to the left. Continuous echocardiographic 
variables were entered per SD increase into the models. Qualitative systolic function and 
diastolic function were entered categorically into the models. Only 10 participants had diastolic 
dysfunction with a restrictive pattern: therefore we combined diastolic dysfunction with 
impaired relaxation or a restrictive pattern for the analysis. Only 16 participants had poor left 
ventricular systolic function, which we therefore combined with moderate systolic function. In 
sensitivity analyses, we excluded participants (n=66) with moderate or poor systolic function 
to determine whether associations remained similar in people with a normal left ventricular 
function. The basic model (model I) was adjusted for age, sex, and type of ultrasonography 
system. The extended model (model II) was additionally adjusted for cardiovascu ar risk factors, 
and for MMSE-score and APOE-ε4 status in dementia analyses only. To further adjust for residual 
confounding by shared etiology, we repeated the analyses adjusting for cardiovascular risk 
factors and MMSE-score as assessed at the examination round prior (1997-2001) to our 
baseline. All analyses with white matter lesion volume were also adjusted for intracranial 
volume.  
We explored potential effect modification by sex, age (stratified at median), b ood pressure 
(stratified at median), and medication use by using interaction terms. 
Missing data on covariates (less than 3.6%) were imputed using multiple imputations. 
Analyses were repeated for ischemic stroke and AD. 
Analyses were done using IBM SPSS Statistics version 20.0 (IBM Corp., Armonk, USA).  
 
Results 
 
Baseline characteristics are presented in Table 1. Mean age (±SD) was 71.4 (±7.1) years and 
60.8% was female. During a mean follow-up of 6.6 (±1.8) years, 164 strokes occurred, of which 
117 were ischemic. During a mean follow-up of 5.9 (±1.5) years, 208 pe ple developed 
de entia, of which 171 w re AD. 
Several measures of diastolic function were associated with the risk of stroke, including 
mitral valve inflow peak A (hazard ratio (HR) per SD increase 1.27 (95% confidence i terval (CI) 
1.08; 1.48)), E/A-ratio (HR 0.82 (0.69; 0.98)), and mitral valve inflow deceleratio  ime (HR 1.22 
(1.05; 1.41)), independently of cardiovascular risk factors. Results were similar for ischemic 
stroke. For systolic function, fractional shortening (HR 0.84 (0.72; 0.98)) and moderate or poor 
qualitative systolic function (HR 2.56 (1.21; 5.43)) we e associated with the risk of stroke, 
independently of cardiovascular risk factors. Results attenuated slightly when we investigated 
ischemic stroke (Table 2).  
Worse diastolic function was also related to an increased risk of dementia through mitral 
valve inflow peak E (HR 0.85 (0.75; 0.96)), E/A-ratio (HR 0.82 (0.70; 0.96)), mitral valve inflow 
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deceleration time (HR 1.16 (1.02; 1.33)), and impaired relaxation or restrictive pattern (HR 1.78 
(1.08; 2.95)). Results were similar for AD. We did not find any associations between 
measurements of systolic function and the risk of dementia or AD (Table 3).  
Results were similar after censoring for both stroke and dementia concomitantly or after 
excluding 66 people with moderate or poor left ventricular systolic function (results not 
shown). 
Associations were also similar after adjusting for cardiovascular risk factors and MMSE-score 
assessed at the examination round prior to our baseline (Supplementary Table I and II). 
We did not find a consistent pattern of effect modification by age, sex, blood pressure, or 
medication use, which was further hampered by smaller sample sizes in the respec ive strata. 
The only potential interaction was observ d between sex and mitral valve inflow peak E for 
stroke (HR 0.71 (0.53; 0.94) in men and 1.27 (1.07; 1.51) in women). For dementia, we found 
potential interactions between sex and mitral valve deceleration time (HR 1.46 (1.16; 1.84) in 
me  and 1.05 (0.89; 1.23) in women) and age and mitral valve deceleration time (HR 1.93 (1.25; 
2.99) for <70.4 years and 1.11 (0.96; 1.27) for >70.4 years). However, such interactions were not 
observed for other parameters related to diastolic function, which might point towards 
spurious associations. 
Of 577 persons with MRI-data, 37 had a silent infarct, of whom 31 a lacunar infarct. Median 
white matter lesion volume was 3.42 ml (interquartile range 2.17-6.43). Mitral valve inflow 
deceleration time and E/A-ratio were associated with silent infarcts, especially lacunar infarcts 
(Table 4). A moderate or poor systolic function was associated with a higher prevalence of silent 
infarcts, but this group only consisted of 4 participants resulting in wide CIs (Table 4). We found 
no associations of cardiac function with white matter lesion volume. 
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Discussion 
 
In people free of clinical cardiac disease, worse diastolic function was associated with an 
increased risk of stroke and dementia, whereas worse systolic function was only associated with 
a higher risk of stroke. Diastolic function was also related to silent infarcts, especially lacunar 
infarcts, on MRI. 
Patients with overt cardiac disease have an increased risk of stroke and dementia. However, 
the associations between subclinical cardiac disease and stroke and dementia are unclear. As 
for stroke, other population-based studies have mostly examined the association of cardiac 
structure and stroke.19,29,30 However, in patients with heart failure, quality of systolic and diastolic 
function provides additional information on stroke risk over markers of cardiac structure 
alone.31 Little data is available in asymptomatic populations on systolic and diastolic function 
related to stroke. While diastolic dysfunction was not associated with stroke in the Strong Heart 
Study, this study population was younger and of different ethnicity than ours.29 The AGES-
Reykjavik study found an association between low E/A ratio and cerebral infarcts on MRI, 
supporting our observations, but this was a cross-sectional study that did not examine clinical 
strokes.32 For systolic function, the Framingham Heart Study found that persons with a lower 
fractional shortening had a higher risk of cardiovascular disease,33 which is in line with our 
observations, although they did not separately examine stroke. Hence, our results provide 
novel evidence that diastolic and systolic dysfunction are both associated with an increased 
risk of stroke, even within ranges of normal values. 
Regarding dementia, the Rotterdam Study previously found a higher prevalence of 
dementia in people with atrial fibrillation.7 Findings from several other population-based 
studies also point towards an association between cardiac dysfunction and dementia. For 
instance, the Framingham Heart Study investigated the association between cardiac function 
and low cognitive performance and MRI markers related to dementia and AD.34 They found a 
U-shaped association between left ventricular end systolic function and cognitive 
performance. Similarly, another study found that diminished cardiac function was related to 
lower brain volume, an important marker of brain aging.35 The Cardiovascular Health Study 
found an association between cardiovascular disease and dementia.9 However, these studies 
only investigated people with cardiac disease,7,9 or were cross-sectional by design.7,34,35 Our 
results suggest that diminished diastolic cardiac function is also associated with an increased 
risk of dementia in people free of cardiac disease. Since results for dementia and AD were 
similar and even remained stable after censoring for stroke, our study also supports the 
growing evidence that vascular factors play an important role in the etiology of AD.36 The 
question remains why diastolic function, but not systolic function, is related to dementia. 
Interestingly, we also found diastolic function to be associated with silent infarcts on MRI, which 
were primarily lacunar infarcts. Cerebral small vessel disease has been suggested to be the 
underlying link between lacunar infarcts and dementia. Future research should therefore 
explore whether diastolic function rather than systolic function relates strongest with 
pathology of the smallest vessels in the brain. Novel imaging techniques, such as arterial spin 
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labeling for brain perfusion and 7T MRI for visualizing small vessels, may play an important role 
here. 
There are several explanations for the relation between cardiac function and the risk of 
neurologic disease, which are supported equally by our data. First, cardiac dysfunction can lead 
to cardioembolism,37 which in turn causes stroke and contributes to the etiology of 
dementia.3,38 Second, impaired cardiac function may lead to cerebral hypoperfusion. In people 
with cardiac arrhythmias, hypoperfusion leads to watershed infarction.39 Furthermore, in 
patients with heart failure, low ejection fraction has been associated with cognitive 
impairment.40 However, low cardiac output is closely related to diminished systolic function, 
which in our study was not associated with dementia. Finally, a non-causal explanation is 
shared etiology, since impaired cardiac function, stroke, and dementia share risk factors.3,4 
Although our results were independent of cardiovascular risk factors, even when assessed up 
to 7 years prior to baseline, there might still be residual confounding.  
Strengths of this study are the population-based design, the long follow-up period, the 
systematic collection and adjudication of events, and the standardized assessment of risk 
factors and echocardiographic parameters. A limitation is that categorization of left ventricular 
diastolic function was based on E/A-ratio and mitral valve deceleration time, and not on the 
early diastolic longitudinal velocity of the mitral annulus (E’).16,22 We were thus unable to sub-
classify diastolic function in approximately one third of our study population. Neither did we 
systematically measure valvular diseases, which are well-known substrates for 
cardioembolisms and can affect cardiac function.38 Another issue is multiple testing, since we 
tested several diastolic and systolic measures of cardiac function. However, as the associations 
we found were not completely independent, adjusting for multiple testing might have led to 
false negative results. Since echocardiography was performed in the fourth examination of the 
original cohort and the second examination of the extended cohort, survival bias cannot be 
ruled out. Finally, most participants of the Rotterdam Study are white and live in a middle 
income district of Rotterdam, which limits the generalizability of our results. 
Our results indicate that in people without clinically overt cardiac disease, impaired diastolic 
function is associated with the risk of clinical stroke, dementia, and silent infarcts on MRI, 
whereas impaired systolic function is only associated with the risk of stroke. Future research 
should determine whether improving cardiac function can prevent stroke and dementia. 
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Although our results were independent of cardiovascular risk factors, even when assessed up 
to 7 years prior to baseline, there might still be residual confounding.  
Strengths of this study are the population-based design, the long follow-up period, the 
systematic collection and adjudication of events, and the standardized assessment of risk 
factors and echocardiographic parameters. A limitation is that categorization of left ventricular 
diastolic function was based on E/A-ratio and mitral valve deceleration time, and not on the 
early diastolic longitudinal velocity of the mitral annulus (E’).16,22 We were thus unable to sub-
classify diastolic function in approximately one third of our study population. Neither did we 
systematically measure valvular diseases, which are well-known substrates for 
cardioembolisms and can affect cardiac function.38 Another issue is multiple testing, since we 
tested several diastolic and systolic measures of cardiac function. However, as the associations 
we found were not completely independent, adjusting for multiple testing might have led to 
false negative results. Since echocardiography was performed in the fourth examination of the 
original cohort and the second examination of the extended cohort, survival bias cannot be 
ruled out. Finally, most participants of the Rotterdam Study are white and live in a middle 
income district of Rotterdam, which limits the generalizability of our results. 
Our results indicate that in people without clinically overt cardiac disease, impaired diastolic 
function is associated with the risk of clinical stroke, dementia, and silent infarcts on MRI, 
whereas impaired systolic function is only associated with the risk of stroke. Future research 
should determine whether improving cardiac function can prevent stroke and dementia. 
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Supplementary information 
 
Supplementary Table I. Characteristics assessed at the examination prior to baseline 
 At risk 
 N=3,291 
Demographics  
Score on MMSE, points  28.0 (1.7) 
Cardiovascular risk factors  
Systolic blood pressure, mm Hg 142 (20) 
Diastolic blood pressure, mm Hg 77 (11) 
Use of blood pressure-lowering medication 634 (20.1%) 
Heart rate, b/min 70 (10) 
Total cholesterol, mmol/L 5.9 (0.9) 
HDL-cholesterol, mmol/L 1.4 (0.4) 
Lipid-lowering medication 314 (9.9%) 
Diabetes mellitus 308 (9.7%) 
Smoking   
Past 1,535 (47.7%) 
Current    639 (19.9%) 
Body mass index 26.8 (3.8) 
APOE-ε4 carrier  850 (26.8%) 
Abbreviations: N = number of persons included in study; HDL = high-density lipoprotein; MMSE = Mini-mental 
state examination; APOE = apolipoprotein E. 
Data are presented as mean (standard deviations) or counts (percentages).  
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Supplementary Table II. Cardiac function and the risk of stroke and dementia, adjusted for potential 
confounders assessed at the examination prior to baseline 
 Stroke 
n/N 164/3,291 
Dementia 
n/N 208/3,291 
Diastolic function   
Quantitative diastolic function   
Mitral valve inflow peak E, per SD 1.09 (0.94; 1.27) 0.89 (0.77; 1.02) 
Mitral valve inflow peak A, per SD 1.21 (1.04; 1.41) 1.03 (0.89; 1.18) 
Mitral valve inflow deceleration timea, per SD 1.21 (1.04; 1.41) 1.16 (1.02; 1.32) 
E/A-ratioa, per SD 0.88 (0.74; 1.03) 0.84 (0.72; 0.97) 
   
Qualitative diastolic function   
Normal Reference Reference 
Indeterminate 1.19 (0.85; 1.66) 1.26 (0.93; 1.70) 
Impaired relaxation or restrictive pattern 1.66 (0.94; 2.94) 1.67 (1.02; 2.74) 
   
Systolic function   
Quantitative systolic function   
Fractional shortening, per SDa 0.83 (0.71; 0.97) 0.97 (0.84; 1.11) 
   
Qualitative systolic function   
Normal  Reference Reference 
Fair 1.35 (0.96; 1.88) 1.15 (0.86; 1.54) 
Moderate or poor 2.62 (1.24; 5.56) 1.26 (0.57; 2.77) 
Abbreviations: n = number of cases; N = number of persons at risk; SD = standard deviation. 
Values are hazard ratios with 95% confidence intervals.  
Adjusted for age, sex, type ultrasonography system, body mass index, systolic blood pressure, diastolic blood 
pressure, blood pressure- lowering medication, total cholesterol, high-density lipoprotein cholesterol, lipid-
lowering medication, diabetes mellitus, current smoking, past smoking, heart rate, and for MMSE-score and 
APOE-ε4 carrier status in dementia analyses only. 
a Natural log or square transformed because of skewed distribution. 
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Abstract 
 
Background and purpose 
Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is a predictor of heart disease. It 
has also been related to stroke, but its association with transient ischemic attacks (TIAs) is 
unclear. Moreover, it is unknown how clinical heart disease influences this relation. Within the 
prospective population-based Rotterdam Study, we examined the association of NT-proBNP 
with stroke and TIA, and investigated the role of heart disease on this association.  
 
Methods 
NT-proBNP was measured in 1997-2001 in 5611 participants (mean age 68.7 years; 57.7% 
women) without a history of stroke, TIA, or heart failure. Follow-up for stroke and TIA finished 
in 2012. Models were adjusted for age and cardiovascular risk factors, and were stratified by 
sex.  
 
Results 
During 22058 person-years 195 men suffered a stroke and 118 a TIA. During 31825 person-
years 230 women suffered a stroke and 187 a TIA. Higher NT-proBNP was associated with a 
higher risk of stroke in men (hazard ratio (HR) per SD increase 1.50, 95% CI 1.29; 1.76) and in 
women (HR 1.24, 95% CI 1.05 1.46). Associations with TIA were only present in women (HR 1.51, 
95% CI 1.26; 1.82), and not in men (HR 1.02, 95% CI 0.83; 1.26). Excluding persons with a history 
of clinical coronary heart disease, heart failure, or atrial fibrillation, and censoring for clinical 
heart disease during follow-up did not change the associations. 
 
Conclusions 
Higher NT-proBNP is associated with incident stroke in men and women and with incident TIA 
only in women. These associations are independent of clinical heart disease preceding 
cerebrovascular disease. 
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Introduction 
 
An important cornerstone of research on cardiovascular diseases, is to identify subclinical 
markers that can elucidate etiology or serve as predictive markers. Amino-terminal pro-B-type 
natriuretic peptide (NT-proBNP) is an emerging marker that is excreted in response to cardiac 
wall stress,1,2 and has recently shown to predict heart disease.3,4 Importantly, NT-proBNP 
provides information on cardiac overload and dysfunction even in absence of clinical heart 
failure and therefore could serve as a subclinical marker.5  
Previous studies have also shown an increased risk of stroke in persons with high NT-
proBNP,3,6-10 but there are still some knowledge gaps. First, it remains unclear how clinical heart 
disease (e.g. coronary heart disease, heart failure, and atrial fibrillation) affects the reported 
association between NT-proBNP and stroke. It is conceivable that persons with high NT-
proBNP, reflecting subclinical heart disease, first suffer from clinical heart disease during follow-
up, which subsequently leads to a stroke.11-13 Second, if NT-proBNP truly could act as a 
subclinical marker of stroke, it is important to study its role in the earliest clinical manifestation 
of cerebrovascular disease, which is often a transient ischemic attack (TIA). Importantly, at time 
of TIA effective therapy can still be installed to prevent subsequent stroke.14 Finally, given the 
differences in occurrence and risk factor profiles of cardiovascular disease between men and 
women,15,16 the association between NT-proBNP with cerebrovascular disease merits further 
investigation for sex differences. 
Therefore, we investigated the association of NT-proBNP with stroke and TIA in men and 
women separately. Furthermore, we studied the role of prevalent and incident heart disease 
on this association.  
 
Materials and Methods 
 
Setting and study population 
This study was embedded within the Rotterdam Study, a prospective population-based cohort 
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the Netherlands.17 The study started in 1990 with 7983 participants and was extended in 2000 
with 3011 persons. Follow-up examinations take place every 3 to 4 years.  
For the current study, baseline data was collected between 1997 and 2001. NT-proBNP was 
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cohort. After excluding 804 participants with a history of stroke, TIA, or heart failure, and 74 
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according to the Population Study Act Rotterdam Study. A written informed consent was 
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Abstract 
 
Background and purpose 
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Methods 
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women) without a history of stroke, TIA, or heart failure. Follow-up for stroke and TIA finished 
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Results 
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of clinical coronary heart disease, heart failure, or atrial fibrillation, and censoring for clinical 
heart disease during follow-up did not change the associations. 
 
Conclusions 
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only in women. These associations are independent of clinical heart disease preceding 
cerebrovascular disease. 
  
N-terminal pro-B-type natriuretic peptide and the risk of stroke and transient ischaemic attack 
39 
Introduction 
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natriuretic peptide (NT-proBNP) is an emerging marker that is excreted in response to cardiac 
wall stress,1,2 and has recently shown to predict heart disease.3,4 Importantly, NT-proBNP 
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differences in occurrence and risk factor profiles of cardiovascular disease between men and 
women,15,16 the association between NT-proBNP with cerebrovascular disease merits further 
investigation for sex differences. 
Therefore, we investigated the association of NT-proBNP with stroke and TIA in men and 
women separately. Furthermore, we studied the role of prevalent and incident heart disease 
on this association.  
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participants with NT-proBNP above the age-specific heart failure limit (50-75 years, 108 pmol/L; 
>75 years, 216 pmol/L),18 a total of 5611 participants (2374 men and 3237 women) were eligible 
for analysis. The Rotterdam Study has been approved by the medical ethics committee 
according to the Population Study Act Rotterdam Study. A written informed consent was 
obtained from all participants. 
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NT-proBNP measurement 
Blood samples for NT-proBNP assessment were collected in glass tubes containing clot 
activator and gel for serum separation and stored at -80ºC. NT-proBNP was measured using a 
commercially available electrochemiluminescence immunoassay (Elecsys proBNP, F Hoffman-
La Roche Ltd) on an Elecsys 2010 analyzer.6 Precision, analytic sensitivity, and stability of the 
system have been described.19  
 
Assessment of cerebrovascular events. 
At study entry, history of stroke and TIA was assessed using home interviews and confirmed by 
reviewing medical records. Subsequently, participants were continuously followed-up for 
stroke and TIA through digital linkage of general practitioners’ files with the study database. 
Furthermore, nursing home physicians’ files and files from general practitioners of participants 
who moved out of the district were checked on a regular basis.20 Of all potential strokes and 
TIAs, hospital discharge letters and information from general practitioner was collected. 
Research physicians reviewed the information and an experienced neurologist verified the 
strokes and TIAs.21,22 Strokes were further classified into ischemic or hemorrhagic based on 
neuroimaging reports. Subarachnoid hemorrhages were excluded. Infarcts that turned 
hemorrhagic were classified as ischemic stroke. If neuroimaging was lacking, a stroke was 
classified as unspecified. TIAs were further classified into focal or mixed. An event was focal if 
only symptoms attributable to dysfunction of one arterial territory of the brain were reported. 
An event was classified as mixed if diffuse nonlocalizing cerebral symptoms were reported as 
well.22 Purely nonfocal events were not analyzed as they are currently not included in the 
internationally used definition of TIA.23 Follow-up was complete until January 1st, 2012 for 95.6% 
of potential person-years.  
 
Covariates 
Details on assessment of anthropometrics, cardiovascular risk factors (blood pressure, total 
cholesterol, high-density cholesterol, creatinine, diabetes mellitus, and smoking), and use of 
medication have been described previously.4 Within the heart disease definition we included: 
heart failure, coronary heart disease (defined as myocardial infarction or coronary 
revascularization procedure), and atrial fibrillation. Heart diseases were assessed through active 
follow-up and adjudicated using standardized definitions similar to the follow-up for stroke 
and TIA.20  
 
Statistical analyses 
NT-proBNP was natural log-transformed and entered per standard deviation (SD) increase into 
Cox proportional hazards models. Hazard ratios (HR) were also calculated for sex-specific 
tertiles of NT-proBNP. We examined the association of NT-proBNP with any cerebrovascular 
event (stroke or TIA), and with stroke or TIA separately, censoring follow-up at the date of the 
other event if that occurred first. Thus, participants were censored at date of stroke, date of TIA, 
date of death, last date of follow-up, or January 1st, 2012, whichever came first. All models were 
adjusted for age and were stratified by sex to allow for sex-specific effects. Interaction terms 
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were tested to identify significant differences between men and women. In multivariate 
adjusted models, we additionally adjusted for cardiovascular risk factors, and blood pressure-
lowering, lipid-lowering, and antithrombotic (including antiplatelet and anticoagulant) drugs. 
Missing data on covariates (for all covariates 4.6% or less) were imputed based on the other 
covariates using multiple imputation with 5 imputation sets.  
In sensitivity analyses, we investigated associations between NT-proBNP and stroke 
without censoring for TIA, we stratified for antiplatelet and anticoagulant drug use, and we 
investigated associations between NT-proBNP and stroke and TIA after additionally excluding 
participants with a history of atrial fibrillation or coronary heart disease at baseline and 
censoring for incident atrial fibrillation, coronary heart disease, and heart failure during follow-
up. Follow-up for atrial fibrillation and heart failure was available until 2008 and 2010, 
respectively. Therefore we did a final sensitivity analysis for stroke and TIA with follow-up 
ending in 2008.  
All analyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
In table 1 the baseline characteristics of the study population are presented. A total of 2374 
men and 3237 women was eligible for analysis. Mean age (±SD) was 67.9 (±7.5) years in men 
and 69.2 (±8.4) years in women. After a mean follow-up of 9.3 (±3.4) years the first presentation 
of a cerebrovascular event was stroke in 195 men and TIA in 118 men. After a mean follow-up 
of 9.8 (±3.3) years the first presentation of a cerebrovascular event was stroke in 230 women 
and TIA in 187 women. 
In Table 2 associations between NT-proBNP levels and cerebrovascular events are 
presented. The risk of any cerebrovascular event was similar in men and women, multivariate 
adjusted HR per SD increase in NT-proBNP in men 1.31 (95% confidence interval (CI) 1.15; 1.48) 
and in women 1.36 (95% CI 1.20; 1.53). Associations with stroke were stronger in men (HR 1.50, 
95% CI 1.29; 1.76) compared to women (HR 1.24, 95% CI 1.05; 1.46), but this difference was not 
statistically significant (p-value 0.21). Associations were found for both ischemic and 
hemorrhagic stroke. Associations with TIA were only present in women (HR 1.51, 95% CI 1.26; 
1.82) and not in men (HR 1.02, 95% CI 0.83; 1.26), which was a statistically significant interaction 
(p<0.01) (Table 2). With NT-proBNP levels in tertiles we also found associations with stroke in 
men and women and with TIA only in women (Table 3, Figure 1). Without censoring for TIA, 
the effect size for stroke in women was higher (HR 1.36, 95% CI 1.16; 1.59) (Table 4).  
Associations with hemorrhagic stroke and mixed TIA attenuated after excluding 
participants with a history of heart disease and censoring at time of incident heart disease 
(Table 5). Other associations remained similar. Ending the study follow-up in 2008 did not 
change the lack of an effect of preceding heart disease on the associations (data not shown). 
Associations were slightly weaker in persons that used either anticoagulant or antiplatelet 
drugs (Supplementary Table I). 
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were tested to identify significant differences between men and women. In multivariate 
adjusted models, we additionally adjusted for cardiovascular risk factors, and blood pressure-
lowering, lipid-lowering, and antithrombotic (including antiplatelet and anticoagulant) drugs. 
Missing data on covariates (for all covariates 4.6% or less) were imputed based on the other 
covariates using multiple imputation with 5 imputation sets.  
In sensitivity analyses, we investigated associations between NT-proBNP and stroke 
without censoring for TIA, we stratified for antiplatelet and anticoagulant drug use, and we 
investigated associations between NT-proBNP and stroke and TIA after additionally excluding 
participants with a history of atrial fibrillation or coronary heart disease at baseline and 
censoring for incident atrial fibrillation, coronary heart disease, and heart failure during follow-
up. Follow-up for atrial fibrillation and heart failure was available until 2008 and 2010, 
respectively. Therefore we did a final sensitivity analysis for stroke and TIA with follow-up 
ending in 2008.  
All analyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
In table 1 the baseline characteristics of the study population are presented. A total of 2374 
men and 3237 women was eligible for analysis. Mean age (±SD) was 67.9 (±7.5) years in men 
and 69.2 (±8.4) years in women. After a mean follow-up of 9.3 (±3.4) years the first presentation 
of a cerebrovascular event was stroke in 195 men and TIA in 118 men. After a mean follow-up 
of 9.8 (±3.3) years the first presentation of a cerebrovascular event was stroke in 230 women 
and TIA in 187 women. 
In Table 2 associations between NT-proBNP levels and cerebrovascular events are 
presented. The risk of any cerebrovascular event was similar in men and women, multivariate 
adjusted HR per SD increase in NT-proBNP in men 1.31 (95% confidence interval (CI) 1.15; 1.48) 
and in women 1.36 (95% CI 1.20; 1.53). Associations with stroke were stronger in men (HR 1.50, 
95% CI 1.29; 1.76) compared to women (HR 1.24, 95% CI 1.05; 1.46), but this difference was not 
statistically significant (p-value 0.21). Associations were found for both ischemic and 
hemorrhagic stroke. Associations with TIA were only present in women (HR 1.51, 95% CI 1.26; 
1.82) and not in men (HR 1.02, 95% CI 0.83; 1.26), which was a statistically significant interaction 
(p<0.01) (Table 2). With NT-proBNP levels in tertiles we also found associations with stroke in 
men and women and with TIA only in women (Table 3, Figure 1). Without censoring for TIA, 
the effect size for stroke in women was higher (HR 1.36, 95% CI 1.16; 1.59) (Table 4).  
Associations with hemorrhagic stroke and mixed TIA attenuated after excluding 
participants with a history of heart disease and censoring at time of incident heart disease 
(Table 5). Other associations remained similar. Ending the study follow-up in 2008 did not 
change the lack of an effect of preceding heart disease on the associations (data not shown). 
Associations were slightly weaker in persons that used either anticoagulant or antiplatelet 
drugs (Supplementary Table I). 
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Table 1. Baseline characteristics 
 Men Women 
 N=2374 N=3237 
Age, years 67.9 (7.5) 69.2 (8.4) 
Systolic blood pressure, mmHg 144 (21) 142 (21) 
Diastolic blood pressure, mmHg 79 (11) 76 (11) 
Blood pressure lowering drugs 459 (20.1%) 738 (24.0%) 
Total cholesterol, mmol/L 5.6 (1.0) 6.0 (0.9) 
High-density lipoprotein cholesterol, mmol/L 1.2 (0.3) 1.5 (0.4) 
Lipid-lowering drugs 296 (12.9%) 367 (11.8%) 
Anticoagulant drugs 85 (3.7%) 44 (1.4%) 
Antiplatelet drugs 373 (16.3%) 333 (10.7%) 
Creatinine, µmol/L 88 (16) 70 (13) 
Diabetes mellitus 284 (12.0%) 322 (10.0%) 
Smoking   
Never 275 (11.7%) 1375 (43.1%) 
Former 1530 (64.9%) 1272 (39.9%) 
Current 552 (23.4%) 541 (17.0%) 
NT-proBNP, pmol/La  7.7 (4.1 – 15.8) 10.5 (5.9 – 18.3) 
NT-proBNP, pmol/Lb   
Tertile 1 0.59 – 5.06 0.59 – 7.30 
Tertile 2 5.06 – 12.30 7.30 – 15.38 
Tertile 3 12.30 – 210.10 15.38 – 212.20 
Data are presented as mean (standard deviations) or counts (percentages).  
a Median and inter-quartile range. 
b Range in each tertile 
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were tested to identify significant differences between men and women. In multivariate 
adjusted models, we additionally adjusted for cardiovascular risk factors, and blood pressure-
lowering, lipid-lowering, and antithrombotic (including antiplatelet and anticoagulant) drugs. 
Missing data on covariates (for all covariates 4.6% or less) were imputed based on the other 
covariates using multiple imputation with 5 imputation sets.  
In sensitivity analyses, we investigated associations between NT-proBNP and stroke 
without censoring for TIA, we stratified for antiplatelet and anticoagulant drug use, and we 
investigated associations between NT-proBNP and stroke and TIA after additionally excluding 
participants with a history of atrial fibrillation or coronary heart disease at baseline and 
censoring for incident atrial fibrillation, coronary heart disease, and heart failure during follow-
up. Follow-up for atrial fibrillation and heart failure was available until 2008 and 2010, 
respectively. Therefore we did a final sensitivity analysis for stroke and TIA with follow-up 
ending in 2008.  
All analyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
In table 1 the baseline characteristics of the study population are presented. A total of 2374 
men and 3237 women was eligible for analysis. Mean age (±SD) was 67.9 (±7.5) years in men 
and 69.2 (±8.4) years in women. After a mean follow-up of 9.3 (±3.4) years the first presentation 
of a cerebrovascular event was stroke in 195 men an  TIA in 118 men. After a mean follow-up 
of 9.8 (±3.3) years the first presentation of a cerebrovascular event was stroke in 230 women 
and TIA in 187 women. 
In Table 2 associations between NT-proBNP levels and cerebrovascular events are 
presented. The risk of any cerebrovascular event was similar in men and women, multivariate 
adjusted HR per SD increase in NT-proBNP in men 1.31 (95% confidence interval (CI) 1.15; 1.48) 
and in women 1.36 (95% CI 1.20; .53). Associations with stroke were stronger in men (HR 1.50, 
95% CI 1.29; 1.76) compared to women (HR 1.24, 95% CI 1.05; 1.46), but this difference was not 
statistically significant (p-value 0.21). Associations were found for both ischemic and 
hemorrhagic stroke. Associations with TIA were only present in women (HR 1.51, 95% CI 1.26; 
1.82) and not in men (HR 1.02, 95% CI 0.83; 1.26), which was a statistically significant interaction 
(p<0.01) (Table 2). With NT-proBNP levels in tertiles we also found associations with stroke in 
men and women and with TIA only in women (Table 3, Figure 1). Without censoring for TIA, 
the effect size for stroke in women was higher (HR 1.36, 95% CI 1.16; 1.59) (Table 4).  
Associations with hemorrhagic stroke and mixed TIA attenuated after excluding 
participants with a history of heart disease and censoring at time of incident heart disease 
(Table 5). Other associations remained similar. Ending the study follow-up in 2008 did not 
change the lack of an effect of preceding heart disease n the associations (data not shown). 
Associations were slightly weaker in persons that used either anticoagulant or antiplatelet 
drugs (Supplementary Table I). 
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Table 1. Baseline characteristics 
 Men Women 
 N=2374 N=3237 
Age, years 67.9 (7.5) 69.2 (8.4) 
Systolic blood pressure, mmHg 144 (21) 142 (21) 
Diastolic blood pressure, mmHg 79 (11) 76 (11) 
Blood pressure lowering drugs 459 (20.1%) 738 (24.0%) 
Total cholesterol, mmol/L 5.6 (1.0) 6.0 (0.9) 
High-density lipoprotein cholesterol, mmol/L 1.2 (0.3) 1.5 (0.4) 
Lipid-lowering drugs 296 (12.9%) 367 (11.8%) 
Anticoagulant drugs 85 (3.7%) 44 (1.4%) 
Antiplatelet drugs 373 (16.3%) 333 (10.7%) 
Creatinine, µmol/L 88 (16) 70 (13) 
Diabetes mellitus 284 (12.0%) 322 (10.0%) 
Smoking   
Never 275 (11.7%) 1375 (43.1%) 
Former 1530 (64.9%) 1272 (39.9%) 
Current 552 (23.4%) 541 (17.0%) 
NT-proBNP, pmol/La  7.7 (4.1 – 15.8) 10.5 (5.9 – 18.3) 
NT-proBNP, pmol/Lb   
Tertile 1 0.59 – 5.06 0.59 – 7.30 
Tertile 2 5.06 – 12.30 7.30 – 15.38 
Tertile 3 12.30 – 210.10 15.38 – 212.20 
Data are presented as mean (standard deviations) or counts (percentages).  
a Median and inter-quartile range. 
b Range in each tertile 
  Ta
b
le
 2
. N
T
-p
ro
B
N
P
 a
n
d
 t
h
e
 r
is
k 
o
f 
c
e
re
b
ro
v
a
sc
u
la
r 
e
v
e
n
ts
 
 
M
e
n
 
N
=
2
3
7
4
 
 
W
o
m
e
n
 
N
=
3
2
3
7
 
 
n
 
M
o
d
e
l 
I 
H
R
 (
9
5
%
 C
I)
 
M
o
d
e
l 
II
 
H
R
 (
9
5
%
 C
I)
 
 
n
 
M
o
d
e
l 
I 
H
R
 (
9
5
%
 C
I)
 
M
o
d
e
l 
II
 
H
R
 (
9
5
%
 C
I)
 
A
n
y 
c
e
re
b
ro
v
a
sc
u
la
r 
e
v
e
n
t 
3
1
3
 
1
.3
7
 (1
.2
2
; 1
.5
4
) 
1
.3
1
 (1
.1
5
; 1
.4
8
) 
 
4
1
7
 
1
.3
6
 (1
.2
1
; 1
.5
3
) 
1
.3
6
 (1
.2
0
; 1
.5
3
) 
 
 
 
 
 
 
 
 
A
n
y 
st
ro
ke
 
1
9
5
 
1
.6
0
 (1
.3
9
; 1
.8
5
) 
1
.5
0
 (1
.2
9
; 1
.7
6
) 
 
2
3
0
 
1
.2
8
 (1
.0
9
; 1
.5
1
) 
1
.2
4
 (1
.0
5
; 1
.4
6
) 
Is
ch
e
m
ic
 s
tr
o
ke
 
1
3
9
 
1
.6
8
 (1
.4
1
; 1
.9
9
) 
1
.5
9
 (1
.3
2
; 1
.9
2
) 
 
1
4
3
 
1
.3
1
 (1
.0
7
; 1
.6
1
) 
1
.3
0
 (1
.0
5
; 1
.6
1
) 
H
e
m
o
rr
h
ag
ic
 s
tr
o
ke
 
1
8
 
1
.8
6
 (1
.1
6
; 2
.9
7
) 
1
.7
0
 (1
.0
2
; 2
.8
4
) 
 
2
6
 
1
.4
3
 (0
.9
0
; 2
.3
0
) 
1
.1
7
 (0
.7
2
; 1
.9
0
) 
U
n
sp
e
ci
fie
d
 s
tr
o
ke
 
3
8
 
1
.3
1
 (0
.9
5
; 1
.8
1
) 
1
.1
4
 (0
.8
0
; 1
.6
3
) 
 
6
1
 
1
.1
5
 (0
.8
4
; 1
.5
8
) 
1
.1
1
 (0
.8
0
; 1
.5
3
) 
 
 
 
 
 
 
 
 
A
n
y 
T
IA
 
1
1
8
 
1
.0
5
 (0
.8
6
; 1
.2
7
) 
1
.0
2
 (0
.8
3
; 1
.2
6
) 
 
1
8
7
 
1
.4
7
 (1
.2
3
; 1
.7
5
) 
1
.5
1
 (1
.2
6
; 1
.8
2
) 
Fo
ca
l T
IA
 
1
0
1
 
1
.0
8
 (0
.8
8
; 1
.3
4
) 
1
.0
5
 (0
.8
3
; 1
.3
1
) 
 
1
4
5
 
1
.4
8
 (1
.2
1
; 1
.8
1
) 
1
.5
5
 (1
.2
6
; 1
.9
0
) 
M
ix
e
d
 T
IA
 
1
7
 
0
.8
5
 (0
.5
0
; 1
.4
5
) 
0
.8
8
 (0
.5
2
; 1
.4
9
) 
 
4
2
 
1
.4
2
 (0
.9
8
; 2
.0
6
) 
1
.4
1
 (0
.9
6
; 2
.0
6
) 
A
b
b
re
vi
at
io
n
s:
 n
 =
 n
u
m
b
e
r 
o
f e
ve
n
ts
; N
 =
 n
u
m
b
e
r 
o
f p
e
rs
o
n
s 
at
 r
is
k;
 S
D
 =
 s
ta
n
d
ar
d
 d
e
vi
at
io
n
. 
V
al
u
e
s 
ar
e
 h
az
ar
d
 r
at
io
s 
p
e
r 
SD
 in
cr
e
as
e
 in
 n
at
u
ra
l l
o
g
-t
ra
n
sf
o
rm
e
d
 N
T-
p
ro
B
N
P
 le
ve
l (
SD
=
0
.9
6
) w
it
h
 9
5
%
 c
o
n
fid
e
n
ce
 in
te
rv
al
s.
  
A
n
al
ys
e
s 
w
it
h
 s
tr
o
ke
 w
e
re
 c
e
n
so
re
d
 fo
r 
in
ci
d
e
n
t 
TI
A
 a
n
d
 a
n
al
ys
e
s 
w
it
h
 T
IA
 w
e
re
 c
e
n
so
re
d
 fo
r 
in
ci
d
e
n
t 
st
ro
ke
. 
M
o
d
e
l I
: a
d
ju
st
e
d
 fo
r 
ag
e
. 
M
o
d
e
l I
I: 
ad
ju
st
e
d
 fo
r 
ag
e
, s
ys
to
lic
 b
lo
o
d
 p
re
ss
u
re
, d
ia
st
o
lic
 b
lo
o
d
 p
re
ss
u
re
, b
lo
o
d
 p
re
ss
u
re
-l
o
w
e
ri
n
g
 d
ru
g
s,
 t
o
ta
l c
h
o
le
st
e
ro
l, 
h
ig
h
-d
e
n
si
ty
 li
p
o
p
ro
te
in
 c
h
o
le
st
e
ro
l, 
lip
id
-l
o
w
e
ri
n
g
 
d
ru
g
s,
 a
n
ti
th
ro
m
b
o
ti
c 
d
ru
g
s,
 c
re
at
in
in
e
, s
m
o
ki
n
g
, a
n
d
 d
ia
b
e
te
s 
m
e
lli
tu
s.
 
 
 
43
N-terminal pro-B-type natriuretic peptide and the risk of stroke and transient ischaemic attack 
1 
were tested to identify significant differences between men and women. In multivariate 
adjusted models, we additionally adjusted for cardiovascular risk factors, and blood pressure-
lowering, lipid-lowering, and antithrombotic (including antiplatelet and anticoagulant) drugs. 
Missing data on covariates (for all covariates 4.6% or less) were imputed based on the other 
covariates using multiple imputation with 5 imputation sets.  
In sensitivity analyses, we investigated associations between NT-proBNP and stroke 
without censoring for TIA, we stratified for antiplatelet and anticoagulant drug use, and we 
investigated associations between NT-proBNP and stroke and TIA after additionally excluding 
participants with a history of atrial fibrillation or coronary heart disease at baseline and 
censoring for incident atrial fibrillation, coronary heart disease, and heart failure during follow-
up. Follow-up for atrial fibrillation and heart failure was available until 2008 and 2010, 
respectively. Therefore we did a final sensitivity analysis for stroke and TIA with follow-up 
ending in 2008.  
All analyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
In table 1 the baseline characteristics of the study population are presented. A total of 2374 
men and 3237 women was eligible for analysis. Mean age (±SD) was 67.9 (±7.5) years in men 
and 69.2 (±8.4) years in women. After a mean follow-up of 9.3 (±3.4) years the first presentation 
of a cerebrovascular event was stroke in 195 men an  TIA in 118 men. After a mean follow-up 
of 9.8 (±3.3) years the first presentation of a cerebrovascular event was stroke in 230 women 
and TIA in 187 women. 
In Table 2 associations between NT-proBNP levels and cerebrovascular events are 
presented. The risk of any cerebrovascular event was similar in men and women, multivariate 
adjusted HR per SD increase in NT-proBNP in men 1.31 (95% confidence interval (CI) 1.15; 1.48) 
and in women 1.36 (95% CI 1.20; .53). Associations with stroke were stronger in men (HR 1.50, 
95% CI 1.29; 1.76) compared to women (HR 1.24, 95% CI 1.05; 1.46), but this difference was not 
statistically significant (p-value 0.21). Associations were found for both ischemic and 
hemorrhagic stroke. Associations with TIA were only present in women (HR 1.51, 95% CI 1.26; 
1.82) and not in men (HR 1.02, 95% CI 0.83; 1.26), which was a statistically significant interaction 
(p<0.01) (Table 2). With NT-proBNP levels in tertiles we also found associations with stroke in 
men and women and with TIA only in women (Table 3, Figure 1). Without censoring for TIA, 
the effect size for stroke in women was higher (HR 1.36, 95% CI 1.16; 1.59) (Table 4).  
Associations with hemorrhagic stroke and mixed TIA attenuated after excluding 
participants with a history of heart disease and censoring at time of incident heart disease 
(Table 5). Other associations remained similar. Ending the study follow-up in 2008 did not 
change the lack of an effect of preceding heart disease n the associations (data not shown). 
Associations were slightly weaker in persons that used either anticoagulant or antiplatelet 
drugs (Supplementary Table I). 
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Chapter 2.2 
0 
NT-proBNP measurement 
Blood samples for NT-proBNP assessment were collected in glass tubes containing clot 
activator and gel for serum separation and stored at -80ºC. NT-proBNP was measured using a 
commercially available electrochemiluminescence immunoassay (Elecsys proBNP, F Hoffman-
La Roche Ltd) on an Elecsys 2010 analyzer.6 Precision, analytic sensitivity, and sta ility of the 
system have been described.19  
 
Assessment of cerebrovascular events. 
At study entry, history of stroke and TIA was assessed using home interviews and confirmed by 
reviewing medical records. Subsequently, participants were continuously followed-up for 
stroke and TIA through digital linkage of general practitioners’ files with the study database. 
Furthermore, nursing home physicians’ files and files from general practitioners of participants 
who moved out of the district were checked on a regular basis.20 Of all potential strokes and 
TIAs, hospital discharge letters and information from general practitioner was collected. 
Research physicians reviewed the information and an experienced neurologist verified the 
strokes and TIAs.21,22 Strokes were further classified into ischemic or hemorrhagic based on 
neuroimaging reports. Subarachnoid hemorrhages were excluded. Infarcts that turned 
hemorrhagic were classified as ischemic stroke. If neuroimaging was lacking, a stroke was 
classified as unspecified. TIAs were further classified into focal or mixed. An event was focal if 
only symptoms attributable to dysfunction of one arterial territory of the brain were reported. 
An event was classified as mixed if diffuse nonlocalizing cerebral symptoms were reported as 
well.22 Purely nonfocal events were not analyzed as they are currently not included in the 
internationally used definition of TIA.23 Follow-up was complete until January 1st, 2012 for 95.6% 
of potential person-years.  
 
Covariates 
Details on assessment of anthropometrics, cardiovascular risk factors (blood pressure, total 
cholesterol, high-density cholesterol, creatinine, diabetes mellitus, and smoking), and use of 
medication have been described previously.4 Within the heart disease definition we included: 
heart failure, coronary heart disease (defined as myocardial infarction or coronary 
revascularization procedure), and atrial fibrillation. Heart diseases were assessed through active 
follow-up and adjudicated using standardized definitions similar to the follow-up for stroke 
and TIA.20  
 
Statistical analyses 
NT-proBNP was natural log-transformed and entered per standard deviation (SD) increase into 
Cox proportional hazards models. Hazard ratios (HR) were also calculated for sex-specific 
tertiles of NT-proBNP. We examined the association of NT-proBNP with any cerebrovascular 
event (stroke or TIA), and with stroke or TIA separately, censoring follow-up at the date of the 
other event if that occurred first. Thus, participants were censored at date of stroke, date of TIA, 
date of death, last date of follow-up, or January 1st, 2012, whichever came first. All models were 
adjusted for age and were stratified by sex to allow for sex-specific effects. Interaction terms 
N-terminal pro-B-type natriuretic peptide and the risk of stroke and transient ischaemic attack 
41 
were tested to identify significant differences between men and women. In multivariate 
adjusted models, we additionally adjusted for cardiovascular risk factors, and blood pressure-
lowering, lipid-lowering, and antithrombotic (including antiplatelet and anticoagulant) drugs. 
Missing data on covariates (for all covariates 4.6% or less) were imputed based on the other 
covariates using multiple imputation with 5 imputation sets.  
In sensitivity analyses, we investigated associations between NT-proBNP and stroke 
without censoring for TIA, we stratified for antiplatelet and anticoagulant drug use, and we 
investigated associations between NT-proBNP and stroke and TIA after additionally excluding 
participants with a history of atrial fibrillation or coronary heart disease at baseline and 
censoring for incident atrial fibrillation, coronary heart disease, and heart failure during follow-
up. Follow-up for atrial fibrillation and heart failure was available until 2008 and 2010, 
respectively. Therefore we did a final sensitivity analysis for stroke and TIA with follow-up 
ending in 2008.  
All a alyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
In table 1 the baseline characteristics of the study population are presented. A total of 2374 
men and 3237 women was eligible for analysis. Mean age (±SD) was 67.9 (±7.5) years in men 
and 69.2 (±8.4) years in women. After a mean follow-up of 9.3 (±3.4) years the first presentation 
of a cerebrovascular event was stroke in 195 men and TIA i  118 men. After a mean follow-up 
of 9.8 (±3.3) years the first presentation of a cerebrovascular event was stroke in 230 women 
and TIA in 187 women. 
In Table 2 associations between NT-proBNP levels and cerebrovascular events are 
presented. The risk of any cerebrovascular event was similar in men and women, multivariate 
adjusted HR per SD increase in NT-proBNP in men 1.31 (95% confid nce interval (CI) 1.15; 1.48) 
and in women 1.36 (95% CI 1.20; 1.53). Associations with stroke were stronger in men (HR 1.50, 
95% CI 1.29; 1.76) compared to women (HR 1.24, 95% CI 1.05; 1.46), ut this difference was not 
st tistically significant (p-value 0.21). Associations were found for both ischemic and 
hemorrhagic stroke. Associations with TIA were only present in women (HR 1.51, 95% CI 1.26; 
1.82) and not in men (HR 1.02, 95% CI 0.83; 1.26), which was a s atistically significant interaction 
(p<0.01) (Table 2). With NT-proBNP levels in tertiles we also found associations with stroke in 
men and women and with TIA only in women (Table 3, Figure 1). Without censoring for TIA, 
the effect size for stroke in women was higher (HR 1.36, 95% CI 1.16; 1.59) (Table 4).  
Associations with hemorrhagic stroke and mixed TIA attenuated after excluding 
participants with a history of heart disease and censoring at time of incident heart disease 
(Table 5). Other associations remained similar. Ending the study follow-up in 2008 did not 
change the lack of an effect of preceding heart disease o  the associations (data not shown). 
Associations were slightly weaker in persons that used either anticoagulant or antiplatelet 
drugs (Supplementary Table I). 
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NT-proBNP measurement 
Blood samples for NT-proBNP assessment were collected in glass tubes containing clot 
activator and gel for serum separation and stored at -80ºC. NT-proBNP was measured using a 
commercially available electrochemiluminescence immunoassay (Elecsys proBNP, F Hoffman-
La Roche Ltd) on an Elecsys 2010 analyzer.6 Precision, analytic sensitivity, and sta ility of the 
system have been described.19  
 
Assessment of cerebrovascular events. 
At study entry, history of stroke and TIA was assessed using home interviews and confirmed by 
reviewing medical records. Subsequently, participants were continuously followed-up for 
stroke and TIA through digital linkage of general practitioners’ files with the study database. 
Furthermore, nursing home physicians’ files and files from general practitioners of participants 
who moved out of the district were checked on a regular basis.20 Of all potential strokes and 
TIAs, hospital discharge letters and information from general practitioner was collected. 
Research physicians reviewed the information and an experienced neurologist verified the 
strokes and TIAs.21,22 Strokes were further classified into ischemic or hemorrhagic based on 
neuroimaging reports. Subarachnoid hemorrhages were excluded. Infarcts that turned 
hemorrhagic were classified as ischemic stroke. If neuroimaging was lacking, a stroke was 
classified as unspecified. TIAs were further classified into focal or mixed. An event was focal if 
only symptoms attributable to dysfunction of one arterial territory of the brain were reported. 
An event was classified as mixed if diffuse nonlocalizing cerebral symptoms were reported as 
well.22 Purely nonfocal events were not analyzed as they are currently not included in the 
internationally used definition of TIA.23 Follow-up was complete until January 1st, 2012 for 95.6% 
of potential person-years.  
 
Covariates 
Details on assessment of anthropometrics, cardiovascular risk factors (blood pressure, total 
cholesterol, high-density cholesterol, creatinine, diabetes mellitus, and smoking), and use of 
medication have been described previously.4 Within the heart disease definition we included: 
heart failure, coronary heart disease (defined as myocardial infarction or coronary 
revascularization procedure), and atrial fibrillation. Heart diseases were assessed through active 
follow-up and adjudicated using standardized definitions similar to the follow-up for stroke 
and TIA.20  
 
Statistical analyses 
NT-proBNP was natural log-transformed and entered per standard deviation (SD) increase into 
Cox proportional hazards models. Hazard ratios (HR) were also calculated for sex-specific 
tertiles of NT-proBNP. We examined the association of NT-proBNP with any cerebrovascular 
event (stroke or TIA), and with stroke or TIA separately, censoring follow-up at the date of the 
other event if that occurred first. Thus, participants were censored at date of stroke, date of TIA, 
date of death, last date of follow-up, or January 1st, 2012, whichever came first. All models were 
adjusted for age and were stratified by sex to allow for sex-specific effects. Interaction terms 
N-terminal pro-B-type natriuretic peptide and the risk of stroke and transient ischaemic attack 
1 
were tested to identify significant differences between men and women. In multivariate 
adjusted models, we additionally adjusted for cardiovascular risk factors, and blood pressure-
lowering, lipid-lowering, and antithrombotic (including antiplatelet and anticoagulant) drugs. 
Missing data on covariates (for all covariates 4.6% or less) were imputed based on the other 
covariates using multiple imputation with 5 imputation sets.  
In sensitivity analyses, we investigated associations between NT-proBNP and stroke 
without censoring for TIA, we stratified for antiplatelet and anticoagulant drug use, and we 
investigated associations between NT-proBNP and stroke and TIA after additionally excluding 
participants with a history of atrial fibrillation or coronary heart disease at baseline and 
censoring for incident atrial fibrillation, coronary heart disease, and heart failure during follow-
up. Follow-up for atrial fibrillation and heart failure was available until 2008 and 2010, 
respectively. Therefore we did a final sensitivity analysis for stroke and TIA with follow-up 
ending in 2008.  
All a alyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
In table 1 the baseline characteristics of the study population are presented. A total of 2374 
men and 3237 women was eligible for analysis. Mean age (±SD) was 67.9 (±7.5) years in men 
and 69.2 (±8.4) years in women. After a mean follow-up of 9.3 (±3.4) years the first presentation 
of a cerebrovascular event was stroke in 195 men and TIA i  118 men. After a mean follow-up 
of 9.8 (±3.3) years the first presentation of a cerebrovascular event was stroke in 230 women 
and TIA in 187 women. 
In Table 2 associations between NT-proBNP levels and cerebrovascular events are 
presented. The risk of any cerebrovascular event was similar in men and women, multivariate 
adjusted HR per SD increase in NT-proBNP in men 1.31 (95% confid nce interval (CI) 1.15; 1.48) 
and in women 1.36 (95% CI 1.20; 1.53). Associations with stroke were stronger in men (HR 1.50, 
95% CI 1.29; 1.76) compared to women (HR 1.24, 95% CI 1.05; 1.46), ut this difference was not 
st tistically significant (p-value 0.21). Associations were found for both ischemic and 
hemorrhagic stroke. Associations with TIA were only present in women (HR 1.51, 95% CI 1.26; 
1.82) and not in men (HR 1.02, 95% CI 0.83; 1.26), which was a s atistically significant interaction 
(p<0.01) (Table 2). With NT-proBNP levels in tertiles we also found associations with stroke in 
men and women and with TIA only in women (Table 3, Figure 1). Without censoring for TIA, 
the effect size for stroke in women was higher (HR 1.36, 95% CI 1.16; 1.59) (Table 4).  
Associations with hemorrhagic stroke and mixed TIA attenuated after excluding 
participants with a history of heart disease and censoring at time of incident heart disease 
(Table 5). Other associations remained similar. Ending the study follow-up in 2008 did not 
change the lack of an effect of preceding heart disease o  the associations (data not shown). 
Associations were slightly weaker in persons that used either anticoagulant or antiplatelet 
drugs (Supplementary Table I). 
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NT-proBNP measurement 
Blood samples for NT-proBNP assessment were collected in glass tubes containing clot 
activator and gel for serum separation and stored at -80ºC. NT-proBNP was measured using a 
commercially available electrochemiluminescence immunoassay (Elecsys proBNP, F Hoffman-
La Roche Ltd) on an Elecsys 2010 analyz r.6 Precision, analytic sensitivity, and stability of the 
system have been described.19  
 
Assessment of cerebrovascular events. 
At study entry, history of stroke and TIA was assessed using home interviews and confirmed by 
reviewing medical records. Subsequently, participants were continuously followed-up for 
stroke and TIA through digital linkage of general practitioners’ files with the study database. 
Furthermore, nursing home physicians’ files and files from general practitioners of participants 
who moved out of the district were checked on a regular basis.20 Of all potential strokes and 
TIAs, hospital discharge letters and information from general practitioner was collected. 
Research physicians reviewed the information and an experienced neurologist verified the 
strokes and TIAs.21,22 Strokes were further classified into ischemic or hemorrhagic based on 
neuroimaging reports. Subarachnoid hemorrhages were excluded. Infarcts that turned 
hemorrhagic were classified as ischemic stroke. If neuroimaging was lacking, a stroke was 
classified as unspecified. TIAs were further classified into focal or mixed. An event was focal if 
only symptoms attributable to dysfunction of one arterial territory of the brain were reported. 
An event was classified as mixed if diffuse nonlocalizing cerebral symptoms were reported as 
well.22 Purely nonfocal events were not analyzed as they are currently not included in the 
internationally used definition of TIA.23 Follow-up was complete until January 1st, 2012 for 95.6% 
of potential person-years.  
 
Covariates 
Details on assessment of anthropometrics, cardiovascular risk factors (blood pressure, total 
cholesterol, high-density cholesterol, creatinine, diabetes mellitus, and smoking), and use of 
medication have been described previously.4 Within the heart disease definition we included: 
heart failure, coronary heart disease (defined as myocardial infarction or coronary 
revascularization procedure), and atrial fibrillation. Heart diseases were assessed through active 
follow-up and adjudicated using standardized definitions similar to the follow-up for stroke 
and TIA.20  
 
Statistical analyses 
NT-proBNP was natural log-transformed and entered per standard deviation (SD) increase into 
Cox proportional hazards models. Hazard ratios (HR) were also calculated for sex-specific 
tertiles of NT-proBNP. We examined the association of NT-proBNP with any cerebrovascular 
event (stroke or TIA), and with stroke or TIA separately, censoring follow-up at the date of the 
other event if that occurred first. Thus, participants were censored at date of stroke, date of TIA, 
date of death, last date of follow-up, or January 1st, 2012, whichever came first. All models were 
adjust d for age and were stratified by sex to allow for sex-specific effects. Interaction terms 
N-terminal pro-B-type natriuretic peptide and the risk of stroke and transient ischaemic attack 
41 
were tested to identify significant differences between men and women. In multivariate 
adjusted models, we additionally adjusted for cardiovascular risk factors, and blood pressure-
lowering, lipid-lowering, and antithrombotic (including antiplatelet and anticoagulant) drugs. 
Missing data on covariates (for all covariates 4.6% or less) were imputed based on the other 
covariates using multiple imputation with 5 imputation sets.  
In sensitivity analyses, we investigated associations between NT-proBNP and stroke 
without censoring for TIA, we stratified for antiplatelet and anticoagulant drug use, and we 
investigate  associations between NT-proBNP and stroke and TIA after additionally excluding 
participants with a history of atrial fibrillation or coronary heart disease at baseline and 
censoring for incident atrial fibrillation, coronary heart disease, and heart failure during follow-
up. Follow-up for atrial fibrillation and heart failure was available until 2008 and 2010, 
respectively. Therefore we did a final sensitivity analysis for stroke and TIA with follow-up 
ending in 2008.  
All analyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
In table 1 the baseline characteristics of the study population are presented. A total of 2374 
men and 3237 women was eligible for analysis. Mean age (±SD) was 67.9 (±7.5) years in men 
and 69.2 (±8.4) years in women. After a mean follow-up of 9.3 (±3.4) years the first presentation 
of a cerebrovascular event was stroke in 195 men an  TIA in 118 men. After a mean follow-up 
of 9.8 (±3.3) years the first presentation of a cerebrovascular event was stroke in 230 women 
and TIA in 187 women. 
In Table 2 associations between NT-proBNP levels and cerebrovascular events are 
presented. The risk of any cerebrovascular event was similar in men and women, multivariate 
adjusted HR per SD increase in NT-proBNP in men 1.31 (95% confidence interval (CI) 1.15; 1.48) 
and in women 1.36 (95% CI 1.20; 1.53). Associations with stroke were stronger in men (HR 1.50, 
95% CI 1.29; 1.76) compared to women (HR 1.24, 95% CI 1.05; 1.46), but this difference was not 
statistically significant (p-value 0.21). Associations were found for both ischemic and 
hemorrhagic stroke. Associations with TIA were only present in women (HR 1.51, 95% CI 1.26; 
1.82) and not in men (HR 1.02, 95% CI 0.83; 1.26), which was a statistically significant interaction 
(p<0.01) (Table 2). With NT-proBNP levels in tertiles we also found associations with stroke in 
men and women and with TIA only in women (Table 3, Figure 1). Without censoring for TIA, 
the effect size for stroke in women was higher (HR 1.36, 95% CI 1.16; 1.59) (Table 4).  
Associations with hemorrhagic stroke and mixed TIA attenuated after excluding 
participants with a history of heart disease and censoring at time of incident heart disease 
(Table 5). Other associations remained similar. Ending the study follow-up in 2008 did not 
change the lack of an effect of preceding heart disease n the associations (data not shown). 
Associations were slightly weaker in persons that used either anticoagulant or antiplatelet 
drugs (Supplementary Table I). 
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NT-proBNP measurement 
Blood samples for NT-proBNP assessment were collected in glass tubes containing clot 
activator and gel for serum separation and stored at -80ºC. NT-proBNP was measured using a 
commercially available electrochemiluminescence immunoassay (Elecsys proBNP, F Hoffman-
La Roche Ltd) on an Elecsys 2010 analyz r.6 Precision, analytic sensitivity, and stability of the 
system have been described.19  
 
Assessment of cerebrovascular events. 
At study entry, history of stroke and TIA was assessed using home interviews and confirmed by 
reviewing medical records. Subsequently, participants were continuously followed-up for 
stroke and TIA through digital linkage of general practitioners’ files with the study database. 
Furthermore, nursing home physicians’ files and files from general practitioners of participants 
who moved out of the district were checked on a regular basis.20 Of all potential strokes and 
TIAs, hospital discharge letters and information from general practitioner was collected. 
Research physicians reviewed the information and an experienced neurologist verified the 
strokes and TIAs.21,22 Strokes were further classified into ischemic or hemorrhagic based on 
neuroimaging reports. Subarachnoid hemorrhages were excluded. Infarcts that turned 
hemorrhagic were classified as ischemic stroke. If neuroimaging was lacking, a stroke was 
classified as unspecified. TIAs were further classified into focal or mixed. An event was focal if 
only symptoms attributable to dysfunction of one arterial territory of the brain were reported. 
An event was classified as mixed if diffuse nonlocalizing cerebral symptoms were reported as 
well.22 Purely nonfocal events were not analyzed as they are currently not included in the 
internationally used definition of TIA.23 Follow-up was complete until January 1st, 2012 for 95.6% 
of potential person-years.  
 
Covariates 
Details on assessment of anthropometrics, cardiovascular risk factors (blood pressure, total 
cholesterol, high-density cholesterol, creatinine, diabetes mellitus, and smoking), and use of 
medication have been described previously.4 Within the heart disease definition we included: 
heart failure, coronary heart disease (defined as myocardial infarction or coronary 
revascularization procedure), and atrial fibrillation. Heart diseases were assessed through active 
follow-up and adjudicated using standardized definitions similar to the follow-up for stroke 
and TIA.20  
 
Statistical analyses 
NT-proBNP was natural log-transformed and entered per standard deviation (SD) increase into 
Cox proportional hazards models. Hazard ratios (HR) were also calculated for sex-specific 
tertiles of NT-proBNP. We examined the association of NT-proBNP with any cerebrovascular 
event (stroke or TIA), and with stroke or TIA separately, censoring follow-up at the date of the 
other event if that occurred first. Thus, participants were censored at date of stroke, date of TIA, 
date of death, last date of follow-up, or January 1st, 2012, whichever came first. All models were 
adjust d for age and were stratified by sex to allow for sex-specific effects. Interaction terms 
N-terminal pro-B-type natriuretic peptide and the risk of stroke and transient ischaemic attack 
1 
were tested to identify significant differences between men and women. In multivariate 
adjusted models, we additionally adjusted for cardiovascular risk factors, and blood pressure-
lowering, lipid-lowering, and antithrombotic (including antiplatelet and anticoagulant) drugs. 
Missing data on covariates (for all covariates 4.6% or less) were imputed based on the other 
covariates using multiple imputation with 5 imputation sets.  
In sensitivity analyses, we investigated associations between NT-proBNP and stroke 
without censoring for TIA, we stratified for antiplatelet and anticoagulant drug use, and we 
investigate  associations between NT-proBNP and stroke and TIA after additionally excluding 
participants with a history of atrial fibrillation or coronary heart disease at baseline and 
censoring for incident atrial fibrillation, coronary heart disease, and heart failure during follow-
up. Follow-up for atrial fibrillation and heart failure was available until 2008 and 2010, 
respectively. Therefore we did a final sensitivity analysis for stroke and TIA with follow-up 
ending in 2008.  
All analyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
In table 1 the baseline characteristics of the study population are presented. A total of 2374 
men and 3237 women was eligible for analysis. Mean age (±SD) was 67.9 (±7.5) years in men 
and 69.2 (±8.4) years in women. After a mean follow-up of 9.3 (±3.4) years the first presentation 
of a cerebrovascular event was stroke in 195 men an  TIA in 118 men. After a mean follow-up 
of 9.8 (±3.3) years the first presentation of a cerebrovascular event was stroke in 230 women 
and TIA in 187 women. 
In Table 2 associations between NT-proBNP levels and cerebrovascular events are 
presented. The risk of any cerebrovascular event was similar in men and women, multivariate 
adjusted HR per SD increase in NT-proBNP in men 1.31 (95% confidence interval (CI) 1.15; 1.48) 
and in women 1.36 (95% CI 1.20; 1.53). Associations with stroke were stronger in men (HR 1.50, 
95% CI 1.29; 1.76) compared to women (HR 1.24, 95% CI 1.05; 1.46), but this difference was not 
statistically significant (p-value 0.21). Associations were found for both ischemic and 
hemorrhagic stroke. Associations with TIA were only present in women (HR 1.51, 95% CI 1.26; 
1.82) and not in men (HR 1.02, 95% CI 0.83; 1.26), which was a statistically significant interaction 
(p<0.01) (Table 2). With NT-proBNP levels in tertiles we also found associations with stroke in 
men and women and with TIA only in women (Table 3, Figure 1). Without censoring for TIA, 
the effect size for stroke in women was higher (HR 1.36, 95% CI 1.16; 1.59) (Table 4).  
Associations with hemorrhagic stroke and mixed TIA attenuated after excluding 
participants with a history of heart disease and censoring at time of incident heart disease 
(Table 5). Other associations remained similar. Ending the study follow-up in 2008 did not 
change the lack of an effect of preceding heart disease n the associations (data not shown). 
Associations were slightly weaker in persons that used either anticoagulant or antiplatelet 
drugs (Supplementary Table I). 
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Discussion 
 
We found that higher levels of NT-proBNP were associated with a higher risk of 
cerebrovascular events. Associations with stroke were present for both men and women, 
whereas associations with TIA were only present in women. Associations were 
independent of clinical heart disease preceding cerebrovascular disease. 
Several other population-based studies have shown that an increased NT-proBNP level 
is related to a higher risk of cerebrovascular events.3,6-10 However, these studies did not 
exclude all participants with history of heart disease or account for the occurrence of heart 
disease during follow-up. One study adjusted for the presence of coronary heart disease, 
heart failure, and atrial fibrillation and found that the association remained unchanged.7 
This was consistent with our finding that associations were independent of clinical heart 
disease preceding the cerebrovascular disease, suggesting that a higher NT-proBNP as 
marker of subclinical heart disease is associated with a higher risk of cerebrovascular 
events. Subclinical heart disease might cause TIA or ischemic stroke through intracardiac 
thrombus formation, the most important reason for stroke in persons with overt heart 
disease.11-13 Another potential mechanism is that TIA or ischemic stroke in persons with an 
increased NT-proBNP is caused by paroxysmal atrial fibrillation which is not picked up by 
diagnostic electrocardiograms.24 Associations with hemorrhagic stroke might be the 
consequence of antithrombotic drug use. Furthermore, the associations with any 
cerebrovascular event might reflect the shared effect of cardiovascular risk factors on NT-
proBNP and cerebrovascular events, although after adjusting for cardiovascular risk factors 
the associations were similar. Still, residual confounding cannot be excluded.  
Previous studies found that the effect of NT-proBNP on cerebrovascular disease was 
similar for men and women.3,6-10 However, those studies did not examine associations with 
only TIA or with stroke independent from TIA. We found that a higher NT-proBNP led to a 
higher risk of TIA in women, whereas in men there was only a higher risk of stroke. This 
suggests that subclinical heart disease, indicated by a higher NT-proBNP, leads to a 
cerebrovascular event that at its first presentation is already more severe in men than in 
women. A reason might be that men have more atherosclerosis25 and therefore an 
additional thrombus from the heart possibly has a greater impact. Women might also 
recover better after a cerebrovascular event caused by subclinical heart disease and 
therefore suffer a TIA instead of a stroke. Furthermore, this might be an indication of 
diagnostic bias, a similar event might be reported as a stroke more often in men and in 
women more often as a TIA. This might happen if men are more likely to have an MRI 
compared to women, because a short-lasting event is more likely to be classified as a stroke 
if a relevant acute infarct is seen. Moreover, sex differences might have occurred by chance. 
Our findings have several implications for future research. The mechanism by which 
NT-proBNP relates to ischemic stroke, hemorrhagic stroke, and TIA needs to be elucidated 
further. As associations with focal TIA were different compared to mixed TIA, differences in 
etiology of those attacks should also be identified. Furthermore, NT-proBNP needs to be 
N-terminal pro-B-type natriuretic peptide and the risk of stroke and transient ischaemic attack 
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investigated for its predictive role in stroke, even in persons free of heart disease. In our 
study NT-proBNP was merely used as a marker for subclinical heart disease, but it might 
even be a target for therapy, as is shown in the PARADIGM HF trial.26 Additionally, studies 
should disentangle the exact role of antithrombotic medication in the associations of NT-
proBNP with cerebrovascular events. Finally, future research should confirm whether 
subclinical heart disease indeed is a more important cause of TIA in women compared to 
men and whether future strokes in women can be prevented with more attention towards 
subclinical heart disease after TIA.  
Strengths of this study are the population-based setting, the large study population 
and the thorough collection of events. A limitation is that follow-up for heart failure and 
atrial fibrillation was incomplete. Events in the last years of follow-up could therefore not 
be censored. However, also with shorter follow-up until 2008 censoring at time of incident 
heart disease did not attenuate the results. Another limitation is that we did not 
systematically measure valvular heart disease as potential confounding factor.12,27  
In conclusion, our results show that higher levels of NT-proBNP are associated with a 
higher risk of cerebrovascular events. For stroke this risk was present in men and women, 
for TIA only in women. These associations were independent of prevalent and incident 
heart disease during follow-up, suggesting that a high NT-proBNP as marker of subclinical 
heart disease leads to an increased risk of stroke in men and women and of TIA in women. 
   
2Chapter 2.2 
48 
Discussion 
 
We found that higher levels of NT-proBNP were associated with a higher risk of 
cerebrovascular events. Associations with stroke were present for both men and women, 
whereas associations with TIA were only present in women. Associations were 
independent of clinical heart disease preceding cerebrovascular disease. 
Several other population-based studies have shown that an increased NT-proBNP level 
is related to a higher risk of cerebrovascular events.3,6-10 However, these studies did not 
exclude all participants with history of heart disease or account for the occurrence of heart 
disease during follow-up. One study adjusted for the presence of coronary heart disease, 
heart failure, and atrial fibrillation and found that the association remained unchanged.7 
This was consistent with our finding that associations were independent of clinical heart 
disease preceding the cerebrovascular disease, suggesting that a higher NT-proBNP as 
marker of subclinical heart disease is associated with a higher risk of cerebrovascular 
events. Subclinical heart disease might cause TIA or ischemic stroke through intracardiac 
thrombus formation, the most important reason for stroke in persons with overt heart 
disease.11-13 Another potential mechanism is that TIA or ischemic stroke in persons with an 
increased NT-proBNP is caused by paroxysmal atrial fibrillation which is not picked up by 
diagnostic electrocardiograms.24 Associations with hemorrhagic stroke might be the 
consequence of antithrombotic drug use. Furthermore, the associations with any 
cerebrovascular event might reflect the shared effect of cardiovascular risk factors on NT-
proBNP and cerebrovascular events, although after adjusting for cardiovascular risk factors 
the associations were similar. Still, residual confounding cannot be excluded.  
Previous studies found that the effect of NT-proBNP on cerebrovascular disease was 
similar for men and women.3,6-10 However, those studies did not examine associations with 
only TIA or with stroke independent from TIA. We found that a higher NT-proBNP led to a 
higher risk of TIA in women, whereas in men there was only a higher risk of stroke. This 
suggests that subclinical heart disease, indicated by a higher NT-proBNP, leads to a 
cerebrovascular event that at its first presentation is already more severe in men than in 
women. A reason might be that men have more atherosclerosis25 and therefore an 
additional thrombus from the heart possibly has a greater impact. Women might also 
recover better after a cerebrovascular event caused by subclinical heart disease and 
therefore suffer a TIA instead of a stroke. Furthermore, this might be an indication of 
diagnostic bias, a similar event might be reported as a stroke more often in men and in 
women more often as a TIA. This might happen if men are more likely to have an MRI 
compared to women, because a short-lasting event is more likely to be classified as a stroke 
if a relevant acute infarct is seen. Moreover, sex differences might have occurred by chance. 
Our findings have several implications for future research. The mechanism by which 
NT-proBNP relates to ischemic stroke, hemorrhagic stroke, and TIA needs to be elucidated 
further. As associations with focal TIA were different compared to mixed TIA, differences in 
etiology of those attacks should also be identified. Furthermore, NT-proBNP needs to be 
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investigated for its predictive role in stroke, even in persons free of heart disease. In our 
study NT-proBNP was merely used as a marker for subclinical heart disease, but it might 
even be a target for therapy, as is shown in the PARADIGM HF trial.26 Additionally, studies 
should disentangle the exact role of antithrombotic medication in the associations of NT-
proBNP with cerebrovascular events. Finally, future research should confirm whether 
subclinical heart disease indeed is a more important cause of TIA in women compared to 
men and whether future strokes in women can be prevented with more attention towards 
subclinical heart disease after TIA.  
Strengths of this study are the population-based setting, the large study population 
and the thorough collection of events. A limitation is that follow-up for heart failure and 
atrial fibrillation was incomplete. Events in the last years of follow-up could therefore not 
be censored. However, also with shorter follow-up until 2008 censoring at time of incident 
heart disease did not attenuate the results. Another limitation is that we did not 
systematically measure valvular heart disease as potential confounding factor.12,27  
In conclusion, our results show that higher levels of NT-proBNP are associated with a 
higher risk of cerebrovascular events. For stroke this risk was present in men and women, 
for TIA only in women. These associations were independent of prevalent and incident 
heart disease during follow-up, suggesting that a high NT-proBNP as marker of subclinical 
heart disease leads to an increased risk of stroke in men and women and of TIA in women. 
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Abstract 
 
Background and purpose 
Intracranial atherosclerosis represents a relatively unexplored, but potentially important cause 
of stroke in whites. We investigated the relationship between intracranial carotid artery 
calcification (ICAC), as marker of intracranial atherosclerosis, and the risk of stroke in a white 
population. 
 
Methods 
Between 2003 and 2006, 2323 stroke-free persons from the general population (mean age: 69.5 
years) underwent computed tomography (CT) to quantify ICAC volume. All participants were 
continuously followed for the occurrence of stroke until January 1, 2012. We constructed Cox 
regression models to relate ICAC with the risk of stroke, adjusting for age and sex. Additionally, 
we adjusted for cardiovascular risk factors, ultrasound carotid plaque score, and CT-assessed 
calcification volume in the coronary arteries, aortic arch and carotid bifurcation. Finally, we 
calculated the proportion of stroke attributable to ICAC, using the population attributable risk 
(PAR).  
 
Results 
During 14,055 person years of follow-up, 91 participants had a stroke, of which 74 were 
ischemic. Larger ICAC volume was related to a higher risk of stroke, independent of 
cardiovascular risk factors, ultrasound carotid plaque score, and calcification in other vessels 
[fully adjusted hazard ratio (HR) per SD increase in ICAC volume: 1.43 (95% CI 1.04; 1.96)]. ICAC 
contributed to 75% of all strokes, whilst for aortic arch and extracranial carotid artery 
calcification this was only 45% and 25% respectively.  
 
Conclusions 
Our findings establish intracranial atherosclerosis as major risk factor for stroke in the general 
white population and suggest that its contribution to the proportion of all strokes may be 
greater than that of large-artery atherosclerosis in more proximal located vessel beds. 
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Introduction 
 
Stroke is the most frequent neurological disease, and the second most important cause of 
global mortality.1-3 The lifetime risk of stroke is estimated to be at least 1 in 6 and in the coming 
decades its burden is expected to increase even further.4,5 
Of all strokes, approximately 80% to 90% are of ischemic origin.2 Ischemic stroke has a 
multifactorial etiology involving various overlapping and interacting pathways, such as 
vascular disease, inflammation, hemostasis, metabolism, and genetic factors.2 Among these, 
vascular disease is by far the most important and has been the target of many preventive and 
therapeutic interventions for stroke.1,2 When studying vascular disease, it is important to 
consider that its burden may vary substantially across different vessel beds.6,7 As such, several 
locations of vascular disease are considered relevant in stroke etiology. First, cardiac diseases, 
such as coronary heart disease and atrial fibrillation, increase the risk of stroke.1,2,8 Second, large-
artery atherosclerosis is recognized as a major risk factor of stroke.2,9,10 Thirdly, strokes may occur 
after occlusion of the small penetrating intracerebral arteries, in so-called cerebral small vessel 
disease.1,2,9 It is important to note that these do not represent mutually exclusive categories, 
but that in most patients vascular pathology is present in multiple sites. 
Within this etiologic framework, large-artery atherosclerosis is considered to include all 
vessels from the aortic arch to the major cerebral arteries. Atherosclerosis of the intracranial 
vasculature is globally considered the most important risk factor for stroke.11 However, current 
numbers are solely driven by populations from Asian and African origin, which make up the 
largest proportion of strokes worldwide.11-14 In contrast, there are no data on the burden of 
stroke attributable to intracranial atherosclerosis in white populations. Yet surprisingly, most 
clinical trials targeting intracranial atherosclerosis include a majority of whites in their 
samples.15,16 There is now an emerging awareness that robust data from white populations on 
the role of intracranial atherosclerosis in ischemic stroke are urgently needed.11,17-19 These can 
then serve as basis for designing future intervention studies.  
Recently, using intracranial carotid artery calcification (ICAC) as proxy, we demonstrated a 
prevalence of intracranial atherosclerosis exceeding 80% in a general white population.20 In this 
report, we set out to investigate in a white population the longitudinal association of ICAC with 
incident stroke over a six year follow-up period. We were specifically interested in estimating 
the total burden of stroke attributable to ICAC in whites. 
 
Methods 
 
Setting 
This study is based on the Rotterdam Study, a prospective, population-based study 
investigating determinants of chronic diseases in the elderly.21 The original cohort consisted of 
7983 participants aged 55 years or older and was extended in 2000-2001 with 3011 persons. At 
study entry and every 3 to 4 years, all participants are re-examined in a dedicated research 
center. The Rotterdam Study represents a homogeneous middle-class population, largely of 
white descent (>96%). 
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For the current study, we used the visit between 2003 and 2006 as baseline, because only 
in this period we invited participants who visited the research center to undergo non-
enhanced computed tomography (CT) of the intracranial carotid arteries.7 We scanned 2524 
participants (response rate 78%). The follow-up for stroke takes place continuously and was 
complete until January 1, 2012. 
This study was approved by the institutional review board of Erasmus Medical Center, 
Rotterdam, the Netherlands. All participants gave informed consent. 
 
Assessment of intracranial atherosclerosis 
We used a 16-slice (n = 785) or 64-slice (n = 1739) multidetector CT-scanner (Somatom 
Sensation 16 or 64, Siemens, Forcheim, Germany) to perform non-enhanced CT-scanning. 
Using a cardiac scan and a scan that reached from the aortic arch to the intracranial vasculature 
(1 cm above the sella turcica), we scanned the following vessel beds: the coronary arteries, the 
aortic arch, the extracranial carotid arteries, and the intracranial carotid arteries. Detailed 
information regarding imaging parameters of both scans is provided elsewhere.7 
As proxy for intracranial atherosclerosis, we measured ICAC bilaterally in the intracranial 
internal carotid artery from its horizontal petrous segment to its top (until the circle of Willis) 
(Figure 1). For quantification of ICAC, we used a semi-automated scoring method which is 
described in detail elsewhere.20 Briefly, we manually drew regions of interest around 
calcification in the course of the intracranial internal carotid arteries in consecutive CT-slices. 
Next, we calculated calcification volumes by multiplying the number of pixels above 130 
Hounsfield Units with the pixel-size and the increment.  
 
 
Figure 1. Example of calcification of the intracranial internal carotid artery. 
The left image shows an axial CT slice in which the white rectangle marks the region of the internal carotid 
arteries. The four images on the right represent the course of the intracranial carotid artery from the petrous 
bone (lower image) to the top (upper image) with calcifications (in red). 
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Calcification volumes in the coronary arteries, aortic arch and extracranial internal carotid 
arteries were quantified using dedicated commercially available software (Syngo 
CalciumScoring, Siemens, Germany).7 All calcification volumes are expressed in mm3. 
Correlations between calcification across the four vessel beds ranged from 0.5 to 0.6.7,22 
 
Follow-up for Stroke 
The definition of stroke was based on the WHO criteria including a syndrome of rapidly 
developing symptoms of focal or global cerebral dysfunction lasting 24 hours or longer or 
leading to death, with apparent vascular cause.23,24 We assessed prevalent stroke at baseline 
during interview and verified these data with medical records.23 After enrolment, we 
continuously monitored participants for incident stroke through linkage of the study database 
with files from general practitioners. Nursing home physicians' files and files from general 
practitioners of participants who moved out of the district were also checked.23 Additional 
information was obtained from hospital records. Potential strokes were reviewed by research 
physicians and verified by an experienced stroke neurologist. We categorized strokes into 
ischemic or haemorrhagic on the basis of neuroimaging-reports. If neuroimaging was 
unavailable, the stroke was classified as unspecified.23 Subarachnoid haemorrhages due to 
ruptured aneurysms were not considered stroke events.23 Follow-up for incident stroke was 
complete until January 1, 2012. 
 
Other measurements in the Rotterdam Study 
We obtained information on cardiovascular risk factors by interview, physical examination and 
blood sampling.21 Obesity was defined as a body-mass index (BMI) ≥ 30 kg/m2. Hypertension 
was defined as a systolic blood pressure ≥ 140mmHg and/or a diastolic blood pressure ≥ 90 
mmHg and/or use of blood pressure-lowering medication.25 Diabetes was defined as fasting 
serum glucose levels ≥ 7.0 mmol/l and/or use of antidiabetic therapy.26 Hypercholesterolemia 
was defined as a serum total cholesterol ≥ 6.2 mmol/l and/or use of lipid-lowering 
medication.27 We defined low high-density lipoprotein (HDL)-cholesterol as HDL-cholesterol < 
1.0 mmol/l.27 Smoking was categorized into never or ever smoked.  
Besides these cardiovascular risk factors, we also assessed other imaging markers of 
atherosclerosis. These were atherosclerotic calcification volumes in the coronary arteries, aortic 
arch and extracranial carotid arteries (as detailed above), and ultrasound carotid plaquescore. 
Using ultrasound, we visualized the common carotid artery, carotid artery bifurcation, and 
internal carotid artery and examined both left and right to assess a weighted plaque score 
ranging from 0 to 6.28  
 
Population for analysis 
We restricted our population to persons from white descent, as assessed by self report (n = 
2452, from the 2524 that underwent CT). Due to image artefacts, 27 from the 2452 CT-
examinations were not gradable for ICAC, leaving a total of 2425 participants with complete 
data on ICAC volume. Persons with prevalent stroke (n = 98) and persons that did not 
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participate in the stroke follow-up (n = 4) were excluded, leaving 2323 participants at risk for 
stroke in the population for analysis.  
 
Statistical analysis 
Due to the non-normal distribution of ICAC volume, we performed a natural log-
transformation and added 1.0 mm3 to the non-transformed values to deal with calcium 
volumes of zero [Ln(ICAC + 1.0 mm3)]. We calculated hazard ratios (HR) for stroke per standard 
deviation (SD) increase in ICAC volume, using Cox regression models. The proportional hazards 
assumption was met. In model 1, we adjusted for age, sex, and scanner type. In model 2, we 
additionally adjusted for the following cardiovascular risk factors: obesity, hypertension, 
diabetes mellitus, hypercholesterolemia, low HDL-cholesterol, and smoking. In model 3, we 
additionally adjusted for the ultrasound carotid plaquescore and CT-assessed calcification 
volumes in the coronary arteries, aortic arch, and extracranial carotid artery.  
Next, we dichotomized ICAC into presence versus absence of ICAC and related that to the 
risk of stroke. In contrast to established categories for absolute coronary calcification scores, i.e. 
Agatston score,29 there are no such categories for ICAC. Therefore, we categorized calcification 
into present versus absent, because this is most readily identified in a clinical situation. We used 
the same three Cox-regression models as above, with the only difference that in model 3, 
calcification in other vessel beds was also dichotomized into present/absent. Stroke-free 
survival in the absence and presence of ICAC was estimated and compared using the Kaplan-
Meier method and log rank test. 
Finally, we calculated the population attributable risk (PAR) for stroke of calcification in each 
of the four vessel beds using the following formula:30 
%1001 x
RR
RRPDPAR 

 −
=  
In this formula, RR represents the relative risk, i.e. HR, which we calculated for the presence of 
calcification in each vessel bed. PD is the proportion of cases exposed to the risk factor (the 
presence of calcification). PAR provides a measure between 0 and 100%, which can be 
interpreted as the fraction of strokes that is due to calcification.30 IBM SPSS Statistics version 20 
(International Business Machines Corporation, Armonk, New York) was used for statistical 
analyses. 
 
Results 
 
Table 1 shows the baseline characteristics of the study population. Mean age was 69.5 years 
and 52.2% of the participants were female. During 14,055 person years of follow-up (mean 6.1 
years), 91 participants had a stroke, of which 74 were ischemic, 10 were haemorrhagic, and 7 
unspecified.  
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Table 1. Baseline characteristics of study participants 
 
Sample size 
N=2323 
Women 52.2% 
Age, years 69.5 (6.7) 
Obesity 23.7% 
Body Mass Index, kg/m2 27.7 (4.0) 
Hypertension 73.9% 
Systolic blood pressure, mmHg 146.7 (20.1) 
Diastolic blood pressure, mmHg 80.2 (10.8) 
Use of blood pressure-lowering medication 39.3% 
Diabetes 10.7% 
Serum glucose, mmol/L 5.7 (1.2) 
Use of antidiabetic medication 6.0% 
Hypercholesterolemia 48.9% 
Serum total cholesterol, mmol/L 5.7 (1.0) 
Use of lipid-lowering medication 23.2% 
Low HDL-cholesterol 10.6% 
Serum HDL-cholesterol, mmol/L 1.4 (0.4) 
Past or current smokers 67.5% 
Presence of intracranial carotid artery calcification 81.4% 
Intracranial carotid artery calcification volumea, mm3 41.1 (6.2 – 135.1) 
Abbreviations: HDL = high-density lipoprotein.  
Values are means (standard deviation) for continuous variables or percentages for dichotomous variables. 
aMedian (interquartile range) 
 
Table 2 shows the associations between ICAC and the risk of stroke. We found that larger 
ICAC volumes were associated with a higher risk of stroke. These results were similar for 
ischemic stroke. Additional adjustment for cardiovascular risk factors did not change any of 
these results [HR per SD increase in ICAC volume: 1.52 (95% CI 1.17; 1.98) for stroke, and 1.53 
(95% CI 1.14; 2.04) for ischemic stroke]. Also after additional adjustment for ultrasound carotid 
plaquescore and calcification volumes in the other vessel beds, we found that larger ICAC 
volumes remained significantly associated with a higher risk of stroke [HR per SD increase in 
ICAC volume: 1.43 (95% CI 1.04; 1.96)] The effect size for the association with ischemic stroke 
was similar, although statistically non-significant (Table 2, model 3, upper panel).  
We found that the presence of ICAC was associated with a higher risk of any stroke and 
ischemic stroke, even after adjustment for cardiovascular risk factors [HR for presence versus 
absence of ICAC: 4.15 (95% CI 1.51; 11.42) for stroke, and 3.43 (95% CI 1.24; 9.51) for ischemic 
stroke]. Additional adjustment for ultrasound carotid plaquescore and the presence of 
calcification in the other vessel beds also did not change these associations (Table 2, model 3, 
lower panel). Kaplan-Meier curves revealed that the stroke-free survival in persons with ICAC 
was significantly shorter than persons without ICAC (Figure 2).  
Table 3 shows the proportion of strokes that is attributable to calcification in each of the 
four vessel beds. We found that ICAC played a role in up to 75% of all strokes, whilst for aortic 
arch calcification and calcification in the extracranial carotid artery this was 45% and 25%, 
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Hypercholesterolemia 48.9% 
Serum total cholesterol, mmol/L 5.7 (1.0) 
Use of lipid-lowering medication 23.2% 
Low HDL-cholesterol 10.6% 
Serum HDL-cholesterol, mmol/L 1.4 (0.4) 
Past or current smokers 67.5% 
Presence of intracranial carotid artery calcification 81.4% 
Intracranial carotid artery calcification volumea, mm3 41.1 (6.2 – 135.1) 
Abbreviations: HDL = high-density lipoprotein.  
Values are means (standard deviation) for continuous variables or percentages for dichotomous variables. 
aMedian (interquartile range) 
 
Table 2 shows the associations between ICAC and the risk of stroke. We found that larger 
ICAC volumes were associated with a higher risk of stroke. These results were similar for 
ischemic stroke. Additional adjustment for cardiovascular risk factors did not change any of 
these results [HR per SD increase in ICAC volume: 1.52 (95% CI 1.17; 1.98) for stroke, and 1.53 
(95% CI 1.14; 2.04) for ischemic stroke]. Also after additional adjustment for ultrasound carotid 
plaquescore and calcification volumes in the other vessel beds, we found that larger ICAC 
volumes remained significantly associated with a higher risk of stroke [HR per SD increase in 
ICAC volume: 1.43 (95% CI 1.04; 1.96)] The effect size for the association with ischemic stroke 
was similar, although statistically non-significant (Table 2, model 3, upper panel).  
We found that the presence of ICAC was associated with a higher risk of any stroke and 
ischemic stroke, even after adjustment for cardiovascular risk factors [HR for presence versus 
absence of ICAC: 4.15 (95% CI 1.51; 11.42) for stroke, and 3.43 (95% CI 1.24; 9.51) for ischemic 
stroke]. Additional adjustment for ultrasound carotid plaquescore and the presence of 
calcification in the other vessel beds also did not change these associations (Table 2, model 3, 
lower panel). Kaplan-Meier curves revealed that the stroke-free survival in persons with ICAC 
was significantly shorter than persons without ICAC (Figure 2).  
Table 3 shows the proportion of strokes that is attributable to calcification in each of the 
four vessel beds. We found that ICAC played a role in up to 75% of all strokes, whilst for aortic 
arch calcification and calcification in the extracranial carotid artery this was 45% and 25%, 
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respectively. For coronary artery calcification we did not calculate the PAR for stroke, because 
the HR was below one. 
 
Table 2. Intracranial carotid artery calcification and the risk of stroke 
 Any stroke Ischemic stroke 
 
ICAC Characteristic 
n/N = 91/2323 
HR (95% CI) 
n/N = 74/2323 
HR (95% CI) 
Continuous, per 1-SD increase   
Model 1 1.53 (1.18; 1.97) 1.51 (1.14; 2.01) 
Model 2 1.52 (1.17; 1.98) 1.53 (1.14; 2.04) 
Model 3 1.43 (1.04; 1.96) 1.39 (0.98; 1.99) 
   
Dichotomous, presence vs absence   
Model 1 4.25 (1.55; 11.66) 3.49 (1.27; 9.64) 
Model 2 4.15 (1.51; 11.42) 3.43 (1.24; 9.51) 
Model 3 4.64 (1.44; 14.95) 3.52 (1.08; 11.47) 
Abbreviations: n = number of cases; N = number of persons at risk; HR = hazard ratio; CI = confidence interval; 
ICAC = intracranial carotid artery calcification; SD = standard deviation. 
Model 1: Adjusted for age, sex, and scanner type. 
Model 2: Adjusted for age, sex, scanner type, obesity, hypertension, diabetes mellitus, hypercholesterolemia, low 
HDL-cholesterol, and smoking. 
Model 3: Adjusted for age, sex, scanner type, obesity, hypertension, diabetes mellitus, hypercholesterolemia, low 
HDL-cholesterol, smoking, ultrasound carotid plaque score, and calcification in the coronary arteries, the aortic 
arch and the carotid bifurcation (as appropriate; volume for continuous analyses, presence for dichotomous 
analyses). 
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Figure 2. Kaplan-Meier survival plot for stroke-free survival in persons with and without intracranial 
carotid artery calcification. 
Abbreviations: ICAC, intracranial carotid artery calcification; CT, computed tomography 
Kaplan-Meier survival curve for the stroke-free survival of persons with and without ICAC. The difference 
between the two groups was statistically significant (P < 0.001 by the log-rank test). 
ICAC absent: number of persons at risk = 431, number of cases = 4. 
ICAC present: number of persons at risk = 1892, number of cases = 87. 
 
 
Table 3. Population attributable risks for stroke per vessel bed 
 Proportion of stroke-cases 
exposed to calcification 
Any stroke 
HR (95% CI) 
PAR 
Presence of calcification in:    
Coronary arteries 0.87 0.80 (0.40;1.57) N.A.a 
Aortic arch 0.98 1.84 (0.44;7.77) 45% 
Extracranial carotid arteries 0.86 1.41 (0.71;2.83) 25% 
Intracranial carotid arteries 0.96 4.64 (1.44;14.95) 75% 
Abbreviations: HR, hazard ratio; CI, confidence interval; PAR, population attributable risk. 
Adjusted for age, sex, scanner type, obesity, hypertension, diabetes mellitus, hypercholesterolemia, low HDL-
cholesterol, smoking, presence of calcification in the other vessel beds, and for ultrasound carotid plaquescore.  
a The PAR for coronary artery calcification was not calculated because the HR is below one. 
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Discussion 
 
In this large population-based cohort study among middle-aged and elderly white persons we 
found that both presence and severity of ICAC were associated with a higher risk of stroke. This 
was independent of both conventional cardiovascular risk factors and atherosclerosis in other 
extracranial vessel beds. We also found that ICAC contributed to 75% of all strokes, whereas for 
aortic arch calcification and extracranial carotid artery calcification this was only 45% and 25%.  
With the current study we demonstrated that intracranial atherosclerosis is a major risk 
factor for stroke in a white population. Thus far, evidence for a role of intracranial atherosclerosis 
in the etiology of stroke mainly comes from research in populations from Asian and African 
descent.14,17,18 In these populations, intracranial atherosclerosis is an established major risk factor 
for ischemic stroke, accounting for up to 50% of all strokes.14,17  
We acknowledge that the total burden of intracranial atherosclerosis comprises 
atherosclerotic disease in more arteries than only the intracranial carotid arteries that we 
measured.14,18 However, atherosclerotic plaques in other cerebral arteries are typically non-
calcified.31,32 Visualisation of non-calcified atherosclerotic disease demands administration of 
intravenous contrast material which was not possible in our population-based setting. Yet, we 
note that autopsy studies have shown that specifically for the intracranial vasculature there is 
a strong correlation between the severity and extent of atherosclerosis across cerebral 
arteries.33,34 Therefore it is likely that if there is more ICAC, there are probably also more 
atherosclerotic changes in the distal cerebral vessels. In this light ICAC would be a marker of 
total intracranial atherosclerosis. On the other hand, there may also be a causal role of 
intracranial carotid artery calcification in stroke. Highly calcified vessels may in some instances 
have a stenotic lumen leading to hemodynamic disturbances.35,36 However, this association is 
complex due to remodeling (i.e. compensatory enlargement) of arteries.35,37 Also, large 
calcification volumes reflect large plaques, which may be a source of emboli. To further unravel 
these mechanisms and the putative causal role of intracranial carotid artery calcification, future 
studies should focus on classifying strokes systemically according to vascular territories. 
Using PAR, we estimated that intracranial atherosclerosis contributes to the occurrence of 
75% of all strokes. The PAR for stroke of intracranial atherosclerosis was notably larger than that 
of atherosclerosis in the aortic arch or carotid bifurcation. Theoretically, a PAR of 75% indicates 
that the incidence of stroke may be reduced by 75% if intracranial atherosclerosis could be 
completely eradicated. However, a few considerations should be noted for better 
interpretation of a PAR. First, this figure of 75% does not mean that only 25% of strokes remain 
to be explained by other causes than intracranial atherosclerosis.30 In fact, the sum of PARs for 
all possible risk factors of stroke exceeds 100%, reflecting interaction between risk factors. This 
also signifies that other unknown causes may still contribute considerably to the development 
of stroke. Nevertheless, the high PAR illustrates the large potential gain in public health that 
could be achieved by further developing therapeutic and preventive strategies aimed at 
reducing the amount of intracranial atherosclerosis. Possibly, earlier and more aggressive 
treatment of modifiable risk factors for intracranial atherosclerosis could stave off its formation 
and may thereby contribute to the primary prevention of stroke. A beneficial effect of 
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aggressive medical management on the occurrence of stroke has already been demonstrated 
in patients with symptomatic intracranial atherosclerotic stenosis.15 Second, although we 
adjusted for conventional cardiovascular risk factors, as well as for calcification in other vessel 
beds, the HR that we used may still be subject to residual confounding. If so, a more unbiased 
HR would have yielded an attenuation of the PAR. Still, the PAR of ICAC was highest among all 
studied vessel beds. 
In the current literature, a major focus is on coronary artery calcification as an emerging 
determinant for various cardiovascular events. Some studies have shown coronary artery 
calcification to even improve the risk prediction of stroke,8 but this remains debatable.38,39 In 
our dataset we found no association between coronary artery calcification and stroke when 
taking into account calcification in all vessel beds. In a post-hoc analysis, we found that 
coronary artery calcification was associated with stroke in a crude age and sex-adjusted model 
only. This further corroborates that ICAC is a more important determinant of stroke than 
coronary artery calcification. Future studies should thus also investigate the predictive value of 
ICAC for stroke. 
Strengths of our study include the population-based setting and the longitudinal design. 
Moreover, we used an accurate image-based method to quantify ICAC. We tried to minimize 
the number of persons that were lost to follow-up by using thorough stroke monitoring 
procedures. These allowed us to identify nearly all stroke events, including fatal strokes and 
strokes in participants living in nursing homes, who were not referred to a hospital. There are 
also several potential limitations that should be taken into account. First, by using non-
enhanced CT we were only able to measure calcification and not the complete atherosclerotic 
plaque. Although strong evidence from autopsy studies shows that CT-based calcification is a 
sensitive and reliable marker of the total underlying atherosclerotic burden,40,41 this might have 
led to misclassification in certain instances. Second, it was not possible to describe any 
additional plaque characteristics, for example shape, stenosis, or ulceration, which may all be 
of importance with regard to future events. Although a high correlation between CT-measured 
calcification and stenosis has been found in the carotid siphon,36,42 advances in plaque imaging 
with other imaging techniques, e.g. MRI, may aid to overcome this issue in the future.  
In conclusion, our findings suggest that intracranial atherosclerosis is a major risk factor for 
stroke in the general white population. Moreover its contribution to the proportion of all 
strokes may be greater than that of large-artery atherosclerosis in other vessel beds. 
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Abstract 
 
Background and Purpose 
Accumulating vascular pathology in cerebral arteries leads to impaired cerebral vasomotor 
reactivity. In turn, impaired cerebral vasomotor reactivity is a risk factor for stroke in clinical 
populations. It remains unclear whether impaired cerebral vasomotor reactivity also reflects 
more systemic vascular damage. We investigated whether cerebral vasomotor reactivity is 
associated with the risk of mortality, focusing particularly on cardiovascular mortality 
independent from stroke.  
 
Methods 
Between 1997-1999, 1695 participants from the Rotterdam Study underwent cerebral 
vasomotor reactivity measurements using transcranial Doppler. Follow-up was complete until 
January 1, 2011. We assessed the associations between cerebral vasomotor reactivity and 
mortality using Cox proportional hazards models, adjusting for age, sex, and blood pressure 
changes and subsequently for cardiovascular risk factors. We additionally censored for incident 
stroke.  
 
Results 
During 17,004 person-years 557 participants died, of whom 181 due to a cardiovascular cause. 
In the fully adjusted model, the hazard ratio per SD decrease in vasomotor reactivity was 1.10 
(95% CI 1.01; 1.19) for all-cause mortality, 1.09 (95% CI 0.94; 1.26) for cardiovascular mortality, 
and 1.10 (95% CI 0.99; 1.21) for non-cardiovascular mortality. These associations remained 
unchanged after censoring for incident stroke.  
 
Conclusions 
We found that lower cerebral vasomotor reactivity is associated with an increased risk of death. 
Incident stroke does not affect this association, suggesting that a lower cerebral vasomotor 
reactivity reflects a generally impaired vascular system. 
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Introduction 
 
Vascular diseases are the main cause of mortality worldwide and lead to considerable societal 
burden, both in terms of care and cost. The World Health Organization estimates that by 2030, 
more than 23 million people will die yearly from vascular diseases.1 Despite the acute clinical 
presentation, an important feature of vascular diseases is the long preclinical phase, during 
which various pathologies interact leading to accumulating vascular damage. These 
pathologies include atherosclerosis, arterial stiffening, inflammation, and endothelial damage.2-
6 In the brain, this pathologic process ultimately manifests itself as either ischemic or 
hemorrhagic stroke.7 
A cornerstone of preventive research has been to identify markers that reflect such 
preclinical vascular pathology and thus may predict shorter survival. For cerebrovascular 
damage, diminished vasomotor reactivity has been identified in recent years as a prognostic 
marker.8 Cerebral vasomotor reactivity reflects the ability of the cerebral arterioles to dilate in 
the event of hypercapnia to improve cerebral blood flow.9,10 Clinically, cerebral vasomotor 
reactivity can be measured using transcranial Doppler. In persons with vascular damage at the 
level of the arterioles, or less hemodynamic reserve as a consequence of vascular disease in 
larger vessels, this ability is significantly diminished.9,11 Most studies investigating vasomotor 
reactivity were in clinical populations of patients with carotid artery stenosis. In these studies 
impaired vasomotor reactivity was associated with an increased risk of stroke and TIA.8,12-17 
However, its role in the general community-dwelling population is less clear. Vasomotor 
reactivity has been measured within the population-based Rotterdam Study, but no 
association between vasomotor reactivity and stroke was found.18, 19 
Still, the question remains whether impaired cerebral vasomotor reactivity associates with 
poorer survival in a general elderly population. Specifically, it is unknown whether any such 
associations are driven by stroke, or whether cerebral vasomotor reactivity actually reflects 
more systemic vascular damage. Therefore, we investigated the association of cerebral 
vasomotor reactivity with all-cause mortality and cardiovascular mortality in a community-
dwelling elderly population. Furthermore, we studied whether any associations were 
independent of incident stroke.  
 
Materials and Methods 
 
Setting 
This study is part of the Rotterdam Study, a prospective population-based cohort study that 
started in 1990 among inhabitants of 55 years and older residing in Ommoord, a suburb of 
Rotterdam, the Netherlands. Of the 10,215 eligible inhabitants, 7983 agreed to participate in 
the baseline examinations. Up until 2013, there have been 4 follow-up examinations. Details of 
the study have been described elsewhere.20 The medical ethics committee at Erasmus 
University of Rotterdam approved the study and written informed consent was obtained from 
all participants. For the current study, the second follow-up examination from 1997-1999 was 
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used as baseline, because transcranial Doppler measurements were performed only at that 
visit.  
 
Transcranial Doppler assessment 
At the examination in 1997-1999, participants underwent transcranial Doppler 
ultrasonography (Multi-Dop X-4; DWL, Sipplingen, Germany). Vasomotor reactivity was 
measured as follows:18 the cerebral blood flow velocity was measured at the middle cerebral 
artery continuously. End diastolic, peak systolic, and mean cerebral blood flow velocities were 
recorded automatically. Mean blood flow velocity was calculated automatically as  
(1/3 * (peak systolic flow velocity + 2 * end diastolic flow velocity)).19 
Blood pressure was measured automatically (Dynamap, Datascope, The Netherlands) 
before and during the transcranial Doppler recordings. The participants first breathed room air 
through an anesthetic mask, tightly fit over mouth and nose, until a steady expiratory end tidal 
CO2 was obtained. One way valves were placed in the tubes for inspiration and expiration. End 
tidal CO2 pressure (kPa), measured in the exhaled air, was recorded continuously with a CO2 
analyzer (Multinex; Datascope, Hoevelaken, the Netherlands). End expiratory CO2 was assumed 
to reflect arterial CO2.21 Participants then inhaled a mixture of 5% carbon dioxide in 95% 
oxygen for 2 minutes. Vasomotor reactivity was defined as the percentage increase in mean 
cerebral blood flow velocity during inspiration of 5% CO2, divided by the absolute increase in 
end tidal CO2 in the same time period (%/kPa). TCD-8 DWL special software (VMR- CO2) was 
used. All transcranial Doppler data were stored on hard disk for offline analysis.  
 
Assessment of mortality 
Deaths were continuously reported through automatic linkage of general practitioner files. In 
addition, municipal records were checked bimonthly for information on vital status. 
Information about cause and circumstances of death was obtained from general practitioner 
and hospital records. Research physicians reviewed all available information and coded the 
events according to the International Classification of Diseases, 10th edition (ICD-10). If the 
cause of death was coded as I20-I25, I46, I50, I61, I63, I64, I66, I68-70, or R96, the cause of death 
was labeled as cardiovascular. A consensus panel, led by a physician with expertise in 
cardiovascular disease, adjudicated the final cause of death according to the ICD-10 codes 
using standardized definitions, as described in detail previously.22 The follow-up was complete 
until January 1, 2011, for 97.1% of potential person-years. 
 
Assessment of stroke 
At study entry, history of stroke was assessed using home interviews and confirmed by 
reviewing medical records. Once participants enter the Rotterdam Study, they are continuously 
followed-up for stroke through automatic linkage of general practitioner files with the study 
database. Also, nursing home physicians’ files and files from general practitioners of 
participants that moved out of the district were checked on a regular basis. Of the potential 
strokes, additional hospital and general practitioner information was collected. Research 
physicians reviewed the stroke information and an experienced neurologist adjudicated the 
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strokes using standardized definitions, as described in detail previously.23 The follow-up was 
complete until January 1, 2011, for 97.3% of potential person-years. 
 
Other measurements 
Covariates were measured during the same examination round as transcranial Doppler 
measurements were performed (1997-1999). Smoking status and medication use were 
assessed using a home interview. Smoking was classified into current smoking, former 
smoking, or never smoking. Diabetes mellitus was defined as having a fasting glucose level of 
7.0 mmol/L or higher or using blood glucose-lowering medication. Total cholesterol and HDL-
cholesterol levels were acquired by an automated enzymatic procedure. Blood pressure was 
measured at the research center twice in the sitting position on the right arm with a random-
zero sphygmomanometer. The average of the two measurements was used in the analyses. 
Blood pressure was also measured prior to and during the vasomotor reactivity measurements. 
We used the difference between these two measurements in the analyses since changes in 
blood pressure caused by CO2 inhalation can influence vasomotor reactivity measurements.24 
Prevalent vascular disease (myocardial infarction, CABG, PCI, heart failure, and peripheral arterial 
disease) was, except for peripheral arterial disease, assessed through active follow-up and 
adjudicated using standardized definitions, as described in detail previously.22 Peripheral 
arterial disease was assessed using the ankle-brachial index. Ankle-brachial index was assessed 
by computing the ratio of systolic blood pressure at the right and left ankle to the systolic blood 
pressure at the right arm. The lowest value was used in the analyses. Values of ankle-brachial 
index greater than 1.4 were excluded because high ankle-brachial index might represent a 
different underlying pathology. Peripheral arterial disease was defined as an ankle-brachial 
index of 0.9 or less.25 To measure carotid intima-media thickness (cIMT), ultrasonography of the 
left and right carotid arteries was performed with a 7.5-MHz linear array transducer (ATL 
UltraMark IV; Advanced Technology Laboratories, Bethel, Washington). The maximal cIMT, 
summarized as the mean of the maximal measurements from the near and far walls of both 
the left and right sides, was used for analysis.25,26  
 
Study population 
Of the 5990 participants that were alive in 1997-1999, 4797 persons participated in the 
examination used as baseline for this study. Of these, 4215 visited the study center. Due to lack 
of technical support, vasomotor reactivity measurements started later in the examination 
round (from July 1, 1997) and could only be offered to 2732 random participants. After 
excluding participants with prevalent stroke at time of transcranial Doppler assessment 
(n=100), 2632 participants were eligible for transcranial Doppler assessment. Of these, 937 
participants were excluded because of window failure on both sides (n=656), restlessness, 
anxiety, and discomfort (n=56), or missing data for other reasons (n=225). This left 1695 
participants eligible for the analysis of this study. Persons with a prevalent stroke (i.e. stroke 
before vasomotor reactivity measurement) have a higher probability of vascular damage of the 
middle cerebral artery where vasomotor reactivity was measured. Moreover, these persons are 
both at a higher risk of a recurrent stroke and at a higher risk of mortality compared to persons 
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without prevalent stroke. Including such persons with prevalent stroke into our analysis, even 
if they had a remote stroke, would therefore bias our results. 
 
Statistical analyses 
We investigated the associations of vasomotor reactivity with all-cause mortality, 
cardiovascular mortality, non-cardiovascular mortality, and stroke using Cox proportional 
hazards models. We used these models since we investigated time-to-event data. The 
underlying time-scale in these models was the follow-up time in years, which was complete 
until January 1, 2011. Participants were censored within this follow-up period at date of death, 
date of loss to follow-up, or January 1, 2011, whichever date came first. The proportional 
hazards assumption was met.  
Because of a right skewed distribution of vasomotor reactivity, we first performed a natural 
logarithmic transformation to obtain a roughly normal distribution of the data. Logarithmic 
transformed vasomotor reactivity was entered continuously per standard deviation (SD) 
decrease into the models, because a decrease reflects an impaired reactivity. We presented the 
results per standard deviation merely for a uniform representation of the data, this presentation 
was also used in the previous paper of Bos MJ et al.19 Furthermore, we studied vasomotor 
reactivity in quartiles taking the upper quartile as reference. All models were adjusted for age, 
sex, and blood pressure changes during vasomotor reactivity measurement. We adjusted 
subsequently for current smoking, former smoking, use of blood pressure-lowering 
medication, systolic blood pressure, diastolic blood pressure, diabetes mellitus, total 
cholesterol, HDL-cholesterol, use of statins, history of vascular disease, and carotid intima-
media thickness for being potential confounders. Missing data on covariates (8.4% or less) were 
imputed based on sex and age using linear regression models. 
To investigate whether vasomotor reactivity within ranges of normal was associated with 
mortality, we repeated the analysis after excluding participants with a vasomotor reactivity 
lower than 10%/kPa.15  
To assess the role of stroke on these associations, we related vasomotor reactivity to stroke 
as well as to mortality after censoring for stroke. We performed an additional analysis to 
investigate whether diminished vasomotor reactivity acts as intermediate between various 
cardiovascular risk factors and risk of mortality. We associated the various cardiovascular risk 
factors with mortality and investigated whether adjustment for vasomotor reactivity affected 
these associations. 
All analyses were done using the IBM SPSS statistics version 20.0 (IBM Corp, Armonk, NY, 
USA). 
 
Results 
 
Table 1 shows baseline characteristics of the study population. Non-participants were older 
and more often women compared to participants. Also, they smoked less, had a higher HDL-
cholesterol, a larger carotid intima-media thickness, had more often prevalent vascular disease, 
and used more often blood pressure-lowering medication and statins than participants. 
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The average follow-up duration for total mortality was 10.0 years, during which a total of 
557 of the 1695 participants died, of whom 181 due to a cardiovascular cause and 376 due to 
a non-cardiovascular cause. The most important cardiovascular causes of death were stroke 
(N=41), heart failure (N=39), cardiac arrest (N=29), other sudden death with unknown cause 
(N=24), and acute myocardial infarction (N=26). The most important non-cardiovascular causes 
of death were cancer (N=170, especially lung (N=45), colon (N=22), pancreas (N=15), and 
breast cancer (N=10)), and dementia (N=40). Of the non-participants, 457 of the 1037 
participants (44.1%) died. This difference was statistically significant compared to the number 
of deaths in the study population. 
A total of 168 participants suffered from a stroke of which 92 participants died, either due 
to the stroke or other causes. After censoring for stroke, a total of 465 participants died, 131 due 
to a cardiovascular cause and 334 due to a non-cardiovascular cause. The most important 
cardiovascular causes of death in this last group were heart failure (N=36), cardiac arrest (N=29), 
other sudden death with unknown cause (N=21), and acute myocardial infarction (N=24). 
Table 2 shows the hazard ratios of all-cause mortality. A lower vasomotor reactivity was 
associated with a higher risk of all-cause mortality (hazard ratio (HR) per SD decrease in 
vasomotor reactivity 1.12; 95% confidence interval (CI) 1.03; 1.21). These associations remained 
unchanged after additional adjustments (HR 1.10, 95% CI 1.01; 1.19). Also, persons in the lowest 
two quartiles had an increased risk of death compared to the upper quartile (Table 2). Figure 1 
shows the corresponding Kaplan-Meier curves for these associations. 
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Table 1. Baseline characteristics 
 Participants Non-participants 
 N=1695 N=1037 
Age, mean (SD), years 70.7 (6.3) 73.2 (6.8)b 
Follow-up time mortality, mean (SD), years 10.0 (3.0) 9.5 (3.3)b 
Female, No. (%) 785 (46.3) 760 (73.3)b 
Systolic blood pressure, mean (SD), mmHg 142.7 (20.8) 145.1 (21.4) 
Diastolic blood pressure, mean (SD), mmHg 75.9 (11.1) 75.2 (11.0) 
Blood pressure-lowering medication, No. (%) 384 (23.2) 293 (29.2)b 
Diabetes mellitus, No. (%) 158 (9.5) 111 (10.9) 
Former smoking, No. (%) 990 (58.8) 447 (43.5)b 
Current smoking, No. (%) 311 (18.5) 176 (17.1) 
Total cholesterol, mean (SD), mmol/L 5.81 (0.99) 5.85 (1.01) 
HDL-cholesterol, mean (SD), mmol/L 1.38 (0.38) 1.42 (0.39)b 
Statins, No. (%) 216 (12.9) 154 (15.1)b 
History of vascular disease, No. (%) 368 (23.3) 256 (27.1)b 
Carotid intima-media thickness, mean (SD), mm 1.06 (0.18) 1.09 (0.20)b 
Difference in systolic blood pressure before and during 
measurement, mean (SD), mmHg 
14.9 (13.8) NA 
Difference in diastolic blood pressure before and during 
measurement, mean (SD), mmHg 
5.7 (7.0) NA 
Vasomotor reactivity, median (IQR)a, %/kPa 39.3 (28.1 – 54.0) NA 
Abbreviations: HDL = high-density lipoprotein; NA = not available. 
Data are presented as mean (standard deviations) or No. (%) unless otherwise specified. Percentages are 
calculated without missing data. For all reported variables, missing numbers occurred in 8.4% or less of all 
participants.  
a Median (interquartile range) presented because of skewed distribution. 
b Significantly different (p<0.05) between participants and non-participants, after sex and age adjustment – if 
applicable. 
 
Associations between vasomotor reactivity and mortality were stronger for cardiovascular 
mortality (HR per SD decrease 1.15, 95% CI 1.00; 1.32), whilst the associations for non-
cardiovascular mortality were weaker (HR 1.10, 95% CI 1.00; 1.21) (Table 3). After additional 
adjustments, the association with cardiovascular mortality attenuated slightly and became 
statistically non-significant (HR 1.09, 95% CI 0.94; 1.26). Again, persons in the lowest two 
quartiles had an increased risk of death compared to the upper quartile (Table 2). However, we 
could not observe a clear dose-response relation between lower vasomotor reactivity and 
higher risk of cardiovascular mortality since quartile 2 showed a stronger association than 
quartile 1. 
After excluding participants with an impaired vasomotor reactivity (<10%/kPa), there were 
only minor changes in effect size (data not shown). 
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Table 2. Vasomotor reactivity and the risk of all-cause mortality 
 All-cause mortality 
  Model I Model II 
Vasomotor reactivitya n/N HR (95% CI) HR (95% CI) 
Quartile 1 182/423 1.40 (1.10; 1.80) 1.30 (1.01; 1.67) 
Quartile 2 154/424 1.36 (1.06; 1.74) 1.33 (1.03; 1.71) 
Quartile 3 117/424 1.04 (0.79; 1.35) 1.07 (0.82; 1.40) 
Quartile 4 104/424 1 (reference) 1 (reference) 
Per SD decrease 557/1695 1.12 (1.03; 1.21) 1.10 (1.01; 1.19) 
Abbreviations: n = number of deaths; N = number of persons at risk; HR = hazard ratio; CI = confidence interval; 
SD = standard deviation; HDL = high-density lipoprotein. 
Values are hazard ratios with 95% confidence intervals. 
The range of vasomotor reactivity for each quartile was as follows: quartile 1: 0–28.1 %/kPa, quartile 2: 28.1-39.3 
%/kPa, quartile 3: 39.3-54.0 %/kPa, quartile 4: 54.0-229.3 %/kPa. 
Model I: Adjusted for age, sex and difference in blood pressure before and during vasomotor reactivity 
measurement.  
Model II: Adjusted for age, sex, current smoking, former smoking, blood pressure-lowering medication, systolic 
blood pressure, diastolic blood pressure, diabetes mellitus, total cholesterol, HDL-cholesterol, statins, history of 
vascular disease, carotid intima-media thickness, and difference in blood pressure before and during vasomotor 
reactivity measurement. 
a Vasomotor reactivity was natural log transformed. 
 
 
Figure 1. Kaplan-Meier curve for crude survival per quartile of vasomotor reactivity 
Quartile 1 represents the lowest vasomotor reactivity, quartile 4 the highest. The range of vasomotor reactivity 
for each quartile was as follows: quartile 1: 0–28.1 %/kPa, quartile 2: 28.1-39.3 %/kPa, quartile 3: 39.3-54.0 
%/kPa, quartile 4: 54.0-229.3 %/kPa. 
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Table 4. Vasomotor reactivity and the risk of stroke 
 Stroke 
  Model I  Model II 
Vasomotor reactivitya n/N HR (95% CI)  HR (95% CI) 
Quartile 1 47/423 1.11 (0.72; 1.71)  1.10 (0.71; 1.70) 
Quartile 2 46/424 1.15 (0.75; 1.77)  1.15 (0.74; 1.77) 
Quartile 3 37/424 0.90 (0.57; 1.43)  0.92 (0.58; 1.45) 
Quartile 4 38/424 1 (reference)  1 (reference) 
Per SD decrease 168/1695 1.06 (0.91; 1.23)  1.06 (0.91; 1.23) 
Abbreviations: n = number of strokes; N = number of persons at risk; HR = hazard ratio; CI = confidence interval; 
SD = standard deviation; HDL = high-density lipoprotein. 
Values are hazard ratios with 95% confidence intervals. 
The range of vasomotor reactivity for each quartile was as follows: quartile 1: 0–28.1 %/kPa, quartile 2: 28.1-39.3 
%/kPa, quartile 3: 39.3-54.0 %/kPa, quartile 4: 54.0-229.3 %/kPa. 
Model I: Adjusted for age, sex and difference in blood pressure before and during vasomotor reactivity 
measurement.  
Model II: Adjusted for age, sex, current smoking, former smoking, blood pressure-lowering medication, systolic 
blood pressure, diastolic blood pressure, diabetes mellitus, total cholesterol, HDL-cholesterol, statins, history of 
vascular disease, carotid intima-media thickness, and difference in blood pressure before and during vasomotor 
reactivity measurement. 
a Vasomotor reactivity was natural log transformed. 
 
Table 5. Vasomotor reactivity and the risk of mortality, after censoring for incident stroke 
  All-cause mortality  Cardiovascular 
mortality 
Vasomotor reactivitya n/N HR (95% CI) n/N HR (95% CI) 
Quartile 1 150/423 1.49 (1.13; 1.96) 41/423 1.76 (1.01; 3.07) 
Quartile 2 128/424 1.39 (1.05; 1.83) 43/424 2.07 (1.20; 3.56) 
Quartile 3 103/424 1.13 (0.85; 1.51) 28/424 1.32 (0.74; 2.38) 
Quartile 4 84/424 1 (reference) 19/424 1 (reference) 
Per SD decrease 465/1695 1.12 (1.03; 1.22) 131/1695 1.20 (1.03; 1.40) 
Abbreviations: n = number of deaths; N = number of persons at risk; HR = hazard ratio; CI = confidence interval; 
SD = standard deviation. 
Values are hazard ratios with 95% confidence intervals.  
The range of vasomotor reactivity for each quartile was as follows: quartile 1: 0–28.1 %/kPa, quartile 2: 28.1-39.3 
%/kPa, quartile 3: 39.3-54.0 %/kPa, quartile 4: 54.0-229.3 %/kPa. 
a Vasomotor reactivity was natural log transformed. 
Models are adjusted for age, sex and difference in blood pressure before and during vasomotor reactivity 
measurement.  
 
Interestingly, vasomotor reactivity was not associated with the risk of stroke (Table 4). 
Instead, the associations with both all-cause mortality and cardiovascular mortality remained 
significant after censoring for incident stroke (Table 5).  
Our additional analyses showed no evidence for vasomotor reactivity being an 
intermediate between various cardiovascular risk factors and risk of mortality (Supplementary 
Table I). 
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Table 1. Baseline characteristics 
 Participants Non-participants 
 N=1695 N=1037 
Age, mean (SD), years 70.7 (6.3) 73.2 (6.8)b 
Follow-up time mortality, mean (SD), years 10.0 (3.0) 9.5 (3.3)b 
Female, No. (%) 785 (46.3) 760 (73.3)b 
Systolic blood pressure, mean (SD), mmHg 142.7 (20.8) 145.1 (21.4) 
Diastolic blood pressure, mean (SD), mmHg 75.9 (11.1) 75.2 (11.0) 
Blood pressure-lowering medication, No. (%) 384 (23.2) 293 (29.2)b 
Diabetes mellitus, No. (%) 158 (9.5) 111 (10.9) 
Former smoking, No. (%) 990 (58.8) 447 (43.5)b 
Current smoking, No. (%) 311 (18.5) 176 (17.1) 
Total cholesterol, mean (SD), mmol/L 5.81 (0.99) 5.85 (1.01) 
HDL-cholesterol, mean (SD), mmol/L 1.38 (0.38) 1.42 (0.39)b 
Statins, No. (%) 216 (12.9) 154 (15.1)b 
History of vascular disease, No. (%) 368 (23.3) 256 (27.1)b 
Carotid intima-media thickness, mean (SD), mm 1.06 (0.18) 1.09 (0.20)b 
Difference in systolic blood pressure before and during 
measurement, mean (SD), mmHg 
14.9 (13.8) NA 
Difference in diastolic blood pressure before and during 
measurement, mean (SD), mmHg 
5.7 (7.0) NA 
Vasomotor r activity, median (IQR)a, %/kPa 39.3 (28.1 – 54.0) NA 
Abbreviations: HDL = high-density lipoprotein; NA = not available. 
Data are presented as mean (standard deviations) or No. (%) unless otherwise specified. Percentages are 
calculated without missing data. For all reported variables, missing numbers occurred in 8.4% or less of all 
participants.  
a Median (interquartile range) presented because of skewed distribution. 
b Significantly different (p<0.05) between participants and non-participants, after sex and age adjustment – if 
applicable. 
 
Associations between vasomotor reactivity and mortality were stronger for cardiovascular 
mortality (HR per SD decrease 1.15, 95% CI 1.00; 1.32), whilst the associations for non-
cardiovascular mortality were weaker (HR 1.10, 95% CI 1.00; 1.21) (Table 3). After additional 
adjustments, the association with cardiovascular ortality attenuated slightly and became 
statistically non-significant (HR 1.09, 95% CI 0.94; 1.26). Again, persons in the lowest two 
quartiles had an increased risk of death compared to the upper quartile (Table 2). However, we 
could not observe a clear dose-response relation between lower vasomotor reactivity and 
higher risk of cardiovascular mortality since quartile 2 showed a stronger association than 
quartile 1. 
After excluding participants with an impair d vasomotor reactivity (<10%/kPa), there were 
only minor changes in effect size (data not shown). 
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Table 4. Vasomotor reactivity and the risk of stroke 
 Stroke 
  Model I  Model II 
Vasomotor reactivitya n/N HR (95% CI)  HR (95% CI) 
Quartile 1 47/423 1.11 (0.72; 1.71)  1.10 (0.71; 1.70) 
Quartile 2 46/424 1.15 (0.75; 1.77)  1.15 (0.74; 1.77) 
Quartile 3 37/424 0.90 (0.57; 1.43)  0.92 (0.58; 1.45) 
Quartile 4 38/424 1 (reference)  1 (reference) 
Per SD decrease 168/1695 1.06 (0.91; 1.23)  1.06 (0.91; 1.23) 
Abbreviations: n = number of strokes; N = number of persons at risk; HR = hazard ratio; CI = confidence interval; 
SD = standard deviation; HDL = high-density lipoprotein. 
Values are hazard ratios with 95% confidence intervals. 
The range of vasomotor reactivity for each quartile was as follows: quartile 1: 0–28.1 %/kPa, quartile 2: 28.1-39.3 
%/kPa, quartile 3: 39.3-54.0 %/kPa, quartile 4: 54.0-229.3 %/kPa. 
Model I: Adjusted for age, sex and difference in blood pressure before and during vasomotor reactivity 
measurement.  
Model II: Adjusted for age, sex, current smoking, former smoking, blood pressure-lowering medication, systolic 
blood pressure, diastolic blood pressure, diabetes mellitus, total cholesterol, HDL-cholesterol, statins, history of 
vascular disease, carotid intima-media thickness, and difference in blood pressure before and during vasomotor 
reactivity measurement. 
a Vasomotor reactivity was natural log transformed. 
 
Table 5. Vasomotor reactivity and the risk of mortality, after censoring for incident stroke 
  All-cause mortality  Cardiovascular 
mortality 
Vasomotor reactivitya n/N HR (95% CI) n/N HR (95% CI) 
Quartile 1 150/423 1.49 (1.13; 1.96) 41/423 1.76 (1.01; 3.07) 
Quartile 2 128/424 1.39 (1.05; 1.83) 43/424 2.07 (1.20; 3.56) 
Quartile 3 103/424 1.13 (0.85; 1.51) 28/424 1.32 (0.74; 2.38) 
Quartile 4 84/424 1 (reference) 19/424 1 (reference) 
Per SD decrease 465/1695 1.12 (1.03; 1.22) 131/1695 1.20 (1.03; 1.40) 
Abbreviations: n = number of deaths; N = number of persons at risk; HR = hazard ratio; CI = confidence interval; 
SD = standard deviation. 
Values are hazard ratios with 95% confidence intervals.  
The range of vasomotor reactivity for each quartile was as follows: quartile 1: 0–28.1 %/kPa, quartile 2: 28.1-39.3 
%/kPa, quartile 3: 39.3-54.0 %/kPa, quartile 4: 54.0-229.3 %/kPa. 
a Vasomotor reactivity was natural log transformed. 
Models are adjusted for age, sex and difference in blood pressure before and during vasomotor reactivity 
measurement.  
 
Interestingly, vasomotor reactivity was not associated with the risk of stroke (Table 4). 
Instead, the associations with both all-cause mortality and cardiovascular mortality remained 
significant after censoring for incident stroke (Table 5).  
Our additional analyses showed no evidence for vasomotor reactivity being an 
intermediate between various cardiovascular risk factors and risk of mortality (Supplementary 
Table I). 
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Table 1. Baseline characteristics 
 Participants Non-participants 
 N=1695 N=1037 
Age, mean (SD), years 70.7 (6.3) 73.2 (6.8)b 
Follow-up time mortality, mean (SD), years 10.0 (3.0) 9.5 (3.3)b 
Female, No. (%) 785 (46.3) 760 (73.3)b 
Systolic blood pressure, mean (SD), mmHg 142.7 (20.8) 145.1 (21.4) 
Diastolic blood pressure, mean (SD), mmHg 75.9 (11.1) 75.2 (11.0) 
Blood pressure-lowering medication, No. (%) 384 (23.2) 293 (29.2)b 
Diabetes mellitus, No. (%) 158 (9.5) 111 (10.9) 
Former smoking, No. (%) 990 (58.8) 447 (43.5)b 
Current smoking, No. (%) 311 (18.5) 176 (17.1) 
Total cholesterol, mean (SD), mmol/L 5.81 (0.99) 5.85 (1.01) 
HDL-cholesterol, mean (SD), mmol/L 1.38 (0.38) 1.42 (0.39)b 
Statins, No. (%) 216 (12.9) 154 (15.1)b 
History of vascular disease, No. (%) 368 (23.3) 256 (27.1)b 
Carotid intima-media thickness, mean (SD), mm 1.06 (0.18) 1.09 (0.20)b 
Difference in systolic blood pressure before and during 
measurement, mean (SD), mmHg 
14.9 (13.8) NA 
Difference in diastolic blood pressure before and during 
measurement, mean (SD), mmHg 
5.7 (7.0) NA 
Vasomotor r activity, median (IQR)a, %/kPa 39.3 (28.1 – 54.0) NA 
Abbreviations: HDL = high-density lipoprotein; NA = not available. 
Data are presented as mean (standard deviations) or No. (%) unless otherwise specified. Percentages are 
calculated without missing data. For all reported variables, missing numbers occurred in 8.4% or less of all 
participants.  
a Median (interquartile range) presented because of skewed distribution. 
b Significantly different (p<0.05) between participants and non-participants, after sex and age adjustment – if 
applicable. 
 
Associations between vasomotor reactivity and mortality were stronger for cardiovascular 
mortality (HR per SD decrease 1.15, 95% CI 1.00; 1.32), whilst the associations for non-
cardiovascular mortality were weaker (HR 1.10, 95% CI 1.00; 1.21) (Table 3). After additional 
adjustments, the association with cardiovascular ortality attenuated slightly and became 
statistically non-significant (HR 1.09, 95% CI 0.94; 1.26). Again, persons in the lowest two 
quartiles had an increased risk of death compared to the upper quartile (Table 2). However, we 
could not observe a clear dose-response relation between lower vasomotor reactivity and 
higher risk of cardiovascular mortality since quartile 2 showed a stronger association than 
quartile 1. 
After excluding participants with an impair d vasomotor reactivity (<10%/kPa), there were 
only minor changes in effect size (data not shown). 
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We found that persons with a lower cerebral vasomotor reactivity have an increased risk of 
mortality. These associations were independent from cardiovascular risk factors and from 
incident stroke.  
Strengths of this study are the population-based design; the thorough collection of events; 
and the long follow-up for both mortality and stroke. A potential limitation is selection bias 
because transcranial Doppler measurements failed in a large group of participants. The 
percentage of participants who died was significantly higher among the excluded participants, 
which indeed might point towards selection bias. Transcranial Doppler measurements failed 
mainly because of window failure, which occurred more often in women and in older 
participants.19 Given that vasomotor reactivity decreases with age27, coupled with higher risk of 
cardiovascular disease with age, this could have led to a dilution of the effect. Another 
consideration is potential survivor effect as transcranial Doppler measurements were only 
performed at the second follow-up examination of the Rotterdam Study. It is possible that 
unhealthy persons may have died during the intermediate time period. This would have 
resulted in an underestimation of the effect. A final remark is that we did not assess extracranial 
carotid stenosis. We did measure carotid intima-media thickness (cIMT), but did not measure 
the lumen of the extracranial carotid artery and were not able to assess extracranial carotid 
stenosis. Given that extracranial carotid artery stenosis is prevalent in the general population 
and influences both cerebral vasomotor reactivity measurements and the risk of stroke, 
extracranial carotid artery stenosis could have influences our results.8,28 
We found that a lower vasomotor reactivity was associated with higher risk of mortality, 
especially cardiovascular mortality. These results suggest that a low vasomotor reactivity is a 
marker of accumulating vascular damage. We did find a dose-response relation between 
vasomotor reactivity and all-cause mortality, however this relation was not found for 
cardiovascular mortality. Moreover, no clear cut-off between normal and abnormal vasomotor 
reactivity values can be obtained from these analyses, as the cut-off points for the quartiles are 
based on this study population and cannot be generalized to other study populations. 
Vasomotor reactivity is measured in the cerebral vessels and previous studies have shown that 
in patients with carotid stenosis, those with a lower vasomotor reactivity have an increased risk 
of stroke.8,12-17 Consequently, our findings with all-cause and cardiovascular mortality could be 
explained by stroke and stroke-related deaths. However, we did not find vasomotor reactivity 
to be associated with stroke. This is consistent with what was found before within the same 
study population, with shorter follow-up.19 Furthermore, the association of lower vasomotor 
reactivity with both all-cause and cardiovascular mortality was independent from incident 
stroke. The main causes of cardiovascular death after censoring for strokes were heart failure, 
cardiac arrest, sudden death with unknown cause, and myocardial infarction. This supports the 
hypothesis that loss of cerebral vasomotor reactivity is a reflection of a more systemic 
dysfunction of the vascular system rather than only cerebrovascular damage. Further evidence 
comes from previous studies that have reported a link between peripheral artery endothelial 
dysfunction and cerebrovascular reactivity.29,30 Still, we note that some studies did not find an 
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association between flow-mediated vasodilatation (FMD) in the brachial artery, which is an 
indirect measure of peripheral endothelial dysfunction, and cerebrovascular reactivity.31,32 
Inconsistencies across studies might be explained by methodological differences and 
differences in study population. 
Although associations with cardiovascular mortality attenuated after adjustment for 
cardiovascular risk factors and became statistically non-significant, an effect size in excess of 1.3 
remained for each of the lowest three quartiles compared to the upper quartile. This suggests 
that part of the effect of vasomotor reactivity is independent from cardiovascular risk factors. 
Also, it is questionable whether such an adjustment is a correction for potential confounders 
or actually an over-adjustment for possible intermediates of the causal chain. Nevertheless, 
some remarks can be made on the results after these adjustments. First, prior studies have 
shown that hypertension, smoking, and dyslipidemia disrupt the vascular homeostasis. This 
might cause endothelial dysfunction, which eventually contributes to cardiovascular 
disease.3,33 Endothelial dysfunction leads to a lower excretion of dilatory factors, such as nitric 
oxide, and could therefore also lead to a lower vasomotor reactivity.2 Second, it is possible that 
participants with unrecognized risk factors did not receive preventative treatment and 
therefore were more at risk for a cardiovascular event than those in whom cardiovascular risk 
factors were present and thus treated. This would lead to a minimal effect of adjusting for such 
risk factors. Third, we adjusted for baseline measurements of cardiovascular risk factors, which 
might be less representative for life-long exposure. A final consideration is that vasomotor 
reactivity reflects a different mechanism of vascular damage, not explained by cardiovascular 
risk factors, but by risk factors that we did not measure, such as genetic factors.34,35 Conversely, 
we found that the associations of cardiovascular risk factors with mortality remained 
unchanged after adjusting for vasomotor reactivity. It is likely that these factors exert their effect 
through many different mediators, among which vasomotor reactivity. 
Since vascular disease is the leading cause of mortality worldwide, there is an urgent need 
for preventive options. As such, markers of early vascular damage are of much interest. Our 
study on vasomotor reactivity and mortality is set in a community-dwelling population. Unlike 
in a clinical setting, our participants are relatively healthy and the amount of available in-depth 
data is limited. We therefore do not have additional data to clarify the potential cause of 
diminished vasomotor reactivity. The association between a lower vasomotor reactivity and 
higher risk of cardiovascular mortality thus merits further investigation. Specifically, unravelling 
the underlying mechanism and the possible contribution to identification of high-risk 
individuals is worthy of future research. Also, it would be of interest to investigate the 
association of vasomotor reactivity and white matter lesions measured on Magnetic Resonance 
Imaging (MRI). 
In conclusion, our results indicate that loss of cerebral vasomotor reactivity is associated 
with an increased risk of mortality, especially cardiovascular mortality, independent of stroke. 
This suggests that impaired cerebral vasomotor reactivity reflects a systemically impaired 
vascular system.  
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because transcranial Doppler measurements failed in a large group of participants. The 
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which indeed might point towards selection bias. Transcranial Doppler measurements failed 
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cardiovascular disease with age, this could have led to a dilution of the effect. Another 
consideration is potential survivor effect as transcranial Doppler measurements were only 
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unhealthy persons may have died during the intermediate time period. This would have 
resulted in an underestimation of the effect. A final remark is that we did not assess extracranial 
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the lumen of the extracranial carotid artery and were not able to assess extracranial carotid 
stenosis. Given that extracranial carotid artery stenosis is prevalent in the general population 
and influences both cerebral vasomotor reactivity measurements and the risk of stroke, 
extracranial carotid artery stenosis could have influences our results.8,28 
We found that a lower vasomotor reactivity was associated with higher risk of mortality, 
especially cardiovascular mortality. These results suggest that a low vasomotor reactivity is a 
marker of accumulating vascular damage. We did find a dose-response relation between 
vasomotor reactivity and all-cause mortality, however this relation was not found for 
cardiovascular mortality. Moreover, no clear cut-off between normal and abnormal vasomotor 
reactivity values can be obtained from these analyses, as the cut-off points for the quartiles are 
based on this study population and cannot be generalized to other study populations. 
Vasomotor reactivity is measured in the cerebral vessels and previous studies have shown that 
in patients with carotid stenosis, those with a lower vasomotor reactivity have an increased risk 
of stroke.8,12-17 Consequently, our findings with all-cause and cardiovascular mortality could be 
explained by stroke and stroke-related deaths. However, we did not find vasomotor reactivity 
to be associated with stroke. This is consistent with what was found before within the same 
study population, with shorter follow-up.19 Furthermore, the association of lower vasomotor 
reactivity with both all-cause and cardiovascular mortality was independent from incident 
stroke. The main causes of cardiovascular death after censoring for strokes were heart failure, 
cardiac arrest, sudden death with unknown cause, and myocardial infarction. This supports the 
hypothesis that loss of cerebral vasomotor reactivity is a reflection of a more systemic 
dysfunction of the vascular system rather than only cerebrovascular damage. Further evidence 
comes from previous studies that have reported a link between peripheral artery endothelial 
dysfunction and cerebrovascular reactivity.29,30 Still, we note that some studies did not find an 
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association between flow-mediated vasodilatation (FMD) in the brachial artery, which is an 
indirect measure of peripheral endothelial dysfunction, and cerebrovascular reactivity.31,32 
Inconsistencies across studies might be explained by methodological differences and 
differences in study population. 
Although associations with cardiovascular mortality attenuated after adjustment for 
cardiovascular risk factors and became statistically non-significant, an effect size in excess of 1.3 
remained for each of the lowest three quartiles compared to the upper quartile. This suggests 
that part of the effect of vasomotor reactivity is independent from cardiovascular risk factors. 
Also, it is questionable whether such an adjustment is a correction for potential confounders 
or actually an over-adjustment for possible intermediates of the causal chain. Nevertheless, 
some remarks can be made on the results after these adjustments. First, prior studies have 
shown that hypertension, smoking, and dyslipidemia disrupt the vascular homeostasis. This 
might cause endothelial dysfunction, which eventually contributes to cardiovascular 
disease.3,33 Endothelial dysfunction leads to a lower excretion of dilatory factors, such as nitric 
oxide, and could therefore also lead to a lower vasomotor reactivity.2 Second, it is possible that 
participants with unrecognized risk factors did not receive preventative treatment and 
therefore were more at risk for a cardiovascular event than those in whom cardiovascular risk 
factors were present and thus treated. This would lead to a minimal effect of adjusting for such 
risk factors. Third, we adjusted for baseline measurements of cardiovascular risk factors, which 
might be less representative for life-long exposure. A final consideration is that vasomotor 
reactivity reflects a different mechanism of vascular damage, not explained by cardiovascular 
risk factors, but by risk factors that we did not measure, such as genetic factors.34,35 Conversely, 
we found that the associations of cardiovascular risk factors with mortality remained 
unchanged after adjusting for vasomotor reactivity. It is likely that these factors exert their effect 
through many different mediators, among which vasomotor reactivity. 
Since vascular disease is the leading cause of mortality worldwide, there is an urgent need 
for preventive options. As such, markers of early vascular damage are of much interest. Our 
study on vasomotor reactivity and mortality is set in a community-dwelling population. Unlike 
in a clinical setting, our participants are relatively healthy and the amount of available in-depth 
data is limited. We therefore do not have additional data to clarify the potential cause of 
diminished vasomotor reactivity. The association between a lower vasomotor reactivity and 
higher risk of cardiovascular mortality thus merits further investigation. Specifically, unravelling 
the underlying mechanism and the possible contribution to identification of high-risk 
individuals is worthy of future research. Also, it would be of interest to investigate the 
association of vasomotor reactivity and white matter lesions measured on Magnetic Resonance 
Imaging (MRI). 
In conclusion, our results indicate that loss of cerebral vasomotor reactivity is associated 
with an increased risk of mortality, especially cardiovascular mortality, independent of stroke. 
This suggests that impaired cerebral vasomotor reactivity reflects a systemically impaired 
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Supplementary information 
 
Supplementary Table I. Associations between cardiovascular risk factors and all-cause mortality, before 
and after adjustment for vasomotor reactivity  
 All-cause mortality 
n/N 557/1695 
 Model I Model II 
 HR (95% CI) HR (95% CI) 
Age 1.12 (1.10; 1.13) 1.12 (1.10; 1.13) 
Sex 0.76 (0.61; 0.94) 0.75 (0.60; 0.93) 
Systolic blood pressure 1.00 (0.99; 1.00) 1.00 (0.99; 1.00) 
Diastolic blood pressure 1.00 (0.99; 1.01) 1.00 (0.99; 1.01) 
Blood pressure-lowering medication 1.17 (0.96; 1.43) 1.16 (0.95; 1.42) 
Diabetes mellitus 1.20 (0.93; 1.54) 1.18 (0.92; 1.52) 
Former smoking 1.16 (0.94; 1.43) 1.17 (0.95; 1.45) 
Current smoking 2.08 (1.65; 2.63) 2.09 (1.66; 2.64) 
Total cholesterol 0.93 (0.85; 1.02) 0.93 (0.84; 1.01) 
HDL-cholesterol 0.86 (0.67; 1.11) 0.87 (0.68; 1.12) 
Statins 0.72 (0.55; 0.95) 0.72 (0.55; 0.95) 
History of vascular disease 1.55 (1.27; 1.88) 1.52 (1.25; 1.85) 
Carotid intima-media thickness 1.84 (1.13; 2.99) 1.81 (1.11; 2.95) 
Abbreviations: n = number of deaths; N = number of persons at risk; HR = hazard ratio; CI = confidence interval; 
HDL = high-density lipoprotein. 
Values are hazard ratios with 95% confidence intervals. 
Model I: Adjusted for age, sex, current smoking, former smoking, blood pressure-lowering medication, systolic 
blood pressure, diastolic blood pressure, diabetes mellitus, total cholesterol, HDL-cholesterol, use of statins, 
history of vascular disease, and carotid intima-media thickness. 
Model II: Adjusted for age, sex, current smoking, former smoking, blood pressure-lowering medication, systolic 
blood pressure, diastolic blood pressure, diabetes mellitus, total cholesterol, HDL-cholesterol, use of statins, 
history of vascular disease, carotid intima-media thickness, and vasomotor reactivity (natural log transformed).
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Abstract  
 
Background and purpose 
Cerebral microbleeds are highly prevalent in people with clinically manifest cerebrovascular 
disease, and have been shown to increase the risk of stroke recurrence. Microbleeds are also 
frequently found in healthy elderly, a population in which the clinical implication of 
microbleeds is unknown.  
 
Methods 
In the population-based Rotterdam Study, presence, number, and location of microbleeds 
were assessed at baseline on brain MRI of 4,759 participants aged ≥45 years. Participants were 
followed for incident stroke throughout the study period (2005 until 2013). We used Cox 
proportional hazards to investigate if people with microbleeds were at increased risk of stroke 
compared to those without microbleeds, adjusting for demographic, genetic, and 
cardiovascular risk, and cerebrovascular imaging markers.  
 
Results 
Microbleed prevalence was 18.7% (median count 1 [1-111]). During mean follow-up of 4.9 years 
(SD 1.6) 93 strokes occurred (72 ischemic, 11 hemorrhagic, and 10 unspecified). Microbleed 
presence was associated with an increased risk of all strokes (HR 1.93, 95% CI 1.25; 2.99). The 
risk increased with greater microbleed count. Compared to those without microbleeds, 
participants with microbleeds in locations suggestive of CAA (lobar with or without cerebellar 
microbleeds) were at increased risk of intracerebral hemorrhage (HR 5.27, 95% CI 1.38; 20.23). 
Microbleeds at other locations were associated with an increased risk of both ischemic stroke 
and intracerebral hemorrhage.  
 
Conclusions 
Microbleeds on MRI are associated with an increased risk of stroke in the general population. 
Our results strengthen the notion that microbleeds mark progression of cerebrovascular 
pathology and represent a precursor of stroke.  
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Introduction 
 
Stroke is the second leading cause of death worldwide and the third most common cause of 
disability-adjusted life-years.1,2 Although stroke has an acute onset, there is abundant evidence 
for a long subclinical period in which cerebrovascular pathology accumulates and can be 
visualized on non-invasive brain imaging. Markers of subclinical cerebrovascular pathology that 
are known to increase the risk of ischemic stroke are white matter lesions and lacunes.3 In the 
last decade, punctuate hemorrhagic lesions in the brain parenchyma, so called cerebral 
microbleeds, have emerged as another manifestation of subclinical cerebrovascular 
pathology.4 In contrast to white matter lesions and lacunes, microbleeds are thought to reflect 
the presence of both ischemic and hemorrhagic brain vasculopathy.5,6 In addition, evidence 
suggests that the location of cerebral microbleeds provides more information on the type of 
underlying vasculopathy, i.e. cerebral amyloid angiopathy (CAA) in the presence of lobar 
microbleeds and hypertensive arteriopathy when deep or mixed microbleeds are seen.4,7,8  
There is a growing need to clarify whether microbleed presence indicates an increased risk 
of stroke, as this may provide new insights in the link between subclinical cerebrovascular 
pathology and stroke. So far, it is known that in patients with a history of stroke microbleed 
presence increases the risk of recurrent stroke, either hemorrhagic or ischemic.9-18 Whether 
microbleeds are associated with an increased risk of stroke in community-dwelling elderly 
without a history of stroke remains unclear. Only two prospective studies investigated the 
association of microbleeds with subsequent stroke in people without a history of 
cerebrovascular events.19,20 Both studies found that microbleed presence was associated with 
an increased risk of stroke, although important limitations were small sample size, absence of 
microbleed subgroup analysis, and lack of generalizability due to an exclusive focus on Asian 
populations.19,20  
In the population-based Rotterdam Study, we investigated whether cerebral microbleeds 
at various locations are associated with an increased risk of recurrent and first-ever ischemic 
stroke and intracerebral hemorrhage.  
 
Methods 
 
Study population 
The Rotterdam Study is an ongoing prospective population-based cohort that studies 
occurrence, determinants and consequences of diseases in an aging population.21 The 
Rotterdam Study has been approved by the medical ethics committee according to the 
Population Study Act Rotterdam Study, executed by the Ministry of Health, Welfare and Sports 
of the Netherlands. The cohort originated in 1990, was expanded twice in 2000 and 2006, and 
now comprises 14,926 participants aged ≥45 years, predominantly of Caucasian origin. All 
participants gave written informed consent. In 2005, brain MRI, including microbleed 
assessment, was implemented within the core protocol of the study.22 Between January 1st 
2005 and January 1st 2013, 5,074 out of 5,735 eligible participants (88.5%) underwent brain 
scanning. Participants with scans that were incomplete (N=72) or of insufficient quality for 
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microbleed rating (N=57) were excluded. Also, we excluded participants (n=186) in whom 
follow-up for incident stroke ended before date of MRI due to the absence of automatic 
linkages between the general practitioners office and our study database, leaving a total of 
4,759 participants for analyses. 
 
Brain MRI and microbleeds 
A 1.5-Tesla MRI scanner (GE Healthcare, Milwaukee, WI) was used to obtain T1-weighted, T2-
weighted, fluid-attenuated inversion recovery (FLAIR), and T2*-weighted sequences.22 Cerebral 
microbleeds were recognized as focal, small, round to ovoid areas of signal loss on T2*-
weighted images (gradient-recalled echo with repetition time= 45ms, echo time= 31, matrix 
size= 320x244, flip angle= 13, field-of-view= 25x17.5cm2, parallel imaging acceleration factor 
= 2, 3D acquisition with 96 slices encoded with a slice thickness of 1.6mm zero padded to 192 
slices of 0.8mm, acquisition time 5min 55sec).23 Their presence, number, and location were 
scored by 1 of 5 trained research physicians using a protocol that is in place since initiation of 
the study in 2005 with good intraobserver (k=0.87) and interobserver agreement (k=0.85). 
Signal voids caused by sulcal vessels, calcifications, and signal averaging from bone were 
considered mimics of microbleeds.4 Raters were blinded to all clinical data. Microbleeds were 
classified based on their location in the brain into groups most befitting their presumed 
etiology. Microbleeds at locations where CAA is highly prevalent (strictly lobar or lobar with 
cerebellar locations) were termed “CAA related” microbleeds, and microbleeds at other 
locations (deep gray matter, deep white matter, and brainstem with or without lobar 
microbleeds; cerebellar with or without deep or brainstem microbleeds) were termed “non-
CAA related” microbleeds.  
Aside from microbleeds we assessed the presence of infarcts and the load of white matter 
lesions. Lacunes were defined as focal lesions between ≥3 and <15mm seen on FLAIR, T1-
weighted, and T2-weighted sequences. If lacunes were ≥15mm they were defined as 
subcortical infarcts, and if cortical gray matter was affected they were classified as cortical 
infarcts. Brain tissue was segmented into gray matter, white matter, and cerebrospinal fluid 
using automated post-processing tools that included conventional k-nearest-neighbor brain 
tissue classifier extended with white matter lesion segmentation.24 Intracranial volume was 
defined as the sum of gray matter, white matter, and white matter lesion volume, and 
cerebrospinal fluid.  
 
Stroke assessment and follow-up 
Upon study entry, history of stroke was assessed using home interviews and by reviewing 
medical records. Subsequently, participants were continuously followed-up for occurrence of 
stroke through automated linkage of general practitioners’ medical records with the study 
database.25 For participants who moved outside the study district or lived in nursing homes, 
medical records were regularly checked by contacting their treating physicians. Research 
physicians reviewed all potential strokes using hospital discharge letters, information from 
general practitioners and from nursing home physicians. An experienced vascular neurologist 
verified the stroke diagnoses. In accordance with World Health Organization (WHO) criteria, 
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stroke was defined as a syndrome of rapidly emerging clinical signs of focal or global 
disturbance of cerebral function. Symptoms should last ≥24 hours or cause death, with no 
apparent cause other than of vascular origin. Strokes were classified into ischemic strokes or 
spontaneous intracerebral hemorrhages based on neuroimaging reports (computed 
tomography). In the absence of neuroimaging, strokes were classified as unspecified.  
Follow-up started on the date that participants came for brain MRI. Participants were 
followed until date of (fatal or non-fatal) stroke occurrence, date of death, date of last contact 
in case of loss to follow up, or January 1st 2013 (end of the study period), whichever came first. 
Follow-up was complete for 23,356 (94.9%) of potential person-years. 
 
Assessments of covariates 
Participants’ demographics, genetic and cardiovascular risk factors were assessed during the 
center visit preceding the brain MRI, using structured interviews, physical, and laboratory 
examinations. We defined various potential cardiovascular confounders. Blood pressure 
measurements were averaged over two readings using a random zero sphygmomanometer. 
Hypertension was defined as a blood pressure of >140 systolic or >90 diastolic, or the use of 
blood pressure-lowering medication. Serum total and high-density lipoprotein (HDL) 
cholesterol were measured using an automated enzymatic procedure. Smoking behavior was 
defined as smoked ‘ever’ versus ‘never’. Participants were considered diabetic when fasting 
blood glucose levels were ≥7.0 mmol/L or when they used glucose-lowering medication. 
Blood pressure-lowering and lipid-lowering medication use was assessed in home interviews. 
Pharmacy records were used to determine the use of antithrombotic medication (ATC code 
B01AA04 acenocoumarol, B01AA07 phenprocoumon, B01AB heparins, and B01AC platelet 
aggregation inhibitors) between baseline MRI and stroke event, death or January 1st 2013, 
whichever came first. Finally, APOE genotyping was done on coded genomic DNA samples.  
 
Statistical analysis 
Student’s t-test and Fisher’s exact test were used to compare characteristics of study 
participants by microbleed status. Cox proportional hazards models were fitted to obtain the 
estimated hazard ratios (HR) and 95% confidence intervals for the association of microbleeds 
with stroke (all fatal and non-fatal strokes, fatal and non-fatal ischemic strokes, and fatal and 
non-fatal intracerebral hemorrhages). We first investigated the risk of recurrent and first-ever 
stroke combined. Afterwards we excluded participants with a history of stroke at baseline (n=8) 
and separately investigated the risk of first-ever stroke. Analyses were repeated for location of 
microbleeds (“CAA related” and “non-CAA related” locations versus no microbleed), and for 
microbleed count to investigate a potential dose-response effect (predefined categories of 1, 
2-4, and >4 microbleeds versus no microbleeds).26-28 We constructed 4 models to adjust for 
potential confounding. In order not to overfit the statistical models we used logistic regression 
to compute propensity scores for cardiovascular risk. In these, microbleed status (yes versus 
no) was considered the dependent variable and the following cardiovascular risk factors were 
considered independent covariates: hypertension, total and HDL cholesterol, smoking status, 
diabetes mellitus status, use of lipid-lowering and antithrombotic medication. The estimated 
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propensity score was the derived predicted value of this equation. Missing covariate data 
(≤7.0%) were imputed based on sex, age, and cardiovascular risk factors using regression 
models. The first model was adjusted for age-squared, sex, and Rotterdam Study subcohort. 
The second model was additionally adjusted for APOE ɛ4 carriership. The third model was 
adjusted for age-squared, sex, Rotterdam Study subcohort and the propensity score described 
above. Finally, the fourth model equaled model 1 with additional adjustments for lacunes, 
white matter lesions, and total intracranial volume. An additional 77 participants were excluded 
in the analysis of model 4 because the white matter lesion segmentation of these MRI scans 
was considered unreliable. The proportionality assumption was tested using Schoenfeld 
residuals.  
Kaplan Meier incident stroke-free survival curves were constructed for groups with 
microbleed count 0,1, 2-4, >4, and compared using the log-rank test. In a sensitivity analysis, 
we repeated the analysis of model 1 after stratification by antithrombotic drug use (ever versus 
never), and applied formal interaction tests to determine significant differences in subgroups.  
Finally, we examined all research and hospital scans of incident intracerebral hemorrhage 
cases, and visually correlated the locations of baseline microbleeds and incident hemorrhages, 
since it was hypothesized that symptomatic hemorrhages would occur in close proximity of 
microbleeds.  
Analyses were done using IBM SPSS statistics for windows, version 21.0 (IBM Corp., Armonk, 
NY), using an alpha-value of 0.05.  
 
Results 
 
Characteristics of the study population are presented in Table 1. Of the total 4,759 participants 
55.3% were women and the average age at baseline was 63.8 years (SD 10.9). Microbleed 
prevalence was 18.7% (median microbleed count 1 [range 1-111]). Older age, hypertension, 
lower total cholesterol, smoking, use of lipid-lowering and antithrombotic medication, and 
ischemic vascular lesions on brain MRI were all significantly associated with microbleed 
presence. At baseline, 8 (0.2%) participants had a history of stroke (six ischemic and two 
unspecified). Over a mean follow up of 4.9 years (SD 1.6), 93 (2.0%) participants suffered a stroke, 
of whom 72 ischemic strokes (3.1 per 1,000 person-years), 11 intracerebral hemorrhages (0.5 
per 1,000 person-years), and 10 unspecified strokes (0.4 per 1,000 person-years).  
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Table 1. Characteristics of the study population 
 Total 
population 
(N=4,759) 
Microbleeds 
absent (N=3,867) 
Microbleeds 
present (N=892) 
P-value 
Age, years 63.8 (10.9) 62.4 (10.5) 69.7 (10.9)a <0.001 
Women 2,631 (55.3) 2,155 (55.7) 476 (53.4) 0.204 
Hypertension 2,914 (61.2) 2,267 (58.6) 647 (72.5)a <0.001 
Total cholesterol, mmol/L 5.5 (1.0) 5.6 (1.0) 5.4 (1.1)a 0.001 
High-density lipoprotein 
cholesterol, mmol/L 
1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 0.720 
Ever smoker  3,315 (69.7) 2,665 (68.9) 650 (72.9)a 0.021 
Diabetes mellitus 410 (8.6) 322 (8.3) 88 (9.9) 0.145 
Lipid-lowering medication use 1,118 (23.5) 860 (22.2) 258 (28.9)a <0.001 
Antithrombotic medication use 1,274 (26.8) 891 (23.0) 383 (42.9)a <0.001 
Apolipoprotein E ɛ4 carriership 1,435 (30.2) 1,137 (29.4) 298 (33.4)a 0.021 
White matter lesion volumeb 2.9 (1.6-6.1) 2.7 (1.5-5.1) 5.0 (2.5-11.7)a <0.001 
Lacunes on MRI 310 (6.5) 194 (5.0) 116 (13.0)a <0.001 
Subcortical infarcts on MRI 8 (0.2) 4 (0.1) 4 (0.4)a 0.045 
Cortical infarcts on MRI 111 (2.3) 85 (2.2) 26 (2.9) 0.218 
Values presented mean (SD) for continuous variables and number (%) for categorical variables.  
aP-value <0.05, indicates significant difference in people with and without microbleeds. 
bPresented as median (IQR) and assessed in 4,687 participants.  
 
People with microbleeds at baseline were at increased risk of developing new strokes 
compared with those without microbleeds (age-squared and sex adjusted HR 1.93, 95% CI 1.25; 
2.99) (Table 2). Risk was highest for participants with microbleeds in brain locations not typically 
affected by CAA (HR 3.35, 95% CI 1.94; 5.78). For subtypes of strokes, we found that microbleeds 
in locations not typically affected by CAA associated with an increased risk of both ischemic 
stroke (HR 3.05, 95% CI 1.65; 5.63) and intracerebral hemorrhage (HR 5.92, 95% CI 1.07; 32.86), 
whereas microbleeds in locations suggestive of CAA were only associated with an increased 
risk of intracerebral hemorrhage (HR 5.27, 95% CI 1.38; 20.23). Additional adjustments for APOE 
ɛ4 carriership, cardiovascular risk, and imaging markers of vascular brain disease weakened 
these associations, but significance remained (Table 2). Microbleed presence was also 
associated with an increased risk of first-ever stroke, in a similar differential pattern for the 
various microbleed locations as described above (Table 3). Especially the presence of multiple 
microbleeds, irrespective of their location, was associated with an increased risk of first-ever 
stroke (Figure 1). Microbleeds did not associate differently with stroke risk after stratifying on 
antithrombotic drug use (Supplementary Table I).  
Six participants with microbleeds at baseline developed a first-ever intracerebral 
hemorrhage during follow-up. All of them presented with multiple microbleeds (median count 
8.5, range 2-17), and three had used antithrombotic agents (either platelet inhibitors or oral 
anticoagulants) during follow-up. The symptomatic hemorrhages were located respectively in 
lobar (thrice), thalamic (twice), and cerebellar region (once). The location of the symptomatic 
hemorrhage of five participants correlated exactly with the anatomical location of one of the 
microbleeds on their prior research scan (Figure 2).   
3Chapter 3.3 
92 
propensity score was the derived predicted value of this equation. Missing covariate data 
(≤7.0%) were imputed based on sex, age, and cardiovascular risk factors using regression 
models. The first model was adjusted for age-squared, sex, and Rotterdam Study subcohort. 
The second model was additionally adjusted for APOE ɛ4 carriership. The third model was 
adjusted for age-squared, sex, Rotterdam Study subcohort and the propensity score described 
above. Finally, the fourth model equaled model 1 with additional adjustments for lacunes, 
white matter lesions, and total intracranial volume. An additional 77 participants were excluded 
in the analysis of model 4 because the white matter lesion segmentation of these MRI scans 
was considered unreliable. The proportionality assumption was tested using Schoenfeld 
residuals.  
Kaplan Meier incident stroke-free survival curves were constructed for groups with 
microbleed count 0,1, 2-4, >4, and compared using the log-rank test. In a sensitivity analysis, 
we repeated the analysis of model 1 after stratification by antithrombotic drug use (ever versus 
never), and applied formal interaction tests to determine significant differences in subgroups.  
Finally, we examined all research and hospital scans of incident intracerebral hemorrhage 
cases, and visually correlated the locations of baseline microbleeds and incident hemorrhages, 
since it was hypothesized that symptomatic hemorrhages would occur in close proximity of 
microbleeds.  
Analyses were done using IBM SPSS statistics for windows, version 21.0 (IBM Corp., Armonk, 
NY), using an alpha-value of 0.05.  
 
Results 
 
Characteristics of the study population are presented in Table 1. Of the total 4,759 participants 
55.3% were women and the average age at baseline was 63.8 years (SD 10.9). Microbleed 
prevalence was 18.7% (median microbleed count 1 [range 1-111]). Older age, hypertension, 
lower total cholesterol, smoking, use of lipid-lowering and antithrombotic medication, and 
ischemic vascular lesions on brain MRI were all significantly associated with microbleed 
presence. At baseline, 8 (0.2%) participants had a history of stroke (six ischemic and two 
unspecified). Over a mean follow up of 4.9 years (SD 1.6), 93 (2.0%) participants suffered a stroke, 
of whom 72 ischemic strokes (3.1 per 1,000 person-years), 11 intracerebral hemorrhages (0.5 
per 1,000 person-years), and 10 unspecified strokes (0.4 per 1,000 person-years).  
  
Cerebral microbleeds are associated with an increased risk of stroke 
93 
Table 1. Characteristics of the study population 
 Total 
population 
(N=4,759) 
Microbleeds 
absent (N=3,867) 
Microbleeds 
present (N=892) 
P-value 
Age, years 63.8 (10.9) 62.4 (10.5) 69.7 (10.9)a <0.001 
Women 2,631 (55.3) 2,155 (55.7) 476 (53.4) 0.204 
Hypertension 2,914 (61.2) 2,267 (58.6) 647 (72.5)a <0.001 
Total cholesterol, mmol/L 5.5 (1.0) 5.6 (1.0) 5.4 (1.1)a 0.001 
High-density lipoprotein 
cholesterol, mmol/L 
1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 0.720 
Ever smoker  3,315 (69.7) 2,665 (68.9) 650 (72.9)a 0.021 
Diabetes mellitus 410 (8.6) 322 (8.3) 88 (9.9) 0.145 
Lipid-lowering medication use 1,118 (23.5) 860 (22.2) 258 (28.9)a <0.001 
Antithrombotic medication use 1,274 (26.8) 891 (23.0) 383 (42.9)a <0.001 
Apolipoprotein E ɛ4 carriership 1,435 (30.2) 1,137 (29.4) 298 (33.4)a 0.021 
White matter lesion volumeb 2.9 (1.6-6.1) 2.7 (1.5-5.1) 5.0 (2.5-11.7)a <0.001 
Lacunes on MRI 310 (6.5) 194 (5.0) 116 (13.0)a <0.001 
Subcortical infarcts on MRI 8 (0.2) 4 (0.1) 4 (0.4)a 0.045 
Cortical infarcts on MRI 111 (2.3) 85 (2.2) 26 (2.9) 0.218 
Values presented mean (SD) for continuous variables and number (%) for categorical variables.  
aP-value <0.05, indicates significant difference in people with and without microbleeds. 
bPresented as median (IQR) and assessed in 4,687 participants.  
 
People with microbleeds at baseline were at increased risk of developing new strokes 
compared with those without microbleeds (age-squared and sex adjusted HR 1.93, 95% CI 1.25; 
2.99) (Table 2). Risk was highest for participants with microbleeds in brain locations not typically 
affected by CAA (HR 3.35, 95% CI 1.94; 5.78). For subtypes of strokes, we found that microbleeds 
in locations not typically affected by CAA associated with an increased risk of both ischemic 
stroke (HR 3.05, 95% CI 1.65; 5.63) and intracerebral hemorrhage (HR 5.92, 95% CI 1.07; 32.86), 
whereas microbleeds in locations suggestive of CAA were only associated with an increased 
risk of intracerebral hemorrhage (HR 5.27, 95% CI 1.38; 20.23). Additional adjustments for APOE 
ɛ4 carriership, cardiovascular risk, and imaging markers of vascular brain disease weakened 
these associations, but significance remained (Table 2). Microbleed presence was also 
associated with an increased risk of first-ever stroke, in a similar differential pattern for the 
various microbleed locations as described above (Table 3). Especially the presence of multiple 
microbleeds, irrespective of their location, was associated with an increased risk of first-ever 
stroke (Figure 1). Microbleeds did not associate differently with stroke risk after stratifying on 
antithrombotic drug use (Supplementary Table I).  
Six participants with microbleeds at baseline developed a first-ever intracerebral 
hemorrhage during follow-up. All of them presented with multiple microbleeds (median count 
8.5, range 2-17), and three had used antithrombotic agents (either platelet inhibitors or oral 
anticoagulants) during follow-up. The symptomatic hemorrhages were located respectively in 
lobar (thrice), thalamic (twice), and cerebellar region (once). The location of the symptomatic 
hemorrhage of five participants correlated exactly with the anatomical location of one of the 
microbleeds on their prior research scan (Figure 2).   
  Ta
b
le
 2
. C
e
re
b
ra
l 
m
ic
ro
b
le
e
d
s 
a
n
d
 t
h
e
 r
is
k 
o
f 
a
n
y 
st
ro
ke
 
 
 
A
ll
 s
tr
o
ke
s 
  
 
 
Is
c
h
e
m
ic
 s
tr
o
ke
 
 
 
 
In
tr
a
c
e
re
b
ra
l 
h
e
m
o
rr
h
a
g
e
 
 
 
n
/N
 
H
R
 (
9
5
%
 C
I)
 
P
-v
a
lu
e
 
 
n
/N
 
H
R
 (
9
5
%
 C
I)
 
P
-v
a
lu
e
 
 
n
/N
 
H
R
 (
9
5
%
 C
I)
 
P
-v
a
lu
e
 
M
o
d
e
l 
1
 
 
 
 
 
 
 
 
 
 
 
 
N
o
 m
ic
ro
b
le
e
d
s 
5
9
/3
,8
6
7
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
 
4
9
/3
,8
6
7
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
 
5
/3
,8
6
7
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
A
n
y 
m
ic
ro
b
le
e
d
s 
3
4
/8
9
2
 
1
.9
3
 (1
.2
5
; 2
.9
9
) 
0
.0
0
4
 
 
2
3
/8
9
2
 
1
.5
2
 (0
.9
1
; 2
.5
3
) 
0
.1
2
4
 
 
6
/8
9
2
 
5
.6
4
 (1
.6
6
; 1
9
.1
3
) 
0
.0
0
6
 
N
o
n
-C
A
A
 r
e
la
te
d
 m
ic
ro
b
le
e
d
s 
1
8
/2
5
9
 
3
.3
5
 (1
.9
4
; 5
.7
8
) 
<
0
.0
0
1
 
 
1
4
/2
5
9
 
3
.0
5
 (1
.6
5
; 5
.6
3
) 
<
0
.0
0
1
 
 
2
/2
5
9
 
5
.9
2
 (1
.0
7
; 3
2
.8
6
) 
0
.0
4
6
 
C
A
A
 r
e
la
te
d
 m
ic
ro
b
le
e
d
s 
1
6
/6
3
3
 
1
.3
0
 (0
.7
4
; 2
.2
8
) 
0
.3
8
3
 
 
9
/6
3
3
 
0
.8
4
 (0
.4
1
; 1
.7
4
) 
0
.6
2
9
 
 
4
/6
3
3
 
5
.2
7
 (1
.3
8
; 2
0
.2
3
) 
0
.0
1
7
 
M
o
d
e
l 
2
 
 
 
 
 
 
 
 
 
 
 
 
N
o
 m
ic
ro
b
le
e
d
s 
5
9
/3
,8
6
7
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
 
4
9
/3
,8
6
7
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
 
5
/3
,8
6
7
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
A
n
y 
m
ic
ro
b
le
e
d
s 
3
4
/8
9
2
 
1
.8
7
 (1
.2
0
; 2
.9
0
) 
0
.0
0
7
 
 
2
3
/8
9
2
 
1
.4
9
 (0
.8
9
; 2
.4
9
) 
0
.1
4
5
 
 
6
/8
9
2
 
5
.3
4
 (1
.5
6
; 1
8
.3
2
) 
0
.0
0
9
 
N
o
n
-C
A
A
 r
e
la
te
d
 m
ic
ro
b
le
e
d
s 
1
8
/2
5
9
 
3
.2
8
 (1
.8
9
; 5
.6
8
) 
<
0
.0
0
1
 
 
1
4
/2
5
9
 
2
.9
7
 (1
.6
1
; 5
.5
1
) 
0
.0
0
1
 
 
2
/2
5
9
 
5
.9
7
 (1
.0
7
; 3
3
.3
9
) 
0
.0
4
6
 
C
A
A
 r
e
la
te
d
 m
ic
ro
b
le
e
d
s 
1
6
/6
3
3
 
1
.2
4
 (0
.7
0
; 2
.1
9
) 
0
.4
7
7
 
 
9
/6
3
3
 
0
.8
1
 (0
.3
9
; 1
.6
8
) 
0
.5
6
0
 
 
4
/6
3
3
 
5
.0
4
 (1
.3
0
; 1
9
.4
7
) 
0
.0
2
1
 
M
o
d
e
l 
3
 
 
 
 
 
 
 
 
 
 
 
 
N
o
 m
ic
ro
b
le
e
d
s 
5
9
/3
,8
6
7
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
 
4
9
/3
,8
6
7
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
 
5
/3
,8
6
7
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
A
n
y 
m
ic
ro
b
le
e
d
s 
3
4
/8
9
2
 
1
.7
9
 (1
.1
6
; 2
.7
8
) 
0
.0
1
0
 
 
2
3
/8
9
2
 
1
.4
0
 (0
.8
4
; 2
.3
4
) 
0
.2
1
3
 
 
6
/8
9
2
 
5
.4
1
 (1
.5
8
; 1
8
.4
6
) 
0
.0
0
8
 
N
o
n
-C
A
A
 r
e
la
te
d
 m
ic
ro
b
le
e
d
s 
1
8
/2
5
9
 
2
.9
2
 (1
.6
9
; 5
.0
4
) 
<
0
.0
0
1
 
 
1
4
/2
5
9
 
2
.6
0
 (1
.4
1
; 4
.8
0
) 
0
.0
0
3
 
 
2
/2
5
9
 
5
.7
7
 (1
.0
1
; 3
2
.8
0
) 
0
.0
5
1
 
C
A
A
 r
e
la
te
d
 m
ic
ro
b
le
e
d
s 
1
6
/6
3
3
 
1
.2
4
 (0
.7
1
; 2
.1
9
) 
0
.4
6
9
 
 
9
/6
3
3
 
0
.8
0
 (0
.3
9
; 1
.6
5
) 
0
.5
3
5
 
 
4
/6
3
3
 
5
.2
5
 (1
.3
7
; 2
0
.1
7
) 
0
.0
1
7
 
M
o
d
e
l 
4
 
 
 
 
 
 
 
 
 
 
 
 
N
o
 m
ic
ro
b
le
e
d
s 
5
5
/3
,8
1
2
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
 
4
5
/3
,8
1
2
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
 
5
/3
,8
1
2
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
A
n
y 
m
ic
ro
b
le
e
d
s 
3
4
/8
7
5
 
1
.6
8
 (1
.0
7
; 2
.6
5
) 
0
.0
2
5
 
 
2
3
/8
7
5
 
1
.2
8
 (0
.7
5
; 2
.1
7
) 
0
.3
7
1
 
 
6
/8
7
5
 
4
.6
4
 (1
.3
3
; 1
6
.1
9
) 
0
.0
1
7
 
N
o
n
-C
A
A
 r
e
la
te
d
 m
ic
ro
b
le
e
d
s 
1
8
/2
5
4
 
2
.3
4
 (1
.3
1
; 4
.1
9
) 
0
.0
0
4
 
 
1
4
/2
5
4
 
2
.0
6
 (1
.0
7
; 3
.9
5
) 
0
.0
3
1
 
 
2
/2
5
4
 
3
.3
8
 (0
.5
3
; 2
1
.5
4
) 
0
.1
9
6
 
C
A
A
 r
e
la
te
d
 m
ic
ro
b
le
e
d
s 
1
6
/6
2
1
 
1
.2
8
 (0
.7
2
; 2
.2
8
) 
0
.3
9
9
 
 
9
/6
2
1
 
0
.8
2
 (0
.3
9
; 1
.7
0
) 
0
.5
8
7
 
 
4
/6
2
1
 
4
.8
8
 (1
.2
7
; 1
8
.8
3
) 
0
.0
2
3
 
A
b
b
re
vi
at
io
n
s:
 n
/N
 =
 n
u
m
b
e
r 
o
f p
e
o
p
le
 w
it
h
 s
tr
o
ke
 p
e
r 
e
xp
o
su
re
 c
at
e
g
o
ry
/ 
to
ta
l n
u
m
b
e
r 
o
f p
ar
ti
ci
p
an
ts
 w
it
h
in
 t
h
e
 e
xp
o
su
re
 c
at
e
g
o
ry
. 
V
al
u
e
s 
re
p
re
se
n
t 
e
st
im
at
e
d
 h
az
ar
d
 r
at
io
s 
w
it
h
 9
5
%
 c
o
n
fid
e
n
ce
 in
te
rv
al
 f
o
r 
an
y 
in
ci
d
e
n
t 
st
ro
ke
 (
re
cu
rr
e
n
t 
o
r 
fir
st
-e
ve
r)
 in
 p
ar
ti
ci
p
an
ts
 w
it
h
 m
ic
ro
b
le
e
d
s 
co
m
p
ar
e
d
 t
o
 t
h
o
se
 w
it
h
o
u
t 
m
ic
ro
b
le
e
d
s.
 “C
A
A
 re
la
te
d
” m
ic
ro
b
le
e
d
s 
in
cl
u
d
e
d
 s
tr
ic
tl
y 
lo
b
ar
 o
r l
o
b
ar
 w
it
h
 c
e
re
b
e
lla
r m
ic
ro
b
le
e
d
s.
 “N
o
n
-C
A
A
 re
la
te
d
” m
ic
ro
b
le
e
d
s 
in
cl
u
d
e
d
 m
ic
ro
b
le
e
d
s 
in
 a
ll 
o
th
e
r b
ra
in
 lo
ca
ti
o
n
s.
 
M
o
d
e
l 1
: a
d
ju
st
e
d
 fo
r 
ag
e
-s
q
u
ar
e
d
, s
e
x,
 a
n
d
 R
o
tt
e
rd
am
 S
tu
d
y 
su
b
co
h
o
rt
. 
M
o
d
e
l 2
: a
s 
m
o
d
e
l 1
, a
d
d
it
io
n
al
ly
 a
d
ju
st
e
d
 fo
r 
A
P
O
E 
ɛ4
 c
ar
ri
e
rs
h
ip
. 
M
o
d
e
l 3
: a
s 
m
o
d
e
l 1
, a
d
d
it
io
n
al
ly
 a
d
ju
st
e
d
 fo
r 
p
ro
p
e
n
si
ty
 s
co
re
.a  
M
o
d
e
l 4
: a
s 
m
o
d
e
l 1
, a
d
d
it
io
n
al
ly
 a
d
ju
st
e
d
 fo
r 
la
cu
n
e
s,
 w
h
it
e
 m
at
te
r 
le
si
o
n
 v
o
lu
m
e
, a
n
d
 in
tr
ac
ra
n
ia
l v
o
lu
m
e
.  
a P
ro
p
e
n
si
ty
 s
co
re
 in
cl
u
d
e
d
: h
yp
e
rt
e
n
si
o
n
, t
o
ta
l a
n
d
 h
ig
h
-d
e
n
si
ty
 li
p
o
p
ro
te
in
 c
h
o
le
st
e
ro
l, 
sm
o
ki
n
g
, d
ia
b
e
te
s 
m
e
lli
tu
s,
 li
p
id
-l
o
w
e
ri
n
g
 m
e
d
ic
at
io
n
, a
n
d
 a
n
ti
th
ro
m
b
o
ti
c 
m
e
d
ic
at
io
n
 u
se
. 
  Ta
b
le
 3
. C
e
re
b
ra
l 
m
ic
ro
b
le
e
d
s 
a
n
d
 t
h
e
 r
is
k 
o
f 
fi
rs
t-
e
v
e
r 
st
ro
ke
 
 
  
A
ll
 s
tr
o
ke
s 
 
 
 
Is
c
h
e
m
ic
 s
tr
o
ke
 
 
 
 
In
tr
a
c
e
re
b
ra
l 
h
e
m
o
rr
h
a
g
e
 
  
 
n
/N
 
H
R
 (
9
5
%
 C
I)
 
P
-v
a
lu
e
 
 
n
/N
 
H
R
 (
9
5
%
 C
I)
 
P
-v
a
lu
e
 
 
n
/N
 
H
R
 (
9
5
%
 C
I)
 
P
-v
a
lu
e
 
M
o
d
e
l 
1
 
 
 
 
 
 
 
 
 
 
 
 
N
o
 m
ic
ro
b
le
e
d
s 
5
6
/3
,8
6
4
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
 
4
7
/3
,8
6
4
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
 
5
/3
,8
6
4
 
1
.0
0
 (R
e
fe
re
n
ce
) 
 
A
n
y 
m
ic
ro
b
le
e
d
s 
2
9
/8
8
7
 
1
.7
1
 (1
.0
8
; 2
.7
3
) 
0
.0
2
6
 
 
1
9
/8
8
7
 
1
.2
8
 (0
.7
4
; 2
.2
2
) 
0
.3
9
5
 
 
6
/8
8
7
 
5
.6
8
 (1
.6
8
; 1
9
.2
7
) 
0
.0
0
6
 
N
o
n
-C
A
A
 r
e
la
te
d
 
m
ic
ro
b
le
e
d
s 
1
5
/2
5
6
 
2
.8
9
 (1
.6
1
; 5
.2
0
) 
<
0
.0
0
1
 
 
1
1
/2
5
6
 
2
.4
5
 (1
.2
5
; 4
.8
1
) 
0
.0
1
1
 
 
2
/2
5
6
 
5
.9
8
 (1
.0
8
; 3
3
.1
6
) 
0
.0
4
4
 
C
A
A
 r
e
la
te
d
 
m
ic
ro
b
le
e
d
s 
1
4
/6
3
1
 
1
.2
0
 (0
.6
6
; 2
.1
8
) 
0
.5
7
0
 
 
8
/6
3
1
 
0
.7
8
 (0
.3
6
; 1
.6
7
) 
0
.7
7
7
 
 
4
/6
3
1
 
5
.3
2
 (1
.3
9
; 2
0
.3
7
) 
0
.0
1
6
 
A
b
b
re
vi
at
io
n
s:
 n
/N
 =
 n
u
m
b
e
r 
o
f p
e
o
p
le
 w
it
h
 s
tr
o
ke
 p
e
r 
e
xp
o
su
re
 c
at
e
g
o
ry
/ 
to
ta
l n
u
m
b
e
r 
o
f p
ar
ti
ci
p
an
ts
 w
it
h
in
 e
xp
o
su
re
 c
at
e
g
o
ry
. 
V
al
u
e
s 
re
p
re
se
n
t 
e
st
im
at
e
d
 a
g
e
-s
q
u
ar
e
d
, s
e
x,
 a
n
d
 R
o
tt
e
rd
am
 S
tu
d
y 
su
b
co
h
o
rt
 a
d
ju
st
e
d
 h
az
ar
d
 r
at
io
s 
w
it
h
 9
5
%
 c
o
n
fid
e
n
ce
 in
te
rv
al
 f
o
r 
in
ci
d
e
n
t 
fir
st
-e
ve
r 
st
ro
ke
 in
 p
ar
ti
ci
p
an
ts
 w
it
h
 
m
ic
ro
b
le
e
d
s 
co
m
p
ar
e
d
 t
o
 t
h
o
se
 w
it
h
o
u
t 
m
ic
ro
b
le
e
d
s.
  
“C
A
A
 r
e
la
te
d
” 
m
ic
ro
b
le
e
d
s 
in
cl
u
d
e
d
 s
tr
ic
tl
y 
lo
b
ar
 o
r 
lo
b
ar
 w
it
h
 c
e
re
b
e
lla
r 
m
ic
ro
b
le
e
d
s.
 “
N
o
n
-C
A
A
 r
e
la
te
d
” 
m
ic
ro
b
le
e
d
s 
in
cl
u
d
e
d
 m
ic
ro
b
le
e
d
s 
in
 a
ll 
o
th
e
r 
b
ra
in
 lo
ca
ti
o
n
s.
  
 
 
94
Cerebral microbleeds are associated with an increased risk of stroke 
93 
Table 1. Characteristics of the study population 
 Total 
population 
(N=4,759) 
Microbleeds 
absent (N=3,867) 
Microbleeds 
present (N=892) 
P-value 
Age, years 63.8 (10.9) 62.4 (10.5) 69.7 (10.9)a <0.001 
Women 2,631 (55.3) 2,155 (55.7) 476 (53.4) 0.204 
Hypertension 2,914 (61.2) 2,267 (58.6) 647 (72.5)a <0.001 
Total cholesterol, mmol/L 5.5 (1.0) 5.6 (1.0) 5.4 (1.1)a 0.001 
High-density lipoprotein 
cholesterol, mmol/L 
1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 0.720 
Ever smoker  3,315 (69.7) 2,665 (68.9) 650 (72.9)a 0.021 
Diabetes mellitus 410 (8.6) 322 (8.3) 88 (9.9) 0.145 
Lipid-lowering medication use 1,118 (23.5) 860 (22.2) 258 (28.9)a <0.001 
Antithrombotic medication use 1,274 (26.8) 891 (23.0) 383 (42.9)a <0.001 
Apolipoprotein E ɛ4 carriership 1,435 (30.2) 1,137 (29.4) 298 (33.4)a 0.021 
White matter lesion volumeb 2.9 (1.6-6.1) 2.7 (1.5-5.1) 5.0 (2.5-11.7)a <0.001 
Lacunes on MRI 310 (6.5) 194 (5.0) 116 (13.0)a <0.001 
Subcortical infarcts on MRI 8 (0.2) 4 (0.1) 4 (0.4)a 0.045 
Cortical infarcts on MRI 111 (2.3) 85 (2.2) 26 (2.9) 0.218 
Values presented mean (SD) for continuous variables and number (%) for categorical variables.  
aP-value <0.05, indicates significant difference in people with and without microbleeds. 
bPresented as median (IQR) and assessed in 4,687 participants.  
 
People with microbleeds at baseline were at increased risk of developing new strokes 
compared with those without microbleeds (age-squared and sex adjusted HR 1.93, 95% CI 1.25; 
2.99) (Table 2). Risk was highest for participants with microbleeds in brain locations not typically 
affected by CAA (HR 3.35, 95% CI 1.94; 5.78). For subtypes of strokes, we found that microbleeds 
in locations not typically affected by CAA associated with an increased risk of both ischemic 
stroke (HR 3.05, 95% CI 1.65; 5.63) and intracerebral hemorrhage (HR 5.92, 95% CI 1.07; 32.86), 
whereas microbleeds in locations suggestive of CAA were only associated with an increased 
risk of intracerebral hemorrhage (HR 5.27, 95% CI 1.38; 20.23). Additional adjustments for APOE 
ɛ4 carriership, cardiovascular risk, and imaging markers of vascular brain disease weakened 
these associations, but significance remained (Table 2). Microbleed presence was also 
associated with an increased risk of first-ever stroke, in a similar differential pattern for the 
various microbleed locations as described above (Table 3). Especially the presence of multiple 
microbleeds, irrespective of their location, was associated with an increased risk of first-ever 
stroke (Figure 1). Microbleeds did not associate differently with stroke risk after stratifying on 
antithrombotic drug use (Supplementary Table I).  
Six participants with microbleeds at baseline developed a first-ever intracerebral 
hemorrhage during follow-up. All of them presented with multiple microbleeds (median count 
8.5, range 2-17), and three had used antithrombotic agents (either platelet inhibitors or oral 
anticoagulants) during follow-up. Th  symptomatic hemorrhages were located respectively in 
lobar (thrice), thalamic (twice), and cerebellar region (once). The location of the symptomatic 
hemorrhage of five participants correlated exactly with the anatomical location of one of the 
microbleeds on their prior research scan (Figure 2).   
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Cerebral microbleeds are associated with an increased risk of stroke 
3 
Table 1. Characteristics of the study population 
 Total 
population 
(N=4,759) 
Microbleeds 
absent (N=3,867) 
Microbleeds 
present (N=892) 
P-value 
Age, years 63.8 (10.9) 62.4 (10.5) 69.7 (10.9)a <0.001 
Women 2,631 (55.3) 2,155 (55.7) 476 (53.4) 0.204 
Hypertension 2,914 (61.2) 2,267 (58.6) 647 (72.5)a <0.001 
Total cholesterol, mmol/L 5.5 (1.0) 5.6 (1.0) 5.4 (1.1)a 0.001 
High-density lipoprotein 
cholesterol, mmol/L 
1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 0.720 
Ever smoker  3,315 (69.7) 2,665 (68.9) 650 (72.9)a 0.021 
Diabetes mellitus 410 (8.6) 322 (8.3) 88 (9.9) 0.145 
Lipid-lowering medication use 1,118 (23.5) 860 (22.2) 258 (28.9)a <0.001 
Antithrombotic medication use 1,274 (26.8) 891 (23.0) 383 (42.9)a <0.001 
Apolipoprotein E ɛ4 carriership 1,435 (30.2) 1,137 (29.4) 298 (33.4)a 0.021 
White matter lesion volumeb 2.9 (1.6-6.1) 2.7 (1.5-5.1) 5.0 (2.5-11.7)a <0.001 
Lacunes on MRI 310 (6.5) 194 (5.0) 116 (13.0)a <0.001 
Subcortical infarcts on MRI 8 (0.2) 4 (0.1) 4 (0.4)a 0.045 
Cortical infarcts on MRI 111 (2.3) 85 (2.2) 26 (2.9) 0.218 
Values presented mean (SD) for continuous variables and number (%) for categorical variables.  
aP-value <0.05, indicates significant difference in people with and without microbleeds. 
bPresented as median (IQR) and assessed in 4,687 participants.  
 
People with microbleeds at baseline were at increased risk of developing new strokes 
compared with those without microbleeds (age-squared and sex adjusted HR 1.93, 95% CI 1.25; 
2.99) (Table 2). Risk was highest for participants with microbleeds in brain locations not typically 
affected by CAA (HR 3.35, 95% CI 1.94; 5.78). For subtypes of strokes, we found that microbleeds 
in locations not typically affected by CAA associated with an increased risk of both ischemic 
stroke (HR 3.05, 95% CI 1.65; 5.63) and intracerebral hemorrhage (HR 5.92, 95% CI 1.07; 32.86), 
whereas microbleeds in locations suggestive of CAA were only associated with an increased 
risk of intracerebral hemorrhage (HR 5.27, 95% CI 1.38; 20.23). Additional adjustments for APOE 
ɛ4 carriership, cardiovascular risk, and imaging markers of vascular brain disease weakened 
these associations, but significance remained (Table 2). Microbleed presence was also 
associated with an increased risk of first-ever stroke, in a similar differential pattern for the 
various microbleed locations as described above (Table 3). Especially the presence of multiple 
microbleeds, irrespective of their location, was associated with an increased risk of first-ever 
stroke (Figure 1). Microbleeds did not associate differently with stroke risk after stratifying on 
antithrombotic drug use (Supplementary Table I).  
Six participants with microbleeds at baseline developed a first-ever intracerebral 
hemorrhage during follow-up. All of them presented with multiple microbleeds (median count 
8.5, range 2-17), and three had used antithrombotic agents (either platelet inhibitors or oral 
anticoagulants) during follow-up. Th  symptomatic hemorrhages were located respectively in 
lobar (thrice), thalamic (twice), and cerebellar region (once). The location of the symptomatic 
hemorrhage of five participants correlated exactly with the anatomical location of one of the 
microbleeds on their prior research scan (Figure 2).   
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2 
propensity score was the deriv d predicted value of this equation. Missing covariat  data 
(≤7.0%) were imputed based on sex, age, and cardiovascular risk factors using regression 
models. The first model was adjusted for age-squared, sex, and Rotterdam Study subcohort. 
The second model was additionally adjusted for APOE ɛ4 carriership. Th  third model was 
adju ted for age-squared, sex, Rotterdam Study subcohort and the propensity score described 
above. Finally, the fourth model equaled model 1 with additional adjustments for lacunes, 
white matter lesions, and total intra ranial volume. An additional 77 participants were excluded 
in the analysis f model 4 because the white matter lesion segmentation of these MRI scans 
was considered unreliable. The proportionality as umption was tested using Schoenfeld 
residuals.  
Kaplan Meier incident stroke-free survival curves were constructed for groups with 
microbleed count 0,1, 2-4, >4, and compared using the log-rank test. In a sensitivity analysis, 
we repeated the analysis of model 1 after stratification by antithrombotic drug use (ever versus 
never), and applied formal interaction tests to determine significant differences in subgroups.  
Finally, we examined all research and hospital scans of incident intracerebral hemorrhage 
cases, and visually correlated the locations of baseline microbleeds and incident hemorrhages, 
since it was hypothesized that symptomatic hemorrhages would occur in close proximity of 
microbleeds.  
Analyses were done using IBM SPSS statistics for windows, version 21.0 (IBM Corp., Armonk, 
NY), using an alpha-value of 0.05.  
 
Results 
 
Characteristics of the study population are presented in Table 1. Of the total 4,759 participants 
55.3% were women and the average age at baseline was 63.8 years (SD 10.9). Microbleed 
prevalence was 18.7% (median microbleed count 1 [range 1-111]). Older age, hypertension, 
lower total cholesterol, smoking, use of lipid-lowering and antithrombotic medication, and 
ischemic vascular lesions on brain MRI were all significantly associated with microbleed 
presence. At baseline, 8 (0.2%) participants had a history of stroke (six ischemic and two 
unspecified). Over a mean follow up of 4.9 years (SD 1.6), 93 (2.0%) participants suffered a stroke, 
of whom 72 ischemic strokes (3.1 per 1,000 person-years), 11 intracerebral hemorrhages (0.5 
per 1,000 person-years), and 10 unspecified strokes (0.4 per 1,000 person-years).  
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Table 1. Characteristics of the study population 
 Total 
population 
(N=4,759) 
Microbleeds 
absent (N=3,867) 
Microbleeds 
present (N=892) 
P-value 
Age, years 63.8 (10.9) 62.4 (10.5) 69.7 (10.9)a <0.001 
Women 2,631 (55.3) 2,155 (55.7) 476 (53.4) 0.204 
Hypertension 2,914 (61.2) 2,267 (58.6) 647 (72.5)a <0.001 
Total cholesterol, mmol/L 5.5 (1.0) 5.6 (1.0) 5.4 (1.1)a 0.001 
High-density lipoprotein 
cholesterol, mmol/L 
1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 0.720 
Ever smoker  3,315 (69.7) 2,665 (68.9) 650 (72.9)a 0.021 
Diabetes mellitus 410 (8.6) 322 (8.3) 88 (9.9) 0.145 
Lipid-lowering medication use 1,118 (23.5) 860 (22.2) 258 (28.9)a <0.001 
Antithrombotic medication use 1,274 (26.8) 891 (23.0) 383 (42.9)a <0.001 
Apolipoprotein E ɛ4 carriership 1,435 (30.2) 1,137 (29.4) 298 (33.4)a 0.021 
White matter lesion volumeb 2.9 (1.6-6.1) 2.7 (1.5-5.1) 5.0 (2.5-11.7)a <0.001 
Lacunes on MRI 310 (6.5) 194 (5.0) 116 (13.0)a <0.001 
Subcortical infarcts on MRI 8 (0.2) 4 (0.1) 4 (0.4)a 0.045 
Cortical infarcts on MRI 111 (2.3) 85 (2.2) 26 (2.9) 0.218 
Values presented mean (SD) for continuous variables and number (%) for categorical variables.  
aP-value <0.05, indicates significant difference in people with and without microbleeds. 
bPresented as median (IQR) and assessed in 4,687 participants.  
 
People with microbleeds at baseline were at increased risk of developing new strokes 
compared with those without microbleeds (age-squared and sex adjusted HR 1.93, 95% CI 1.25; 
2.99) (Table 2). Risk was highest for participants with microbleeds in brain locations not typically 
affected by CAA (HR 3.35, 95% CI 1.94; 5.78). For subtypes of strokes, we found that microbleeds 
in locations not typically affected by CAA associated with an increased risk of both ischemic 
stroke (HR 3.05, 95% CI 1.65; 5.63) and intracerebral hemorrhage (HR 5.92, 95% CI 1.07; 32.86), 
whereas microbleeds in locations suggestive of CAA were only associated with an increased 
risk of intracerebral hemorrhage (HR 5.27, 95% CI 1.38; 20.23). Additional adjustments for APOE 
ɛ4 carriership, cardiovascular risk, and imaging markers of vascular brain disease weakened 
these associations, but significance remained (Table 2). Microbleed presence was also 
associated with an increased risk of first-ever stroke, in a similar differential pattern for the 
various microbleed locations as described above (Table 3). Especially the presence of ultiple 
microbleeds, irrespective of their location, was associated with an increased risk of first-ever 
stroke (Figure 1). Microbleeds did not associate differently with stroke risk after stratifyi g on 
antithrombotic drug use (Supplementary Table I).  
Six participants with microbleeds at baseline developed a first-ever intracerebral 
hemorrhage during follow-up. All of them presented with multiple microbleeds (median count 
8.5, range 2-17), and three had used antithrombotic agents (either platelet inhibitors or oral 
anticoagulants) during follow-up. The symptomatic hemorrhages were located respective y in 
lobar (thrice), thalamic (twice), and cerebellar region (once). The location of the symptomatic 
hemorrhage of five participants correlated exactly with the anatomical location of one of the 
microbleeds on their prior research scan (Figure 2).   
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propensity score was the deriv d predicted value of this equation. Missing covariat  data 
(≤7.0%) were imputed based on sex, age, and cardiovascular risk factors using regression 
models. The first model was adjusted for age-squared, sex, and Rotterdam Study subcohort. 
The second model was additionally adjusted for APOE ɛ4 carriership. Th  third model was 
adju ted for age-squared, sex, Rotterdam Study subcohort and the propensity score described 
above. Finally, the fourth model equaled model 1 with additional adjustments for lacunes, 
white matter lesions, and total intra ranial volume. An additional 77 participants were excluded 
in the analysis f model 4 because the white matter lesion segmentation of these MRI scans 
was considered unreliable. The proportionality as umption was tested using Schoenfeld 
residuals.  
Kaplan Meier incident stroke-free survival curves were constructed for groups with 
microbleed count 0,1, 2-4, >4, and compared using the log-rank test. In a sensitivity analysis, 
we repeated the analysis of model 1 after stratification by antithrombotic drug use (ever versus 
never), and applied formal interaction tests to determine significant differences in subgroups.  
Finally, we examined all research and hospital scans of incident intracerebral hemorrhage 
cases, and visually correlated the locations of baseline microbleeds and incident hemorrhages, 
since it was hypothesized that symptomatic hemorrhages would occur in close proximity of 
microbleeds.  
Analyses were done using IBM SPSS statistics for windows, version 21.0 (IBM Corp., Armonk, 
NY), using an alpha-value of 0.05.  
 
Results 
 
Characteristics of the study population are presented in Table 1. Of the total 4,759 participants 
55.3% were women and the average age at baseline was 63.8 years (SD 10.9). Microbleed 
prevalence was 18.7% (median microbleed count 1 [range 1-111]). Older age, hypertension, 
lower total cholesterol, smoking, use of lipid-lowering and antithrombotic medication, and 
ischemic vascular lesions on brain MRI were all significantly associated with microbleed 
presence. At baseline, 8 (0.2%) participants had a history of stroke (six ischemic and two 
unspecified). Over a mean follow up of 4.9 years (SD 1.6), 93 (2.0%) participants suffered a stroke, 
of whom 72 ischemic strokes (3.1 per 1,000 person-years), 11 intracerebral hemorrhages (0.5 
per 1,000 person-years), and 10 unspecified strokes (0.4 per 1,000 person-years).  
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Table 1. Characteristics of the study population 
 Total 
population 
(N=4,759) 
Microbleeds 
absent (N=3,867) 
Microbleeds 
present (N=892) 
P-value 
Age, years 63.8 (10.9) 62.4 (10.5) 69.7 (10.9)a <0.001 
Women 2,631 (55.3) 2,155 (55.7) 476 (53.4) 0.204 
Hypertension 2,914 (61.2) 2,267 (58.6) 647 (72.5)a <0.001 
Total cholesterol, mmol/L 5.5 (1.0) 5.6 (1.0) 5.4 (1.1)a 0.001 
High-density lipoprotein 
cholesterol, mmol/L 
1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 0.720 
Ever smoker  3,315 (69.7) 2,665 (68.9) 650 (72.9)a 0.021 
Diabetes mellitus 410 (8.6) 322 (8.3) 88 (9.9) 0.145 
Lipid-lowering medication use 1,118 (23.5) 860 (22.2) 258 (28.9)a <0.001 
Antithrombotic medication use 1,274 (26.8) 891 (23.0) 383 (42.9)a <0.001 
Apolipoprotein E ɛ4 carriership 1,435 (30.2) 1,137 (29.4) 298 (33.4)a 0.021 
White matter lesion volumeb 2.9 (1.6-6.1) 2.7 (1.5-5.1) 5.0 (2.5-11.7)a <0.001 
Lacunes on MRI 310 (6.5) 194 (5.0) 116 (13.0)a <0.001 
Subcortical infarcts on MRI 8 (0.2) 4 (0.1) 4 (0.4)a 0.045 
Cortical infarcts on MRI 111 (2.3) 85 (2.2) 26 (2.9) 0.218 
Values presented mean (SD) for continuous variables and number (%) for categorical variables.  
aP-value <0.05, indicates significant difference in people with and without microbleeds. 
bPresented as median (IQR) and assessed in 4,687 participants.  
 
People with microbleeds at baseline were at increased risk of developing new strokes 
compared with those without microbleeds (age-squared and sex adjusted HR 1.93, 95% CI 1.25; 
2.99) (Table 2). Risk was highest for participants with microbleeds in brain locations not typically 
affected by CAA (HR 3.35, 95% CI 1.94; 5.78). For subtypes of strokes, we found that microbleeds 
in locations not typically affected by CAA associated with an increased risk of both ischemic 
stroke (HR 3.05, 95% CI 1.65; 5.63) and intracerebral hemorrhage (HR 5.92, 95% CI 1.07; 32.86), 
whereas microbleeds in locations suggestive of CAA were only associated with an increased 
risk of intracerebral hemorrhage (HR 5.27, 95% CI 1.38; 20.23). Additional adjustments for APOE 
ɛ4 carriership, cardiovascular risk, and imaging markers of vascular brain disease weakened 
these associations, but significance remained (Table 2). Microbleed presence was also 
associated with an increased risk of first-ever stroke, in a similar differential pattern for the 
various microbleed locations as described above (Table 3). Especially the presence of ultiple 
microbleeds, irrespective of their location, was associated with an increased risk of first-ever 
stroke (Figure 1). Microbleeds did not associate differently with stroke risk after stratifyi g on 
antithrombotic drug use (Supplementary Table I).  
Six participants with microbleeds at baseline developed a first-ever intracerebral 
hemorrhage during follow-up. All of them presented with multiple microbleeds (median count 
8.5, range 2-17), and three had used antithrombotic agents (either platelet inhibitors or oral 
anticoagulants) during follow-up. The symptomatic hemorrhages were located respective y in 
lobar (thrice), thalamic (twice), and cerebellar region (once). The location of the symptomatic 
hemorrhage of five participants correlated exactly with the anatomical location of one of the 
microbleeds on their prior research scan (Figure 2).   
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Discussion 
 
In the population-based Rotterdam Study we investigated whether microbleed presence on 
MRI is a determinant of future stroke. We found that the presence of microbleeds, and 
especially multiple microbleeds, was associated with an increased risk of stroke, including first-
ever stroke. Cerebral microbleeds located in regions not typically affected by CAA were 
associated with an increased risk of both ischemic stroke and intracerebral hemorrhage, 
whereas microbleeds located in regions where CAA is known to be highly prevalent seemed 
to particularly associate with an increased risk of intracerebral hemorrhage.  
In a population of community-dwelling middle-aged people and elderly we found that 
microbleeds on MRI associated with an increased risk of both ischemic stroke and intracerebral 
hemorrhage. The latter has been demonstrated previously in patients with lobar intracerebral 
hemorrhages due to CAA. These patients were at increased risk of recurrent stroke when 
microbleeds were present on MRI.9,17 Evidence that microbleeds also associate with ischemic 
or occlusive brain disease was found in a recent meta-analysis of clinical studies.29 They showed 
that Caucasian patients with microbleeds who were admitted for acute ischemic stroke or 
transient neurological attack had a 3.87 times (95% CI 0.91; 16.4) higher odds of spontaneous 
intracerebral hemorrhage, and 2.23 times (95% CI 1.29; 3.85) higher odds of ischemic stroke 
compared to patients without microbleeds. We now showed that these results can be 
extrapolated to Caucasian community-dwelling persons without a history of stroke.  
We found that the risk of stroke subtype differed according to the location of microbleeds 
in the brain, and thus possibly differs with underlying vasculopathy. Our results suggest that 
microbleeds, regardless of their presumed underlying pathology (either CAA or hypertensive 
arteriopathy) strongly associate with intracerebral hemorrhage. Only microbleeds in non-lobar 
brain regions (suspected of hypertensive arteriopathy) were related to ischemic stroke. It may 
be that in the general population CAA-related microbleeds do not relate to overt ischemic 
stroke or that our sample of ischemic stroke cases was too small to detect a significant 
association. The latter may be more accurate given prior findings from other studies, which 
suggest that CAA related microbleeds associate with silent and overt ischemic brain lesions.5,29  
We also observed that intracerebral hemorrhages were predisposed to occur in the same 
anatomical location as pre-existing microbleeds. Although we previously showed that 
microbleeds indicate the presence of more widespread small vessel disease,28 this finding 
implies that microbleeds may be of value in pinpointing focal areas in the brain with more 
active vasculopathy. It should be noted, however, that the number of ICH cases was small and 
hampered our ability to conduct relevant statistical analysis. Therefore, the overlap in anatomic 
location between microbleeds and ICH may also be due to chance. 
Only two previous studies, both in Asian populations, investigated the association of 
microbleeds with stroke in elderly without a history of cerebrovascular events.19,20 One study 
found an increased risk of ischemic stroke in participants with any microbleeds compared with 
no microbleeds.19 The other study found that deep or mixed (i.e., both in deep and lobar brain 
regions) microbleeds was associated with an increased risk of ischemic stroke and deep 
intracerebral hemorrhage.20 Methodological limitations of both studies included, small number 
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of stroke cases, limited or no correction for potential confounders, and absence of subgroup 
analysis for microbleed location. Compared to our study, both studies had an 
overrepresentation of intracerebral hemorrhage cases compared with ischemic stroke cases, 
which could be explained by ethnic differences in study population as Asians on average have 
a two-times higher risk of intracerebral hemorrhages compared with Caucasians.29,30 In 
addition, blood vessels in Asian intracerebral hemorrhage patients may more often be affected 
by fibrohyalinosis rather than b-amyloid deposition, reflecting differences in cardiovascular risk 
for Asians and Caucasians.31 
In line with another clinical study,9 our results suggest a dose-response effect, with higher 
risk of stroke in people with multiple microbleeds on MRI. We should, however, consider that 
small vessel pathology progresses gradually and cut-off points are not easily chosen, especially 
since microbleed detection – and the perceived number – strongly depends on technical 
imaging parameters.32 Also, the presence of microbleeds (including just a single microbleed) 
has been associated with an increased risk of new bleeds, and to relate to more diffuse brain 
damage, i.e., to white matter.28,33 Although microbleed burden may thus be used as a severity 
measure, we note that their presence in itself seems to indicate diffuse vascular brain disease 
which is progressive in nature.  
The use of antithrombotic drugs in people with microbleeds on MRI remains a topic of 
debate, and is fueled by studies like ours that show that microbleed presence is associated with 
an increased risk of both ischemic stroke and intracerebral hemorrhage. Our current results 
suggest that stroke risk associated with microbleeds was not affected by antithrombotic drugs 
use. However, we were unable to investigate this association separately for intracerebral 
hemorrhage due to the small number of cases. Results from ongoing clinical trials and cost-
benefit studies should settle whether the benefits of ischemic stroke prevention by use of 
antithrombotic drugs outweigh the risk of intracerebral hemorrhage in people with 
microbleeds.  
Strengths of our study include the population-based character, the longitudinal design, 
and a systematic stroke detection protocol that allows for thorough collection of fatal and non-
fatal stroke events, both in-hospital and outside. Some potential limitations have to be 
mentioned before discussing the implication of our findings. First, participants who were 
eligible and underwent brain MRI scanning were on average younger and had lower 
cardiovascular risk than those who were eligible for MRI but did not participate.33 Also, 
excluding participants with incomplete follow-up for incident stroke may have been a source 
of bias, as these participants might have been less healthy on average. This potentially induced 
selection bias in our study and may have led to an underestimation of associations. Second, in 
accordance with the incidence of intracerebral hemorrhage in the general population the 
number of intracerebral hemorrhage cases during follow-up in our study was small, and 
hampered our ability to conduct in depth statistics. Third, microbleeds were rated by trained 
research physicians. Since microbleed detection depends on rater expertise, our results may 
not translate directly to routine clinical practice. Fourth, the categorization into “CAA related” 
and “non-CAA related” microbleeds, though in line with current research and clinical practice, 
is artificial and does not accurately reflect the multifactorial nature of microbleeds, in whatever 
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In the population-based Rotterdam Study we investigated whether microbleed presence on 
MRI is a determinant of future stroke. We found that the presence of microbleeds, and 
especially multiple microbleeds, was associated with an increased risk of stroke, including first-
ever stroke. Cerebral microbleeds located in regions not typically affected by CAA were 
associated with an increased risk of both ischemic stroke and intracerebral hemorrhage, 
whereas microbleeds located in regions where CAA is known to be highly prevalent seemed 
to particularly associate with an increased risk of intracerebral hemorrhage.  
In a population of community-dwelling middle-aged people and elderly we found that 
microbleeds on MRI associated with an increased risk of both ischemic stroke and intracerebral 
hemorrhage. The latter has been demonstrated previously in patients with lobar intracerebral 
hemorrhages due to CAA. These patients were at increased risk of recurrent stroke when 
microbleeds were present on MRI.9,17 Evidence that microbleeds also associate with ischemic 
or occlusive brain disease was found in a recent meta-analysis of clinical studies.29 They showed 
that Caucasian patients with microbleeds who were admitted for acute ischemic stroke or 
transient neurological attack had a 3.87 times (95% CI 0.91; 16.4) higher odds of spontaneous 
intracerebral hemorrhage, and 2.23 times (95% CI 1.29; 3.85) higher odds of ischemic stroke 
compared to patients without microbleeds. We now showed that these results can be 
extrapolated to Caucasian community-dwelling persons without a history of stroke.  
We found that the risk of stroke subtype differed according to the location of microbleeds 
in the brain, and thus possibly differs with underlying vasculopathy. Our results suggest that 
microbleeds, regardless of their presumed underlying pathology (either CAA or hypertensive 
arteriopathy) strongly associate with intracerebral hemorrhage. Only microbleeds in non-lobar 
brain regions (suspected of hypertensive arteriopathy) were related to ischemic stroke. It may 
be that in the general population CAA-related microbleeds do not relate to overt ischemic 
stroke or that our sample of ischemic stroke cases was too small to detect a significant 
association. The latter may be more accurate given prior findings from other studies, which 
suggest that CAA related microbleeds associate with silent and overt ischemic brain lesions.5,29  
We also observed that intracerebral hemorrhages were predisposed to occur in the same 
anatomical location as pre-existing microbleeds. Although we previously showed that 
microbleeds indicate the presence of more widespread small vessel disease,28 this finding 
implies that microbleeds may be of value in pinpointing focal areas in the brain with more 
active vasculopathy. It should be noted, however, that the number of ICH cases was small and 
hampered our ability to conduct relevant statistical analysis. Therefore, the overlap in anatomic 
location between microbleeds and ICH may also be due to chance. 
Only two previous studies, both in Asian populations, investigated the association of 
microbleeds with stroke in elderly without a history of cerebrovascular events.19,20 One study 
found an increased risk of ischemic stroke in participants with any microbleeds compared with 
no microbleeds.19 The other study found that deep or mixed (i.e., both in deep and lobar brain 
regions) microbleeds was associated with an increased risk of ischemic stroke and deep 
intracerebral hemorrhage.20 Methodological limitations of both studies included, small number 
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of stroke cases, limited or no correction for potential confounders, and absence of subgroup 
analysis for microbleed location. Compared to our study, both studies had an 
overrepresentation of intracerebral hemorrhage cases compared with ischemic stroke cases, 
which could be explained by ethnic differences in study population as Asians on average have 
a two-times higher risk of intracerebral hemorrhages compared with Caucasians.29,30 In 
addition, blood vessels in Asian intracerebral hemorrhage patients may more often be affected 
by fibrohyalinosis rather than b-amyloid deposition, reflecting differences in cardiovascular risk 
for Asians and Caucasians.31 
In line with another clinical study,9 our results suggest a dose-response effect, with higher 
risk of stroke in people with multiple microbleeds on MRI. We should, however, consider that 
small vessel pathology progresses gradually and cut-off points are not easily chosen, especially 
since microbleed detection – and the perceived number – strongly depends on technical 
imaging parameters.32 Also, the presence of microbleeds (including just a single microbleed) 
has been associated with an increased risk of new bleeds, and to relate to more diffuse brain 
damage, i.e., to white matter.28,33 Although microbleed burden may thus be used as a severity 
measure, we note that their presence in itself seems to indicate diffuse vascular brain disease 
which is progressive in nature.  
The use of antithrombotic drugs in people with microbleeds on MRI remains a topic of 
debate, and is fueled by studies like ours that show that microbleed presence is associated with 
an increased risk of both ischemic stroke and intracerebral hemorrhage. Our current results 
suggest that stroke risk associated with microbleeds was not affected by antithrombotic drugs 
use. However, we were unable to investigate this association separately for intracerebral 
hemorrhage due to the small number of cases. Results from ongoing clinical trials and cost-
benefit studies should settle whether the benefits of ischemic stroke prevention by use of 
antithrombotic drugs outweigh the risk of intracerebral hemorrhage in people with 
microbleeds.  
Strengths of our study include the population-based character, the longitudinal design, 
and a systematic stroke detection protocol that allows for thorough collection of fatal and non-
fatal stroke events, both in-hospital and outside. Some potential limitations have to be 
mentioned before discussing the implication of our findings. First, participants who were 
eligible and underwent brain MRI scanning were on average younger and had lower 
cardiovascular risk than those who were eligible for MRI but did not participate.33 Also, 
excluding participants with incomplete follow-up for incident stroke may have been a source 
of bias, as these participants might have been less healthy on average. This potentially induced 
selection bias in our study and may have led to an underestimation of associations. Second, in 
accordance with the incidence of intracerebral hemorrhage in the general population the 
number of intracerebral hemorrhage cases during follow-up in our study was small, and 
hampered our ability to conduct in depth statistics. Third, microbleeds were rated by trained 
research physicians. Since microbleed detection depends on rater expertise, our results may 
not translate directly to routine clinical practice. Fourth, the categorization into “CAA related” 
and “non-CAA related” microbleeds, though in line with current research and clinical practice, 
is artificial and does not accurately reflect the multifactorial nature of microbleeds, in whatever 
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location. Therefore, this categorization will inherently have led to misclassification between 
categories. Nevertheless, it is important to note that the most robust results were found for any 
versus no microbleeds. In addition, the prevalence of CAA-related microbleeds may have been 
diluted because we included relatively young participants in our study. Fifth, residual 
confounding due to unmeasured confounders, e.g., atrial fibrillation, may have affected our 
results to some extent.”  
In conclusion, in the general population, microbleed presence on MRI was associated with 
an increased risk of stroke, both ischemic and hemorrhagic. The risk differs for the subtypes of 
stroke depending on the location of the cerebral microbleeds. Those with the largest 
microbleed burden are at highest risk of stroke. Microbleeds may thus present a subclinical 
precursor of stroke. Future studies should investigate whether microbleed presence 
contributes to stroke risk on an individual level.  
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Abstract 
 
Background and purpose  
A stroke is often attributed to one causal mechanism. However, pathological mechanisms may 
interact. One hypothesis is that people with small vessel disease, which can be visualized using 
retinal diameters, may be more vulnerable to a decrease in brain perfusion. Within the 
Rotterdam Study, we examined whether total brain perfusion and retinal vessel interact for 
their risk of stroke or TIA.  
 
Methods 
Data on total brain perfusion and retinal vessel diameter was collected in 2004-2008 in 3000 
participants (mean age 58.8 years, 56.4% women) without history of a stroke or TIA. Follow-up 
finished in 2014. Models were adjusted for age, sex, cardiovascular risk factors, and the other 
vessel diameter. Effect modification was tested using an interaction term of total brain 
perfusion and vessel diameter and by stratification in tertiles. 
 
Results 
During 19,007 person-years, 29 people suffered a stroke and 48 a TIA. We observed a significant 
interaction between retinal venular diameter and brain perfusion. Stratified analyses showed 
that venular diameter was only associated with stroke or TIA in people with the lowest tertile 
of total brain perfusion (hazard ratio (HR) 1.71, 95% confidence interval (CI) 1.17; 2.59). Total 
brain perfusion was only associated with stroke in people with the largest tertile of venular 
diameter (HR 1.69, 95% CI 1.11; 2.58) or arteriolar diameter (HR 1.74, 95% CI 1.10; 2.68).  
 
Conclusions  
Our results suggest that the risk of stroke and TIA is only increased in people with a 
combination of impaired brain perfusion and small vessel disease.  
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Introduction 
 
Annualy, 17 million people suffer a first-ever stroke worldwide.1 About 80% of these strokes is 
ischemic and the consequence of insufficient blood flow to the brain. Reasons for that may be 
hypoperfusion or an occlusion, which can have its origin anywhere in the vascular system, from 
the heart to the brain.2,3 For each stroke, usually one location is indicated as cause.2 Yet, people 
often have vascular disease at multiple locations, for instance in the large and small vessels.4-6 
Since people with vascular disease at multiple locations seem to have a higher risk of stroke,5 it 
may be that assigning one cause is insufficient. Several pathological mechanisms may interact.  
Two mechanisms that have the potential to interact are a diminished brain perfusion and 
small vessel disease. Individually, a low cerebral blood flow has been related to stroke in people 
with severe intracranial atherosclerotic disease.7 Small vessel disease, as visualized through the 
retinal vessels, has been related to stroke in the general population.8,9 It has been hypothesized 
that if these markers are present together, their effect is amplified. Specifically, a previous study 
showed that a diminished cerebral blood flow had a stronger association with cognitive 
decline in combination with white matter lesions, suggesting that people with small vessel 
disease may be more vulnerable to changes in cerebral perfusion.10 This could also mean that 
people with small vessel disease are more likely to get a stroke if cerebral perfusion is low 
compared to people without small vessel disease. 
Against this background, our aim was to examine whether brain perfusion and retinal 
vessel diameter interact in their relation with stroke or TIA. First, we measured their individual 
effect in our general population. Then, we measured possible effect modification.  
 
Methods 
 
Setting and study population 
This study was conducted within the Rotterdam Study, a prospective population-based study 
that aims to investigate occurrence and determinants of invalidating diseases in the elderly. 
Details regarding the objectives and design of the study have been reported previously.11,12 The 
study started in 1990 amongst 7983 participants (Rotterdam Study I (RS-I)) and was extended 
twice: in 2000 with 3011 persons (RS-II) and in 2006 with 3932 persons (RS-III). The study now 
consists of 14,926 participants aged 45 years and older. Data on both cerebral perfusion and 
retinal vessels were collected in the second visit of RS-II (2004-2005) and the first visit of RS-III 
(2006-2008). In these periods, 6438 participants participated, of whom 4599 were invited for an 
MRI scan and 4161 actually underwent MRI scanning. Participants with an incomplete MRI 
(n=429), no fundus color photography for the assessment of retinal vessels (n=538), no 
informed consent for collection of follow-up data (n=21), prevalent stroke or TIA (n=132), silent 
cortical infarcts (n=34), incomplete follow-up (n=6), and an outlier (n=1) were excluded (Figure 
1). Eventually, 3000 participants were eligible for analysis.  
The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All participants 
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provided written informed consent to participate in the study and to obtain information from 
their treating physicians. 
 
 
Figure 1. Study population 
 
Brain MRI and brain perfusion 
Magnetic resonance imaging was performed on a 1.5T MRI scanner (GE Healthcare, Milwaukee, 
WI, USA), using an 8-channel head coil. Flow measurement was performed using 2D phase-
contrast imaging, as described previously.13 Additionally, three high-resolution axial MRI 
sequences were performed, namely a T1-weighted sequence, a proton-density-weighted 
sequence, and a fluid attenuated inversion recovery sequence.13 
Cerebral blood flow was calculated from the phase-contrast images using interactive data 
language-based custom software (Cinetool version 4, General Electric Healthcare, Milwaukee, 
WI, USA). Regions of interest were drawn manually around both carotids and the basilar artery 
at a level just under the skull base. Flow rates were calculated using the velocity and cross-
sectional area of the vessels. To calculate total cerebral blood flow (tCBF), flow rates for the 
carotid arteries and the basilar artery were summed and expressed in mL/min. Total brain 
perfusion (in mL/min per 100mL) was calculated by dividing tCBF by each individual’s brain 
volume (mL) and multiplying the obtained result by 100.13 
Two independent experienced technicians drew all manual regions of interest and 
subsequently performed the flow measurements (interrater correlations (n=533) >0.94 for all 
vessels).13  
 
Retinal vessel measurements 
Details regarding retinal vessel measurements have been described previously.8,14 Participants 
underwent a full eye examination including simultaneous stereoscopic fundus color 
photography of the optic disc (20º field, Topcon Optical Company, Tokyo, Japan) after 
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pharmacologic mydriasis. For each participant, the image with the best quality (left or right 
eye) was analyzed with the Retinal Vessel Measurement System (Retinal Analysis, Optimate, WI; 
Department of Ophthalmology & Visual Science, University of Wisconsin-Madison).15 For each 
participant, one summary measure was calculated for the arteriolar diameters (in µm) and one 
for the venular diameters, corrected for magnification changes attributable to refractive errors 
of the eye. In a random subsample of 100 participants in RS-I, we found no differences between 
the right and left eyes for the arteriolar and venular calibers. Measurements were performed by 
2 trained raters, blinded to the clinical characteristics and outcomes of the participants.  
Pearson’s correlation coefficients for interrater agreement varied 0.87 for arteriolar caliber 
and 0.91 for venular caliber in RS-II and 0.85 for arteriolar caliber and 0.87 for venular caliber in 
RS-III. Intrarater agreement ranged from 0.65-0.87.16,17  
 
Assessment of stroke and TIA 
History of stroke and TIA was assessed during the home interview at baseline and confirmed 
by reviewing medical records.18,19 Subsequently, participants were continuously followed for 
occurrence of stroke and TIA through automatic linkage of general practitioners’ medical 
records with the study database. Additionally, general practitioners’ medical records of 
participants who moved out of the district and nursing home physicians’ medical records were 
checked on a regular basis. For all potential strokes and TIAs, information from general 
practitioners and hospital discharge letters were collected and reviewed by research 
physicians. An experienced vascular neurologist verified the diagnoses.18,19 Strokes were 
defined according to the World Health Organization Criteria20 and subclassified into ischemic 
or hemorrhagic using neuroimaging reports. A stroke was classified as unspecified if 
neuroimaging was lacking.18 Follow-up was complete until January 1, 2014, for 97.2% of 
potential person-years.  
 
Assessment of covariates 
Covariates were assessed during the same examination round as the fundus photography, with 
the use of structured interviews, physical examinations, and blood sampling.21 Medication use 
and smoking status were assessed by interview. Smoking was categorized into current, former, 
or never smoking. Blood pressure was measured twice on the right arm with a random zero 
sphygmomanometer. The average of the two measurements was used. Total cholesterol and 
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provided written informed consent to participate in the study and to obtain information from 
their treating physicians. 
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pharmacologic mydriasis. For each participant, the image with the best quality (left or right 
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Statistical analysis 
We analyzed the association of total brain perfusion and of retinal vessel diameter with 
ischemic stroke and TIA using Cox proportional hazards models. We combined ischemic stroke 
and TIA to increase power, which is reasonable since they have a similar pathophysiology.23 
Follow-up started at the date of MRI scan. We censored participants at date of stroke, date of 
TIA, date of death, end of follow-up, or January 1st 2014, whichever came first. Adjusted hazard 
ratio’s (HR’s) with 95% confidence intervals (CI’s) were calculated adding total brain perfusion 
and retinal vessel diameters per standard deviation (SD) increase or decrease into the models. 
All models were adjusted for age and sex. In all models with vessel diameter as exposure, we 
adjusted for the other vessel diameter (venular diameter was adjusted for arteriolar diameter 
and arteriolar diameter for venular diameter). In the multivariable model, we additionally 
adjusted for study cohort, systolic blood pressure, diastolic blood pressure, blood pressure-
lowering medication, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering 
medication, smoking, diabetes mellitus, body mass index, and carotid stenosis. Effect 
modification between total brain perfusion and retinal vessel diameter was tested using an 
interaction term.  
In order to further explore possible effect modification, we additionally performed a 
stratified analysis. Within tertiles of retinal diameter (venular and arteriolar), we examined the 
association between total brain perfusion and stroke or TIA, and within tertiles of total brain 
perfusion we examined the association between retinal vessel diameter and stroke. Finally, we 
categorized the participants based on both tertiles of retinal diameter and tertiles of cerebral 
perfusion and related these categories to the risk of stroke or TIA.  
All analyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
The baseline characteristics of the study population are presented in Table 1. Participants had 
a mean age (±SD) of 58.8 (±7.1) years and 56.4% was women. After an average follow-up of 6.3 
(±1.2) years, 29 participants had a stroke, and 48 a TIA.  
Table 2 describes the association between total brain perfusion, retinal venular diameter, 
and retinal arteriolar diameter with stroke or TIA. We only observed an association of retinal 
venular diameter with stroke or TIA (multivariable adjusted HR per SD increase in venular 
diameter 1.39, 95% CI 1.07; 1.81). Total brain perfusion was not associated with stroke or TIA in 
the total population (HR 1.17, 95% CI 0.91; 1.49). However, stratified for age at median, we did 
find an association in people younger than 58.7 years (HR 1.61, 95% CI 1.01; 2.56). In the total 
population, we observed interactions between total brain perfusion and both the venular (p-
value = 0.006) and arteriolar diameter (p-value = 0.020).  
In Table 3, the results of the stratified analyses are shown. Total brain perfusion was only 
associated with stroke or TIA in people with the largest tertile of venular diameter (HR 1.70, 95% 
CI 1.12; 2.59) or the largest tertile of arteriolar diameter (HR 1.71, 95% CI 1.10; 2.68). Venular 
diameter was only associated with stroke or TIA in people with the lowest tertile of total brain 
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perfusion (HR 1.75, 95% CI 1.17; 2.60). Arteriolar diameter was not associated with stroke in any 
tertile of brain perfusion.  
Combining all this information in one graph (Figure 2), it appeared that risk of stroke or TIA 
was mainly large in people with both the lowest tertile of cerebral perfusion and the highest 
tertile of venular diameter. The HR of being in tertile 1 of cerebral perfusion and tertile 3 of 
venular diameter, compared to the reference category (tertile 3 of cerebral perfusion and tertile 
1 of venular diameter) was 2.11 (95% CI 0.77; 5.79). Since the group with tertile 1 of cerebral 
perfusion and tertile 3 of venular diameter stood out of the rest, we also compared this 
category with all other categories, which gave a HR of 1.93 (95% CI 1.07; 3.47). The pattern with 
arteriolar diameter was less clear. 
 
Table 1. Baseline characteristics 
 At risk for stroke or TIA 
 N=3000 
Age, years 58.8 (7.1) 
Women 1691 (56.4%) 
Systolic blood pressure, mmHg 134 (19) 
Diastolic blood pressure, mmHg 82 (11) 
Blood pressure lowering medication 674 (22.6%) 
Total cholesterol, mmol/L 5.6 (1.0) 
High-density lipoprotein cholesterol, mmol/L 1.4 (0.4) 
Lipid-lowering medication 614 (20.6%) 
Diabetes mellitus 243 (8.2%) 
Smoking  
Never 878 (29.4%) 
Former 1400 (46.9%) 
Current 708 (23.7%) 
Body mass index, kg/m2 27.5 (4.3) 
Carotid stenosis >50% on ultrasound 55 (1.8%) 
Total brain perfusion, mL/min per 100 mL 57.3 (9.4) 
Venular diameter, µm 238.3 (22.8) 
Arteriolar diameter, µm 156.8 (15.9) 
Abbreviations: N = number of persons included in study. 
Data are presented as mean (standard deviations) or counts (percentages). 
Percentages are calculated without missing data. 
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perfusion (HR 1.75, 95% CI 1.17; 2.60). Arteriolar diameter was not associated with stroke in any 
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Table 2. Total brain perfusion and retinal vessel diameter and the risk of ischemic stroke or TIA 
 Ischemic stroke or TIA 
n/N 77/3000 
 Model I Model II Model III 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Total brain perfusion, per SD decrease 1.16 (0.91; 1.49) 1.16 (0.91; 1.49) 1.17 (0.91; 1.49) 
Retinal venular diameter, per SD increase 1.40 (1.08; 1.81) 1.39 (1.07; 1.81) 1.39 (1.07; 1.81) 
Retinal arteriolar diameter, per SD 
decrease 
1.07 (0.82; 1.41) 1.06 (0.80; 1.42) 1.06 (0.80; 1.41) 
Values are hazard ratios per standard deviation increase in the determinant with 95% confidence intervals. 
Model I: Adjusted for age, sex, study cohort, and other retinal vessel if applicable. 
Model II: As model I, additionally adjusted for systolic blood pressure, diastolic blood pressure, blood pressure-
lowering medication, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering medication, smoking, 
diabetes mellitus, BMI, and carotid stenosis. 
Model III: As model II, additionally adjusted for brain perfusion in analyses with vessel diameters, and for vessel 
diameters in analyses with brain perfusion. 
 
Table 3. Total brain perfusion and retinal vessel diameter and the risk of ischemic stroke or TIA, within 
tertiles of retinal vessel diameter or brain perfusion  
  Ischemic stroke or TIA 
  n/N Model I Model II 
   HR (95% CI) HR (95% CI) 
Venular diameter Total brain 
perfusion 
   
Tertile 1 per SD decrease 26/1000 0.89 (0.59; 1.36) 0.88 (0.57; 1.35) 
Tertile 2 per SD decrease 21/1000 0.97 (0.61; 1.53) 0.96 (0.60; 1.52) 
Tertile 3 per SD decrease 30/1000 1.69 (1.11; 2.58) 1.70 (1.12; 2.59) 
     
Total brain perfusion Venular diameter    
Tertile 3 per SD increase 16/1000 0.89 (0.49; 1.62) 0.95 (0.51; 1.76) 
Tertile 2 per SD increase 28/1000 1.36 (0.90; 2.05) 1.29 (0.84; 1.99) 
Tertile 1 per SD increase 33/1000 1.70 (1.16; 2.51) 1.75 (1.17; 2.60) 
     
Total brain perfusion Arteriolar diameter    
Tertile 3 per SD decrease 16/1000 0.97 (0.52; 1.80) 0.97 (0.50; 1.87) 
Tertile 2 per SD decrease 28/1000 1.12 (0.71; 1.76) 1.14 (0.72; 1.81) 
Tertile 1 per SD decrease 33/1000 1.01 (0.66; 1.54) 1.05 (0.67; 1.63) 
     
Arteriolar diameter Total brain 
perfusion 
   
Tertile 3 per SD decrease 27/1000 1.74 (1.12; 2.69) 1.71 (1.10; 2.68) 
Tertile 2 per SD decrease 20/1000 1.14 (0.70; 1.87) 1.14 (0.70; 1.86) 
Tertile 1 per SD decrease 30/1000 0.89 (0.63; 1.28) 0.93 (0.64; 1.33) 
Values are hazard ratios per standard deviation increase in the determinant with 95% confidence intervals. 
Model I: Adjusted for age, sex, study cohort, and other retinal vessel. 
Model II: Adjusted for age, sex, study cohort, systolic blood pressure, diastolic blood pressure, blood pressure-
lowering medication, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering medication, smoking, 
diabetes mellitus, BMI, carotid stenosis, and other retinal vessel. 
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Figure 2. Interaction brain perfusion and venular diameter and risk of ischemic stroke or TIA  
Values are hazard ratio’s compared to the reference category: tertile 3 of cerebral perfusion and tertile 1 of 
venular diameter. Adjusted for age, sex, study cohort, systolic blood pressure, diastolic blood pressure, blood 
pressure-lowering medication, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering 
medication, smoking, diabetes mellitus, BMI, carotid stenosis, and other retinal vessel. 
*Hazard ratio (HR) 2.11 (95% CI 0.77; 5.79) compared to reference category. HR 1.93 (95% CI 1.07; 3.47) 
compared to all other categories combined. 
 
Discussion 
 
In this population-based study, we observed that wider retinal venules were associated with 
an increased risk of stroke or TIA. Total cerebral perfusion was not associated with the risk of 
stroke in the total population. Interestingly, we observed an interaction between cerebral 
perfusion and both retinal venules and retinal arterioles for their risk of stroke or TIA. Total 
cerebral perfusion was associated with stroke or TIA in the highest tertile of venular diameter 
and in the highest tertile of arteriolar diameter. Correspondingly, venular diameter was only 
associated with stroke or TIA in the lowest tertile of cerebral perfusion.  
A low cerebral blood flow7 and a small venular diameter8,24,25 were separately related to 
stroke in previous studies. The reason why we did not find an association of low cerebral 
perfusion and stroke in our total population may be explained by our different study 
population. We included a general population and the previous study included patients with 
severe stenosis in the intracranial vessels.7 People in the previous study therefore had a larger 
impairment of the blood flow than people in our general population. The brain has 
compensatory mechanisms to keep the local blood perfusion intact for a long time, i.e. cerebral 
autoregulation, which may be sufficient if people do not have a severe stenosis.26  
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severe stenosis in the intracranial vessels.7 People in the previous study therefore had a larger 
impairment of the blood flow than people in our general population. The brain has 
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In people with cerebral small vessel disease, cerebral autoregulation can be impaired.27 
Although a diminished autoregulation by itself seemed not sufficient to increase the risk of 
stroke in a previous study,28 it may increase the risk of stroke or TIA in combination with a low 
perfusion.29 A high perfusion may compensate for a diminished autoregulation and a good 
autoregulation for a diminished perfusion. If both fail, however, this may lead to an increased 
risk of stroke and TIA. This is a possible explanation for our finding that a lower cerebral 
perfusion was associated with an increased risk of stroke or TIA in people with large retinal 
venules, reflecting small vessel disease, and that large retinal vessels were only associated with 
an increased risk of stroke in people with a low perfusion. It implies that in people with a stroke 
or TIA based on small vessel disease, also a source of diminished perfusion should be sought. 
For instance, large artery atherosclerosis.7 In people with a low perfusion, the amount of small 
vessel disease should be examined. Another possible explanation is the risk factor load that 
may be higher in people with both a low perfusion and small vessel disease. However, 
associations remained after adjustment for many possible confounders. Furthermore, a 
diminished perfusion may relate to stroke mediated by small vessel disease,6,17 although it is 
uncertain whether a diminished perfusion leads to small vessel disease or whether this 
association is inverse.30 A final explanation therefore is that small vessel disease gives rise to 
white matter lesions31 and that these can reduce the blood flow due to a diminished metabolic 
demand.30 It may be that small vessel disease only relates to stroke if it is severe enough to 
demand a lower perfusion.  
The finding that a low brain perfusion also associated with stroke in people with wider 
arterioles is actually the opposite of what we expected, since arteriolar narrowing is associated 
with atherosclerosis.9,32 An explanation may be that arteriolar and venular diameter are highly 
correlated and people with wide venules therefore have wide arterioles.32 However, we 
adjusted the analyses with arteriolar diameter for venular diameter and associations remained. 
Another explanation may be that arterioles keep the ability to dilate in response to a poor blood 
flow.8,33 This may reflect an exhausted autoregulation or vasomotor reactivity.33 If arterioles are 
fully widened in response to the usual blood flow in a person, they may not be able to widen 
any further in response to extra stimuli, which could lead to a stroke or TIA.29,33  
Strengths of our study are the population-based setting and the thorough follow-up for 
stroke and TIA. A limitation is that pathophysiological subtypes were unavailable for many 
ischemic strokes. Therefore, we could not define whether the increased risk was the 
consequence of strokes based on large or small vessel disease. We even had a limited amount 
of stroke cases, so we had to pool the results of ischemic stroke and TIA. This seems reliable 
since stroke and TIA have the same etiology.23 However, these findings should be replicated in 
a study with more power.  
In conclusion, total brain perfusion and retinal vessel diameter interact in their risk of stroke 
or TIA. This suggests that a combination of a low brain perfusion and small vessel disease is 
necessary to increase the risk of stroke or TIA. If people have a stroke or TIA based on one of 
both, it may be useful to search for the other too. Future studies should examine the 
pathophysiological pathway of this effect and whether prediction of stroke can be improved 
taking both markers into account.   
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In people with cerebral small vessel disease, cerebral autoregulation can be impaired.27 
Although a diminished autoregulation by itself seemed not sufficient to increase the risk of 
stroke in a previous study,28 it may increase the risk of stroke or TIA in combination with a low 
perfusion.29 A high perfusion may compensate for a diminished autoregulation and a good 
autoregulation for a diminished perfusion. If both fail, however, this may lead to an increased 
risk of stroke and TIA. This is a possible explanation for our finding that a lower cerebral 
perfusion was associated with an increased risk of stroke or TIA in people with large retinal 
venules, reflecting small vessel disease, and that large retinal vessels were only associated with 
an increased risk of stroke in people with a low perfusion. It implies that in people with a stroke 
or TIA based on small vessel disease, also a source of diminished perfusion should be sought. 
For instance, large artery atherosclerosis.7 In people with a low perfusion, the amount of small 
vessel disease should be examined. Another possible explanation is the risk factor load that 
may be higher in people with both a low perfusion and small vessel disease. However, 
associations remained after adjustment for many possible confounders. Furthermore, a 
diminished perfusion may relate to stroke mediated by small vessel disease,6,17 although it is 
uncertain whether a diminished perfusion leads to small vessel disease or whether this 
association is inverse.30 A final explanation therefore is that small vessel disease gives rise to 
white matter lesions31 and that these can reduce the blood flow due to a diminished metabolic 
demand.30 It may be that small vessel disease only relates to stroke if it is severe enough to 
demand a lower perfusion.  
The finding that a low brain perfusion also associated with stroke in people with wider 
arterioles is actually the opposite of what we expected, since arteriolar narrowing is associated 
with atherosclerosis.9,32 An explanation may be that arteriolar and venular diameter are highly 
correlated and people with wide venules therefore have wide arterioles.32 However, we 
adjusted the analyses with arteriolar diameter for venular diameter and associations remained. 
Another explanation may be that arterioles keep the ability to dilate in response to a poor blood 
flow.8,33 This may reflect an exhausted autoregulation or vasomotor reactivity.33 If arterioles are 
fully widened in response to the usual blood flow in a person, they may not be able to widen 
any further in response to extra stimuli, which could lead to a stroke or TIA.29,33  
Strengths of our study are the population-based setting and the thorough follow-up for 
stroke and TIA. A limitation is that pathophysiological subtypes were unavailable for many 
ischemic strokes. Therefore, we could not define whether the increased risk was the 
consequence of strokes based on large or small vessel disease. We even had a limited amount 
of stroke cases, so we had to pool the results of ischemic stroke and TIA. This seems reliable 
since stroke and TIA have the same etiology.23 However, these findings should be replicated in 
a study with more power.  
In conclusion, total brain perfusion and retinal vessel diameter interact in their risk of stroke 
or TIA. This suggests that a combination of a low brain perfusion and small vessel disease is 
necessary to increase the risk of stroke or TIA. If people have a stroke or TIA based on one of 
both, it may be useful to search for the other too. Future studies should examine the 
pathophysiological pathway of this effect and whether prediction of stroke can be improved 
taking both markers into account.   
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Abstract 
 
Background and purpose 
Hypertension is a major modifiable risk factor for stroke. Associations of blood pressure with 
incident stroke are mostly based on single or average blood pressure levels. However, this 
approach does not take into account long-term trajectories of blood pressure, which can vary 
considerably in the elderly.  
 
Methods 
Within the population-based Rotterdam Study, we examined trajectories of systolic blood 
pressure in 6745 participants (60.0% women) over an age-range from 55-106 years and jointly 
modeled their risk of stroke and competing causes of death using joint latent class mixed 
modeling.  
 
Results 
Four trajectories were identified. Class 1 was characterized by blood pressure increasing 
gradually from on average 120 to 160 mmHg over five decades (N=4938). Compared to this 
class, class 2, characterized by a similar mid-life blood pressure, but a steep increase (N=822, 
increasing from 120 to 200 mmHg), and class 4, characterized by a high mid-life blood pressure 
(N=115, average 160 mmHg), had a higher risk of stroke and death. Class 3, characterized by a 
moderate mid-life blood pressure (N=870, average 140 mmHg), had a similar risk of death as 
class 1, but the highest risk of stroke. 
 
Conclusions 
Assessing trajectories of blood pressure provides a more nuanced understanding of the 
associations between blood pressure, stroke, and mortality. In particular, high blood pressure 
and rapidly increasing blood pressure patterns are associated with a high risk of stroke and 
death, while moderately high blood pressure is only related to an increased risk of stroke. 
Future studies should explore the potential etiologic significance of these patterns.  
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Introduction 
 
Hypertension is a major treatable risk factor for stroke, with an estimated attributable risk of 
35% to 50%.1,2 Most studies that examined the association between hypertension and incident 
stroke used a single measurement or the average of blood pressure levels assessed over time. 
Results from such approaches have suggested that the risk of stroke increases with increasing 
blood pressure levels and that even prehypertension is associated with stroke.3-6 Indeed, the 
current guideline to treat people above a certain target level of blood pressure (e.g. 150/90 
mmHg7 or 140/90 mmHg8-10) is largely based on such knowledge. However, long-term patterns 
(i.e. trajectories) of blood pressure may further influence stroke risk. Studies in young and 
middle aged adults showed that increases in blood pressure over long periods (10 to 30 years) 
are related to an increased risk of stroke and cardiovascular disease,11-13 and that trajectories of 
higher blood pressure relate to a higher risk of subclinical atherosclerosis.14 Trajectories in older 
people may vary even more, because it is particularly in later ages that arterial stiffness 
increases, which is associated with increases in blood pressure and blood pressure variability.15-
17 Furthermore, studies suggest that lower blood pressures might also be harmful in this 
population, leading to an increased risk of myocardial infarction or death.18-20 This has 
particularly been observed for low diastolic blood pressures,18,19 although low systolic blood 
pressures also seemed to be harmful in patients with vascular disease and diabetes.20 To date, 
no study of long-term blood pressure trajectories in mid- to late-life has been conducted. 
Furthermore, it is unknown whether such trajectories relate to stroke. If we hope to empirically 
inform and refine prevention guidelines, a much-needed first step is to describe the prototypic 
and commonly observed patterns of blood pressure trajectories. 
Therefore, the aim of our study was to identify long-term trajectories of blood pressure in a 
population-based study and to examine the risk of stroke within those trajectories. We focused 
on systolic blood pressure (SBP) because it is the best predictor of cardiovascular events.21  
 
Methods 
 
Setting and study population 
This study was conducted within the prospective, population-based Rotterdam Study. Details 
regarding the objectives and design of the study have been described elsewhere.22 Baseline 
examinations started in 1990 among 7983 people of 55 years and older residing in Ommoord, 
a suburb of Rotterdam, the Netherlands. Follow-up examinations take place every 3-4 years.  
For the current study, data from five follow-up visits from 1990 to 2011 were used. 
Participants with no informed consent for follow-up data collection (n=226), prevalent stroke 
at baseline (n=243), no center visit prior to a stroke (n=668), and completely missing 
information on blood pressure and blood pressure-lowering medication (n=101) were 
excluded, resulting in 6745 participants eligible for the current analysis. Only measurements 
before occurrence of stroke were used. We had 6679, 5018, 3570, 2891, and 1499 
measurements at each of the five center visits, respectively, totaling 19,657 measurements. 
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The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All participants 
provided written informed consent to participate in the study and to obtain information from 
their treating physicians. 
 
Assessment of blood pressure 
During each visit, blood pressure was measured twice in the right arm, in sitting position, after 
a resting period of five minutes. The average of the two measurements was used in the 
analyses. Up until November 7th 2006, a Hawksley random-zero sphygmomanometer was 
used,23 and for measurements after this date Omron M6 Comfort and Omron M7 devices were 
used.24,25  
 
Assessment of stroke  
Stroke was defined according to WHO criteria as a syndrome of rapidly developing clinical signs 
of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer 
or leading to death and no apparent cause other than of vascular origin.26 This corresponds to 
ICD10 codes I61, I63, and I64. At baseline, history of stroke was assessed by interview and 
verified using medical records.27 Subsequently, participants were continuously followed for 
occurrence of incident stroke, by digital linkage of the general practitioners’ medical records 
with the study database. Nursing home physicians’ medical records and general practitioners’ 
medical records of participants who moved out of the Ommoord district were checked on a 
regular basis as well. Of all potential strokes, medical records from general practitioners and 
hospital discharge letters were collected and reviewed by research physicians. An experienced 
vascular neurologist verified the diagnoses.  
Follow-up through January 1st 2013 was complete for 98.9% of potential person-years.28 
 
Covariates 
Covariates were assessed at each center visit. Details on the assessment of anthropometrics, 
cardiovascular risk factors (total cholesterol, high-density lipoprotein cholesterol, diabetes 
mellitus type 2, and smoking) and use of medication have been described previously.29 Current 
alcohol use was assessed during each home interview and categorized into yes versus no. Use 
of blood pressure-lowering medication included the use of diuretics, beta blocking agents, 
calcium blockers, angiotensin receptor blockers, and ACE-inhibitors, if prescribed for the 
indication hypertension. The second center visit had limited examinations, and in particular 
had no assessment of cholesterol, high-density lipoprotein cholesterol and diabetes mellitus 
status. Therefore, measurements from the preceding center visit were carried forward.  
 
Statistical analysis 
We investigated the association of longitudinal trajectories in systolic blood pressure over age 
with the risk of stroke using a joint latent class mixed model. The main goal of a joint latent 
class mixed model is to describe the link between a continuous progression of diseases 
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through longitudinal markers such as blood pressure, and the incidence of clinical events.30,31 
The model uses all available information from the blood pressure and outcome measurements 
to model trajectories and co-occurring events like stroke and death.30,31 Since hypertension has 
been associated with both ischemic and hemorrhagic strokes,16 we examined the risk with all 
stroke types. Models were fit using the ‘Jointlcmm’ function of the ‘lcmm’ package in R.32 The 
joint latent class mixed model assumes that people’s blood pressure trajectories cluster in a set 
of mutually-exclusive patterns or ‘latent classes’. That is, there are prototypical patterns in blood 
pressure trajectories that individuals follow. In the current analysis, the model differentiates the 
population into groups (latent classes) with different profiles of blood pressure, and links these 
classes to potential risk of stroke.30,31,33 Trajectories of blood pressure over age from 55 years 
onwards were modeled using a class-specific linear mixed model with age as time.34 Since 
blood pressure may have a non-linear pattern, we also added a class-specific quadratic age 
term. We included random intercepts and random slopes in all analyses. We added class-
specific adjustments for sex and baseline blood-pressure lowering medication, since we 
expected these variables may influence the evolution of blood pressure. People entered at 
study baseline and were censored at date of stroke, date of death, last date of follow-up or 
January 1, 2013, whichever came first. The optimal number of classes was defined by the model 
with the lowest Bayesian information criterion (BIC).31 Analyses were repeated using different 
random starting values to ensure convergence to the global maximum of the model.31 We 
were primarily interested in stroke as outcome, but added stroke-free mortality since it is an 
important competing risk. The joint survival model was therefore defined by a two-parameter 
Weibull distribution with a class-specific baseline risk function for both stroke and the 
competing risk of mortality due to any other cause than stroke.30,35 This includes cardiovascular 
deaths. The survival function was adjusted for sex and blood pressure lowering medication and 
in the multivariable model we additionally adjusted for visit-specific cholesterol, high-density 
lipoprotein cholesterol, lipid-lowering medication, body mass index, smoking, alcohol use, 
diabetes mellitus type 2, and antithrombotic medication. Adjustments in the survival part of 
the analysis were only made for baseline characteristics. However, we do provide 
characteristics of later visits, in order to compare the evolution of these characteristics together 
with blood pressure. Analysis of covariance was used to study differences in baseline 
characteristics between subjects within the different estimated trajectory classes, adjusted for 
age and sex. Covariates were missing for up to a maximum of 4.6% across assessments. Missing 
values were imputed by the mean of 5 imputations, using multiple imputation based on the 
other covariates of the same visit. Class-specific trajectories of blood pressure or cumulative 
incidences of stroke or death were estimated for the mean value for all covariates. A Monte 
Carlo method was used to calculate the confidence intervals of the cumulative incidences.32  
 
Sensitivity analyses 
Sensitivity analyses were conducted to explore the robustness of our results to modeling 
decisions, missing data, and censorship. First, we inspected models based on one fewer and 
one greater trajectory than the model chosen based on lowest BIC. Second, we added a cubic 
age term. Third, to understand the robustness of our observed patterns to missing values and 
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The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All participants 
provided written informed consent to participate in the study and to obtain information from 
their treating physicians. 
 
Assessment of blood pressure 
During each visit, blood pressure was measured twice in the right arm, in sitting position, after 
a resting period of five minutes. The average of the two measurements was used in the 
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alcohol use was assessed during each home interview and categorized into yes versus no. Use 
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one greater trajectory than the model chosen based on lowest BIC. Second, we added a cubic 
age term. Third, to understand the robustness of our observed patterns to missing values and 
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censoring for stroke or death in between the measurements we repeated our analyses based 
on data from only the first 3 visits (from 1989 to 1999) in the people without missing values in 
these visits and examined the survival curves thereafter (from 1999 to 2013). Fourth, since few 
participants were alive and stroke-free after the age of 80, we wanted to understand whether 
our identified trajectories were similar in only younger ages. Therefore, we also repeated 
analyses in which we only included systolic blood pressure measurements assessed between 
the ages of 55 to 80 years. Finally, while latent class modeling is a useful data-reduction tool for 
understanding general patterns, individual membership in a class or trajectory is probabilistic. 
As a posterior check to see how observed trajectories of blood pressure of individual 
participants aligned with the identified trajectories in our final model, as well as to visually 
assess missing data patterns, we plotted the individual blood pressure values by most likely 
trajectory class, visit, outcome, and age.36  
 
Results 
 
Characteristics of the trajectory classes 
Participants had a mean (± standard deviation) follow-up of 13.5 ±6.8 years, during which 1053 
strokes occurred. 
When investigating the trajectories, we found that the joint latent class model with 4 
classes had the best fit, with the lowest BIC (Supplementary Table I). Mean posterior class 
membership probabilities (i.e. the probability that a person belongs to his or her most likely 
class) were at least 63% for each class in this model. Figure 1A shows the four identified 
trajectories of systolic blood pressure, based on the joint latent class mixed model. The largest 
class was characterized by a gradually increasing blood pressure, starting at on average 120 
mmHg at the age of 55 years and increasing up to on average 160 mmHg at the age of 95 years 
(class 1, N=4938). A smaller class was characterized by a similar blood pressure at the age of 55 
years, but a much steeper increase up to on average 200 mmHg (class 2, N=822). Two classes 
were characterized by a relatively higher baseline blood pressure: one of on average 140 
mmHg, with modest variation over time (class 3, N=870), and the other of on average 160 
mmHg, which decreased after age 65 (class 4, N=115). Supplementary Figure I shows the 
model-based trajectories compared to the mean observed values in the classes. The predicted 
values only diverge slightly from the observed values in people at old age. For instance, the 
observed values of the high baseline SBP class plateau at old age, whereas the predicted 
trajectory continues to increase. 
People in class 4 were more frequently men (Table 1). Mean and maximum baseline blood 
pressure assessments were highest in class 4 followed by the class 3 and class 2. Use of blood 
pressure-lowering medication was similar between classes at baseline, but at the end of follow-
up the class 3 and class 4 had higher proportions of blood pressure-lowering medication users. 
Values on other covariates at each study visit are presented in Supplementary Table II. We 
found a large difference in frequency of current smokers among classes, with particularly 
higher frequencies in class 2 and class 4.  
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Figure 1. Trajectories of blood pressure and risk of stroke and competing causes of death  
A: trajectories of systolic blood pressure over time, as predicted by the joint latent class mixed model. The 
solid line represents the average blood pressure in a class for the mean of covariates. Dotted lines represent 
confidence intervals. B: average class-specific cumulative incidence of stroke. C: average class-specific 
cumulative incidence of competing death due to any other cause than stroke. Cumulative incidences are 
plotted for the mean of covariates. Covariates are sex and blood-pressure lowering medication. 
 
Risk of stroke and death for the separate trajectories 
Relative to class 1, the increased risk of stroke was apparent in class 4 beginning at age 55 years 
onwards, while increased stroke risk began later (approximately age 65) for class 2 and 3 (Figure 
1B). The three classes had a significantly and substantially higher risk of stroke than class 1 (e.g., 
4.7-13.6% compared to 0.7%). The estimated risks up to age 75 appeared higher in class 4 
(13.6%) than in classes 2 (8.1%) and 3 (4.7%), although the wide confidence intervals limited 
interpretability (Supplementary Table III). Class 2 and 4 also had the highest risk of dying 
through other causes (Figure 1C). The cumulative incidence curves in those classes plateaued 
around ages 75-85 years, at that time roughly all people in the classes were diagnosed as 
having a stroke or died. The risk of stroke in class 3 continued to increase until older age. 
However, the risk of dying was lower than in class 2 and 4, similar to class 1.  
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through other causes (Figure 1C). The cumulative incidence curves in those classes plateaued 
around ages 75-85 years, at that time roughly all people in the classes were diagnosed as 
having a stroke or died. The risk of stroke in class 3 continued to increase until older age. 
However, the risk of dying was lower than in class 2 and 4, similar to class 1.  
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At the end of follow-up, 2546 people (51.5%) in class 1, 575 (70.0%) people in class 2, 288 
(33.1%) people in class 3, and 87 (75.7%) people in class 4 died due to a non-stroke-related 
cause. Between 25 and 38% of non-stroke deaths in each class were due to cardiovascular 
events (Supplementary Figure II).  
Multivariable-adjusted models were relatively similar, although some people’s most 
probable class membership switched. Risks of stroke in class 2 and 4 attenuated, whereas the 
risk became stronger in class 3 (Figure 2).  
 
Figure 2. Trajectories of blood pressure and risk of stroke and competing causes of death, multivariable 
adjusted  
A: trajectories of systolic blood pressure over time, as predicted by the joint latent class mixed model. The 
solid line represents the average blood pressure in a class for the mean of covariates. Dotted lines represent 
confidence intervals. B: average class-specific cumulative incidence of stroke. C: average class-specific 
cumulative incidence of competing death due to any other cause than stroke. Cumulative incidences are 
plotted for the mean of covariates. Covariates are sex, blood-pressure lowering medication, cholesterol, high-
density lipoprotein cholesterol, lipid-lowering medication, body mass index, smoking, alcohol use, diabetes 
mellitus type 2, and antithrombotic medication. 
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Figure 1. Trajectories of blood pressure and risk of stroke and competing causes of death  
A: trajectories of systolic blood pressure over time, as predicted by the joint latent class mixed model. The 
solid line represents the average blood pressure in a class for the mean of covariates. Dotted lines represent 
confidence intervals. B: average class-specific cumulative incidence of stroke. C: average class-specific 
cumulative incidence of competing death due to any other cause than stroke. Cumulative incidences are 
plotted for the mean of covariates. Covariates are sex and blood-pressure lowering medication. 
 
Risk of stroke and death for the separate trajectories 
Relative to class 1, the increased risk of stroke was apparent in class 4 beginning at age 55 ye rs 
onwards, while increased stroke risk began later (approximately age 65) for class 2 n  3 (Figure 
1B). The three classes had a significantly and substantially higher risk of stroke than class 1 (e.g., 
4.7-13.6% compared to 0.7%). The estimated risks up to age 75 appeared higher in class 4 
(13.6%) than in classes 2 (8.1%) and 3 (4.7%), although the wide confidence intervals limited 
interpretability (Supplementary Table III). Class 2 and 4 also had the highest risk of dying 
through other causes (Figure 1C). The cumulative incidence curves in those classes plate ued 
around ages 75-85 years, at hat time roughly all people i  the classes were diagn sed as 
having a stroke or died. The risk of stroke in class 3 continued to increase until older age. 
However, the risk f dying was lower than in class 2 and 4, similar to class 1.  
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At the end of follow-up, 2546 people (51.5%) in class 1, 575 (70.0%) people in class 2, 288 
(33.1%) people in class 3, and 87 (75.7%) people in class 4 died due to a non-stroke-related 
cause. Between 25 and 38% of non-stroke deaths in each class were due to cardiovascular 
events (Supplementary Figure II).  
Multivariable-adjusted models were relatively similar, although some people’s most 
probable class membership switched. Risks of stroke in class 2 and 4 attenuated, whereas the 
risk became stronger in class 3 (Figure 2).  
 
Figure 2. Trajectories of blood pressure and risk of stroke and competing causes of death, multivariable 
adjusted  
A: trajectories of systolic blood pressure over time, as predicted by the joint latent class mixed model. The 
solid line represents the average blood pressure in a class for the mean of covariates. Dotted lines represent 
confidence intervals. B: average class-specific cumulative incidence of stroke. C: average class-specific 
cumulative incidence of competing death due to any other cause than stroke. Cumulative incidences are 
plotted for the mean of covariates. Covariates are sex, blood-pressure lowering medication, cholesterol, high-
density lipoprotein cholesterol, lipid-lowering medication, body mass index, smoking, alcohol use, diabetes 
mellitus type 2, and antithrombotic medication. 
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Figure 1. Trajectories of blood pressure and risk of stroke and competing causes of death  
A: trajectories of systolic blood pressure over time, as predicted by the joint latent class mixed model. The 
solid line represents the average blood pressure in a class for the mean of covariates. Dotted lines represent 
confidence intervals. B: average class-specific cumulative incidence of stroke. C: average class-specific 
cumulative incidence of competing death due to any other cause than stroke. Cumulative incidences are 
plotted for the mean of covariates. Covariates are sex and blood-pressure lowering medication. 
 
Risk of stroke and death for the separate trajectories 
Relative to class 1, the increased risk of stroke was apparent in class 4 beginning at age 55 ye rs 
onwards, while increased stroke risk began later (approximately age 65) for class 2 n  3 (Figure 
1B). The three classes had a significantly and substantially higher risk of stroke than class 1 (e.g., 
4.7-13.6% compared to 0.7%). The estimated risks up to age 75 appeared higher in class 4 
(13.6%) than in classes 2 (8.1%) and 3 (4.7%), although the wide confidence intervals limited 
interpretability (Supplementary Table III). Class 2 and 4 also had the highest risk of dying 
through other causes (Figure 1C). The cumulative incidence curves in those classes plate ued 
around ages 75-85 years, at hat time roughly all people i  the classes were diagn sed as 
having a stroke or died. The risk of stroke in class 3 continued to increase until older age. 
However, the risk f dying was lower than in class 2 and 4, similar to class 1.  
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Sensitivity analyses 
Visual assessment of individual blood pressure patterns by participants’ most likely class 
membership, visit, age, and outcome suggested that the model-based patterns were unlikely 
to be influenced by missing data and that the described trajectories reflected observable 
patterns within and across individuals (Supplementary Figure II). On the other hand, differences 
in blood pressure over time seen between class 1 and 2 were mainly apparent in older people. 
Further, people assigned to class 4 often had a stroke or death at young age, with few people 
within this class having decreases in blood pressure, suggesting that the model-estimated 
decrease in this trajectory may be an artefact of a small number of survivors. 
The three- and five-class model did not provide any additional insights. In the three-class 
model, no class resembling class 4 was identified. In the five-class model, the class resembling 
class 4 with respect to the high mid-life blood pressure was further subdivided into a class that 
was increasing and a class that was decreasing. For classes that heuristically overlapped with 
those identified in the four-class models, patterns of stroke and mortality risk were similar. The 
class with a high mid-life blood pressure that was increasing, was related to both stroke and 
death, while the class with a high mid-life blood pressure that was decreasing, was associated 
only with death; for both classes, numbers were low. 
In the sensitivity analysis in which we only included people that completed the three first 
visits of blood pressure measurement, trajectories of blood pressure remained similar. 
Furthermore, we found a similar risk of death in the different classes. The risk of stroke was 
highest in class 3 class, followed by class 2. Class 4 did not have an increased risk of stroke 
(Supplementary Figure III).  
In another sensitivity analysis in which trajectories were formed based only on 
measurements at the ages of 55 to 80 only, trajectories and associated risks of stroke were 
similar to our main findings (Supplementary Figure IV).  
We report the results of trajectories that only allowed for a quadratic effect of age over time. 
As sensitivity analysis we did add a cubic age term, but this did not provide any additional 
insight (Supplementary Figure V).  
 
Discussion 
 
In this population-based study of people aged 55 years and older, we identified four trajectories 
of blood pressure: a class characterized by a gradually increasing blood pressure from 
approximately 120 to 160 mmHg (on average) over five decades (class 1); a class characterized 
by a more steep increase from an average of approximately 120 to 200 mmHg (class 2); a class 
characterized by a moderate blood pressure (140 mmHg) at mid-life and throughout (class 3); 
and a class characterized by a high blood pressure (160 mmHg) at mid-life that decreased (class 
4). The class with a high blood pressure at midlife and the class with a steep increase had the 
highest risks of stroke and death through age 80 years. The class with a moderate blood 
pressure only had an increased risk of stroke, but not death, compared to the class with a low 
blood pressure at midlife and a gradual increase.  
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The trajectories that we identified extend results from prior studies of blood pressure 
trajectories in young to middle aged people. Those studies identified four to five parallel 
trajectories in which trajectories with long-term higher blood pressure related to more 
cardiovascular pathology.12-14 In our older population, we also observed that the class with a 
high mid-life blood pressure had the highest risk of stroke and death compared to the class 
with the lowest blood pressure. However, a novel finding of our study is that the slope of 
increase was associated with an increasing risk of stroke and competing causes of death. 
Namely, we identified two classes characterized by equally low baseline blood pressure and 
increasing trajectories, but only the class characterized by steep increases had a high risk of 
stroke and death. Of note, the risks in that class were even similar to the class with a high mid-
life blood pressure.  
The trajectories and risk patterns identified in this paper could inform future research on 
etiology and potentially treatment guidelines, but the current study does not itself address 
such etiologic or treatment questions. Latent class mixture modeling is a useful data-reduction 
tool and is particularly helpful to describe prototypical and common patterns. It does not, 
however, account for time-dependent confounding or selection biases that may explain the 
trajectories and risks estimated. Therefore, the associations with stroke risk seen across our four 
trajectories could be due in part or whole to a number of non-causal explanations, including 
differences in health behaviors, healthcare utilization, and competing risks throughout the 
study period.37,38 Moreover, findings from the classes are not necessarily applicable to individual 
participants’ blood pressure effects, particularly because class membership is probabilistic. On 
the other hand, identifying the patterns described in our study are an important step, since 
they evoke new causal and treatment questions that can motivate future studies to explore 
the etiologic significance and predictive value of the associations. Questions raised by the 
patterns in our study are: would we reduce stroke risk if we recommended blood pressure 
medication to non-hypertensive middle-aged to older patients with fast increases in blood 
pressure? Or, would we reduce stroke risk if the current treatment level of 140/90 mmHg or 
150/90 mmHg is lowered to also include people with moderately elevated blood pressure? In 
addition, trajectories may inform physicians about people that need further attention for their 
high risk of stroke or death.  
Combining our study results with prior evidence, we can speculate to the biologic 
plausibility that treating middle-aged to older patients with (i) moderate blood pressure or (ii) 
fast increasing blood pressure could reduce strokes. The first is supported by previous studies 
that found a relation between prehypertension and stroke, and less of prehypertension with 
other vascular disease.39-41 This suggests that the brain may be particular vulnerable to vascular 
damage. Whether it is likely that treatment of fast increasing blood pressure reduces stroke and 
death is less clear. It is known that vascular stiffness increases with ageing.15,42 This leads to an 
increase in blood pressure and may explain the gradually increasing blood pressure trajectory 
in the largest part of the population.15,42 However, this does not explain why another class was 
characterized by a much steeper increase. It may be that this trajectory reflects a higher vascular 
age.43 This is supported by our findings that associations with stroke attenuated after adjusting 
for other cardiovascular risk factors. They may have stiffer vessels, which could lead to a steeper 
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Sensitivity analyses 
Visual assessment of individual blood pressure patterns by participants’ most likely class 
membership, visit, age, and outcome suggested that the model-based patterns were unlikely 
to be influenced by missing data and that the described trajectories reflected observable 
patterns within and across individuals (Supplementary Figure II). On the other hand, differences 
in blood pressure over time seen between class 1 and 2 were mainly apparent in older people. 
Further, people assigned to class 4 often had a stroke or death at young age, with few people 
within this class having decreases in blood pressure, suggesting that the model-estimated 
decrease in this trajectory may be an artefact of a small number of survivors. 
The three- and five-class model did not provide any additional insights. In the three-class 
model, no class resembling class 4 was identified. In the five-class model, the class resembling 
class 4 with respect to the high mid-life blood pressure was further subdivided into a class that 
was increasing and a class that was decreasing. For classes that heuristically overlapped with 
those identified in the four-class models, patterns of stroke and mortality risk were similar. The 
class with a high mid-life blood pressure that was increasing, was related to both stroke and 
death, while the class with a high mid-life blood pressure that was decreasing, was associated 
only with death; for both classes, numbers were low. 
In the sensitivity analysis in which we only included people that completed the three first 
visits of blood pressure measurement, trajectories of blood pressure remained similar. 
Furthermore, we found a similar risk of death in the different classes. The risk of stroke was 
highest in class 3 class, followed by class 2. Class 4 did not have an increased risk of stroke 
(Supplementary Figure III).  
In another sensitivity analysis in which trajectories were formed based only on 
measurements at the ages of 55 to 80 only, trajectories and associated risks of stroke were 
similar to our main findings (Supplementary Figure IV).  
We report the results of trajectories that only allowed for a quadratic effect of age over time. 
As sensitivity analysis we did add a cubic age term, but this did not provide any additional 
insight (Supplementary Figure V).  
 
Discussion 
 
In this population-based study of people aged 55 years and older, we identified four trajectories 
of blood pressure: a class characterized by a gradually increasing blood pressure from 
approximately 120 to 160 mmHg (on average) over five decades (class 1); a class characterized 
by a more steep increase from an average of approximately 120 to 200 mmHg (class 2); a class 
characterized by a moderate blood pressure (140 mmHg) at mid-life and throughout (class 3); 
and a class characterized by a high blood pressure (160 mmHg) at mid-life that decreased (class 
4). The class with a high blood pressure at midlife and the class with a steep increase had the 
highest risks of stroke and death through age 80 years. The class with a moderate blood 
pressure only had an increased risk of stroke, but not death, compared to the class with a low 
blood pressure at midlife and a gradual increase.  
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The trajectories that we identified extend results from prior studies of blood pressure 
trajectories in young to middle aged people. Those studies identified four to five parallel 
trajectories in which trajectories with long-term higher blood pressure related to more 
cardiovascular pathology.12-14 In our older population, we also observed that the class with a 
high mid-life blood pressure had the highest risk of stroke and death compared to the class 
with the lowest blood pressure. However, a novel finding of our study is that the slope of 
increase was associated with an increasing risk of stroke and competing causes of death. 
Namely, we identified two classes characterized by equally low baseline blood pressure and 
increasing trajectories, but only the class characterized by steep increases had a high risk of 
stroke and death. Of note, the risks in that class were even similar to the class with a high mid-
life blood pressure.  
The trajectories and risk patterns identified in this paper could inform future research on 
etiology and potentially treatment guidelines, but the current study does not itself address 
such etiologic or treatment questions. Latent class mixture modeling is a useful data-reduction 
tool and is particularly helpful to describe prototypical and common patterns. It does not, 
however, account for time-dependent confounding or selection biases that may explain the 
trajectories and risks estimated. Therefore, the associations with stroke risk seen across our four 
trajectories could be due in part or whole to a number of non-causal explanations, including 
differences in health behaviors, healthcare utilization, and competing risks throughout the 
study period.37,38 Moreover, findings from the classes are not necessarily applicable to individual 
participants’ blood pressure effects, particularly because class membership is probabilistic. On 
the other hand, identifying the patterns described in our study are an important step, since 
they evoke new causal and treatment questions that can motivate future studies to explore 
the etiologic significance and predictive value of the associations. Questions raised by the 
patterns in our study are: would we reduce stroke risk if we recommended blood pressure 
medication to non-hypertensive middle-aged to older patients with fast increases in blood 
pressure? Or, would we reduce stroke risk if the current treatment level of 140/90 mmHg or 
150/90 mmHg is lowered to also include people with moderately elevated blood pressure? In 
addition, trajectories may inform physicians about people that need further attention for their 
high risk of stroke or death.  
Combining our study results with prior evidence, we can speculate to the biologic 
plausibility that treating middle-aged to older patients with (i) moderate blood pressure or (ii) 
fast increasing blood pressure could reduce strokes. The first is supported by previous studies 
that found a relation between prehypertension and stroke, and less of prehypertension with 
other vascular disease.39-41 This suggests that the brain may be particular vulnerable to vascular 
damage. Whether it is likely that treatment of fast increasing blood pressure reduces stroke and 
death is less clear. It is known that vascular stiffness increases with ageing.15,42 This leads to an 
increase in blood pressure and may explain the gradually increasing blood pressure trajectory 
in the largest part of the population.15,42 However, this does not explain why another class was 
characterized by a much steeper increase. It may be that this trajectory reflects a higher vascular 
age.43 This is supported by our findings that associations with stroke attenuated after adjusting 
for other cardiovascular risk factors. They may have stiffer vessels, which could lead to a steeper 
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increase or a blood pressure resistant to treatment.44 The higher vascular age may then 
contribute to the increased risk of stroke and death. Furthermore, the steep increase in blood 
pressure may trigger rupture of an arteriole leading to a hemorrhagic stroke.45 Knowing 
whether a fast increasing blood pressure causally relates to stroke and death is important, 
because people with fast increasing blood pressure may be missed using current guidelines, 
leading to undertreatment. Correspondingly, only 33% of the people in the fast increasing class 
used blood pressure-lowering medication at their end of follow-up. On the other hand, this 
could also mean that this class reflects people with more unhealthy behavior that are less 
adherent to medication themselves. Further research is necessary to unravel the etiological 
background of the trajectories. This should include the question whether some trajectories 
reflect advancing stages of vascular ageing. For example, with advancing vascular age people 
may move from an increasing trajectory to the trajectory of consistently high blood pressure. 
Strengths of our study are the large study population, the use of repeated measures of 
blood pressure over a long follow-up, and the thorough collection of stroke assessments. 
However, our study also has some limitations. We only examined associations with all stroke, 
numbers were too small to examine stroke subtypes. Furthermore, we obtained a maximum 
of only five measurements of blood pressure per person. More measurements would probably 
lead to more precise results and possibly more or differently defined trajectories. It might also 
reduce the effect of regression to the mean and within-individual variability. Moreover, there 
may have been misclassification among classes due to individual variability or reliability in 
blood pressure assessments. Nevertheless, the trajectories may aid detection of high-risk 
persons even if the trajectories are in part explained by a white coat effect or variability. 
Additionally, the trajectories may be less reliable at very old ages when we had fewer 
measurements, although our trajectories were consistent up through age 80 whether or not 
later assessments were included in the model. Finally, we did not have information about blood 
pressure at earlier ages. Future studies should examine the lifetime trajectory of blood pressure 
and the risk of stroke.  
In conclusion, treatment of blood pressure to reduce the risk of stroke is currently focused 
on blood pressure levels. In this population-based study on blood pressure trajectories, we had 
the novel finding that the trajectory with fast increasing blood pressure was related to a high 
risk of stroke and death. It shows that single values of blood pressure do not tell the whole 
story. This may inspire future studies to examine the predictive value of blood pressure 
trajectories for stroke and mortality. Additionally, future studies are needed to determine the 
etiologic significance of blood pressure changes. If the blood pressure slope is causally related 
to stroke and not just a reflection of an individual’s health behavior, it may be a novel target for 
prevention.  
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increase or a blood pressure resistant to treatment.44 The higher vascular age may then 
contribute to the increased risk of stroke and death. Furthermore, the steep increase in blood 
pressure may trigger rupture of an arteriole leading to a hemorrhagic stroke.45 Knowing 
whether a fast increasing blood pressure causally relates to stroke and death is important, 
because people with fast increasing blood pressure may be missed using current guidelines, 
leading to undertreatment. Correspondingly, only 33% of the people in the fast increasing class 
used blood pressure-lowering medication at their end of follow-up. On the other hand, this 
could also mean that this class reflects people with more unhealthy behavior that are less 
adherent to medication themselves. Further research is necessary to unravel the etiological 
background of the trajectories. This should include the question whether some trajectories 
reflect advancing stages of vascular ageing. For example, with advancing vascular age people 
may move from an increasing trajectory to the trajectory of consistently high blood pressure. 
Strengths of our study are the large study population, the use of repeated measures of 
blood pressure over a long follow-up, and the thorough collection of stroke assessments. 
However, our study also has some limitations. We only examined associations with all stroke, 
numbers were too small to examine stroke subtypes. Furthermore, we obtained a maximum 
of only five measurements of blood pressure per person. More measurements would probably 
lead to more precise results and possibly more or differently defined trajectories. It might also 
reduce the effect of regression to the mean and within-individual variability. Moreover, there 
may have been misclassification among classes due to individual variability or reliability in 
blood pressure assessments. Nevertheless, the trajectories may aid detection of high-risk 
persons even if the trajectories are in part explained by a white coat effect or variability. 
Additionally, the trajectories may be less reliable at very old ages when we had fewer 
measurements, although our trajectories were consistent up through age 80 whether or not 
later assessments were included in the model. Finally, we did not have information about blood 
pressure at earlier ages. Future studies should examine the lifetime trajectory of blood pressure 
and the risk of stroke.  
In conclusion, treatment of blood pressure to reduce the risk of stroke is currently focused 
on blood pressure levels. In this population-based study on blood pressure trajectories, we had 
the novel finding that the trajectory with fast increasing blood pressure was related to a high 
risk of stroke and death. It shows that single values of blood pressure do not tell the whole 
story. This may inspire future studies to examine the predictive value of blood pressure 
trajectories for stroke and mortality. Additionally, future studies are needed to determine the 
etiologic significance of blood pressure changes. If the blood pressure slope is causally related 
to stroke and not just a reflection of an individual’s health behavior, it may be a novel target for 
prevention.  
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Abstract 
 
Background and purpose  
Worldwide, chronic obstructive pulmonary disease (COPD) and stroke are leading causes of 
death. Increasing evidence suggests an association between both diseases, either caused by 
an increased atherosclerosis risk in patients with COPD, or as a consequence of shared risk 
factors between stroke and COPD. Our aim was to examine the associations between COPD 
and subtypes of stroke in the general population and to explore the role of cardiovascular risk 
factors and exacerbations on these associations. 
 
Methods 
Within the prospective population-based Rotterdam Study, we followed 13115 participants 
without history of stroke for occurrence of stroke. Follow-up started in 1990-2008 and ended 
in 2012. COPD was related to stroke using a time-dependent Cox proportional hazard model. 
 
Results  
COPD was diagnosed in 1566 participants. During 126347 person-years, 1250 participants 
suffered a stroke, of which 701 were ischemic and 107 hemorrhagic. Adjusted for age, age2, and 
sex, COPD was significantly associated with all stroke (HR 1.20, 95% CI 1.00; 1.43), ischemic 
stroke (HR 1.27, 95% CI 1.02; 1.59), and hemorrhagic stroke (HR 1.70, 95% CI 1.01; 2.84). Adjusting 
for cardiovascular risk factors gave similar effect sizes. In contrast, additional adjusting for 
smoking attenuated the effect sizes: HR 1.09 (95% CI 0.91; 1.31) for all stroke, HR 1.13 (95% CI 
0.91; 1.42) for ischemic stroke, and HR 1.53 (95% CI 0.91; 2.59) for hemorrhagic stroke. Following 
an acute severe exacerbation subjects with COPD had a 6.66-fold (95% CI 2.42; 18.20) increased 
risk of stroke. 
 
Conclusions 
Our cohort study demonstrated a higher risk of both ischemic and hemorrhagic stroke in 
subjects with COPD, and revealed the importance of smoking as a shared risk factor. 
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Introduction 
 
Chronic obstructive pulmonary disease (COPD) and stroke are both leading causes of morbidity 
and mortality worldwide.1,2 COPD is primarily characterized by persistent airflow limitation that 
is associated with an abnormal inflammatory response of the lungs to noxious particles or 
gases, but is also frequently associated with systemic effects and/or comorbidities. The most 
prevalent comorbidities in patients with COPD encompass hypertension, ischemic heart 
disease, chronic heart failure, osteoporosis, muscle weakness, depression, and lung cancer.3-7 
Since comorbidities have a major impact on the severity and prognosis of COPD, the recent 
ATS/ERS Research Statement on COPD launched an urgent call for studies to confirm or 
exclude associations between specific comorbidities and COPD.8 In addition, studies to 
elucidate the pathobiological mechanisms linking COPD to its comorbidities are eagerly 
awaited.  
A few previous population-based studies found associations between COPD and stroke.9-13 
However, important limitations were their cross-sectional design,10-13 lack of information about 
possible confounders,10,13 and absence of analysis of stroke subtypes.9-13 Therefore, several 
important issues remain unanswered. First, it is unknown whether the observed associations 
between COPD and stroke are causal, for instance through inflammation5,14 or hypoxia,15,16 
aggravated by COPD exacerbations,17 or whether they are merely due to confounding by 
shared risk factors. Considering that smoking is the main risk factor for COPD and a risk factor 
for stroke, this might be an important confounder.7,18 Other confounders could be 
cardiovascular risk factors and concomitant diseases such as diabetes and hypertension.4,7,18 
Second, it is unknown whether associations are only present for ischemic stroke, or also for 
hemorrhagic stroke, and whether they are present for different subtypes of ischemic stroke.19 
Given that the pathophysiology and preventive options for ischemic and hemorrhagic stroke 
are different, it is necessary to study associations with both subtypes separately.  
Therefore, the aim of our prospective population-based study was to examine the 
associations between COPD and stroke, taking into account the different subtypes of stroke. 
Furthermore, to gain more insight into the pathophysiology of these associations we 
investigated the role of smoking, other cardiovascular risk factors, serum high-sensitivity C-
reactive protein (hs-CRP), carotid intima-media thickness (cIMT), and exacerbations.  
 
Methods 
 
Setting and study population 
This study was conducted within the Rotterdam Study, a large prospective population-based 
cohort study, which aims to assess incidence of, and risk factors for chronic diseases in the 
elderly. Initially, from 1990 onwards 7983 persons aged 55 years and older and living in the 
Ommoord district in the city of Rotterdam were included (Rotterdam Study I). The cohort was 
extended in 2000 with 3011 participants who moved into the study district or had become 55 
years or older since the start of the study (Rotterdam Study II). In 2006, the study was further 
extended with 3932 persons that were aged 45 years and older (Rotterdam Study III). Follow-
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Introduction 
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Given that the pathophysiology and preventive options for ischemic and hemorrhagic stroke 
are different, it is necessary to study associations with both subtypes separately.  
Therefore, the aim of our prospective population-based study was to examine the 
associations between COPD and stroke, taking into account the different subtypes of stroke. 
Furthermore, to gain more insight into the pathophysiology of these associations we 
investigated the role of smoking, other cardiovascular risk factors, serum high-sensitivity C-
reactive protein (hs-CRP), carotid intima-media thickness (cIMT), and exacerbations.  
 
Methods 
 
Setting and study population 
This study was conducted within the Rotterdam Study, a large prospective population-based 
cohort study, which aims to assess incidence of, and risk factors for chronic diseases in the 
elderly. Initially, from 1990 onwards 7983 persons aged 55 years and older and living in the 
Ommoord district in the city of Rotterdam were included (Rotterdam Study I). The cohort was 
extended in 2000 with 3011 participants who moved into the study district or had become 55 
years or older since the start of the study (Rotterdam Study II). In 2006, the study was further 
extended with 3932 persons that were aged 45 years and older (Rotterdam Study III). Follow-
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up examinations take place every three to four years. Details regarding the objective and 
design of the Rotterdam Study have been described elsewhere.20 
The study population consisted of participants who gave informed consent for follow-up 
and had no history of stroke at baseline. Patients with physician diagnosed asthma or potential 
asthma-COPD overlap syndrome (ACOS) were excluded. ACOS was defined as a physician 
diagnosis of COPD in subjects with previously diagnosed asthma. The Rotterdam Study has 
been approved by the medical ethics committee of the Erasmus MC, Rotterdam (02/2015), and 
the review board of The Netherlands Ministry of Health, Welfare and Sports (3098760). A written 
informed consent was obtained from all participants. 
 
Assessment of COPD 
The diagnosis of COPD was based on an obstructive spirometry (proportion of the forced vital 
capacity exhaled in the first second (FEV1/FVC) < 0.7, assessed pre-bronchodilator) during the 
research center visits or in absence of spirometry, on information collected continuously from 
medical records of general practitioners and lung physicians.21,22 All participants with physician-
diagnosed COPD were validated through thorough examination of medical files and 
specialists’ letters. Date of incident COPD was defined as the date of obstructive lung function 
examination, the date of COPD diagnosis in the medical records, or the date of a first COPD 
medication prescription in someone with established COPD, whichever came first. Medication 
use was obtained through automated linkage with pharmacy filled prescription data. The 
follow-up for COPD was complete until January 1st, 2012 for 99.1% of potential person-years. 
Patients were classified as having frequent exacerbations if they had on average and rounded 
two or more moderate or severe exacerbations a year. Moderate exacerbations were defined 
as needing a course of steroids and/or antibiotics and severe exacerbations as needing 
hospitalization.23 The high-risk period following an exacerbation was defined as 1 day to 7 
weeks after start of the exacerbation, conform a previous study.17 Follow-up for exacerbations 
was complete until December 31st, 2010. 
The severity of COPD was assessed in people with an interpretable lung function test at the 
research center in 2002-2008 (n=4141). We used the GOLD 2013 criteria,24 including the 
percentage predicted of the forced expiratory volume in 1s (FEV1), the exacerbation rate, and 
the grade of dyspnea. Dyspnea score was based on 5 dyspnea-questions and scored from 0 
(never dyspneic) to 5 (even dyspneic at rest). 
In a subgroup of 1158 participants with lung function measurements between 2009-2012, 
we measured the diffusion capacity of the lungs using carbon monoxide (DLCO) and corrected 
for the haemoglobin concentration (DLCO,c). 
 
Assessment of stroke 
Stroke was defined according to the World Health Organization criteria as syndrome of rapidly 
developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms 
lasting 24 hours or leading to death, with no apparent cause other than of vascular origin.25 
Prevalent stroke at baseline was assessed using the home interview and verified by reviewing 
medical records. From baseline onwards, all participants were continuously followed-up for 
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occurrence of stroke through automatic linkage of general practitioners’ medical records with 
the study database. Additionally, nursing home physicians’ medical records and medical 
records from general practitioners of participants who moved out of the Ommoord district 
were inspected on a regular basis. Research physicians reviewed potential strokes using 
hospital discharge letters and information from general practitioners and an experienced 
neurologist verified the stroke diagnoses.26 Strokes were subclassified in ischemic or 
hemorrhagic stroke based on neuroimaging reports. If no neuroimaging was performed, 
strokes were classified as unspecified. Ischemic strokes were further subclassified in two ways. 
They were subclassified in cortical or lacunar ischemic stroke, based on neuroimaging reports 
or clinical symptoms.27 Furthermore, they were subclassified according to TOAST criteria based 
on the diagnostic workup mentioned in medical records.28 The follow-up for stroke was 
complete until January 1st, 2012 for 96.3% of potential person-years. 
 
Covariates 
Covariates were measured at baseline of each cohort. Smoking status and medication use were 
assessed during a home interview. Smoking was categorized into current, past, and never 
smoking. Cigarette pack-years were calculated as the duration of smoking in years, multiplied 
by the number of smoked cigarettes, divided by 20.22 Additionally, cardiovascular risk factors 
were measured during a visit at the study center.29 Blood pressure was measured twice in 
sitting position on the right arm with a random-zero sphygmomanometer. The average of the 
two consecutive measurements was used in the analyses. Hypertension was defined as a 
systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg and/or the 
use of blood pressure-lowering medication with the indication hypertension. Pulse oxygen 
saturation (SaO2) was measured twice on the right index finger. The average of the two 
measurements was used in the analysis. A low pulse oxygen saturation was defined as ≤95%. 
Total cholesterol, high-density lipoprotein (HDL) cholesterol, and hs-CRP were measured in 
serum. Diabetes mellitus was defined as having an overnight fasting glucose level 7.0 mmol/L 
or higher, a non-fasting glucose level of 11.0 mmol/L or higher, or use of antidiabetic 
medication. Carotid intima-media thickness (cIMT) was measured by ultrasonography of the 
left and right carotid arteries, performed with a 7.5 MHz linear array transducer (ATL UltraMark 
IV; Advanced Technology Laboratories, Bethel, Washington). The maximal cIMT, which is the 
mean of maximal measurements from the near and far walls of both the left and right sides, 
was used for analysis.29 The presence of atrial fibrillation at baseline was based on medical 
records from general practitioners and on the ECG performed during the baseline visit at the 
study center.30  
 
Statistical analyses 
Analysis of covariance was used to study differences in baseline characteristics between 
subjects with incident versus prevalent COPD and between subjects with COPD (incident or 
prevalent) versus subjects without COPD during follow-up, adjusted for age and sex. 
Associations between COPD and stroke were evaluated using Cox proportional hazards 
regression. COPD was added as time-varying covariate in the analysis, which captured persons 
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Associations between COPD and stroke were evaluated using Cox proportional hazards 
regression. COPD was added as time-varying covariate in the analysis, which captured persons 
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with prevalent COPD at baseline and persons that developed COPD during follow-up. 
Participants were censored at date of stroke, date of death, last date of follow-up, or January 
1st, 2012, whichever came first. We examined associations of COPD with both ischemic and 
hemorrhagic stroke and additionally with cortical or lacunar ischemic stroke and TOAST 
subclassifications of ischemic stroke. All models were adjusted for age, age squared (age2), and 
sex. To determine effects of inflammation, cardiovascular risk factors, and in particular smoking 
on the associations, we constructed the following consecutive models: model I adjusted for 
age, age2 and sex; model II adjusted for age, age2, sex, and CRP; model III adjusted for age, age2, 
sex, and cIMT; model IV adjusted for age, age2, sex, and hypertension; model V adjusted for age, 
age2, sex, and anticoagulant or antiplatelet medication; model VI adjusted for age, age2, sex, 
and the cardiovascular risk factors: systolic blood pressure, diastolic blood pressure, blood 
pressure-lowering medication, total cholesterol, HDL cholesterol, lipid-lowering medication, 
diabetes mellitus, BMI, and atrial fibrillation; model VII adjusted for age, age2, sex, and smoking; 
model VIII adjusted for age, age2, sex, and pack-years, and model IX adjusted for all covariates. 
In a subgroup of participants we also adjusted for pulse oxygen saturation. CRP was natural log 
transformed because of skewed distribution.  
As additional analysis we related COPD with stroke categorizing COPD as diagnosed based 
on lung function or medical records and analyzed the risk of COPD in the participants with 
ACOS that were excluded for the other analyses. Furthermore, we categorized COPD as with 
few or many exacerbations and related that to the risk of stroke. In another analysis we 
examined the risk of stroke during the high-risk period of an exacerbation itself. This high risk 
period was defined conform an earlier study as starting one day after the start of an 
exacerbation, until 7 weeks after the exacerbation.17 To examine the risk of stroke in this period, 
we added exacerbations as time-dependent covariate to the Cox proportional hazards models, 
in which people were considered at high risk starting one day after the start of an exacerbation, 
until 7 weeks after the exacerbation. If subjects had multiple exacerbations they were 
considered at risk for 7 weeks after each of those. The reference period was formed by the 
remaining follow-up time in which subjects did not suffer from exacerbations. For this analysis 
we only included participants with COPD and censored them at date of stroke, date of death, 
last date of follow-up, or February 19th (7 weeks after the end of exacerbation follow-up), 
whichever came first. 
In a subgroup of people with lung function in 2002-2008, we examined the risk of stroke 
according to the severity of COPD as measured by the GOLD criteria and according to the 
severity of airflow limitation as measured by FEV1. 
Missing data on covariates (for cIMT 21.5%, for all covariates 14.1% or less) were imputed 
based on the other covariates using multiple imputation with 5 imputation sets.  
We constructed cumulative incidence curves according to the Kaplan-Meier method, 
starting at date of COPD for the people with COPD and at baseline for the reference population.  
To examine the impact of cardiovascular risk factors for the risk of stroke in subjects with 
COPD, we calculated the population attributable risks (PARs) using the Interactive Risk 
Attributable Program version 2.2 (US National Cancer Institute),31 conform a previous study.32 
This program calculates hazard ratio’s (HR’s) with 95% CI based on a Poisson model and enables 
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the calculation of PARs with 95% CI. We calculated the PARs in people with prevalent COPD at 
baseline, because at this time the risk factors were assessed. We assessed the PARs of the major 
risk factors for stroke, namely hypertension, smoking, diabetes mellitus, and atrial fibrillation, 
and of the combination of these risk factors, adjusted for age, age2, sex, and the other risk 
factors if applicable. For the missing data, the mean of the 5 imputation sets as described above 
was used.  
All analyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY), R 
Statistical Software version 3.1.2 (The R Foundation for Statistical Computing, Vienna, Austria), 
and IRAP version 2.2 (US National Cancer Institute). 
 
Results  
 
General characteristics 
Participants who did not give informed consent for collection of follow-up data (n=238), or had 
a history of stroke at baseline (n=453), or a history of asthma or Asthma and COPD Overlap 
Syndrome (ACOS) at baseline (n=1120) were excluded. Consequently, 13115 participants were 
eligible for analysis (Figure 1). 
 
 
Figure 1. Study population 
 
Baseline characteristics of the study population are presented in Table 1. Follow-up duration 
was on average 9.6 (±6.0) years. 538 participants had COPD at baseline and 1028 participants 
developed COPD during follow-up. 1298 (82.9%) diagnoses were based on spirometry 
performed either at the research center (868 cases since January 2002) or by a pulmonologist 
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with prevalent COPD at baseline and persons that developed COPD during follow-up. 
Participants were censored at date of stroke, date of death, last date of follow-up, or January 
1st, 2012, whichever came first. We examined associations of COPD with both ischemic and 
hemorrhagic stroke and additionally with cortical or lacunar ischemic stroke and TOAST 
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model VIII adjusted for age, age2, sex, and pack-years, and model IX adjusted for all covariates. 
In a subgroup of participants we also adjusted for pulse oxygen saturation. CRP was natural log 
transformed because of skewed distribution.  
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severity of airflow limitation as measured by FEV1. 
Missing data on covariates (for cIMT 21.5%, for all covariates 14.1% or less) were imputed 
based on the other covariates using multiple imputation with 5 imputation sets.  
We constructed cumulative incidence curves according to the Kaplan-Meier method, 
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Baseline characteristics of the study population are presented in Table 1. Follow-up duration 
was on average 9.6 (±6.0) years. 538 participants had COPD at baseline and 1028 participants 
developed COPD during follow-up. 1298 (82.9%) diagnoses were based on spirometry 
performed either at the research center (868 cases since January 2002) or by a pulmonologist 
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(430 subjects). In 268 (17.1%) subjects the diagnosis of COPD was made by their general 
practitioner. The mean age at baseline (±SD) was 67.0 years (±9.3) for persons with prevalent 
COPD, 65.2 (±7.4) for persons who developed COPD during follow-up, and 65.8 (±10.6) for 
persons without COPD. Persons with COPD were more often male and (current) smokers.  
In the subgroup of participants with lung function measurements in 2002-2008, we found 
that the mean FEV1 was 110% (±18%) in participants without COPD, 76% (±20%) in participants 
with prevalent COPD and 100% (±22%) in participants who developed COPD during follow-
up. 
1250 subjects suffered a stroke during follow-up. 701 strokes were classified as ischemic 
stroke, and 107 as hemorrhagic stroke. In the 442 participants in whom no neuroimaging was 
performed, their stroke was classified as unspecified. Of all ischemic strokes, 40.2% was 
classified as cortical, and 7.3% was classified according to the TOAST criteria as based on large 
artery atherosclerosis.  
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Table 1. Baseline characteristics 
 No COPD Prevalent COPD Incident COPD 
 N=11549 N=538 N=1028 
Age, years 65.8 (10.6) 67.0 (9.3)ab 65.2 (7.4)a 
Female 6971 (60.4%) 250 (46.5%)a 449 (43.7%)a 
Smoking    
Never 4052 (35.9%) 80 (15.0%)a 151 (14.8%)a 
Past 4797 (42.5%) 240 (44.9%)b 410 (40.2%)a 
Current 2449 (21.7%) 214 (40.1%)a 459 (45.0%)a 
Pack-years for cigarette smokers 22.9 (22.2) 37.0 (26.8)a 34.5 (24.3)a 
Systolic blood pressure, mmHg 138 (22) 139 (21) 137 (21) 
Diastolic blood pressure, mmHg 77 (12) 77 (12)b 76 (12)a 
Use of blood pressure-lowering 
medication 
2573 (22.4%) 120 (22.3%) 207 (20.2%) 
Hypertension 5964 (56.0%) 278 (57.1%) 519 (52.4%) 
Total cholesterol, mmol/L 6.2 (1.2) 6.1 (1.2)b 6.3 (1.2)a 
HDL-cholesterol, mmol/L 1.37 (0.39) 1.43 (0.44)ab 1.34 (0.36) 
Use of lipid-lowering medication 1047 (9.1%) 62 (11.6%)ab 74 (7.2%)a 
Use of anticoagulant drugs 345 (3.0%) 23 (4.3%) 32 (3.1%) 
Use of antiplatelet drugs 587 (5.1%) 44 (8.2%)a 61 (5.9%) 
Diabetes mellitus 922 (9.1%) 55 (11.9%)b 67 (7.1%)a 
Body mass index 26.9 (4.0) 26.4 (4.1)a 26.0 (3.8)a 
Atrial fibrillation 405 (4.1%) 33 (7.3%)ab 31 (3.3%) 
Carotid intima-media thickness 0.98 (0.20) 1.03 (0.22)a 1.01 (0.19)a 
hs-CRP, mg/Lc 1.5 (0.6 – 3.1) 2.2 (0.9 – 4.3)ab 1.8 (0.8 – 3.7)a 
Pulse oxygen saturation <95% 250 (13.2%) 26 (25.0%)a 27 (16.5%) 
Abbreviations: N = number of persons included in study; HDL = high-density lipoprotein; hs-CRP = high-
sensitivity C-reactive protein.  
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squared (age2), and sex, we found a significant association of COPD with all stroke (HR 1.20, 95% 
CI 1.00; 1.43), ischemic stroke (HR 1.27, 95% CI 1.02; 1.59), and hemorrhagic stroke (HR 1.70, 95% 
CI 1.01; 2.84) (Figure 2, Figure 3). Associations were slightly, but not significantly weaker in 
subjects with COPD diagnosed based on spirometry (HR 1.16, 95% CI 0.95; 1.42) compared to 
COPD subjects diagnosed based by their general practitioner (HR 1.31, 95% CI 0.95; 1.82). 
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(430 subjects). In 268 (17.1%) subjects the diagnosis of COPD was made by their general 
practitioner. The mean age at baseline (±SD) was 67.0 years (±9.3) for persons with prevalent 
COPD, 65.2 (±7.4) for persons who developed COPD during follow-up, and 65.8 (±10.6) for 
persons without COPD. Persons with COPD were more often male and (current) smokers.  
In the subgroup of participants with lung function measurements in 2002-2008, we found 
that the mean FEV1 was 110% (±18%) in participants without COPD, 76% (±20%) in participants 
with prevalent COPD and 100% (±22%) in participants who developed COPD during follow-
up. 
1250 subjects suffered a stroke during follow-up. 701 strokes were classified as ischemic 
stroke, and 107 as hemorrhagic stroke. In the 442 participants in whom no neuroimaging was 
performed, their stroke was classified as unspecified. Of all ischemic strokes, 40.2% was 
classified as cortical, and 7.3% was classified according to the TOAST criteria as based on large 
artery atherosclerosis.  
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Table 1. Baseline characteristics 
 No COPD Prevalent COPD Incident COPD 
 N=11549 N=538 N=1028 
Age, years 65.8 (10.6) 67.0 (9.3)ab 65.2 (7.4)a 
Female 6971 (60.4%) 250 (46.5%)a 449 (43.7%)a 
Smoking    
Never 4052 (35.9%) 80 (15.0%)a 151 (14.8%)a 
Past 4797 (42.5%) 240 (44.9%)b 410 (40.2%)a 
Current 2449 (21.7%) 214 (40.1%)a 459 (45.0%)a 
Pack-years for cigarette smokers 22.9 (22.2) 37.0 (26.8)a 34.5 (24.3)a 
Systolic blood pressure, mmHg 138 (22) 139 (21) 137 (21) 
Diastolic blood pressure, mmHg 77 (12) 77 (12)b 76 (12)a 
Use of blood pressure-lowering 
medication 
2573 (22.4%) 120 (22.3%) 207 (20.2%) 
Hypertension 5964 (56.0%) 278 (57.1%) 519 (52.4%) 
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Use of antiplatelet drugs 587 (5.1%) 44 (8.2%)a 61 (5.9%) 
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Pulse oxygen saturation <95% 250 (13.2%) 26 (25.0%)a 27 (16.5%) 
Abbreviations: N = number of persons included in study; HDL = high-density lipoprotein; hs-CRP = high-
sensitivity C-reactive protein.  
Data are presented as mean (standard deviations) or counts (percentages). 
a Significantly different between persons with and without COPD, after sex and age adjustment – if applicable. 
b Significantly different between persons with prevalent and incident COPD, after sex and age adjustment – if 
applicable. 
c Median and inter-quartile range because of skewed distribution. 
 
Association between COPD and the risk of stroke 
In Figure 2 we show associations between COPD and the risk of stroke. Adjusting for age, age 
squared (age2), and sex, we found a significant association of COPD with all stroke (HR 1.20, 95% 
CI 1.00; 1.43), ischemic stroke (HR 1.27, 95% CI 1.02; 1.59), and hemorrhagic stroke (HR 1.70, 95% 
CI 1.01; 2.84) (Figure 2, Figure 3). Associations were slightly, but not significantly weaker in 
subjects with COPD diagnosed based on spirometry (HR 1.16, 95% CI 0.95; 1.42) compared to 
COPD subjects diagnosed based by their general practitioner (HR 1.31, 95% CI 0.95; 1.82). 
 
Chapter 4.1 
152 
Figure 2. COPD and the risk of stroke (N=13115) 
Values are hazard ratios with 95% confidence intervals. Hs-CRP = high-sensitivity C-reactive protein, cIMT = 
carotid intima-media thickness, CV = cardiovascular. All models were adjusted for age, age2, and sex. 
Antithrombotics include both antiplatelet drugs and anticoagulants. Cardiovascular risk factors are systolic 
blood pressure, diastolic blood pressure, blood pressure-lowering medication, total cholesterol, high-density 
lipoprotein cholesterol, lipid-lowering medication, diabetes mellitus, body mass index, and atrial fibrillation. 
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Figure 3. Cumulative incidence curve of stroke according to COPD status 
A: all stroke, B: ischemic stroke, C: hemorrhagic stroke. 
 
Influence of covariates 
Adjusting for serum hs-CRP as marker for systemic inflammation or cIMT as marker for carotid 
atherosclerosis both led to a modest change of the associations (HR for all stroke additionally 
adjusted for hs-CRP 1.17, 95% CI 0.98; 1.39, HR for all stroke additionally adjusted for cIMT 1.16, 
95% CI 0.97; 1.39) (Figure 2). Adjustment for hypertension or all cardiovascular risk factors other 
than smoking did not change the associations. Adjusting for pulse oxygen saturation in a 
subgroup had a modest effect (data not shown). However, additional adjusting for smoking 
clearly attenuated the associations: HR all stroke 1.09 (95% CI 0.91; 1.31), ischemic stroke 1.13 
(95% CI 0.91; 1.42), hemorrhagic stroke 1.53 (95% CI 0.91; 2.59). Adjustment for cumulative 
smoking exposure (i.e. pack-years) had a similar effect as adjustment for smoking status. 
Although not statistically significant, effect sizes of COPD and ischemic stroke were higher for 
persons with a cortical stroke (HR adjusted for age, age2, sex, and smoking 1.36, 95% CI 0.97; 
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subgroup had a modest effect (data not shown). However, additional adjusting for smoking 
clearly attenuated the associations: HR all stroke 1.09 (95% CI 0.91; 1.31), ischemic stroke 1.13 
(95% CI 0.91; 1.42), hemorrhagic stroke 1.53 (95% CI 0.91; 2.59). Adjustment for cumulative 
smoking exposure (i.e. pack-years) had a similar effect as adjustment for smoking status. 
Although not statistically significant, effect sizes of COPD and ischemic stroke were higher for 
persons with a cortical stroke (HR adjusted for age, age2, sex, and smoking 1.36, 95% CI 0.97; 
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1.90) and persons with an ischemic stroke based on large artery atherosclerosis (HR adjusted 
for age, age2, sex, and smoking 1.78, 95% CI 0.89; 3.57).  
In subjects with COPD, similar to what was observed in the general population,32 we found 
that hypertension was the most important modifiable risk factor, with a PAR of 0.30 (95% CI 
0.09; 0.65), adjusted for age, age2, sex, smoking, diabetes, and atrial fibrillation (Supplementary 
Table I). 
 
Influence of exacerbations 
The stratification for frequent exacerbators did not show a significantly higher risk in COPD 
subjects with a mean of two or more exacerbations a year (HR adjusted for age, age2, sex and 
smoking 1.13, 95% CI 0.80; 1.59), compared to COPD subjects without exacerbations or less 
than two a year (HR 1.06, 95% CI 0.86; 1.29) (Supplementary Table II).  
Interestingly, we observed that 22 of the 145 strokes that occurred in patients with COPD, 
occurred within 7 weeks after the start of an acute exacerbation of COPD. 11 strokes were 
classified as ischemic and 11 as unspecified. Among 1530 subjects with COPD, 329 COPD 
subjects did not suffer from any exacerbation during follow-up. The remaining 1201 COPD 
subjects had a total of 11904 exacerbations. Stratified for severity of exacerbations we found 
that 11373 moderate exacerbations occurred in 1197 subjects and 531 severe exacerbations in 
268 subjects. The risk of any stroke following an acute exacerbation period (within 7 weeks after 
start of the exacerbation) was not significantly increased compared to a stable period (HR 1.28, 
95% CI 0.81; 2.02). Importantly, the risk of stroke after a severe exacerbation of COPD was 
significantly higher than during stable disease (HR 6.66, 95% CI 2.42; 18.20), adjusted for age, 
age2, sex and smoking (Table 2). 
 
Table 2. The risk of stroke within 7 weeks after the onset of an acute exacerbation in patients with COPD 
compared to stable disease 
 Stroke 
 n/Na 142/1530 
 Model I Model II 
No exacerbation / stable period 1 (reference) 1 (reference) 
Exacerbation period (n = 11904)b 1.30 (0.82; 2.05) 1.28 (0.81; 2.02) 
   
Moderate exacerbation period (n = 11373)b 1.10 (0.67; 1.81) 1.09 (0.66; 1.79) 
Severe exacerbation period (n = 531)b 7.02 (2.57; 19.18) 6.66 (2.42; 18.20) 
a n = number of strokes; N = number of persons included in study. 
b n = number of exacerbations. 
Values are hazard ratios with 95% confidence intervals.  
Model I: Adjusted for age, age2, and sex.  
Model II: Adjusted for age, age2, sex, and smoking. 
 
Influence of severity 
With increasing severity of airflow limitation as measured by FEV1, we found an increased risk 
of stroke (Supplementary table III). When we combined the severity of airflow limitation with 
exacerbation rate and grade of dyspnea, we found that the risk of stroke was increased in 
subjects with GOLD classification A and was even higher in subjects with GOLD classification B 
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(Table 3). For the classes C and D we did not find significant results, although for class C the 
effect size was similar to class B. The risk was not further increased for COPD subjects belonging 
to group D. 
 
Table 3. COPD severity based on the GOLD 2013 classification and the risk of stroke. 
  Stroke 
 n/N Model I Model II 
No COPD 91/3589 1 (reference) 1 (reference) 
GOLD A  19/308 1.74 (1.06; 2.87) 1.64 (0.99; 2.71) 
GOLD B  14/146 2.32 (1.31; 4.11) 2.13 (1.20; 3.79) 
GOLD C  3/34 2.38 (0.75; 7.60) 2.07 (0.65; 6.63) 
GOLD D  4/64 1.62 (0.59; 4.44) 1.43 (0.86; 2.40) 
Abbreviations: n = number of cases; N = number of persons included in study. 
Values are hazard ratios with 95% confidence intervals.  
Model I: Adjusted for age, age2, and sex.  
Model II: Adjusted for age, age2, sex, and smoking. 
GOLD A: mild/moderate airflow limitation, exacerbation rate <2/year, dyspnea < grade 2. 
GOLD B: mild/moderate airflow limitation, exacerbation rate <2/year, dyspnea >= grade 2. 
GOLD C: severe/very severe airflow limitation or exacerbation rate >=2/year, or severe exacerbation rate 
>=1/year, and dyspnea < grade 2. 
GOLD D: severe/very severe airflow limitation or exacerbation rate >=2/year, or severe exacerbation rate 
>=1/year, and dyspnea >= grade 2. 
 
 
Discussion 
 
In this large prospective population-based cohort study, we found that COPD was associated 
with a higher risk of ischemic stroke as well as hemorrhagic stroke. Associations between COPD 
and stroke were no longer significant after adjusting for smoking, although effect sizes 
remained high for cortical ischemic stroke, hemorrhagic stroke and ischemic stroke based on 
large artery atherosclerosis. Furthermore, we found that subjects with COPD were significantly 
at higher risk of stroke following severe exacerbations. 
Our results showed that people with COPD have an approximately 20% increased risk of 
stroke, which was similar to findings from previous studies.10-13 Only one study found a much 
stronger risk, but this was driven by the younger age groups until 54 years.9  
However, the association between COPD and stroke is weaker than expected in the light 
of our previous findings. For instance, carotid artery plaques were twice as frequent in subjects 
with COPD, whereas we only found an overall 20% increased risk of stroke.22 Competing risks 
might partially explain this discrepancy. Previous studies showed that in people with COPD the 
risk of cardiovascular disease is higher than the risk of stroke, implicating that either COPD 
subjects die due to a cardiac cause before a stroke might occur, or the cardiovascular treatment 
started for cardiac disease might prevent subsequent stroke.9-13,23 Yet, although not statistically 
significant after adjustment for smoking, the hazard ratio of COPD on ischemic stroke based on 
large artery atherosclerosis was 1.8 and on cortical ischemic stroke 1.4, suggesting that there 
might be link between COPD and ischemic stroke through large vessel disease.  
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1.90) and persons with an ischemic stroke based on large artery atherosclerosis (HR adjusted 
for age, age2, sex, and smoking 1.78, 95% CI 0.89; 3.57).  
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that hypertension was the most important modifiable risk factor, with a PAR of 0.30 (95% CI 
0.09; 0.65), adjusted for age, age2, sex, smoking, diabetes, and atrial fibrillation (Supplementary 
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smoking 1.13, 95% CI 0.80; 1.59), compared to COPD subjects without exacerbations or less 
than two a year (HR 1.06, 95% CI 0.86; 1.29) (Supplementary Table II).  
Interestingly, we observed that 22 of the 145 strokes that occurred in patients with COPD, 
occurred within 7 weeks after the start of an acute exacerbation of COPD. 11 strokes were 
classified as ischemic and 11 as unspecified. Among 1530 subjects with COPD, 329 COPD 
subjects did not suffer from any exacerbation during follow-up. The remaining 1201 COPD 
subjects had a total of 11904 exacerbations. Stratified for severity of exacerbations we found 
that 11373 moderate exacerbations occurred in 1197 subjects and 531 severe exacerbations in 
268 subjects. The risk of any stroke following an acute exacerbation period (within 7 weeks after 
start of the exacerbation) was not significantly increased compared to a stable period (HR 1.28, 
95% CI 0.81; 2.02). Importantly, the risk of stroke after a severe exacerbation of COPD was 
significantly higher than during stable disease (HR 6.66, 95% CI 2.42; 18.20), adjusted for age, 
age2, sex and smoking (Table 2). 
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a n = number of strokes; N = number of persons included in study. 
b n = number of exacerbations. 
Values are hazard ratios with 95% confidence intervals.  
Model I: Adjusted for age, age2, and sex.  
Model II: Adjusted for age, age2, sex, and smoking. 
 
Influence of severity 
With increasing severity of airflow limitation as measured by FEV1, we found an increased risk 
of stroke (Supplementary table III). When we combined the severity of airflow limitation with 
exacerbation rate and grade of dyspnea, we found that the risk of stroke was increased in 
subjects with GOLD classification A and was even higher in subjects with GOLD classification B 
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remained high for cortical ischemic stroke, hemorrhagic stroke and ischemic stroke based on 
large artery atherosclerosis. Furthermore, we found that subjects with COPD were significantly 
at higher risk of stroke following severe exacerbations. 
Our results showed that people with COPD have an approximately 20% increased risk of 
stroke, which was similar to findings from previous studies.10-13 Only one study found a much 
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of our previous findings. For instance, carotid artery plaques were twice as frequent in subjects 
with COPD, whereas we only found an overall 20% increased risk of stroke.22 Competing risks 
might partially explain this discrepancy. Previous studies showed that in people with COPD the 
risk of cardiovascular disease is higher than the risk of stroke, implicating that either COPD 
subjects die due to a cardiac cause before a stroke might occur, or the cardiovascular treatment 
started for cardiac disease might prevent subsequent stroke.9-13,23 Yet, although not statistically 
significant after adjustment for smoking, the hazard ratio of COPD on ischemic stroke based on 
large artery atherosclerosis was 1.8 and on cortical ischemic stroke 1.4, suggesting that there 
might be link between COPD and ischemic stroke through large vessel disease.  
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An important novelty of our study is that we examined for the first time associations with 
hemorrhagic stroke. Most important causes of hemorrhagic strokes are hypertension, small 
vessel disease, and use of anticoagulants.33 Adjustment for hypertension or anticoagulants at 
baseline did not change our association, suggesting independent effects. This indicates small 
vessel disease as a likely explanation, which is further supported by our previous finding that 
COPD was related to microbleeds, with a similar OR of 1.7.34 Nevertheless, residual confounding 
too remains a possibility, either due to single measurements versus lifelong exposures or 
therapy initiation after baseline.  
In summary, our results support findings of previous studies that people with COPD have 
higher risk of both large vessel22,35 and small vessel34,36,37 damage.  
Still, the question remains: What is the underlying mechanism of the association between 
COPD and stroke? Our results indicate that smoking is the strongest explanatory factor since 
effect estimates remained more or less constant after adjustment for other cardiovascular risk 
factors, but were highly attenuated after adjustment for smoking. The HR for stroke in people 
with COPD decreased from 1.19 to 1.09 and became non-significant. Although one previous 
study still found an OR of 1.6 (95% CI 1.1; 2.3),11 our results were in line with two other studies 
that did not find a significant effect of COPD on stroke in older subjects after adjusting for 
smoking.9,12 Since the effect size of COPD independent of smoking is quite small and the 
prevalence of COPD is lower than prevalence of hypertension or smoking, presence of COPD 
adds little to the global population attributable risk of stroke.32  
Nonetheless, we still found effect estimates varying from 1.4 to 1.8 after adjustment for 
smoking, namely for associations of COPD with hemorrhagic stroke, and with ischemic strokes 
that were cortical or from the atherosclerotic subtype. This could mean that there still is residual 
confounding by smoking or that smoking is not the only explanatory factor and that the 
potential causal role of other explanatory factors like inflammation should be further 
investigated. Especially during COPD exacerbations, pulmonary inflammation can lead to 
systemic inflammation,5 eliciting instable atherosclerotic plaques and a pro-thrombotic state, 
and eventually a stroke.14,38,39 This is supported by recent studies showing that in patients with 
COPD carotid arterial plaque burden is increased and more prone to rupture, independent 
from smoking status.22,40,41 In our current study we could not find strong evidence for an effect 
of chronic systemic inflammation, as we only found a modest attenuation of the association 
between COPD and stroke after adjusting for serum hs-CRP at baseline. This was in line with a 
previous study on lung function and the risk of stroke in which adjustment for hs-CRP did not 
change the effect.42 However, hs-CRP at baseline might not be representative for the systemic 
inflammation that occurs during follow-up and during exacerbations. Importantly, following 
an acute severe exacerbation the risk of stroke was sixfold higher than during stable disease, 
suggesting that acute inflammation might lead to a higher risk of stroke. Otherwise, this might 
be a result of hypoxia during exacerbations. Hypoxia could lead to endothelial dysfunction 
which might predispose to stroke.15,16,43 We could not confirm or refute this possibility, because 
we only had information about hypoxia at baseline in a limited group of participants and not 
during exacerbations. However, we did find that participants with GOLD class B had a higher 
risk of stroke compared to class A, suggesting that dyspnea might lead to a higher risk. We did 
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not find the same for class D, but this might again be explained by the low numbers (i.e. lack 
of power) or competing risks. People with very severe COPD might indeed die before a stroke 
can occur.  
More research is necessary to define whether associations are completely due to the shared 
risk factor smoking or whether other mechanisms such as systemic inflammation or hypoxia 
still play a role. Furthermore, future studies should define if, and to what extent, ischemic and 
hemorrhagic stroke share the same underlying mechanisms. In addition to smoking cessation, 
further research into preventive options in patients with COPD, such as aggressive control of 
cardiovascular risk factors such as hypertension, is necessary to reduce the risk of stroke. 
Hypertension remains, similar as in subjects without COPD, the most important modifiable risk 
factor for stroke. 
The strengths of our study are the longitudinal design with long-term follow-up, the 
population-based setting, and the thorough prospective collection of COPD and stroke 
information during follow-up. This study also has limitations. We adjusted for baseline 
covariates, whereas the status of those variables might change during follow-up. This might 
have led to residual confounding. Moreover, we did not adjust for seasonality. Although our 
stroke data did not show a clear seasonal pattern, winter and cold weather are associated with 
an increased risk of exacerbations44 and might increase risk of stroke because of 
hemoconcentration due to peripheral vasoconstriction and a raised blood pressure.45 Another 
limitation is that not all strokes could be subclassified in ischemic or hemorrhagic, and not all 
ischemic strokes into lacunar or cortical or according to etiologic cause based on the TOAST 
criteria, because we were limited by the diagnostic workup performed in stroke cases. 
Furthermore, not all COPD cases were identified similarly. Some COPD cases were diagnosed 
based on spirometry either pre-bronchodilator at the research center or by the pulmonologist, 
others were diagnosed by their general practitioner. This might have led to some 
misclassification. However, associations with stroke in both groups were not significantly 
different.  
In conclusion, we found that COPD was associated with both ischemic and hemorrhagic 
stroke. Our study reveals the importance of smoking as shared risk factor and implicates that 
clinicians should be aware of the higher risk of both stroke subtypes in subjects with COPD, 
especially following severe exacerbations.   
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risk of stroke compared to class A, suggesting that dyspnea might lead to a higher risk. We did 
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not find the same for class D, but this might again be explained by the low numbers (i.e. lack 
of power) or competing risks. People with very severe COPD might indeed die before a stroke 
can occur.  
More research is necessary to define whether associations are completely due to the shared 
risk factor smoking or whether other mechanisms such as systemic inflammation or hypoxia 
still play a role. Furthermore, future studies should define if, and to what extent, ischemic and 
hemorrhagic stroke share the same underlying mechanisms. In addition to smoking cessation, 
further research into preventive options in patients with COPD, such as aggressive control of 
cardiovascular risk factors such as hypertension, is necessary to reduce the risk of stroke. 
Hypertension remains, similar as in subjects without COPD, the most important modifiable risk 
factor for stroke. 
The strengths of our study are the longitudinal design with long-term follow-up, the 
population-based setting, and the thorough prospective collection of COPD and stroke 
information during follow-up. This study also has limitations. We adjusted for baseline 
covariates, whereas the status of those variables might change during follow-up. This might 
have led to residual confounding. Moreover, we did not adjust for seasonality. Although our 
stroke data did not show a clear seasonal pattern, winter and cold weather are associated with 
an increased risk of exacerbations44 and might increase risk of stroke because of 
hemoconcentration due to peripheral vasoconstriction and a raised blood pressure.45 Another 
limitation is that not all strokes could be subclassified in ischemic or hemorrhagic, and not all 
ischemic strokes into lacunar or cortical or according to etiologic cause based on the TOAST 
criteria, because we were limited by the diagnostic workup performed in stroke cases. 
Furthermore, not all COPD cases were identified similarly. Some COPD cases were diagnosed 
based on spirometry either pre-bronchodilator at the research center or by the pulmonologist, 
others were diagnosed by their general practitioner. This might have led to some 
misclassification. However, associations with stroke in both groups were not significantly 
different.  
In conclusion, we found that COPD was associated with both ischemic and hemorrhagic 
stroke. Our study reveals the importance of smoking as shared risk factor and implicates that 
clinicians should be aware of the higher risk of both stroke subtypes in subjects with COPD, 
especially following severe exacerbations.   
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Supplementary Table I. Population attributable risks of presumed etiologic factors for stroke in patients 
with COPD at baseline (n=538) 
Risk factors Classification Prevalence (%) HR (95% CI) PAR (95% CI) 
Hypertension  57.1% 1.77 (0.94; 3.33) 0.30 (0.09; 0.65) 
Smoking Past 45.4% 0.91 (0.39; 2.17) 
0.03 (0.00; 1.00) 
 Current 39.8% 1.23 (0.51; 2.97) 
Diabetes mellitus  10.8% 1.46 (0.63; 3.37) 0.05 (0.00; 0.41) 
Atrial fibrillation  6.9% 1.03 (0.36; 2.96) 0.003 (0.00; 1.00) 
Total    0.35 (0.06; 0.81) 
Abbreviations: PAR = population attributable risk; HR = hazard ratio. 
Values are hazard ratios (95% confidence intervals) or population attributable risks (95% confidence intervals). 
All analyses were adjusted for age, age2, sex, hypertension, smoking, diabetes mellitus, and atrial fibrillation, 
where appropriate.  
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Abstract 
 
Background and purpose 
It is unclear whether anxiety is a risk factor for stroke. We assessed the association between 
anxiety and the risk of incident stroke. 
 
Methods 
This population-based cohort study was based on two rounds of the Rotterdam Study. Each 
round was taken separately as baseline. In 1993-1995, anxiety symptoms were measured using 
the HADS-A. In 2002-2004, anxiety disorders were assessed using the M-CIDI. Participants were 
followed for incident stroke until January 2012.  
 
Results 
In the sample undergoing HADS-A (N=2,625; mean age at baseline 68.4 years), 332 strokes 
occurred during 32,720 years of follow-up. HADS-A score was not associated with the risk of 
stroke during complete follow-up (adjusted HR 1.02, 95% confidence interval (CI) 0.74; 1.43, for 
HADS-A ≥8 compared to HADS-A <8), although we did find an increased risk after a shorter 
follow-up of 3 years (adjusted HR 2.68, 95% CI 1.33; 5.41). In the sample undergoing M-CIDI 
(N=8,662; mean age at baseline 66.1 years), 340 strokes occurred during 48,703 years of follow-
up. Participants with any anxiety disorder had no higher risk of stroke than participants without 
anxiety disorder (adjusted HR 0.95, 95% CI 0.64; 1.43). We also did not observe an increased risk 
of stroke for the different subtypes of anxiety. 
 
Conclusions 
Anxiety disorders were not associated with stroke in our general population study. Anxiety 
symptoms were only related to stroke in the short-term, which needs further exploration. 
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Introduction 
 
An increasing body of evidence suggests that anxiety is associated with the risk of coronary 
heart disease.1,2 Literature on the association between anxiety and stroke is scarce and 
inconsistent. Whereas one study found no association between generalized anxiety disorder 
(GAD) and stroke,3 another study showed that the risk of stroke increased with increasing 
anxiety symptom score.4 Therefore, these findings require further corroboration. We assessed 
the association between anxiety and the risk of stroke in the general population. 
 
Methods 
 
Setting and study population  
The Rotterdam Study is a prospective population-based cohort study, with repeat examination 
rounds every 3 to 4 years.5 The original cohort (RS-I) started in 1990 and was expanded twice 
in 2000 (RS-II) and 2006 (RS-III). Currently, the study consists of 14,926 participants aged ≥45 
years.5  
Anxiety symptoms were assessed once, in the 2nd round of the RS-I subcohort (1993-1995). 
This round was attended by 6,315 participants. A random half of these participants (N=3,060) 
was invited to undergo the Hospital Anxiety and Depression Scale – Anxiety (HADS-A), of 
whom 2,975 were sufficiently screened on anxiety symptoms. We excluded participants 
without informed consent for retrieval of follow-up data (n=22), with prevalent stroke (n=84) 
or with prevalent (n=38) or missing data on dementia (n=206). Therefore, 2,625 participants 
were eligible for the analysis.  
Anxiety disorders were assessed in the 4th round of the RS-I subcohort, the 2nd round of the 
RS-II subcohort, and the 1st round of the RS-III subcohort (2002-2004), using the Munich version 
of the Composite International Diagnostic Interview (M-CIDI). Of the 9,996 participants that 
attended these rounds, 9,974 underwent the interview. Of these, 9,426 participants had a valid 
anxiety assessment. After excluding participants without informed consent (n=62), with 
prevalent stroke (n=364), with prevalent (n=52) or missing data on dementia (n=280), or 
incomplete follow-up (n=6), 8,662 participants were eligible for this analysis. In total, 1,460 
participants were overlapping across the sample that received the HADS-A and the sample 
that received the M-CIDI. 
The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All participants 
provided written informed consent to participate in the study and to obtain information from 
their treating physicians. 
 
Assessment of anxiety  
We used the HADS-A to measure anxiety symptoms. Participants filled in the questionnaire by 
themselves. The HADS-A is a subscale of the HADS,6 a brief questionnaire that is used for the 
self-assessment of anxiety (HADS-A) and depressive symptoms (HADS-D). It measures anxiety 
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including 7 items. The total score ranges from 0-21, and the HADS-A has an optimal balance 
between sensitivity and specificity for identifying anxiety disorder cases at a cutoff score of ≥8.6 
We also used a cutoff score of >11, which includes fewer false positives.7 
The 1-year prevalence of anxiety disorders was assessed using a slightly adapted version of 
the M-CIDI.8 The M-CIDI was administered by trained interviewers. They were trained by a 
medical doctor (HT), who followed a formal training in M-CIDI by the Wittchen group in 
Dresden.9 This score does not allow for a personal interpretation of the participant’s answers. 
Rather a computerized diagnostic algorithm was used to calculate the following anxiety 
disorders according to the DSM-IV-TR criteria: generalized anxiety disorder, panic disorder, 
agoraphobia, social phobia, and specific phobia.8  
 
Assessment of stroke  
Stroke was defined according to World Health Organization criteria.10 After enrollment, 
participants were continuously monitored for incident stroke through automated linkage of 
the study database with medical records from general practitioners. Additional information 
was obtained from hospital records as described previously.10 Strokes were classified as 
ischemic or hemorrhagic based on neuroimaging reports. Strokes were classified as 
unspecified if no neuroimaging was performed.10 The follow-up was complete until January 1, 
2012, for 93.1% of potential person-years. 
 
Assessment of covariates  
We considered age, sex, systolic blood pressure, diastolic blood pressure, blood pressure-
lowering medication, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering 
medication, smoking, diabetes mellitus type 2, body mass index, and myocardial infarction as 
potential confounders and their assessment has been described previously.5,11 Information 
about cholesterol, lipid-lowering medication, and diabetes mellitus was unavailable for the visit 
of the HADS cohort and was therefore obtained from one visit earlier. Depressive symptoms 
were obtained from the HADS Depression subscale (HADS-D).6  
 
Statistical analysis 
We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) with Cox proportional 
hazards models using IBM SPSS Statistics version 21. We analyzed participants based on HADS-
A score (continuously per standard deviation (SD) and categorically using score ≥8 versus score 
<8 and score ≥11 versus score <11) and based on M-CIDI (at least one disorder [generalized 
anxiety disorder, panic disorder, agoraphobia, social phobia, or specific phobia] versus no 
disorder, and the separate subtypes of anxiety disorder versus no disorder). Participants were 
censored at date of stroke, date of death, last date of follow-up or January 1, 2012. Additionally, 
we constructed Kaplan-Meier curves to detect possible short-term effects. Covariates were 
missing up to a maximum of 9% and imputed based on the other covariates using multiple 
imputation with 5 imputation sets. 
 
 
Anxiety and the risk of stroke 
167 
Results 
 
Baseline characteristics of the study samples are presented in Table 1. Average (±SD) follow-up 
in the sample undergoing HADS-A was 12.5 (±5.3) years during which 332 strokes occurred: 
204 ischemic and 30 hemorrhagic. Average follow-up in the sample undergoing M-CIDI was 
5.6 (±2.1) years during which 340 strokes occurred: 237 ischemic and 40 hemorrhagic. 
 
Table 1. Baseline characteristics 
 Anxiety symptoms 
HADS-A sample (N=2,625) 
Anxiety disorders 
M-CIDI sample (N=8,662) 
Age, years 68.4 (8.4) 66.1 (10.5) 
Female sex 1453 (55.4%) 4999 (57.7%) 
Percentage with HADS-A ≥8 343 (13.1%) NA 
Percentage with HADS-A ≥11 147 (5.6%) NA 
HADS-A, score 3.7 (3.6) NA 
Any anxiety disordera NA 728 (8.4%) 
Generalized anxiety disorder NA 224 (2.6%) 
Panic disorder NA 79 (0.9%) 
Agoraphobia NA 301 (3.5%) 
Social phobia NA 104 (1.2%) 
Specific phobia NA 143 (1.7%) 
Systolic blood pressure, mmHg 139 (22) 142 (22) 
Diastolic blood pressure, mmHg 77 (11) 81 (11) 
Use of blood pressure-lowering 
medication 
585 (23.9%) 2564 (29.7%) 
Total cholesterol, mmol/L 6.6 (1.2) 5.6 (1.0) 
High-density lipoprotein cholesterol, 
mmol/L 
1.4 (0.4) 1.4 (0.4) 
Use of lipid-lowering medication 72 (2.7%) 1869 (21.7%) 
Body mass index 26.3 (3.6) 27.7 (4.3) 
Smoking   
Current  567 (22.3%) 1728 (20.0%) 
Past 1243 (48.9%) 4476 (51.7%) 
Never 732 (28.8%) 2456 (28.4%) 
Diabetes mellitus 153 (6.0%) 1062 (12.4%) 
Myocardial infarction 118 (4.5%) 409 (4.7%) 
Abbreviations: NA = not available, HADS-A = Hospital Anxiety and Depression Scale anxiety subscale, M-CIDI = 
Munich version of the Composite International Diagnostic Interview. 
Data are presented as mean (standard deviations) or counts (percentages). 
a Generalized anxiety disorder, panic disorder, agoraphobia, social phobia, or specific phobia.  
 
Neither anxiety symptoms nor anxiety disorders were associated with the risk of stroke after 
complete follow-up (Table 2, Supplementary Table I): the multivariate adjusted HR was 1.02 
(95% CI 0.74; 1.43) for anxiety symptoms (HADS-A≥8 compared to HADS-A<8) and 0.95 (95% 
CI 0.64; 1.43) for any versus no anxiety disorder. The stricter dichotomization of HADS-A (≥11 
versus <11) resulted in stronger effects, though still not significant. We also did not observe any 
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5.6 (±2.1) years during which 340 strokes occurred: 237 ischemic and 40 hemorrhagic. 
 
Table 1. Baseline characteristics 
 Anxiety symptoms 
HADS-A sample (N=2,625) 
Anxiety disorders 
M-CIDI sample (N=8,662) 
Age, years 68.4 (8.4) 66.1 (10.5) 
Female sex 1453 (55.4%) 4999 (57.7%) 
Percentage with HADS-A ≥8 343 (13.1%) NA 
Percentage with HADS-A ≥11 147 (5.6%) NA 
HADS-A, score 3.7 (3.6) NA 
Any anxiety disordera NA 728 (8.4%) 
Generalized anxiety disorder NA 224 (2.6%) 
Panic disorder NA 79 (0.9%) 
Agoraphobia NA 301 (3.5%) 
Social phobia NA 104 (1.2%) 
Specific phobia NA 143 (1.7%) 
Systolic blood pressure, mmHg 139 (22) 142 (22) 
Diastolic blood pressure, mmHg 77 (11) 81 (11) 
Use of blood pressure-lowering 
medication 
585 (23.9%) 2564 (29.7%) 
Total cholesterol, mmol/L 6.6 (1.2) 5.6 (1.0) 
High-density lipoprotein cholesterol, 
mmol/L 
1.4 (0.4) 1.4 (0.4) 
Use of lipid-lowering medication 72 (2.7%) 1869 (21.7%) 
Body mass index 26.3 (3.6) 27.7 (4.3) 
Smoking   
Current  567 (22.3%) 1728 (20.0%) 
Past 1243 (48.9%) 4476 (51.7%) 
Never 732 (28.8%) 2456 (28.4%) 
Diabetes mellitus 153 (6.0%) 1062 (12.4%) 
Myocardial infarction 118 (4.5%) 409 (4.7%) 
Abbreviations: NA = not available, HADS-A = Hospital Anxiety and Depression Scale anxiety subscale, M-CIDI = 
Munich version of the Composite International Diagnostic Interview. 
Data are presented as mean (standard deviations) or counts (percentages). 
a Generalized anxiety disorder, panic disorder, agoraphobia, social phobia, or specific phobia.  
 
Neither anxiety symptoms nor anxiety disorders were associated with the risk of stroke after 
complete follow-up (Table 2, Supplementary Table I): the multivariate adjusted HR was 1.02 
(95% CI 0.74; 1.43) for anxiety symptoms (HADS-A≥8 compared to HADS-A<8) and 0.95 (95% 
CI 0.64; 1.43) for any versus no anxiety disorder. The stricter dichotomization of HADS-A (≥11 
versus <11) resulted in stronger effects, though still not significant. We also did not observe any 
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association for the separate subtypes of anxiety disorder or when we examined anxiety 
symptoms on a continuous scale (Supplementary Table II, Table 2). 
 
Inspection of the survival curve (Supplementary Figure I) pointed towards a possible short-
term effect for anxiety symptoms. Indeed, an increased HADS was associated with an increased 
risk of stroke in the first 3 years of follow-up (HR 2.55, 95% CI 1.45; 4.46 for HADS-A ≥8 compared 
to HADS-A <8) (Supplementary Table III). After additional adjustment for depressive symptoms, 
the association remained similar.  
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Results 
 
Baseline characteristics of the study samples are presented in Table 1. Average (±SD) follow-up 
in the sample undergoing HADS-A was 12.5 (±5.3) years during which 332 strokes occurred: 
204 ischemic and 30 hemorrhagic. Average follow-up in the sample undergoing M-CIDI was 
5.6 (±2.1) years during which 340 strokes occurred: 237 ischemic and 40 hemorrhagic. 
 
Table 1. Baseline characteristics 
 Anxiety symptoms 
HADS-A sample (N=2,625) 
Anxiety disorders 
M-CIDI sample (N=8,662) 
Age, years 68.4 (8.4) 66.1 (10.5) 
Female sex 1453 (55.4%) 4999 (57.7%) 
Percentage with HADS-A ≥8 343 (13.1%) NA 
Percentage with HADS-A ≥11 147 (5.6%) NA 
HADS-A, score 3.7 (3.6) NA 
Any anxiety disordera NA 728 (8.4%) 
Generalized anxiety disorder NA 224 (2.6%) 
Panic disorder NA 79 (0.9%) 
Agoraphobia NA 301 (3.5%) 
Social phobia NA 104 (1.2%) 
Specific phobia NA 143 (1.7%) 
Systolic blood pressure, mmHg 139 (22) 142 (22) 
Diastolic blood pressure, mmHg 77 (11) 81 (11) 
Use of blood pressure-lowering 
medication 
585 (23.9%) 2564 (29.7%) 
Total cholesterol, mmol/L 6.6 (1.2) 5.6 (1.0) 
High-density lipoprotein cholesterol, 
mmol/L 
1.4 (0.4) 1.4 (0.4) 
Use of lipid-lowering medication 72 (2.7%) 1869 (21.7%) 
Body mass index 26.3 (3.6) 27.7 (4.3) 
Smoking   
Current  567 (22.3%) 1728 (20.0%) 
Past 1243 (48.9%) 4476 (51.7%) 
Never 732 (28.8%) 2456 (28.4%) 
Diabetes mellitus 153 (6.0%) 1062 (12.4%) 
Myocardial infarction 118 (4.5%) 409 (4.7%) 
Abbreviations: NA = not available, HADS-A = Hospital Anxiety and Depression Scale anxiety subscale, M-CIDI = 
Munich version of the Composite International Diagnostic Interview. 
Data are presented as mean (standard deviations) or counts (percentages). 
a Generalized anxiety disorder, panic disorder, agoraphobia, social phobia, or specific phobia.  
 
Neither anxiety symptoms nor anxiety disorders were associated with the risk of stroke after 
complete follow-up (Table 2, Supplementary Table I): the multivariate adjusted HR was 1.02 
(95% CI 0.74; 1.43) for anxiety symptoms (HADS-A≥8 compared to HADS-A<8) and 0.95 (95% 
CI 0.64; 1.43) for any versus no anxiety disorder. The stricter dichotomization of HADS-A (≥11 
versus <11) resulted in stronger effects, though still not significant. We also did not observe any 
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association for the separate subtypes of anxiety disorder or when we examined anxiety 
symptoms on a continuous scale (Supplementary Table II, Table 2). 
 
Inspection of the survival curve (Supplementary Figure I) pointed towards a possible short-
term effect for anxiety symptoms. Indeed, an increased HADS was associated with an increased 
risk of stroke in the first 3 years of follow-up (HR 2.55, 95% CI 1.45; 4.46 for HADS-A ≥8 compared 
to HADS-A <8) (Supplementary Table III). After additional adjustment for depressive symptoms, 
the association remained similar.  
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Results 
 
Baseline characteristics of the study samples are presented in Table 1. Average (±SD) follow-up 
in the sample undergoing HADS-A was 12.5 (±5.3) years during which 332 strokes occurred: 
204 ischemic and 30 hemorrhagic. Average follow-up in the sample undergoing M-CIDI was 
5.6 (±2.1) years during which 340 strokes occurred: 237 ischemic and 40 hemorrhagic. 
 
Table 1. Baseline characteristics 
 Anxiety symptoms 
HADS-A sample (N=2,625) 
Anxiety disorders 
M-CIDI sample (N=8,662) 
Age, years 68.4 (8.4) 66.1 (10.5) 
Female sex 1453 (55.4%) 4999 (57.7%) 
Percentage with HADS-A ≥8 343 (13.1%) NA 
Percentage with HADS-A ≥11 147 (5.6%) NA 
HADS-A, score 3.7 (3.6) NA 
Any anxiety disordera NA 728 (8.4%) 
Generalized anxiety disorder NA 224 (2.6%) 
Panic disorder NA 79 (0.9%) 
Agoraphobia NA 301 (3.5%) 
Social phobia NA 104 (1.2%) 
Specific phobia NA 143 (1.7%) 
Systolic blood pressure, mmHg 139 (22) 142 (22) 
Diastolic blood pressure, mmHg 77 (11) 81 (11) 
Use of blood pressure-lowering 
medication 
585 (23.9%) 2564 (29.7%) 
Total cholesterol, mmol/L 6.6 (1.2) 5.6 (1.0) 
High-density lipoprotein cholesterol, 
mmol/L 
1.4 (0.4) 1.4 (0.4) 
Use of lipid-lowering medication 72 (2.7%) 1869 (21.7%) 
Body mass index 26.3 (3.6) 27.7 (4.3) 
Smoking   
Current  567 (22.3%) 1728 (20.0%) 
Past 1243 (48.9%) 4476 (51.7%) 
Never 732 (28.8%) 2456 (28.4%) 
Diabetes mellitus 153 (6.0%) 1062 (12.4%) 
Myocardial infarction 118 (4.5%) 409 (4.7%) 
Abbreviations: NA = not available, HADS-A = Hospital Anxiety and Depression Scale anxiety subscale, M-CIDI = 
Munich version of the Composite International Diagnostic Interview. 
Data are presented as mean (standard deviations) or counts (percentages). 
a Generalized anxiety disorder, panic disorder, agoraphobia, social phobia, or specific phobia.  
 
Neither anxiety symptoms nor anxiety disorders were associated with the risk of stroke after 
complete follow-up (Table 2, Supplementary Table I): the multivariate adjusted HR was 1.02 
(95% CI 0.74; 1.43) for anxiety symptoms (HADS-A≥8 compared to HADS-A<8) and 0.95 (95% 
CI 0.64; 1.43) for any versus no anxiety disorder. The stricter dichotomization of HADS-A (≥11 
versus <11) resulted in stronger effects, though still not significant. We also did not observe any 
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Discussion 
 
In this prospective population-based cohort study, we found no long-term association 
between anxiety and the risk of stroke.  
Two previous cohort studies assessed the association between anxiety and stroke: in one 
study, the risk of stroke increased with increasing anxiety symptom score,4 whereas in the other 
study, psychological distress was associated with stroke, but not generalized anxiety disorder.3 
A reason for the differences may be the different scores to assess anxiety. Anxiety symptoms 
coincide with depressive symptoms and stress symptoms. Vice versa, depressive symptoms 
and stress symptoms have been related to stroke before.12,13 In our study, we only detected a 
short-term increased risk of stroke in people with anxiety symptoms, independent of 
depressive symptoms. This may be a true effect with possible mechanisms being activation of 
the hypothalamic-pituitary-adrenal axis and sympathetic nervous system or adverse health 
behaviors.1 This is further supported by the finding that a stricter dichotomization of the anxiety 
symptom score resulted in stronger effects. Moreover, there may have been some non-
differential misclassification in our assessment of anxiety, which could have resulted in an 
underestimation of the true effect. In contrast, the lack of a long-term effect argues against a 
true effect. Moreover, we found no associations with anxiety disorders, for which any 
mechanism should have a similar effect. An alternative explanation may thus be reversed 
causality, as suggested previously for mortality.14 Given that patients with stroke have a high 
cardiovascular risk, they may experience a worsening health in the years preceding stroke and 
get anxious in response.  
Strengths of our study are the population-based setting, the long follow-up period, the 
stringent stroke monitoring and the limited loss of follow-up. A limitation is that lacking 
neuroimaging after stroke, 20% of all strokes remained of unspecified subtype. Additionally, we 
did not perform a formal evaluation of the reliability of our anxiety assessments. Furthermore, 
we may have missed weak associations: assuming α=0.05, our study had a power of 0.77 to 
detect the HR of 1.43 that was found previously for high versus low anxiety (in our study HADS-
A score ≥8 versus <8).4,15  
In conclusion, anxiety disorders were not associated with stroke in this general population 
study. Anxiety symptoms were only associated to stroke in the short term, which needs further 
exploration. 
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Discussion 
 
In this prospective population-based cohort study, we found no long-term association 
between anxiety and the risk of stroke.  
Two previous cohort studies assessed the association between anxiety and stroke: in one 
study, the risk of stroke increased with increasing anxiety symptom score,4 whereas in the other 
study, psychological distress was associated with stroke, but not generalized anxiety disorder.3 
A reason for the differences may be the different scores to assess anxiety. Anxiety symptoms 
coincide with depressive symptoms and stress symptoms. Vice versa, depressive symptoms 
and stress symptoms have been related to stroke before.12,13 In our study, we only detected a 
short-term increased risk of stroke in people with anxiety symptoms, independent of 
depressive symptoms. This may be a true effect with possible mechanisms being activation of 
the hypothalamic-pituitary-adrenal axis and sympathetic nervous system or adverse health 
behaviors.1 This is further supported by the finding that a stricter dichotomization of the anxiety 
symptom score resulted in stronger effects. Moreover, there may have been some non-
differential misclassification in our assessment of anxiety, which could have resulted in an 
underestimation of the true effect. In contrast, the lack of a long-term effect argues against a 
true effect. Moreover, we found no associations with anxiety disorders, for which any 
mechanism should have a similar effect. An alternative explanation may thus be reversed 
causality, as suggested previously for mortality.14 Given that patients with stroke have a high 
cardiovascular risk, they may experience a worsening health in the years preceding stroke and 
get anxious in response.  
Strengths of our study are the population-based setting, the long follow-up period, the 
stringent stroke monitoring and the limited loss of follow-up. A limitation is that lacking 
neuroimaging after stroke, 20% of all strokes remained of unspecified subtype. Additionally, we 
did not perform a formal evaluation of the reliability of our anxiety assessments. Furthermore, 
we may have missed weak associations: assuming α=0.05, our study had a power of 0.77 to 
detect the HR of 1.43 that was found previously for high versus low anxiety (in our study HADS-
A score ≥8 versus <8).4,15  
In conclusion, anxiety disorders were not associated with stroke in this general population 
study. Anxiety symptoms were only associated to stroke in the short term, which needs further 
exploration. 
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In this prospective population-based cohort study, we found no long-term association 
between anxiety and the risk of stroke.  
Two previous cohort studies assessed the association between anxiety and stroke: in one 
study, the risk of stroke increased with increasing anxiety symptom score,4 whereas in the other 
study, psychological distress was associated with stroke, but not generalized anxiety disorder.3 
A reason for the differences may be the different scores to assess anxiety. Anxiety symptoms 
coincide with depressive symptoms and stress symptoms. Vice versa, depressive symptoms 
and stress symptoms have been related to stroke before.12,13 In our study, we only detected a 
short-term increased risk of stroke in people with anxiety symptoms, independent of 
depressive symptoms. This may be a true effect with possible mechanisms being activation of 
the hypothalamic-pituitary-adrenal axis and sympathetic nervous system or adverse health 
behaviors.1 This is further supported by the finding that a stricter dichotomization of the anxiety 
symptom score resulted in stronger effects. Moreover, there may have been some non-
differential misclassification in our assessment of anxiety, which could have resulted in an 
underestimation of the true effect. In contrast, the lack of a long-term effect argues against a 
true effect. Moreover, we found no associations with anxiety disorders, for which any 
mechanism should have a similar effect. An alternative explanation may thus be reversed 
causality, as suggested previously for mortality.14 Given that patients with stroke have a high 
cardiovascular risk, they may experience a worsening health in the years preceding stroke and 
get anxious in response.  
Strengths of our study are the population-based setting, the long follow-up period, the 
stringent stroke monitoring and the limited loss of follow-up. A limitation is that lacking 
neuroimaging after stroke, 20% of all strokes remained of unspecified subtype. Additionally, we 
did not perform a formal evaluation of the reliability of our anxiety assessments. Furthermore, 
we may have missed weak associations: assuming α=0.05, our study had a power of 0.77 to 
detect the HR of 1.43 that was found previously for high versus low anxiety (in our study HADS-
A score ≥8 versus <8).4,15  
In conclusion, anxiety disorders were not associated with stroke in this general population 
study. Anxiety symptoms were only associated to stroke in the short term, which needs further 
exploration. 
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Discussion 
 
In this prospective population-based cohort study, we found no long-term association 
between anxiety and the risk of stroke.  
Two previous cohort studies assessed the association between anxiety and stroke: in one 
study, the risk of stroke increased with increasing anxiety symptom score,4 whereas in the other 
study, psychological distress was associated with stroke, but not generalized anxiety disorder.3 
A reason for the differences may be the different scores to assess anxiety. Anxiety symptoms 
coincide with depressive symptoms and stress symptoms. Vice versa, depressive symptoms 
and stress symptoms have been related to stroke before.12,13 In our study, we only detected a 
short-term increased risk of stroke in people with anxiety symptoms, independent of 
depressive symptoms. This may be a true effect with possible mechanisms being activation of 
the hypothalamic-pituitary-adrenal axis and sympathetic nervous system or adverse health 
behaviors.1 This is further supported by the finding that a stricter dichotomization of the anxiety 
symptom score resulted in stronger effects. Moreover, there may have been some non-
differential misclassification in our assessment of anxiety, which could have resulted in an 
underestimation of the true effect. In contrast, the lack of a long-term effect argues against a 
true effect. Moreover, we found no associations with anxiety disorders, for which any 
mechanism should have a similar effect. An alternative explanation may thus be reversed 
causality, as suggested previously for mortality.14 Given that patients with stroke have a high 
cardiovascular risk, they may experience a worsening health in the years preceding stroke and 
get anxious in response.  
Strengths of our study are the population-based setting, the long follow-up period, the 
stringent stroke monitoring and the limited loss of follow-up. A limitation is that lacking 
neuroimaging after stroke, 20% of all strokes remained of unspecified subtype. Additionally, we 
did not perform a formal evaluation of the reliability of our anxiety assessments. Furthermore, 
we may have missed weak associations: assuming α=0.05, our study had a power of 0.77 to 
detect the HR of 1.43 that was found previously for high versus low anxiety (in our study HADS-
A score ≥8 versus <8).4,15  
In conclusion, anxiety disorders were not associated with stroke in this general population 
study. Anxiety symptoms were only associated to stroke in the short term, which needs further 
exploration. 
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Abstract 
 
Background and Purpose 
Left-sided strokes are reported to be more common than right-sided strokes, but it is unknown 
whether they occur more often or are simply recognized more easily by clinicians. In a large 
unselected community-dwelling population we examined the frequency of clinical left- and 
right-sided strokes and transient ischemic attacks (TIAs) and compared it with the frequency of 
left- and right-sided infarcts on MRI. 
 
Methods 
This study was conducted within the population-based Rotterdam Study. Between 1990-2012, 
13,894 participants were followed-up for first-ever stroke and TIA. MRI scans were performed 
within a random subgroup of 5081 persons and were rated for presence of supratentorial 
cortical and lacunar infarcts. We compared frequencies of left- and right-sided strokes, TIAs, or 
MRI-infarcts using binomial and Fisher exact tests.  
 
Results 
After a mean follow-up of 9.6 (±6.0) years, 1252 persons suffered a stroke, of which 704 were 
ischemic, and 799 participants had a TIA. Within the subgroup with MRI, we identified 673 
infarcts. Ischemic strokes were more frequently left-sided (57.7%, 95% CI 53.7; 61.6) than right-
sided, similar to TIAs (57.8% left-sided, 95% CI 53.4; 62.3). In contrast, we found no left-right 
difference in distribution of infarcts on MRI (51.9% left-sided, 95% CI 48.1; 55.6). 
 
Conclusions 
Clinical ischemic strokes and TIAs are more frequently left-sided than right-sided, whereas this 
difference is not present for infarcts on MRI. This suggests that left-sided strokes and TIAs are 
more easily recognized. Consequently, there should be more attention for symptoms of right-
sided strokes and TIAs. 
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181 
Introduction 
 
Several hospital-based studies have reported that left-sided strokes are more frequent than 
right-sided strokes.1-3 A predilection for the left side may be explained by characteristics of the 
atherosclerotic plaque in the left carotid artery or by anatomy.3 The finding that isolated 
aphasia is a typical presentation of cardioembolic stroke or transient ischemic attack (TIA) also 
suggests that cardiac thrombi may preferably affect the left hemisphere.4 Another hypothesis 
is that the strokes in hospitals are a selection of strokes with symptoms that are better 
recognized or perceived as more severe. Left-sided strokes might be referred more frequently, 
because they lead to clear symptoms like aphasia, whereas right-sided strokes may lead to less 
explicit symptoms like hemineglect or spatial disorientation.1,5  
Previous MRI studies also suggested that right-sided strokes are more often unnoticed, 
since they found more right-sided silent infarcts in persons with carotid stenosis and atrial 
fibrillation.6,7 An important advantage of MRI-studies is that these not only detect clinical 
strokes, but also clinically silent infarcts, thereby providing a better estimate of the true 
distribution of left- and right-sided infarcts. To our knowledge, no study has compared the 
distribution of clinical strokes to that of MRI-defined cerebral infarcts within an unselected 
community-dwelling population. This can distinguish between an actual higher frequency of 
left-sided infarcts versus a higher frequency of clinically recognized strokes. 
In a population-based study we investigated the frequency of left- and right-sided ischemic 
strokes and TIAs and compared this to the frequency of left- and right-sided cerebral infarcts 
on MRI. 
 
Methods 
 
Population 
This study was embedded within the prospective population-based Rotterdam Study. Details 
regarding the objective and design of the Rotterdam Study have been described elsewhere.8 
The study started in 1990 among 7983 subjects aged 55 years and older residing in Ommoord, 
a suburb of Rotterdam, the Netherlands. In 2000 the cohort was extended with 3011 
participants who had become 55 years of age or moved into the study district. In 2006 another 
3932 subjects living in Ommoord were included, aged 45-54 years. After excluding 256 
participants that did not give informed consent for collection of follow-up information and 
excluding 776 persons with prevalent stroke or TIA, 13894 participants (mean age at baseline 
65.5±10.3 years, 59.3% female) were followed-up for first ever stroke and TIA. MRI scans were 
performed in 5081 participants (mean age 64.2±11.1, 55.0% female) of the Rotterdam Scan 
Study, which is a substudy of the Rotterdam Study that started in 2005.9 The Rotterdam Study 
has been approved by the medical ethics committee according to the Population Study Act 
Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the Netherlands. A 
written informed consent was obtained from all participants. 
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Assessment of clinical stroke and TIA 
History of stroke and transient ischemic attack (TIA) was assessed using home interviews and 
confirmed reviewing medical records. From baseline onwards persons were continuously 
followed-up for occurrence of stroke and TIA through automatic linkage of general 
practitioners’ files with the study database. Furthermore, nursing home physicians’ files and 
files from general practitioners of participants that moved out of the study area, were checked 
on a regular basis. Of all potential strokes and TIAs, hospital discharge letters and information 
from general practitioner was collected. Research physicians reviewed the information and an 
experienced vascular neurologist verified the strokes according to World Health Organization 
criteria.10 Strokes were further classified into ischemic or hemorrhagic on basis of neuroimaging 
reports.11 If no neuroimaging was performed, strokes were classified as unspecified. We defined 
TIAs as temporary attacks with presence of focal symptoms, which are attributable to 
dysfunction of one arterial territory of the brain.12 Assessment of the hemispheric side of strokes 
and TIAs was based on clinical symptoms and CT/MRI-images described in the medical records. 
Follow-up for both stroke and TIA was complete until January 1st, 2012 for 96.3% of potential 
person-years. 
 
Cerebral infarcts on MRI 
All scans were performed on a 1.5T MRI scanner (General Electric Healthcare, Milwaukee, USA).9 
Infarcts were rated on FLAIR, PD-weighted, and T1-weighted sequences by experienced raters 
under supervision of a neuroradiologist. Lacunar infarcts were defined as focal lesions ≥ 3 mm 
and <15 mm in size with the same signal characteristics as CSF on all sequences, and with a 
hyperintense rim on the FLAIR sequence.9  
To assess symptomatic and silent infarcts, we coupled our MRI-dataset with the clinical 
stroke and TIA dataset. We recorded an MRI-infarct as symptomatic if there was a previous 
clinical ischemic stroke or TIA (either a first-ever event or a recurrent event) matching with the 
hemispheric side of the MRI-infarct. Similarly, to adjudicate an MRI-infarct as silent, there should 
be no previous clinical ischemic stroke or TIA matching with the hemispheric side of that MRI-
infarct.  
 
Statistical analysis 
We restricted our analyses to the cerebral hemispheres. We calculated frequencies of first-ever 
left- and right-sided strokes, TIAs, and MRI-infarcts with 95% confidence intervals (CIs). These 
frequencies were compared with the expected frequency of 50 percent using a binomial test. 
Furthermore, the Fisher’s exact test was used to compare distribution of clinical stroke and TIA 
side with distribution of infarcts on MRI. For strokes and TIAs and the combination ischemic 
stroke and TIA we included only the first event. We included all MRI-infarcts, because we could 
not separate recent from chronic infarcts, also if a participant had infarcts on both sides. As 
sensitivity analysis we performed linear mixed models to account for multiple MRI-infarcts in 
one person. All analyses were done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, 
NY). 
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Results 
 
During 9.6 ±6.0 years of follow-up, 1252 participants suffered a clinical stroke and 799 a TIA 
(mean age 78.7 ±9.2, 61.6% female). 588 ischemic strokes and 465 TIAs occurred 
supratentorially (Figure 1).  
 
 
Figure 1. Flowchart of the study population 
 
We identified cerebral infarcts on MRI in 510 participants. Participants with only 
infratentorial infarcts were excluded (n=110). Of the remaining 400 participants, 166 had 
infarcts only on the left side, 149 only on the right side, and 85 on both sides. The location was 
not registered for 7 cortical and 5 lacunar infarcts. In total we identified 673 supratentorial 
infarcts, of which 224 were cortical and 449 lacunar.  
Ischemic strokes occurred more often left- than right-sided (57.7% left-sided, 95% CI 53.7; 
61.6), similar to TIAs (57.8% left-sided, 95% CI 53.4; 62.3). We did not find a significant left-right 
difference for cerebral infarcts on MRI (51.9% left-sided, 95% CI 48.1; 55.6, Figure 2). Importantly, 
direct comparison revealed that clinical ischemic stroke and TIA were significantly more 
frequently left-sided than infarcts on MRI (p=0.02). Figure 2 and Supplementary Figure I also 
show the left-right distribution for various subtypes of clinical strokes and MRI-infarcts (e.g. 
lacunar versus cortical; symptomatic versus silent MRI-infarct). 
Calculating the percentage of MRI-infarcts using linear mixed models did not change our 
results in any way (data not shown).  
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Figure 2. Frequency of left- and right-sided clinical strokes, TIAs, and cerebral infarcts on MRI  
Data are presented as counts (percentages). p-values are presented for the left-right difference and for the 
difference in distribution between clinical stroke and TIA and MRI-infarcts.  
 
Discussion 
 
In this population-based study, we found that clinical ischemic strokes and TIAs occur more 
often left-sided than right-sided, whereas we did not find such a difference for cerebral infarcts 
on MRI.  
Previous studies found a similar higher incidence of clinical left-sided strokes and TIAs, but 
did not compare their results to infarcts on MRI, which includes clinically silent infarcts. These 
studies therefore did not help to distinguish between a true higher incidence of left-sided 
stroke due to a predilection of infarcts for the left side versus a difference in recognition of left- 
and right-sided strokes.1-3 In our study, clinical ischemic strokes and TIAs were more frequently 
left-sided than right-sided. This was different from the distribution of infarcts on MRI. This 
suggests that left-sided strokes are recognized better or perceived as more severe whilst right-
sided strokes are missed. This might be the consequence of complex right-sided symptoms 
such as hemineglect and spatial disorientation. Furthermore, patients might not present 
themselves to the hospital because of anosognosia. However, this is speculative, as we do not 
routinely examine our participants to detect symptoms that might have been missed. 
To determine the impact of missing right-sided strokes, future studies should examine 
differences in long-term disability between left- and right-sided strokes. 
Strengths of this study are the thorough collection of strokes and the availability of MRI in 
a subgroup of the study population. A limitation is that we could not compare frequencies of 
clinical strokes and TIAs with frequencies of MRI-infarcts in exactly the same population, 
because of small overlap. Also, participants with a severe stroke probably did not visit the study 
center for MRI scanning because of their physical limitations. This might have led to some 
selection bias in the MRI population. Furthermore, due to lack of clinical neuroimaging after 
stroke, not all strokes could be classified into ischemic or hemorrhagic and remained 
unspecified. Many of those unspecified strokes were not referred to hospital, partly because 
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they were perceived as less severe. Left-sided strokes were not more frequent in this group, 
which supports our other results that left-sided strokes are perceived as more severe and 
referred to a hospital more often. A final consideration is that the distribution of left-sided MRI-
infarcts was not exactly 50-50, especially for cortical MRI-infarcts. It is therefore possible, that 
there also is a small, but true predilection for left-sided strokes, which remained obscured in 
our study due to insufficient power.  
In conclusion, our findings suggest that the higher frequency in clinical left-sided strokes 
and TIAs compared with right-sided events is in a large part due to a better recognition of 
those. Consequently, there should be more attention for symptoms of right-sided strokes and 
TIAs. 
  
5Chapter 5.1 
184 
Figure 2. Frequency of left- and right-sided clinical strokes, TIAs, and cerebral infarcts on MRI  
Data are presented as counts (percentages). p-values are presented for the left-right difference and for the 
difference in distribution between clinical stroke and TIA and MRI-infarcts.  
 
Discussion 
 
In this population-based study, we found that clinical ischemic strokes and TIAs occur more 
often left-sided than right-sided, whereas we did not find such a difference for cerebral infarcts 
on MRI.  
Previous studies found a similar higher incidence of clinical left-sided strokes and TIAs, but 
did not compare their results to infarcts on MRI, which includes clinically silent infarcts. These 
studies therefore did not help to distinguish between a true higher incidence of left-sided 
stroke due to a predilection of infarcts for the left side versus a difference in recognition of left- 
and right-sided strokes.1-3 In our study, clinical ischemic strokes and TIAs were more frequently 
left-sided than right-sided. This was different from the distribution of infarcts on MRI. This 
suggests that left-sided strokes are recognized better or perceived as more severe whilst right-
sided strokes are missed. This might be the consequence of complex right-sided symptoms 
such as hemineglect and spatial disorientation. Furthermore, patients might not present 
themselves to the hospital because of anosognosia. However, this is speculative, as we do not 
routinely examine our participants to detect symptoms that might have been missed. 
To determine the impact of missing right-sided strokes, future studies should examine 
differences in long-term disability between left- and right-sided strokes. 
Strengths of this study are the thorough collection of strokes and the availability of MRI in 
a subgroup of the study population. A limitation is that we could not compare frequencies of 
clinical strokes and TIAs with frequencies of MRI-infarcts in exactly the same population, 
because of small overlap. Also, participants with a severe stroke probably did not visit the study 
center for MRI scanning because of their physical limitations. This might have led to some 
selection bias in the MRI population. Furthermore, due to lack of clinical neuroimaging after 
stroke, not all strokes could be classified into ischemic or hemorrhagic and remained 
unspecified. Many of those unspecified strokes were not referred to hospital, partly because 
Left-sided strokes are more often recognized than right-sided strokes 
 
185 
they were perceived as less severe. Left-sided strokes were not more frequent in this group, 
which supports our other results that left-sided strokes are perceived as more severe and 
referred to a hospital more often. A final consideration is that the distribution of left-sided MRI-
infarcts was not exactly 50-50, especially for cortical MRI-infarcts. It is therefore possible, that 
there also is a small, but true predilection for left-sided strokes, which remained obscured in 
our study due to insufficient power.  
In conclusion, our findings suggest that the higher frequency in clinical left-sided strokes 
and TIAs compared with right-sided events is in a large part due to a better recognition of 
those. Consequently, there should be more attention for symptoms of right-sided strokes and 
TIAs. 
  
Chapter 5.1 
186 
References 
 
1. Foerch C, Misselwitz B, Sitzer M, et al. Difference in recognition of right and left hemispheric stroke. 
Lancet. 2005;366(9483):392-393. 
2. Hedna VS, Bodhit AN, Ansari S, et al. Hemispheric differences in ischemic stroke: is left-hemisphere 
stroke more common? J Clin Neurol. 2013;9(2):97-102. 
3. Rodriguez Hernandez SA, Kroon AA, van Boxtel MP, et al. Is there a side predilection for 
cerebrovascular disease? Hypertension. 2003;42(1):56-60. 
4. Fennis TF, Compter A, van den Broek MW, Koudstaal PJ, Algra A, Koehler PJ. Is isolated aphasia a typical 
presentation of presumed cardioembolic transient ischemic attack or stroke? Cerebrovasc Dis. 
2013;35(4):337-340. 
5. Fink JN, Selim MH, Kumar S, et al. Is the association of National Institutes of Health Stroke Scale scores 
and acute magnetic resonance imaging stroke volume equal for patients with right- and left-
hemisphere ischemic stroke? Stroke. 2002;33(4):954-958. 
6. Brott T, Tomsick T, Feinberg W, et al. Baseline silent cerebral infarction in the Asymptomatic Carotid 
Atherosclerosis Study. Stroke. 1994;25(6):1122-1129. 
7. Silent brain infarction in nonrheumatic atrial fibrillation. EAFT Study Group. European Atrial Fibrillation 
Trial. Neurology. 1996;46(1):159-165. 
8. Hofman A, Darwish Murad S, van Duijn CM, et al. The Rotterdam Study: 2014 objectives and design 
update. Eur J Epidemiol. 2013;28(11):889-926. 
9. Ikram MA, van der Lugt A, Niessen WJ, et al. The Rotterdam Scan Study: design and update up to 2012. 
Eur J Epidemiol. 2011;26(10):811-824. 
10. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 
1976;54(5):541-553. 
11. Wieberdink RG, Ikram MA, Hofman A, Koudstaal PJ, Breteler MM. Trends in stroke incidence rates and 
stroke risk factors in Rotterdam, the Netherlands from 1990 to 2008. Eur J Epidemiol. 2012;27(4):287-
295. 
12. Bos MJ, van Rijn MJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Incidence and prognosis of 
transient neurological attacks. JAMA. 2007;298(24):2877-2885. 
  
Left-sided strokes are more often recognized than right-sided strokes 
 
187 
Supplementary information 
 
 
Supplementary Figure I. Frequencies of symptomatic and silent infarcts on MRI  
Data are presented as counts (percentages). p-values are presented for the left-right difference.  
 
5Chapter 5.1 
186 
References 
 
1. Foerch C, Misselwitz B, Sitzer M, et al. Difference in recognition of right and left hemispheric stroke. 
Lancet. 2005;366(9483):392-393. 
2. Hedna VS, Bodhit AN, Ansari S, et al. Hemispheric differences in ischemic stroke: is left-hemisphere 
stroke more common? J Clin Neurol. 2013;9(2):97-102. 
3. Rodriguez Hernandez SA, Kroon AA, van Boxtel MP, et al. Is there a side predilection for 
cerebrovascular disease? Hypertension. 2003;42(1):56-60. 
4. Fennis TF, Compter A, van den Broek MW, Koudstaal PJ, Algra A, Koehler PJ. Is isolated aphasia a typical 
presentation of presumed cardioembolic transient ischemic attack or stroke? Cerebrovasc Dis. 
2013;35(4):337-340. 
5. Fink JN, Selim MH, Kumar S, et al. Is the association of National Institutes of Health Stroke Scale scores 
and acute magnetic resonance imaging stroke volume equal for patients with right- and left-
hemisphere ischemic stroke? Stroke. 2002;33(4):954-958. 
6. Brott T, Tomsick T, Feinberg W, et al. Baseline silent cerebral infarction in the Asymptomatic Carotid 
Atherosclerosis Study. Stroke. 1994;25(6):1122-1129. 
7. Silent brain infarction in nonrheumatic atrial fibrillation. EAFT Study Group. European Atrial Fibrillation 
Trial. Neurology. 1996;46(1):159-165. 
8. Hofman A, Darwish Murad S, van Duijn CM, et al. The Rotterdam Study: 2014 objectives and design 
update. Eur J Epidemiol. 2013;28(11):889-926. 
9. Ikram MA, van der Lugt A, Niessen WJ, et al. The Rotterdam Scan Study: design and update up to 2012. 
Eur J Epidemiol. 2011;26(10):811-824. 
10. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 
1976;54(5):541-553. 
11. Wieberdink RG, Ikram MA, Hofman A, Koudstaal PJ, Breteler MM. Trends in stroke incidence rates and 
stroke risk factors in Rotterdam, the Netherlands from 1990 to 2008. Eur J Epidemiol. 2012;27(4):287-
295. 
12. Bos MJ, van Rijn MJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Incidence and prognosis of 
transient neurological attacks. JAMA. 2007;298(24):2877-2885. 
  
Left-sided strokes are more often recognized than right-sided strokes 
 
187 
Supplementary information 
 
 
Supplementary Figure I. Frequencies of symptomatic and silent infarcts on MRI  
Data are presented as counts (percentages). p-values are presented for the left-right difference.  
 
 188 
  
 
189 
Chapter 5.2 
 
Role of prestroke vascular pathology in long-term prognosis after stroke  
Marileen L.P. Portegies, Michiel J. Bos, Albert Hofman, Jan Heeringa, Oscar H. Franco, Peter J. 
Koudstaal, M. Arfan Ikram  
 
Stroke. 2016;47:80-87 
 188 
  
 
189 
Chapter 5.2 
 
Role of prestroke vascular pathology in long-term prognosis after stroke  
Marileen L.P. Portegies, Michiel J. Bos, Albert Hofman, Jan Heeringa, Oscar H. Franco, Peter J. 
Koudstaal, M. Arfan Ikram  
 
Stroke. 2016;47:80-87 
Chapter 5.2 
190 
Abstract 
 
Background and purpose 
Mortality after stroke remains high for years, mostly due to cardiovascular causes. Given that 
cardiovascular pathology plays an important role in causing the initial stroke, such pre-stroke 
pathology might also influence the prognosis after stroke. Within the population-based 
Rotterdam Study, we examined the proportion of deaths after stroke that are attributable to 
pre-existent cardiovascular risk factors before stroke (the population attributable risk (PAR)). 
 
Methods 
We examined 1,237 first-ever stroke patients and 4,928 stroke-free persons (between 1990-
2012), matched on age, sex, examination round and stroke date (index date). Cardiovascular 
risk factors measured on average 4 years before index date were used as determinants. Persons 
were continuously followed-up for mortality (average 6 years) after the index date. We 
calculated separate and combined PAR of hypertension, total cholesterol, HDL cholesterol, BMI, 
diabetes mellitus, smoking, TIA, and atrial fibrillation. 
 
Results 
919 stroke patients and 2,654 stroke-free persons died. The combined PAR in persons with 
stroke was 27% (95% CI 14-45%) and in stroke-free persons 19% (95% CI 12-29%). PARs of 
diabetes mellitus, smoking, and atrial fibrillation were higher in persons with stroke compared 
to the reference group due to a higher prevalence of risk factors. Additionally, people with atrial 
fibrillation and stroke had a higher hazard ratio for death compared to those with only atrial 
fibrillation. 
 
Conclusions 
A quarter of deaths after stroke could theoretically be prevented with rigorous cardiovascular 
prevention and treatment, but this should preferably start before stroke occurrence. 
Additionally, research into factors explaining the remaining deaths needs to be encouraged. 
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Introduction 
 
Stroke is the second leading cause of death worldwide.1 Many patients die in the acute phase 
after stroke,2 but the risk of death remains high for years, particularly due to cardiovascular 
deaths.3-6 Accumulation of cardiovascular pathology is a slow process spanning many years 
and it is likely that such pathology does not only cause stroke,7 but also plays a role in mortality 
after stroke. This could mean that preventive and therapeutic measures for cardiovascular 
health, which are often implemented following a stroke,8 may be starting too late.  
Most studies investigating risk factors for mortality after stroke were performed in clinical 
settings among stroke patients.9-16 In such settings, the influence of reverse causality cannot be 
disentangled from the true effect of these risk factors. In other words, a stroke itself induces 
changes in risk factors, such as blood pressure, cholesterol, and diabetes mellitus, which then 
are not a true reflection of their status prior to the stroke.17-19  
Therefore, the aim of our study was to examine the role of pre-stroke cardiovascular risk 
factors in mortality after stroke. We first calculated mortality rates in persons with and without 
stroke. Subsequently, we estimated the impact of pre-stroke cardiovascular risk factors on the 
risk of mortality using the population attributable risk (PAR). This shows the maximum 
proportion of deaths that can theoretically be prevented with complete elimination of the 
cardiovascular risk factors, assuming that risk factors are causally linked and completely 
modifiable.20 Furthermore, we compared this to the PAR in stroke-free participants.  
 
Materials and methods 
 
Setting 
This study was conducted within the prospective, population-based Rotterdam Study. Details 
regarding the objectives and design of the study have been described elsewhere.21 In brief, 
baseline examinations started in 1990 among 7,983 persons of 55 years and older residing in 
Ommoord, a suburb of Rotterdam, the Netherlands. Examinations took place every 3-4 years, 
which means participants were invited for a visit in 1990-1993, 1993-1995, 1997-1999, 2002-
2004, and 2009-2011. In 2000, the cohort was extended with 3,011 persons that had become 
55 since the start of the study or moved into the research area. They were invited for a visit in 
2000-2001, 2004-2005, and 2011-2012. In 2006 another 3,932 subjects were included, aged 45 
years and older. These participants visited the center in 2006-2008. 
For the current study, participants with prevalent stroke (n=453) or who did not give 
informed consent for collection of follow-up information (n=238) were excluded. 
Consequently, 14,235 participants were at risk for stroke. The Rotterdam Study has been 
approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, 
Welfare and Sport of the Netherlands, implementing the “Wet Bevolkings-onderzoek: ERGO 
(Population Studies Act: Rotterdam Study)”. All participants provided written informed consent 
to participate in the study and to obtain information from their treating physicians.  
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Assessment of stroke and mortality 
History of stroke was assessed during the home interview at baseline and confirmed by 
reviewing medical records.22 Strokes were defined according to World Health Organization 
criteria.23 From baseline onwards, participants were continuously followed-up for stroke and 
death by automatic linkage of general practitioners’ medical records with the study database. 
In addition, nursing home physicians’ medical records, municipal records and medical records 
from general practitioners of participants who moved out of the Ommoord district were 
examined on a regular basis. Potential strokes were reviewed by research physicians and 
verified by an experienced vascular neurologist.  
Follow-up for stroke was complete for 96.3% of potential person-years and for vital status 
for 99.2% of potential person-years.  
 
Assessment of cardiovascular risk factors 
History of smoking and medication use were assessed during the home interview. Smoking 
status was categorized as current, former, and never smoking. Physical examinations were 
performed during the visits at the study center.24 Body mass index was calculated as weight 
divided by length squared. Underweight was defined as a body mass index <18.5. 
Hypertension was defined as a systolic blood pressure ≥140mmHg and/or a diastolic blood 
pressure ≥90mmHg and/or the use of blood pressure-lowering medication with the indication 
hypertension.25 Hypercholesterolemia was defined as a total cholesterol >6.2 mmol/L.26 A low 
high-density lipoprotein (HDL)-cholesterol was defined as a HDL-cholesterol ≤1.0 mmol/L.26 
Diabetes mellitus was defined as a fasting glucose level ≥7.0 mmol/L, non-fasting glucose level 
≥11.0 mmol/L, or use of antidiabetic medication.27  
Occurrence of transient ischemic attacks (TIAs) and atrial fibrillation was assessed through 
active follow-up and verified using standardized definitions similar to the follow-up for 
stroke.28,29 However, follow-up for atrial fibrillation was only complete until 2010, which means 
that people with atrial fibrillation after 2010 were missed. 
 
Statistical analysis 
Cardiovascular risk factors obtained during the closest available examination preceding the 
stroke were used for the analyses. In every visit we had information about BMI and smoking 
status. Cholesterol and glucose (necessary for diabetes mellitus status) were measured in each 
visit, except from the second center visit (1993-1995) of the first cohort. Blood pressure was 
also measured in each visit, but the hypertension variable including blood pressure medication 
with the indication of hypertension is not available for the fifth visit of the first cohort (2009-
2011) and the third visit of the second cohort (2011-2012). Therefore information on these 
missing variables was obtained from a visit earlier. Participants were continuously followed up 
for occurrence of TIA and atrial fibrillation. Hence, presence of TIA or atrial fibrillation at any 
moment before stroke was used in the analysis.  
To compare risks and risk factors of death between participants with stroke and a stroke-
free group, we first defined an exposed group: all persons who suffered an incident stroke. For 
this exposed group the at risk time for mortality started at the stroke date. Then, we defined a 
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non-exposed or stroke-free group. This non-exposed group consisted of 4 participants per 
stroke case, randomly matched to this case on age (within 1 year), sex, and visiting the same 
examination round, using an incidence density sampling approach.30 This non-exposed group 
was free of stroke until the stroke date of their matched case (index date) and their at risk time 
for mortality started at the index date. Note that persons could be included as non-exposed 
several times and could become exposed later on. Further of note, this is different from a case-
control design. 
We used Poisson regression to calculate age and sex adjusted mortality rates and rate ratios 
for persons with and without stroke, starting at the index date. As sensitivity analysis we also 
calculated cardiovascular and non-cardiovascular mortality rates separately.  
Associations between pre-stroke cardiovascular risk factors and mortality after stroke were 
calculated using the Interactive Risk Attributable Program (IRAP).31 This program calculates 
hazard ratio’s (HRs) with 95% confidence intervals (CI) based on a Poisson model and enables 
the calculation of population attributable risks (PARs) with 95% CI. We provide logit 
transformed 95% CI accompanying the PARs as these are more easily interpretable and more 
stringent with regard to our combined PAR estimate.32 The PAR is estimated adjusting for 
confounding using the following formulas: 
PAR = 1 −   


  

| 
where 
| = Pr ( = 1| = ,  = )Pr ( = 1| = ,  = ) 
and    
 = Pr  =  ,  =  = 1 
 
with D=1 denoting presence of disease, X denoting exposure with i levels, and C denoting a 
confounder with j levels. We calculated the PAR for each risk factor separately and calculated 
the combined PAR. The combined PAR included the PARs that were associated with mortality 
in the expected direction, meaning that the HR was higher than 1. PARs cannot be calculated 
for a HR below one, because this will result in a PAR that cannot be interpreted.33  
We checked the proportional hazards assumption by inspecting log minus log plots. 
Follow-up started at the index date. Information on the investigated cardiovascular risk factors 
was missing up to a maximum of 9.7% and was imputed based on the other covariates using 
multiple imputation with 5 imputation sets. The mean of these 5 imputation sets was used to 
implement in the Interactive Risk Attributable Program. In each model, we adjusted for age, 
sex, time between center date and index date, and for the categories of hypertension, 
cholesterol, HDL cholesterol, BMI, diabetes mellitus, smoking, and atrial fibrillation, if 
appropriate. As sensitivity analysis we also calculated the PARs for cardiovascular and non-
cardiovascular mortality. We explored potential effect modification by presence of stroke by 
using an interaction term of the stroke status with the potential risk factor. Differences in 
prevalence of risk factors between participants with stroke and stroke-free participants and 
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status. Cholesterol and glucose (necessary for diabetes mellitus status) were measured in each 
visit, except from the second center visit (1993-1995) of the first cohort. Blood pressure was 
also measured in each visit, but the hypertension variable including blood pressure medication 
with the indication of hypertension is not available for the fifth visit of the first cohort (2009-
2011) and the third visit of the second cohort (2011-2012). Therefore information on these 
missing variables was obtained from a visit earlier. Participants were continuously followed up 
for occurrence of TIA and atrial fibrillation. Hence, presence of TIA or atrial fibrillation at any 
moment before stroke was used in the analysis.  
To compare risks and risk factors of death between participants with stroke and a stroke-
free group, we first defined an exposed group: all persons who suffered an incident stroke. For 
this exposed group the at risk time for mortality started at the stroke date. Then, we defined a 
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control design. 
We used Poisson regression to calculate age and sex adjusted mortality rates and rate ratios 
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calculated cardiovascular and non-cardiovascular mortality rates separately.  
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calculated using the Interactive Risk Attributable Program (IRAP).31 This program calculates 
hazard ratio’s (HRs) with 95% confidence intervals (CI) based on a Poisson model and enables 
the calculation of population attributable risks (PARs) with 95% CI. We provide logit 
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with D=1 denoting presence of disease, X denoting exposure with i levels, and C denoting a 
confounder with j levels. We calculated the PAR for each risk factor separately and calculated 
the combined PAR. The combined PAR included the PARs that were associated with mortality 
in the expected direction, meaning that the HR was higher than 1. PARs cannot be calculated 
for a HR below one, because this will result in a PAR that cannot be interpreted.33  
We checked the proportional hazards assumption by inspecting log minus log plots. 
Follow-up started at the index date. Information on the investigated cardiovascular risk factors 
was missing up to a maximum of 9.7% and was imputed based on the other covariates using 
multiple imputation with 5 imputation sets. The mean of these 5 imputation sets was used to 
implement in the Interactive Risk Attributable Program. In each model, we adjusted for age, 
sex, time between center date and index date, and for the categories of hypertension, 
cholesterol, HDL cholesterol, BMI, diabetes mellitus, smoking, and atrial fibrillation, if 
appropriate. As sensitivity analysis we also calculated the PARs for cardiovascular and non-
cardiovascular mortality. We explored potential effect modification by presence of stroke by 
using an interaction term of the stroke status with the potential risk factor. Differences in 
prevalence of risk factors between participants with stroke and stroke-free participants and 
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between men and women were calculated using the Chi-Square test. Interactions with sex 
were tested adding an interaction term of the dependent variable with sex.  
All analyses were performed using IRAP version 2.2 (US National Cancer Institute), IBM SPSS 
Statistics version 21.0 (IBM Corp., Armonk, NY) and SAS version 9.3 (SAS Institute Inc., Cary, NC). 
 
Results 
 
Characteristics of the study population  
Of the 14,235 participants at risk for stroke that were followed-up for a mean (±SD) of 9.6 (±6.0) 
years, 1,325 participants suffered a stroke. 1,243 of these participants had a center visit before 
the stroke. Due to old age, 6 of those participants could not be matched and another 8 stroke 
cases could only be matched to 1 or 2 stroke-free participants. Eventually we had 1,237 
participants with stroke and 4,928 participants without stroke eligible for analysis (Figure 1). 
Because people could serve as control multiple times and could become case later in time, 
these control participants consisted out of 3,377 study participants. 2,079 were included only 
once, 1,298 were included multiple times, of which 378 became a case later in time.  
 
 
Figure 1. Study population  
*Consists of 3377 participants: 2079 were included only once, 1298 were included multiple times of 
which 378 became a case later in time. 
 
Mean age of persons with stroke was 79.9 (± 8.7) years, 60.4% was female, and 
cardiovascular risk factors were measured for a mean of 3.7 (± 3.2) years before stroke. Due to 
matching, these statistics were similar in persons without stroke (Table 1).  
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Table 1. Baseline characteristics 
 Persons with 
stroke 
N=1237 
Matched persons 
without stroke 
N=4928 
Age at index date (years) 79.9 (8.7) 79.8 (8.7) 
Time-interval between center visit and index date (years) 3.7 (3.2) 3.7 (3.4) 
Female 747 (60.4%) 2978 (60.4%) 
Hypertension 1007 (85.2%) 3653 (76.2%) 
Blood pressure-lowering medication 575 (47.7%) 1989 (41.3%) 
Cholesterol   
Hypercholesterolemia 443 (39.6%) 1913 (41.6%) 
Lipid-lowering medication 107 (9.6%) 486 (10.6%) 
Low HDL cholesterol 225 (19.9%) 771 (16.7%) 
Body mass index   
<18.5 9 (0.8%) 35 (0.8%) 
18.5-25 327 (30.1%) 1455 (32.5%) 
>=25 751 (69.1%) 2992 (66.8%) 
Diabetes mellitus 212 (18.7%) 525 (11.4%) 
Smoking   
Never 328 (29.3%) 1651 (36.3%) 
Past 515 (46.0%) 2197 (48.3%) 
Current 276 (24.7%) 698 (15.4%) 
TIA  194 (15.7%) 407 (8.3%) 
Atrial fibrillation 203 (18.4%) 484 (10.6%) 
Abbreviations: N = number of persons at risk; HDL = high-density lipoprotein; TIA = transient ischemic attack. 
Percentages are calculated without missing values.  
Data are presented as mean (standard deviations) or counts (percentages). 
 
Mortality rates 
During on average 3.8 (± 4.4) years (median [5th – 95th percentile range]: 2.3 [0 – 13.1] years), 
919 persons with a stroke died, 515 (56.0%) due to a cardiovascular cause. During 6.5 (± 4.7) 
years (median [5th – 95th percentile range]: 5.5 [0.6 – 15.8] years), 2,654 persons without a stroke 
died, 806 (30.4%) due to a cardiovascular cause. Mortality rates after stroke were highest in the 
first 30 days (2.56 events per person-year, 95% CI 2.22; 2.95) and remained stable after one year 
around 0.14 (95% CI 0.13; 0.15) events per person-year. These mortality rates were 51.7 (95% CI 
34.3; 78.0) times higher compared to the matched stroke-free group in the first 30 days and 
remained almost two times higher (Mortality rate ratio (MRR) 1.9, 95% CI 1.7; 2.1)) from 1 year 
onwards after the stroke (Figure 2). The increased risk of death in the first 30 days was mainly 
due to cardiovascular causes (MRR 183.7; 95% CI 81.7; 413.4) compared to the reference 
population). Similarly, the increased risk of death after 1 year was mainly due to cardiovascular 
causes (MRR 2.4, 95% CI 2.0; 2.9) compared to the reference population), but stroke patients 
also had a higher risk of non-cardiovascular deaths (MRR 1.6, 95% CI 1.4; 1.9) (Supplementary 
Figure I).  
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Figure 2. Mortality rates  
Age- and sex adjusted mortality rates in the first year (left) or one year after baseline (right). 
 
Population attributable risk 
Persons with stroke had more often hypertension, low HDL cholesterol, diabetes mellitus, 
previous TIA or atrial fibrillation, and smoked more compared to stroke-free persons (Table 2).  
In persons with stroke strongest harmful associations were found for underweight (HR 2.06, 
95% CI 1.05; 4.03), diabetes mellitus (HR 1.48, 95% CI 1.24; 1.75), atrial fibrillation (HR 1.44, 95% 
CI 1.21; 1.70), current smoking (HR 1.40, 95% CI 1.15; 1.72), and hypertension (HR 1.07, 95% CI 
0.88; 1.31). In combination with the prevalence, the most important modifiable risk factors were 
smoking (PAR 0.13, 95% CI 0.06; 0.25), diabetes mellitus (PAR 0.06, 95% CI 0.04; 0.10), atrial 
fibrillation (PAR 0.06, 95% CI 0.03; 0.09), and hypertension (PAR 0.06, 95% CI 0.00; 0.57). Smaller 
attributable risks were found for a low HDL cholesterol (PAR 0.02, 95% CI 0.00; 0.10) and being 
underweight (PAR 0.01, 95% CI 0.00; 0.02). The total proportion of deaths that was attributable 
to these modifiable risk factors combined was 0.27 (95% CI 0.14; 0.45) (Table 2). 
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Table 1. Baseline characteristics 
 Persons with 
stroke 
N=1237 
Matched persons 
without stroke 
N=4928 
Age at index date (years) 79.9 (8.7) 79.8 (8.7) 
Time-interval between center visit and index date (years) 3.7 (3.2) 3.7 (3.4) 
Female 747 (60.4%) 2978 (60.4%) 
Hypertension 1007 (85.2%) 3653 (76.2%) 
Blood pressure-lowering medication 575 (47.7%) 1989 (41.3%) 
Cholesterol   
Hypercholesterolemia 443 (39.6%) 1913 (41.6%) 
Lipid-lowering medication 107 (9.6%) 486 (10.6%) 
Low HDL cholesterol 225 (19.9%) 771 (16.7%) 
Body mass index   
<18.5 9 (0.8%) 35 (0.8%) 
18.5-25 327 (30.1%) 1455 (32.5%) 
>=25 751 (69.1%) 2992 (66.8%) 
Diabetes mellitus 212 (18.7%) 525 (11.4%) 
Smoking   
Never 328 (29.3%) 1651 (36.3%) 
Past 515 (46.0%) 2197 (48.3%) 
Current 276 (24.7%) 698 (15.4%) 
TIA  194 (15.7%) 407 (8.3%) 
Atrial fibrillation 203 (18.4%) 484 (10.6%) 
Abbreviations: N = number of persons at risk; HDL = high-density lipoprotein; TIA = transient ischemic attack. 
Percentages are calculated without missing values.  
Data are presented as mean (standard deviations) or counts (percentages). 
 
Mortality rates 
During on average 3.8 (± 4.4) years (median [5th – 95th percentile range]: 2.3 [0 – 13.1] years), 
919 persons with a stroke died, 515 (56.0%) due to a cardiovascular cause. During 6.5 (± 4.7) 
years (median [5th – 95th percentile range]: 5.5 [0.6 – 15.8] years), 2,654 persons without a stroke 
died, 806 (30.4%) due to a cardiovascular cause. Mortality rates after stroke were highest in the 
fir t 30 days (2.56 events per person-year, 95% CI 2.22; 2.95) and remained stable after one year 
around 0.14 (95% CI 0.13; 0.15) events per person-year. These mortality rates were 51.7 (95% CI 
34.3; 78.0) times higher compared to the matched stroke-free group in the first 30 days and 
remained almost two times higher (Mortality rate ratio (MRR) 1.9, 95% CI 1.7; 2.1)) from 1 year 
onwards after the stroke (Figure 2). The increased risk of death in the first 30 days was mainly 
due to cardiovascular causes (MRR 183.7; 95% CI 81.7; 413.4) ompar d to the reference 
population). Similarly, the increased risk of death after 1 year was mainly due to cardiovascular 
causes (MRR 2.4, 95% CI 2.0; 2.9) compared to the reference population), but stroke patients 
also had a higher risk of non-cardiovascular deaths (MRR 1.6, 95% CI 1.4; 1.9) (Supplementary 
Figure I).  
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Figure 2. Mortality rates  
Age- and sex adjusted mortality rates in the first year (left) or one year after baseline (right). 
 
Population attributable risk 
Persons with stroke had more often hypertension, low HDL cholesterol, diabetes mellitus, 
previous TIA or atrial fibrillation, and smoked more compared to stroke-free persons (Table 2).  
In persons with stroke strongest harmful associations were found for underweight (HR 2.06, 
95% CI 1.05; 4.03), diabetes mellitus (HR 1.48, 95% CI 1.24; 1.75), atrial fibrillation (HR 1.44, 95% 
CI 1.21; 1.70), current smoking (HR 1.40, 95% CI 1.15; 1.72), and hypertension (HR 1.07, 95% CI 
0.88; 1.31). In combination with the prevalence, the most important modifiable risk factors were 
smoking (PAR 0.13, 95% CI 0.06; 0.25), diabetes mellitus (PAR 0.06, 95% CI 0.04; 0.10), atrial 
fibrillation (PAR 0.06, 95% CI 0.03; 0.09), and hypertension (PAR 0.06, 95% CI 0.00; 0.57). Smaller 
attributable risks were found for a low HDL cholesterol (PAR 0.02, 95% CI 0.00; 0.10) and being 
underweight (PAR 0.01, 95% CI 0.00; 0.02). The total proportion of deaths that was attributable 
to these modifiable risk factors combined was 0.27 (95% CI 0.14; 0.45) (Table 2). 
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Table 1. Baseline characteristics 
 Persons with 
stroke 
N=1237 
Matched persons 
without stroke 
N=4928 
Age at index date (years) 79.9 (8.7) 79.8 (8.7) 
Time-interval between center visit and index date (years) 3.7 (3.2) 3.7 (3.4) 
Female 747 (60.4%) 2978 (60.4%) 
Hypertension 1007 (85.2%) 3653 (76.2%) 
Blood pressure-lowering medication 575 (47.7%) 1989 (41.3%) 
Cholesterol   
Hypercholesterolemia 443 (39.6%) 1913 (41.6%) 
Lipid-lowering medication 107 (9.6%) 486 (10.6%) 
Low HDL cholesterol 225 (19.9%) 771 (16.7%) 
Body mass index   
<18.5 9 (0.8%) 35 (0.8%) 
18.5-25 327 (30.1%) 1455 (32.5%) 
>=25 751 (69.1%) 2992 (66.8%) 
Diabetes mellitus 212 (18.7%) 525 (11.4%) 
Smoking   
Never 328 (29.3%) 1651 (36.3%) 
Past 515 (46.0%) 2197 (48.3%) 
Current 276 (24.7%) 698 (15.4%) 
TIA  194 (15.7%) 407 (8.3%) 
Atrial fibrillation 203 (18.4%) 484 (10.6%) 
Abbreviations: N = number of persons at risk; HDL = high-density lipoprotein; TIA = transient ischemic attack. 
Percentages are calculated without missing values.  
Data are presented as mean (standard deviations) or counts (percentages). 
 
Mortality rates 
During on average 3.8 (± 4.4) years (median [5th – 95th percentile range]: 2.3 [0 – 13.1] years), 
919 persons with a stroke died, 515 (56.0%) due to a cardiovascular cause. During 6.5 (± 4.7) 
years (median [5th – 95th percentile range]: 5.5 [0.6 – 15.8] years), 2,654 persons without a stroke 
died, 806 (30.4%) due to a cardiovascular cause. Mortality rates after stroke were highest in the 
fir t 30 days (2.56 events per person-year, 95% CI 2.22; 2.95) and remained stable after one year 
around 0.14 (95% CI 0.13; 0.15) events per person-year. These mortality rates were 51.7 (95% CI 
34.3; 78.0) times higher compared to the matched stroke-free group in the first 30 days and 
remained almost two times higher (Mortality rate ratio (MRR) 1.9, 95% CI 1.7; 2.1)) from 1 year 
onwards after the stroke (Figure 2). The increased risk of death in the first 30 days was mainly 
due to cardiovascular causes (MRR 183.7; 95% CI 81.7; 413.4) ompar d to the reference 
population). Similarly, the increased risk of death after 1 year was mainly due to cardiovascular 
causes (MRR 2.4, 95% CI 2.0; 2.9) compared to the reference population), but stroke patients 
also had a higher risk of non-cardiovascular deaths (MRR 1.6, 95% CI 1.4; 1.9) (Supplementary 
Figure I).  
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In the reference population the PARs of diabetes mellitus (0.03, 95% CI 0.02; 0.05), atrial 
fibrillation (0.03, 95% CI 0.02; 0.05), and smoking (0.05, 95% CI 0.02; 0.13) were lower compared 
to the PARs of participants with stroke. For diabetes mellitus and smoking hazard ratios were 
similar compared to persons with stroke, but the prevalence of both was lower. For atrial 
fibrillation both the prevalence and the hazard ratio were lower, although the HR only 
borderline significant (HR 1.27; 95% CI 1.14; 1.43, p for interaction 0.10). In persons without 
stroke no attributable risk for underweight could be calculated, due to an inversed hazard ratio 
(HR 0.75, 95% CI 0.46; 1.20, p for interaction 0.02). The PAR for hypertension was similar in the 
reference population (0.06; 95% CI 0.02; 0.19). In total, the proportion of deaths attributable to 
cardiovascular risk factors in the reference population was 0.19 (95% CI 0.12; 0.29) (Table 2). 
The risk of cardiovascular deaths attributable to cardiovascular risk factors was lower in 
stroke patients (0.32; 95% CI 0.15; 0.55) compared to the reference population (0.49; 95% CI 
0.37; 0.61). In the reference population we found that more cardiovascular deaths were 
attributable to hypertension, cholesterol, and BMI, whereas in the stroke population more 
deaths were attributable to diabetes and atrial fibrillation (Table 3). In contrast, in stroke patients 
more non-cardiovascular deaths were attributable to cardiovascular risk factors than in the 
reference population (PAR 0.21, 95% CI 0.05; 0.55) in stroke population, PAR 0.07 (95% CI 0.02; 
0.22) in reference population) (Supplementary Table I). 
In Supplementary Table II and III the stratified analyses for men and women are presented. 
Men smoked more compared to women and women with a low HDL cholesterol had a higher 
risk of death after stroke compared to men. In total, the proportion of death attributable to 
cardiovascular risk factors was 0.29 (95% CI 0.13; 0.53) in men with stroke, 0.42 (95% CI 0.29; 
0.57) in men without stroke, 0.25 (95% CI 0.18; 0.34) in women with stroke, and 0.14 (95% CI 
0.06; 0.29) in women without stroke. Largest differences between men and women were found 
for hypertension. In men with stroke more deaths were attributable to hypertension (PAR 0.22, 
95% 0.07; 0.52), compared to in men without stroke (PAR 0.07, 95% CI 0.01; 0.28). In women 
with stroke no deaths were attributable to hypertension, whereas in women without stroke we 
found a PAR of 0.05 (95% CI 0.01; 0.29). In women we found stronger PARs for diabetes, 
smoking, and a low HDL cholesterol compared to men, but only a low HDL cholesterol had a 
significantly higher HR in women compared to men.  
 
Discussion 
 
We found that participants with stroke had a long-term mortality rate that was two-fold higher 
compared with stroke-free persons. This is partly due to cardiovascular risk factors already 
present before stroke, since 27% deaths after stroke were attributable to these factors. In total, 
this was only 8% higher than in people without stroke. Deaths after stroke were mainly 
cardiovascular, but only 32% of those deaths were attributable to cardiovascular risk factors 
before stroke, compared to 49% in stroke-free persons. Nevertheless, attributable risks of 
diabetes mellitus and atrial fibrillation were almost twice as high in persons with stroke 
compared with stroke-free persons for both all cause and cardiovascular mortality.  
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between men and women were calculated using the Chi-Square test. Interactions with sex 
were tested adding an interaction term of the dependent variable with sex.  
All analyses were performed using IRAP version 2.2 (US National Cancer Institute), IBM SPSS 
Statistics version 21.0 (IBM Corp., Armonk, NY) and SAS version 9.3 (SAS Institute Inc., Cary, NC). 
 
Results 
 
Characteristics of the study population  
Of the 14,235 participants at risk for stroke that were followed-up for a mean (±SD) of 9.6 (±6.0) 
years, 1,325 participants suffered a stroke. 1,243 of these participants had a center visit before 
the stroke. Due to old age, 6 of those participants could not be matched and another 8 stroke 
cases could only be matched to 1 or 2 stroke-free participants. Eventually we had 1,237 
participants with stroke and 4,928 participants without stroke eligible for analysis (Figure 1). 
Because people could serve as control multiple times and could become case later in time, 
these control participants consisted out of 3,377 study participants. 2,079 were included only 
once, 1,298 were included multiple times, of which 378 became a case later in time.  
 
 
Figure 1. Study population  
*Consists of 3377 participants: 2079 were included only once, 1298 were included multiple times of 
which 378 became a case later in time. 
 
Mean age of persons with stroke was 79.9 (± 8.7) years, 60.4% was female, and 
cardiovascular risk factors w re measured for a mean of 3.7 (± 3.2) years before stroke. Due to 
matching, these statistics were similar in persons without stroke (Table 1).  
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In the reference population the PARs of diabetes mellitus (0.03, 95% CI 0.02; 0.05), atrial 
fibrillation (0.03, 95% CI 0.02; 0.05), and smoking (0.05, 95% CI 0.02; 0.13) were lower compared 
to the PARs of participants with stroke. For diabetes mellitus and smoking hazard ratios were 
similar compared to persons with stroke, but the prevalence of both was lower. For atrial 
fibrillation both the prevalence and the hazard ratio were lower, although the HR only 
borderline significant (HR 1.27; 95% CI 1.14; 1.43, p for interaction 0.10). In persons without 
stroke no attributable risk for underweight could be calculated, due to an inversed hazard ratio 
(HR 0.75, 95% CI 0.46; 1.20, p for interaction 0.02). The PAR for hypertension was similar in the 
reference population (0.06; 95% CI 0.02; 0.19). In total, the proportion of deaths attributable to 
cardiovascular risk factors in the reference population was 0.19 (95% CI 0.12; 0.29) (Table 2). 
The risk of cardiovascular deaths attributable to cardiovascular risk factors was lower in 
stroke patients (0.32; 95% CI 0.15; 0.55) compared to the reference population (0.49; 95% CI 
0.37; 0.61). In the reference population we found that more cardiovascular deaths were 
attributable to hypertension, cholesterol, and BMI, whereas in the stroke population more 
deaths were attributable to diabetes and atrial fibrillation (Table 3). In contrast, in stroke patients 
more non-cardiovascular deaths were attributable to cardiovascular risk factors than in the 
reference population (PAR 0.21, 95% CI 0.05; 0.55) in stroke population, PAR 0.07 (95% CI 0.02; 
0.22) in reference population) (Supplementary Table I). 
In Supplementary Table II and III the stratified analyses for men and women are presented. 
Men smoked more compared to women and women with a low HDL cholesterol had a higher 
risk of death after stroke compared to men. In total, the proportion of death attributable to 
cardiovascular risk factors was 0.29 (95% CI 0.13; 0.53) in men with stroke, 0.42 (95% CI 0.29; 
0.57) in men without stroke, 0.25 (95% CI 0.18; 0.34) in women with stroke, and 0.14 (95% CI 
0.06; 0.29) in women without stroke. Largest differences between men and women were found 
for hypertension. In men with stroke more deaths were attributable to hypertension (PAR 0.22, 
95% 0.07; 0.52), compared to in men without stroke (PAR 0.07, 95% CI 0.01; 0.28). In women 
with stroke no deaths were attributable to hypertension, whereas in women without stroke we 
found a PAR of 0.05 (95% CI 0.01; 0.29). In women we found stronger PARs for diabetes, 
smoking, and a low HDL cholesterol compared to men, but only a low HDL cholesterol had a 
significantly higher HR in women compared to men.  
 
Discussion 
 
We found that participants with stroke had a long-term mortality rate that was two-fold higher 
compared with stroke-free persons. This is partly due to cardiovascular risk factors already 
present before stroke, since 27% deaths after stroke were attributable to these factors. In total, 
this was only 8% higher than in people without stroke. Deaths after stroke were mainly 
cardiovascular, but only 32% of those deaths were attributable to cardiovascular risk factors 
before stroke, compared to 49% in stroke-free persons. Nevertheless, attributable risks of 
diabetes mellitus and atrial fibrillation were almost twice as high in persons with stroke 
compared with stroke-free persons for both all cause and cardiovascular mortality.  
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between men and women were calculated using the Chi-Square test. Interactions with sex 
were tested adding an interaction term of the dependent variable with sex.  
All analyses were performed using IRAP version 2.2 (US National Cancer Institute), IBM SPSS 
Statistics version 21.0 (IBM Corp., Armonk, NY) and SAS version 9.3 (SAS Institute Inc., Cary, NC). 
 
Results 
 
Characteristics of the study population  
Of the 14,235 participants at risk for stroke that were followed-up for a mean (±SD) of 9.6 (±6.0) 
years, 1,325 participants suffered a stroke. 1,243 of these participants had a center visit before 
the stroke. Due to old age, 6 of those participants could not be matched and another 8 stroke 
cases could only be matched to 1 or 2 stroke-free participants. Eventually we had 1,237 
participants with stroke and 4,928 participants without stroke eligible for analysis (Figure 1). 
Because people could serve as control multiple times and could become case later in time, 
these control participants consisted out of 3,377 study participants. 2,079 were included only 
once, 1,298 were included multiple times, of which 378 became a case later in time.  
 
 
Figure 1. Study population  
*Consists of 3377 participants: 2079 were included only once, 1298 were included multiple times of 
which 378 became a case later in time. 
 
Mean age of persons with stroke was 79.9 (± 8.7) years, 60.4% was female, and 
cardiovascular risk factors w re measured for a mean of 3.7 (± 3.2) years before stroke. Due to 
matching, these statistics were similar in persons without stroke (Table 1).  
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Despite the changes in stroke treatment over the last decades with improvement of 
incidence and mortality rates,22,34-36 the two-fold higher mortality rate in persons with stroke 
compared with stroke-free persons is similar to what was found a decade earlier3-5,12 and in 
young adults.6 In other words, the improvement in healthcare of stroke patients has not 
exceeded the improvement in healthcare experienced in the general population. Hence, the 
room for improving long-term prognosis after stroke remains substantial. An important 
contribution of our study is that we investigated and quantified to what extent pre-existent 
cardiovascular risk factors can contribute to post-stroke survival.  
Main risk factors for death after stroke in our study were smoking, diabetes, atrial fibrillation, 
and in men hypertension. Smoking and diabetes were previously also identified as risk factors, 
in a study examining factors before stroke,37 as well as in studies that started at stroke onset 
and might be influenced by reversed causality.10, 13, 14 Results with respect to atrial fibrillation 
were conflicting, some studies did find an increased risk of death,11,13,16 other studies did not. 
10,14 Differences might be due to adjustments for severity, which could actually be a mediator 
in the pathway, although one study found an effect independent from severity.13 Hypertension 
was previously not found as an important risk factor, but the studies did not stratify for 
sex.10,13,15,16  
A novelty of our study is that we measured PAR and compared this to a reference 
population. Although cardiovascular risk factor management is an important cornerstone of 
treatment after stroke,8 we found that a quarter of deaths after stroke is attributable to 
cardiovascular risk factors. An explanation might be that pathologic changes leading to those 
deaths were already present before the stroke, which is supported by the fact that the risk 
factors were measured years before the stroke. Aggressive risk factor control after stroke might 
therefore be too late. Yet, the proportion of cardiovascular deaths attributable to cardiovascular 
risk factors was lower in the stroke population compared to the reference population. To 
properly interpret these results, a few considerations need to be taken into account. First, the 
stroke population suffered many more cardiovascular deaths than the reference population, 
which is obvious since stroke itself is a cardiovascular disease. Second, this larger number also 
means that the absolute number of cardiovascular deaths in stroke patients due to 
cardiovascular risk factors is higher than the reference population, even though the relative 
proportions (attributable risks) were inversed. Similar reasoning holds for the opposite 
difference in attributable risks for non-cardiovascular mortality. A third consideration to 
properly interpret our findings on cardiovascular mortality is that patients with stroke are more 
aggressively treated after the index date compared to the reference population. That might 
have reduced some of the harmful effect of cardiovascular risk factors. More importantly, our 
findings emphasize that other factors too should be explored to understand the causes of 
death following stroke. This is further emphasized by the 73% of deaths that remain 
unexplained. Such novel factors may include other pre-stroke risk factors, e.g. genetic factors; 
post-stroke factors, e.g. proper medical care, response to treatment, or frailty caused by the 
stroke; and characteristics of the stroke itself, e.g. hemorrhagic transformation or size of the 
stroke.11,38,39  
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At the same time, we have to consider that the PAR for diabetes mellitus, smoking, and 
atrial fibrillation was almost twice as high in people with stroke compared to stroke-free people. 
Differences in PAR can be caused by a difference in effect size or a difference in prevalence.33 
The PAR in our study was mostly driven by the higher prevalence of diabetes mellitus, smoking, 
and atrial fibrillation in people with stroke, probably because these factors are also important 
risk factors for the stroke itself.40  
Interestingly, we found effect modification of stroke for the effect of atrial fibrillation and 
underweight with stronger effect sizes for death in people with stroke compared to people 
without stroke. This might be due to more severe strokes and more complications after stroke 
in people with atrial fibrillation.41 For people with underweight, the increased risk of death after 
stroke might be due to frailty in combination with dysphagia.37,42 Underweight participants 
might be more vulnerable to undernutrition. Furthermore they may reflect people with a high 
morbidity and increased risk of both stroke and death, e.g. patients with cancer. This is 
supported by the finding that especially non-cardiovascular deaths are attributable to 
underweight. However, due to low numbers these results have to be interpreted with caution. 
Strengths of this study are the long follow-up, the availability of cardiovascular risk factors 
measured before stroke occurrence which avoids reversed causality, and that we could 
compare people with stroke to a reference population from the same study population. This 
study also has some limitations. For instance, the PAR might be an overestimation of the 
amount of deaths that could be prevented, as for some risk factors optimal treatment cannot 
completely reduce the harmful effect.40,43 Irreversible damage might already have occurred 
before starting of the optimal treatment. Moreover, we only used a single measurement of the 
cardiovascular risk factor before stroke, while the long-term pattern (i.e. trajectory) of a risk 
factor before and after stroke might further influence the risk of dying. However, we were 
interested in the effect of pre-stroke risk factors on death after stroke and adding post-stroke 
information might obscure this effect. We also missed information about physical activity, 
which is an important risk factor for stroke44 and possibly for stroke mortality.37 So our estimates 
might be an underestimation of the effect of cardiovascular risk factors. Another limitation is 
that we did not measure severity of stroke, which is an important risk factor for mortality.11 This 
could have led to some residual confounding. However, severity is likely to be an intermediate 
as well in the causal pathway and adjusting might in fact lead to over-adjustment. Furthermore, 
not all persons with stroke (6.2%) had visited our research center before the stroke occurred. 
This could have led to selection bias if persons that did come to the center were more healthy. 
A final consideration is that we had missing values up to 9.7% per variable. We imputed these 
missing values to prevent selection bias, but this might have led to some misclassification. 
Furthermore, atrial fibrillation follow-up was only complete until 2010. This could have led to 
misclassification in participants with an index date after 2010, since their atrial fibrillation status 
was outdated.  
In conclusion, the long-term risk of mortality after stroke remains increased and is almost 
twice as high compared to persons without stroke. A quarter of stroke deaths might be 
prevented with optimal cardiovascular prevention and treatment of mainly diabetes, atrial 
fibrillation, and smoking, starting before stroke. These findings underline the importance of 
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Despite the changes in stroke treatment over the last decades with improvement of 
incidence and mortality rates,22,34-36 the two-fold higher mortality rate in persons with stroke 
compared with stroke-free persons is similar to what was found a decade earlier3-5,12 and in 
young adults.6 In other words, the improvement in healthcare of stroke patients has not 
exceeded the improvement in healthcare experienced in the general population. Hence, the 
room for improving long-term prognosis after stroke remains substantial. An important 
contribution of our study is that we investigated and quantified to what extent pre-existent 
cardiovascular risk factors can contribute to post-stroke survival.  
Main risk factors for death after stroke in our study were smoking, diabetes, atrial fibrillation, 
and in men hypertension. Smoking and diabetes were previously also identified as risk factors, 
in a study examining factors before stroke,37 as well as in studies that started at stroke onset 
and might be influenced by reversed causality.10, 13, 14 Results with respect to atrial fibrillation 
were conflicting, some studies did find an increased risk of death,11,13,16 other studies did not. 
10,14 Differences might be due to adjustments for severity, which could actually be a mediator 
in the pathway, although one study found an effect independent from severity.13 Hypertension 
was previously not found as an important risk factor, but the studies did not stratify for 
sex.10,13,15,16  
A novelty of our study is that we measured PAR and compared this to a reference 
population. Although cardiovascular risk factor management is an important cornerstone of 
treatment after stroke,8 we found that a quarter of deaths after stroke is attributable to 
cardiovascular risk factors. An explanation might be that pathologic changes leading to those 
deaths were already present before the stroke, which is supported by the fact that the risk 
factors were measured years before the stroke. Aggressive risk factor control after stroke might 
therefore be too late. Yet, the proportion of cardiovascular deaths attributable to cardiovascular 
risk factors was lower in the stroke population compared to the reference population. To 
properly interpret these results, a few considerations need to be taken into account. First, the 
stroke population suffered many more cardiovascular deaths than the reference population, 
which is obvious since stroke itself is a cardiovascular disease. Second, this larger number also 
means that the absolute number of cardiovascular deaths in stroke patients due to 
cardiovascular risk factors is higher than the reference population, even though the relative 
proportions (attributable risks) were inversed. Similar reasoning holds for the opposite 
difference in attributable risks for non-cardiovascular mortality. A third consideration to 
properly interpret our findings on cardiovascular mortality is that patients with stroke are more 
aggressively treated after the index date compared to the reference population. That might 
have reduced some of the harmful effect of cardiovascular risk factors. More importantly, our 
findings emphasize that other factors too should be explored to understand the causes of 
death following stroke. This is further emphasized by the 73% of deaths that remain 
unexplained. Such novel factors may include other pre-stroke risk factors, e.g. genetic factors; 
post-stroke factors, e.g. proper medical care, response to treatment, or frailty caused by the 
stroke; and characteristics of the stroke itself, e.g. hemorrhagic transformation or size of the 
stroke.11,38,39  
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At the same time, we have to consider that the PAR for diabetes mellitus, smoking, and 
atrial fibrillation was almost twice as high in people with stroke compared to stroke-free people. 
Differences in PAR can be caused by a difference in effect size or a difference in prevalence.33 
The PAR in our study was mostly driven by the higher prevalence of diabetes mellitus, smoking, 
and atrial fibrillation in people with stroke, probably because these factors are also important 
risk factors for the stroke itself.40  
Interestingly, we found effect modification of stroke for the effect of atrial fibrillation and 
underweight with stronger effect sizes for death in people with stroke compared to people 
without stroke. This might be due to more severe strokes and more complications after stroke 
in people with atrial fibrillation.41 For people with underweight, the increased risk of death after 
stroke might be due to frailty in combination with dysphagia.37,42 Underweight participants 
might be more vulnerable to undernutrition. Furthermore they may reflect people with a high 
morbidity and increased risk of both stroke and death, e.g. patients with cancer. This is 
supported by the finding that especially non-cardiovascular deaths are attributable to 
underweight. However, due to low numbers these results have to be interpreted with caution. 
Strengths of this study are the long follow-up, the availability of cardiovascular risk factors 
measured before stroke occurrence which avoids reversed causality, and that we could 
compare people with stroke to a reference population from the same study population. This 
study also has some limitations. For instance, the PAR might be an overestimation of the 
amount of deaths that could be prevented, as for some risk factors optimal treatment cannot 
completely reduce the harmful effect.40,43 Irreversible damage might already have occurred 
before starting of the optimal treatment. Moreover, we only used a single measurement of the 
cardiovascular risk factor before stroke, while the long-term pattern (i.e. trajectory) of a risk 
factor before and after stroke might further influence the risk of dying. However, we were 
interested in the effect of pre-stroke risk factors on death after stroke and adding post-stroke 
information might obscure this effect. We also missed information about physical activity, 
which is an important risk factor for stroke44 and possibly for stroke mortality.37 So our estimates 
might be an underestimation of the effect of cardiovascular risk factors. Another limitation is 
that we did not measure severity of stroke, which is an important risk factor for mortality.11 This 
could have led to some residual confounding. However, severity is likely to be an intermediate 
as well in the causal pathway and adjusting might in fact lead to over-adjustment. Furthermore, 
not all persons with stroke (6.2%) had visited our research center before the stroke occurred. 
This could have led to selection bias if persons that did come to the center were more healthy. 
A final consideration is that we had missing values up to 9.7% per variable. We imputed these 
missing values to prevent selection bias, but this might have led to some misclassification. 
Furthermore, atrial fibrillation follow-up was only complete until 2010. This could have led to 
misclassification in participants with an index date after 2010, since their atrial fibrillation status 
was outdated.  
In conclusion, the long-term risk of mortality after stroke remains increased and is almost 
twice as high compared to persons without stroke. A quarter of stroke deaths might be 
prevented with optimal cardiovascular prevention and treatment of mainly diabetes, atrial 
fibrillation, and smoking, starting before stroke. These findings underline the importance of 
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primary prevention, as it does not only reduce the risk of stroke, but also its long-term 
prognosis. At the same time, equally important, our findings indicate the need of finding factors 
that explain the remaining three-quarter of deaths and the doubled risk of death in people 
with stroke compared to those without stroke, because it cannot only be explained by 
cardiovascular risk factors. 
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Supplementary Figure I. Cardiovascular and non-cardiovascular mortality rates 
Age- and sex adjusted cardiovascular mortality rates (left) and non-cardiovascular mortality rates (right). 
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Table 1. Baseline characteristics 
 Persons with 
stroke 
N=1237 
Matched persons 
without stroke 
N=4928 
Age at index date (years) 79.9 (8.7) 79.8 (8.7) 
Time-interval between center visit and index date (years) 3.7 (3.2) 3.7 (3.4) 
Female 747 (60.4%) 2978 (60.4%) 
Hypertension 1007 85.2%) 3653 (76.2%) 
Blood pressure-lowering medication 575 (47.7%) 1989 (41.3%) 
Cholesterol   
Hypercholesterolemia 443 (39.6%) 1913 (41.6%) 
Lipid-lowering medication 107 (9.6%) 486 (10.6%) 
Low HDL cholesterol 225 (19.9%) 771 (16.7%) 
Body mass index   
<18.5 9 (0.8%) 35 (0.8%) 
18.5-25 327 (30.1%) 1455 (32.5%) 
>=25 751 (69.1%) 2992 (66.8%) 
Diabetes mellitus 212 (18.7%) 525 (11.4%) 
Smoking   
Never 328 (29.3%) 1651 (36.3%) 
Past 515 (46.0%) 2197 (48.3%) 
Current 276 (24.7%) 698 (15.4%) 
TIA  194 (15.7%) 407 (8.3%) 
Atrial fibrillation 203 (18.4%) 484 (10.6%) 
Abbreviations: N = number of persons at risk; HDL = high-density lipoprotein; TIA = transient ischemic attack. 
Percentages are calculated without missing values.  
Data are presented as mean (standard deviations) or counts (percentages). 
 
Mortality rates 
During on average 3.8 (± 4.4) years (median [5th – 95th percentile range]: 2.3 [0 – 13.1] years), 
919 persons with a stroke died, 515 (56.0%) due to a cardiovascular cause. During 6.5 (± 4.7) 
years (median [5th – 95th percentile range]: 5.5 [0.6 – 15.8] years), 2,654 persons without a stroke 
died, 806 (30.4%) due to a cardiovascular cause. Mortality rates after stroke were highest in the 
first 30 days (2.56 vents per person-year, 95% CI 2.22; 2.95) and remai ed stable after one year 
around 0.14 (95% CI 0.13; 0.15) events per person-year. These mortality rates were 51.7 (95% CI 
34.3; 78.0) times higher compared to the matched stroke-free group in the first 30 days and 
remained almost two times higher (Mortality rate ratio (MRR) 1.9, 95% CI 1.7; 2.1)) from 1 year 
onwards after the stroke (Figure 2). The increased risk of death in the first 30 days was mainly 
due to cardiovascular causes (MRR 183.7; 95% CI 81.7; 413.4) compared to th  reference 
population). Similarly, the increas d risk of death after 1 year was mainly due to cardiovascular 
causes (MRR 2.4, 95% CI 2.0; 2.9) compared to the reference p pulation), but stroke patients 
also had a higher risk of non-cardiovascular deaths (MRR 1.6, 95% CI 1.4; 1.9) (Supplementary 
Figure I).  
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Supplementary Figure I. Cardiovascular and non-cardiovascular mortality rates 
Age- and sex adjusted cardiovascular mortality rates (left) and non-cardiovascular mortality rates (right). 
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Table 1. Baseline characteristics 
 Persons with 
stroke 
N=1237 
Matched persons 
without stroke 
N=4928 
Age at index date (years) 79.9 (8.7) 79.8 (8.7) 
Time-interval between center visit and index date (years) 3.7 (3.2) 3.7 (3.4) 
Female 747 (60.4%) 2978 (60.4%) 
Hypertension 1007 85.2%) 3653 (76.2%) 
Blood pressure-lowering medication 575 (47.7%) 1989 (41.3%) 
Cholesterol   
Hypercholesterolemia 443 (39.6%) 1913 (41.6%) 
Lipid-lowering medication 107 (9.6%) 486 (10.6%) 
Low HDL cholesterol 225 (19.9%) 771 (16.7%) 
Body mass index   
<18.5 9 (0.8%) 35 (0.8%) 
18.5-25 327 (30.1%) 1455 (32.5%) 
>=25 751 (69.1%) 2992 (66.8%) 
Diabetes mellitus 212 (18.7%) 525 (11.4%) 
Smoking   
Never 328 (29.3%) 1651 (36.3%) 
Past 515 (46.0%) 2197 (48.3%) 
Current 276 (24.7%) 698 (15.4%) 
TIA  194 (15.7%) 407 (8.3%) 
Atrial fibrillation 203 (18.4%) 484 (10.6%) 
Abbreviations: N = number of persons at risk; HDL = high-density lipoprotein; TIA = transient ischemic attack. 
Percentages are calculated without missing values.  
Data are presented as mean (standard deviations) or counts (percentages). 
 
Mortality rates 
During on average 3.8 (± 4.4) years (median [5th – 95th percentile range]: 2.3 [0 – 13.1] years), 
919 persons with a stroke died, 515 (56.0%) due to a cardiovascular cause. During 6.5 (± 4.7) 
years (median [5th – 95th percentile range]: 5.5 [0.6 – 15.8] years), 2,654 persons without a stroke 
died, 806 (30.4%) due to a cardiovascular cause. Mortality rates after stroke were highest in the 
first 30 days (2.56 vents per person-year, 95% CI 2.22; 2.95) and remai ed stable after one year 
around 0.14 (95% CI 0.13; 0.15) events per person-year. These mortality rates were 51.7 (95% CI 
34.3; 78.0) times higher compared to the matched stroke-free group in the first 30 days and 
remained almost two times higher (Mortality rate ratio (MRR) 1.9, 95% CI 1.7; 2.1)) from 1 year 
onwards after the stroke (Figure 2). The increased risk of death in the first 30 days was mainly 
due to cardiovascular causes (MRR 183.7; 95% CI 81.7; 413.4) compared to th  reference 
population). Similarly, the increas d risk of death after 1 year was mainly due to cardiovascular 
causes (MRR 2.4, 95% CI 2.0; 2.9) compared to the reference p pulation), but stroke patients 
also had a higher risk of non-cardiovascular deaths (MRR 1.6, 95% CI 1.4; 1.9) (Supplementary 
Figure I).  
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between men and women were calculated using the Chi-Square test. Interactions with sex 
were tested adding an interaction term of the dependent variable with sex.  
All analyses were performed using IRAP version 2.2 (US National Cancer Institute), IBM SPSS 
Statistics version 21.0 (IBM Corp., Armonk, NY) and SAS version 9.3 (SAS Institute Inc., Cary, NC). 
 
Results 
 
Characteristics of the study population  
Of the 14,235 participants at risk for stroke that were followed-up for a mean (±SD) of 9.6 (±6.0) 
years, 1,325 participants suffered a stroke. 1,243 of these participants had a center visit before 
the stroke. Due to old age, 6 of those participants could not be matched and another 8 stroke 
cases could only be matched to 1 or 2 stroke-free participants. Eventually we had 1,237 
participants with stroke and 4,928 participants without stroke eligible for analysis (Figure 1). 
Because peopl  could serve as control multiple times and could become case later in time, 
these control participants consisted out of 3,377 study participants. 2,079 were included only 
once, 1,298 were included multiple times, of which 378 became a case later in time.  
 
 
Figure 1. Study population  
*Consists of 3377 participants: 2079 were included only once, 1298 were included multiple times of 
which 378 became a case later in time. 
 
Mean age of persons with stroke was 79.9 (± 8.7) years, 60.4% was female, and 
cardiovascular risk factors were measured for a mean of 3.7 (± 3.2) years before stroke. Due to 
matching, these statistics were similar in persons without stroke (Table 1).  
Role of prestroke vascular pathology in long-term prognosis after stroke 
195 
 
 
Table 1. Baseline characteristics 
 Persons with 
stroke 
N=1237 
Matched persons 
without stroke 
N=4928 
Age at index date (years) 79.9 (8.7) 79.8 (8.7) 
Time-interval between center visit and index date (years) 3.7 (3.2) 3.7 (3.4) 
Female 747 (60.4%) 2978 (60.4%) 
Hypertension 1007 (85.2%) 3653 (76.2%) 
Blood pressure-lowering medication 575 (47.7%) 1989 (41.3%) 
Cholesterol   
Hypercholesterolemia 443 (39.6%) 1913 (41.6%) 
Lipid-lowering medication 107 (9.6%) 486 (10.6%) 
Low HDL cholesterol 225 (19.9%) 771 (16.7%) 
Body mass index   
<18.5 9 (0.8%) 35 (0.8%) 
18.5-25 327 (30.1%) 1455 (32.5%) 
>=25 751 (69.1%) 2992 (66.8%) 
Diabetes mellitus 212 (18.7%) 525 (11.4%) 
Smoking   
Never 328 (29.3%) 1651 (36.3%) 
Past 515 (46.0%) 2197 (48.3%) 
Current 276 (24.7%) 698 (15.4%) 
TIA  194 (15.7%) 407 (8.3%) 
Atrial fibrillation 203 (18.4%) 484 (10.6%) 
Abbreviations: N = number of persons at risk; HDL = high-density lipoprotein; TIA = transient ischemic attack. 
Percentages are calculated without missing values.  
Data are presented as mean (standard deviations) or counts (percentages). 
 
M rtality rates 
During on average 3.8 (± 4.4) years (median [5th – 95th percentile range]: 2.3 [0 – 13.1] years), 
919 persons with a stroke died, 515 (56.0%) due to a cardiovascular cause. During 6.5 (± 4.7) 
years (median [5th – 95th percentile range]: 5.5 [0.6 – 15.8] years), 2,654 persons without a stroke 
died, 806 (30.4%) due to a cardiovascular cause. Mortality rates after stroke were highest in the 
first 30 days (2.56 events per person-year, 95% CI 2.22; 2.95) and remained stable after one year 
around 0.14 (95% CI 0.13; 0.15) events per person-year. These mortality rates were 51.7 (95% CI 
34.3; 78.0) times higher compared to the matched stroke-free group in the first 30 days and 
remained almost two times higher (Mortality rate ratio (MRR) 1.9, 95% CI 1.7; 2.1)) from 1 year 
onwards after the stroke (Figure 2). The increased risk of death in the first 30 days was mainly 
due to cardiovascular causes (MRR 183.7; 95% CI 81.7; 413.4) compared to the reference 
population). Similarly, the incr ased risk of death after 1 year was mainly due to cardiovascular 
causes (MRR 2.4, 95% CI 2.0; 2.9) compared to the reference population), but stroke patients 
also had a higher risk of non-cardiovascular deaths (MRR 1.6, 95% CI 1.4; 1.9) (Supplementary 
Figure I).  
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between men and women were calculated using the Chi-Square test. Interactions with sex 
were tested adding an interaction term of the dependent variable with sex.  
All analyses were performed using IRAP version 2.2 (US National Cancer Institute), IBM SPSS 
Statistics version 21.0 (IBM Corp., Armonk, NY) and SAS version 9.3 (SAS Institute Inc., Cary, NC). 
 
Results 
 
Characteristics of the study population  
Of the 14,235 participants at risk for stroke that were followed-up for a mean (±SD) of 9.6 (±6.0) 
years, 1,325 participants suffered a stroke. 1,243 of these participants had a center visit before 
the stroke. Due to old age, 6 of those participants could not be matched and another 8 stroke 
cases could only be matched to 1 or 2 stroke-free participants. Eventually we had 1,237 
participants with stroke and 4,928 participants without stroke eligible for analysis (Figure 1). 
Because peopl  could serve as control multiple times and could become case later in time, 
these control participants consisted out of 3,377 study participants. 2,079 were included only 
once, 1,298 were included multiple times, of which 378 became a case later in time.  
 
 
Figure 1. Study population  
*Consists of 3377 participants: 2079 were included only once, 1298 were included multiple times of 
which 378 became a case later in time. 
 
Mean age of persons with stroke was 79.9 (± 8.7) years, 60.4% was female, and 
cardiovascular risk factors were measured for a mean of 3.7 (± 3.2) years before stroke. Due to 
matching, these statistics were similar in persons without stroke (Table 1).  
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Table 1. Baseline characteristics 
 Persons with 
stroke 
N=1237 
Matched persons 
without stroke 
N=4928 
Age at index date (years) 79.9 (8.7) 79.8 (8.7) 
Time-interval between center visit and index date (years) 3.7 (3.2) 3.7 (3.4) 
Female 747 (60.4%) 2978 (60.4%) 
Hypertension 1007 (85.2%) 3653 (76.2%) 
Blood pressure-lowering medication 575 (47.7%) 1989 (41.3%) 
Cholesterol   
Hypercholesterolemia 443 (39.6%) 1913 (41.6%) 
Lipid-lowering medication 107 (9.6%) 486 (10.6%) 
Low HDL cholesterol 225 (19.9%) 771 (16.7%) 
Body mass index   
<18.5 9 (0.8%) 35 (0.8%) 
18.5-25 327 (30.1%) 1455 (32.5%) 
>=25 751 (69.1%) 2992 (66.8%) 
Diabetes mellitus 212 (18.7%) 525 (11.4%) 
Smoking   
Never 328 (29.3%) 1651 (36.3%) 
Past 515 (46.0%) 2197 (48.3%) 
Current 276 (24.7%) 698 (15.4%) 
TIA  194 (15.7%) 407 (8.3%) 
Atrial fibrillation 203 (18.4%) 484 (10.6%) 
Abbreviations: N = number of persons at risk; HDL = high-density lipoprotein; TIA = transient ischemic attack. 
Percentages are calculated without missing values.  
Data are presented as mean (standard deviations) or counts (percentages). 
 
M rtality rates 
During on average 3.8 (± 4.4) years (median [5th – 95th percentile range]: 2.3 [0 – 13.1] years), 
919 persons with a stroke died, 515 (56.0%) due to a cardiovascular cause. During 6.5 (± 4.7) 
years (median [5th – 95th percentile range]: 5.5 [0.6 – 15.8] years), 2,654 persons without a stroke 
died, 806 (30.4%) due to a cardiovascular cause. Mortality rates after stroke were highest in the 
first 30 days (2.56 events per person-year, 95% CI 2.22; 2.95) and remained stable after one year 
around 0.14 (95% CI 0.13; 0.15) events per person-year. These mortality rates were 51.7 (95% CI 
34.3; 78.0) times higher compared to the matched stroke-free group in the first 30 days and 
remained almost two times higher (Mortality rate ratio (MRR) 1.9, 95% CI 1.7; 2.1)) from 1 year 
onwards after the stroke (Figure 2). The increased risk of death in the first 30 days was mainly 
due to cardiovascular causes (MRR 183.7; 95% CI 81.7; 413.4) compared to the reference 
population). Similarly, the incr ased risk of death after 1 year was mainly due to cardiovascular 
causes (MRR 2.4, 95% CI 2.0; 2.9) compared to the reference population), but stroke patients 
also had a higher risk of non-cardiovascular deaths (MRR 1.6, 95% CI 1.4; 1.9) (Supplementary 
Figure I).  
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Abstract 
 
Background and purpose 
Improved survival after stroke has increased the necessity to understand factors that determine 
the risk of long-term clinical hazards after stroke, such as recurrent stroke and dementia. This 
risk may be largely influenced by exposure to cardiovascular risk factors before the initial stroke. 
Within the population-based Rotterdam Study, we determined the proportion of recurrent 
strokes and post-stroke dementia cases that are attributable to pre-stroke cardiovascular risk 
factors (i.e. the population attributable risk (PAR)). 
 
Methods  
We followed 1,237 first-ever stroke patients and 4,928 stroke-free participants, matched on age, 
sex, examination round, and stroke date (index date), for the occurrence of a new stroke or 
dementia. We calculated incidence rates in both groups using Poisson regression, and 
estimated the individual and combined PAR of pre-stroke cardiovascular risk factors (measured 
on average 4 years before stroke) for both outcomes.  
 
Results 
Short-term incidence rates of recurrent stroke and dementia were particularly high, but from 
one to ten years after stroke, stroke patients retained a threefold increased risk of recurrent 
stroke and an almost twofold increased risk of dementia compared to people without stroke. 
In total, 39% (95% CI 18%-66%) of recurrent strokes and 10% (95% CI 0%-91%) of post-stroke 
dementia cases were attributable to pre-stroke cardiovascular risk factors. These percentages 
were similar for first-ever stroke and dementia in the matched stroke-free population.  
 
Conclusions  
Long-term consequences of stroke are substantially influenced by pre-stroke risk factors, 
emphasizing the need for optimizing primary prevention. The search for other modifiable 
factors also needs to be continued. 
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Introduction  
 
Survival after stroke has improved over the last decades thanks to the implementation of 
thrombolysis, specialized stroke care units, and better secondary prevention.1-4 However, stroke 
is still notorious for its high risk of disability,5 and prolonged survival will lead to more people 
suffering from long-term hazard of stroke, such as recurrent stroke and dementia.6-8 In the first 
year after stroke, approximately 11.1% suffers a recurrent stroke and 7.4% suffers from 
dementia.7,9 Yet, the long-term risks of recurrent stroke and post-stroke dementia are not well 
documented, nor are the factors that determine this risk. 
So far, studies investigating risk factors of stroke outcomes have established that the risk of 
recurrent stroke is strongly determined by cardiovascular risk factors measured at time of 
stroke, whilst the risk of post-stroke dementia is driven by characteristics of the stroke itself (i.e. 
location and severity).9,10 Yet, it is important to note that risk factors that led to the initial stroke 
may also predispose to clinical adverse events occurring after stroke. Indeed, we previously 
showed that 27% of all deaths after stroke can be attributed to risk factors already present 
before stroke, i.e. hypertension and diabetes mellitus.11 A key consideration here is that 
measuring these factors after stroke can suffer from reverse causality, i.e. the levels of these 
factors may have changed due to the stroke and hence not reflect their long-term pre-stroke 
level.12-14 Therefore, studying the true contribution of pre-stroke pathology in post-stroke 
prognosis requires a population-based study with information on risk factors available prior to 
the stroke. This contribution can then be quantified using the population attributable risk, 
which informs about the proportion of incident outcome events that can be attributed to the 
risk factors under investigation.15 
Our study had two aims. First, to detect the excess risk of a new stroke and dementia in 
people with stroke compared to those without. Second, to investigate the role of pre-stroke 
cardiovascular risk factors on the occurrence of those diseases.  
 
Materials and methods 
 
Setting 
This study was conducted within the prospective population-based Rotterdam Study. Details 
regarding the objectives and design of the study have been described elsewhere.16  
The original cohort consisted of 7,983 participants aged 55 years and older. These 
participants were invited for a visit in 1990-1993, 1993-1995, 1997-1999, 2002-2004, and 2009-
2011. The cohort was extended with 3,011 participants in 2000. These participants were invited 
for a visit in 2000-2001, 2004-2005, and 2011-2012. In 2006 another 3,932 subjects were 
included, aged 45 years and older. They visited the center in 2006-2008. The Rotterdam Study 
has been approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry 
of Health, Welfare and Sport of the Netherlands, implementing the “Wet Bevolkingsonderzoek: 
ERGO (Population Studies Act: Rotterdam Study)”. All participants provided written informed 
consent to participate in the study and to obtain information from their treating physicians. 
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Study design  
Within the original cohort, we first defined an exposed group, including all participants who 
suffered an incident stroke. For this exposed group, the at risk time for a recurrent stroke and 
dementia started at the time of stroke. Then, we defined a non-exposed or stroke-free group, 
consisting of 4 participants per stroke patient, randomly matched to this patient on age (± 1 
year), sex, and visiting the same examination round, using an incidence density sampling 
approach.17 This non-exposed group was free of stroke at the stroke date of their matched 
stroke patient (index date) and their time at risk of stroke and dementia was from this index 
date onwards. Persons could be included as a non-exposed match for multiple stroke patients, 
and could become exposed themselves later on. Of note, this design is not a case-control study, 
but is actually a cohort study in which exposure is defined by incident stroke status, and 
matched individuals are subsequently followed in time for the outcome.11  
 
Study population 
After excluding participants with prevalent stroke (n=453) and those who refused informed 
consent for collection of follow-up information (n=238), 14,235 participants were followed for 
occurrence of stroke. After a mean (±SD) follow-up of 9.6 (±6.0) years, 1,325 participants 
suffered a stroke. We excluded 82 stroke patients because they lacked any pre-stroke center 
visit. Remaining 1,243 participants were eligible for the exposed group and matched to people 
who were non-exposed at their index date. Due to old age, 6 stroke patients could not be 
matched and 8 could only be matched to 1 or 2 stroke-free participants. Consequently, 1,237 
participants with stroke and 4,928 stroke-free participants were eligible for analysis. These non-
exposed participants consisted out of 3,377 study participants. 2,079 were included once, 1,298 
were included multiple times, of whom 378 became exposed later in time.11 
For the dementia analyses, we additionally excluded the participants with insufficient 
baseline or follow-up information (n=188), or with prevalent dementia (n=621). In the people 
with stroke 186 (15.8%) had prevalent dementia, in the people without stroke 435 (9.1%). In 
total, 993 dementia-free participants with stroke and 4,363 without stroke were eligible for 
analysis. 
 
Assessment of stroke  
History of stroke at baseline was assessed during the home interview and confirmed by 
reviewing medical records.18 From baseline onwards, participants were continuously followed-
up for occurrence of first-ever and recurrent stroke through automatic linkage between 
general practitioners’ medical records and the study database. In addition, nursing home 
physicians’ medical records and medical records from participants who moved out of the study 
district were checked on a regular basis. Additional information was obtained from hospital 
records. Potential strokes as identified in medical records were checked by research physicians 
and verified by an experienced vascular neurologist, in accordance with World Health 
Organization criteria.18,19 Follow-up for stroke was complete until January 1st 2012 for 96.3% of 
potential person-years. 
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Assessment of dementia 
For the detection of dementia we used the following 3-step protocol. Screening was done 
using the Mini-Mental State Examination (MMSE) and the Geriatric Mental Schedule (GMS) 
organic level. Screen-positives (MMSE<26 or GMS organic level >0) underwent an examination 
and informant interview with the Cambridge Examination for Mental Disorders in the Elderly. 
Participants suspected of dementia underwent further neuropsychological testing if necessary. 
Additionally, all participants were continuously followed for dementia, similar to the follow-up 
for stroke, by automatic linkage of the study database with medical records from general 
practitioners and the Regional Institute for Outpatient Mental Health Care. When clinical 
neuroimaging was available, it was used for decision-making on the diagnosis.20 The final 
diagnosis was determined by a consensus panel, led by a neurologist, in accordance with 
international criteria.21,22 Follow-up for dementia was complete until January 1st 2012 for 98.6% 
of potential person-years.  
 
Assessment of cardiovascular risk factors 
Pre-stroke cardiovascular risk factors were obtained from the patient’s most recent center date 
preceding the index date, with the use of interview, physical examinations, and laboratory 
examinations.23 For the matched stroke-free participants, these were obtained from the same 
center visit as their matched stroke patient. Information on medication use and smoking was 
assessed during the home interview. Body mass index was calculated as weight divided by 
length squared and categorized in underweight (<18.5 kg/m2), normal weight (18.5-25 kg/m2), 
and overweight (>25 kg/m2). Hypertension was defined as a blood pressure ≥140/90 mmHg 
and/or the use of blood pressure-lowering medication with the indication hypertension. 
Hypercholesterolemia was defined as a total cholesterol >6.2 mmol/L.24 A low high-density 
lipoprotein (HDL)-cholesterol was defined as a HDL-cholesterol ≤1.0 mmol/L.24 Diabetes 
mellitus was defined as a fasting glucose level ≥7.0 mmol/L, non-fasting glucose level ≥11.0 
mmol/L, or use of antidiabetic medication. In the second center visit (1993-1995) of the first 
cohort, we did not have information on cholesterol and diabetes mellitus status. In the fifth 
visit of the first cohort and the third visit of the second cohort (2011-2012) we did not have 
information about hypertension. Therefore, information on these missing values was carried 
forward from the preceding center visit.  
Occurrence of transient ischemic attacks (TIAs) and atrial fibrillation was assessed through 
active follow-up and verified by standardized definitions similar to the follow-up of stroke.25,26 
Therefore, presence of TIA or atrial fibrillation at any time before stroke was considered a pre-
stroke cardiovascular risk factor. However, follow-up for atrial fibrillation was only complete 
until 2010, which means that we missed people with atrial fibrillation after 2010.  
 
Statistical analysis 
The methods for statistical analysis used for this study were described in detail previously.11  
We used Poisson regression adjusted for age and sex to determine incidence rates of a new 
stroke and dementia in the group with stroke patients and the stroke-free group. Follow-up 
started at the index date.  
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physicians’ medical records and medical records from participants who moved out of the study 
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records. Potential strokes as identified in medical records were checked by research physicians 
and verified by an experienced vascular neurologist, in accordance with World Health 
Organization criteria.18,19 Follow-up for stroke was complete until January 1st 2012 for 96.3% of 
potential person-years. 
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Assessment of dementia 
For the detection of dementia we used the following 3-step protocol. Screening was done 
using the Mini-Mental State Examination (MMSE) and the Geriatric Mental Schedule (GMS) 
organic level. Screen-positives (MMSE<26 or GMS organic level >0) underwent an examination 
and informant interview with the Cambridge Examination for Mental Disorders in the Elderly. 
Participants suspected of dementia underwent further neuropsychological testing if necessary. 
Additionally, all participants were continuously followed for dementia, similar to the follow-up 
for stroke, by automatic linkage of the study database with medical records from general 
practitioners and the Regional Institute for Outpatient Mental Health Care. When clinical 
neuroimaging was available, it was used for decision-making on the diagnosis.20 The final 
diagnosis was determined by a consensus panel, led by a neurologist, in accordance with 
international criteria.21,22 Follow-up for dementia was complete until January 1st 2012 for 98.6% 
of potential person-years.  
 
Assessment of cardiovascular risk factors 
Pre-stroke cardiovascular risk factors were obtained from the patient’s most recent center date 
preceding the index date, with the use of interview, physical examinations, and laboratory 
examinations.23 For the matched stroke-free participants, these were obtained from the same 
center visit as their matched stroke patient. Information on medication use and smoking was 
assessed during the home interview. Body mass index was calculated as weight divided by 
length squared and categorized in underweight (<18.5 kg/m2), normal weight (18.5-25 kg/m2), 
and overweight (>25 kg/m2). Hypertension was defined as a blood pressure ≥140/90 mmHg 
and/or the use of blood pressure-lowering medication with the indication hypertension. 
Hypercholesterolemia was defined as a total cholesterol >6.2 mmol/L.24 A low high-density 
lipoprotein (HDL)-cholesterol was defined as a HDL-cholesterol ≤1.0 mmol/L.24 Diabetes 
mellitus was defined as a fasting glucose level ≥7.0 mmol/L, non-fasting glucose level ≥11.0 
mmol/L, or use of antidiabetic medication. In the second center visit (1993-1995) of the first 
cohort, we did not have information on cholesterol and diabetes mellitus status. In the fifth 
visit of the first cohort and the third visit of the second cohort (2011-2012) we did not have 
information about hypertension. Therefore, information on these missing values was carried 
forward from the preceding center visit.  
Occurrence of transient ischemic attacks (TIAs) and atrial fibrillation was assessed through 
active follow-up and verified by standardized definitions similar to the follow-up of stroke.25,26 
Therefore, presence of TIA or atrial fibrillation at any time before stroke was considered a pre-
stroke cardiovascular risk factor. However, follow-up for atrial fibrillation was only complete 
until 2010, which means that we missed people with atrial fibrillation after 2010.  
 
Statistical analysis 
The methods for statistical analysis used for this study were described in detail previously.11  
We used Poisson regression adjusted for age and sex to determine incidence rates of a new 
stroke and dementia in the group with stroke patients and the stroke-free group. Follow-up 
started at the index date.  
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Population attributable risks (PARs) with 95% confidence interval (CI) were calculated using 
the Interactive Risk Attributable Program (IRAP).27 A PAR adjusted for confounding is estimated 
by the following: 
PAR = 1 −   


  

| 
where 
| = Pr ( = 1| = ,  = )Pr ( = 1| = ,  = ) 
and 
 = Pr =  ,  =  = 1 
 
given D = 1 denoting presence of disease, X denoting exposure with i levels and C denoting a 
confounder with j levels. The hazard ratio’s (HRs) with 95% CI are based on a Poisson model. 
The proportional hazards assumption was checked by inspecting log minus log plots. We 
calculated the PAR for each risk factor separately and calculated the combined PAR. The 
combined PAR included the PARs of modifiable risk factors which were associated with an 
increased risk of recurrent stroke or dementia.28 We provide logit transformed 95% CI for the 
PARs as they are more easily interpretable and more stringent with regard to our combined 
PAR estimate.29 Because of small numbers, we did not explore the PAR for subtypes of stroke 
and dementia. Differences in prevalence of risk factors between participants with stroke and 
stroke-free participants and between men and women were calculated using the Chi-Square 
test. We explored potential effect modification by presence of stroke or sex by using an 
interaction term of the stroke or sex status with the potential risk factor.  
Information on cardiovascular risk factors was missing for up to 9.7% of cases, and imputed 
based on the other covariates using multiple imputation with 5 imputation sets. The mean of 
these 5 sets was used to implement in the Interactive Risk Attributable Program. In each model, 
we adjusted for age, sex, time between center date and index date, and for the categories of 
hypertension, cholesterol, HDL cholesterol, BMI, diabetes, smoking, and atrial fibrillation, if 
appropriate.  
All analyses were performed using IRAP version 2.2 (US National Cancer Institute), IBM SPSS 
Statistics version 21.0 (IBM Corp., Armonk, NY) and SAS version 9.3 (SAS Institute Inc., Cary, NC). 
 
Results 
 
Characteristics of the study population are reported in Table 1.  
 
The participants with stroke had a mean age of 79.9 (±8.7) years, 60.4% was female and 
cardiovascular risk factors were measured at a mean of 3.7 (±3.2) years before the stroke. Due 
to matching, these characteristics were similar in participants without stroke. 
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Table 1. Baseline characteristics 
  People with 
stroke 
N=1237 
 Matched people 
without stroke 
N=4928 
Age at index date (years)  79.9 (8.7)  79.8 (8.7) 
Time-interval between center visit and index date 
(years) 
 3.7 (3.2)  3.7 (3.4) 
Female  747 (60.4%)  2978 (60.4%) 
Hypertension  1007 (85.2%)  3653 (76.2%) 
Blood pressure-lowering medication  575 (47.7%)  1989 (41.3%) 
Cholesterol     
Hypercholesterolemia  443 (39.6%)  1913 (41.6%) 
Lipid-lowering medication  107 (9.6%)  486 (10.6%) 
Low HDL cholesterol  225 (19.9%)  771 (16.7%) 
Body mass index     
<18.5 kg/m2  9 (0.8%)  35 (0.8%) 
18.5-25 kg/m2  327 (30.1%)  1455 (32.5%) 
>=25 kg/m2  751 (69.1%)  2992 (66.8%) 
Diabetes mellitus  212 (18.7%)  525 (11.4%) 
Smoking     
Never  328 (29.3%)  1651 (36.3%) 
Past  515 (46.0%)  2197 (48.3%) 
Current  276 (24.7%)  698 (15.4%) 
TIA   194 (15.7%)  407 (8.3%) 
Atrial fibrillation  203 (18.4%)  484 (10.6%) 
Abbreviations: N = number of persons at risk; HDL = high-density lipoprotein; TIA = transient ischemic attack. 
Percentages are calculated without missing values.  
Data are presented as mean (standard deviations) or counts (percentages). 
 
Incidence rates  
A recurrent stroke occurred in 233 stroke patients during 4,085 person-years of follow-up 
(median [interquartile range]: 1.68 [0.12-5.00] years), and 520 stroke-free participants suffered a 
first-ever stroke during 30,710 person-years (median 5.22 [2.47-9.08] years). Of the stroke 
patients, 7.0% suffered a recurrent stroke in the first year, and 18% in the first ten years after 
stroke. Corresponding incidence rates, adjusted for age and sex, were 0.11 (95% CI 0.09; 0.13) 
per person-year for the first year and 0.07 (95% CI 0.06; 0.08) per person-year for the first ten 
years. Compared to the people without stroke, incidence rates in stroke patients were 5.67 
(95% CI 4.23; 7.61) times higher in the first year, particularly due to high rates in the first month, 
and subsequently declined. In year 1 to 10 incidence rates were 3.16 (95% CI 2.59; 3.85) times 
higher, but the difference between people with and without stroke was only significant in year 
1 to 5 (Figure 1).  
During 3,859 person-years of follow-up (median 2.41 [0.18-6.05] years), 146 stroke patients 
developed dementia, and during 27,670 person-years of follow-up (median 5.43 [2.59-9.14] 
years) 653 participants without stroke developed dementia. Of the stroke patients, 3.9% 
developed dementia in the first year after stroke, and 14.4% in the first 10 years after stroke. 
Corresponding incidence rates, adjusted for age and sex, were 0.05 (95% CI 0.04; 0.07) per 
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Incidence rates  
A recurrent stroke occurred in 233 stroke patients during 4,085 person-years of follow-up 
(median [interquartile range]: 1.68 [0.12-5.00] years), and 520 stroke-free participants suffered a 
first-ever stroke during 30,710 person-years (median 5.22 [2.47-9.08] years). Of the stroke 
patients, 7.0% suffered a recurrent stroke in the first year, and 18% in the first ten years after 
stroke. Corresponding incidence rates, adjusted for age and sex, were 0.11 (95% CI 0.09; 0.13) 
per person-year for the first year and 0.07 (95% CI 0.06; 0.08) per person-year for the first ten 
years. Compared to the people without stroke, incidence rates in stroke patients were 5.67 
(95% CI 4.23; 7.61) times higher in the first year, particularly due to high rates in the first month, 
and subsequently declined. In year 1 to 10 incidence rates were 3.16 (95% CI 2.59; 3.85) times 
higher, but the difference between people with and without stroke was only significant in year 
1 to 5 (Figure 1).  
During 3,859 person-years of follow-up (median 2.41 [0.18-6.05] years), 146 stroke patients 
developed dementia, and during 27,670 person-years of follow-up (median 5.43 [2.59-9.14] 
years) 653 participants without stroke developed dementia. Of the stroke patients, 3.9% 
developed dementia in the first year after stroke, and 14.4% in the first 10 years after stroke. 
Corresponding incidence rates, adjusted for age and sex, were 0.05 (95% CI 0.04; 0.07) per 
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person-year in the first year and 0.04 (95% CI 0.03; 0.04) per person-year in the first ten years. 
Compared to people without stroke, incidence rates in stroke patients were 3.32 (95% CI 2.26; 
4.87) times higher in the first year, particularly due to high rates in the first month. Following, 
incidence rates declined, but remained 1.73 (95% CI 1.38; 2.17) times increased in stroke 
patients versus those without in year 1 to 10 after stroke. This difference was only significant in 
year 1 to 5 (Figure 1). 
 
Figure 1. Rates of new stroke and dementia in participants with and without stroke at baseline  
Age- and sex adjusted incidence rates for a new stroke (upper panels) or dementia (lower panels), in the first 
year (left) or starting one year after baseline (right). Dotted lines represent 95% confidence intervals.  
 
 
Population attributable risk for recurrent stroke 
Participants with stroke had a worse cardiovascular profile than the participants without stroke, 
more people had hypertension, diabetes, a previous TIA, atrial fibrillation, and more people 
were current smokers (Table 2).  
Only underweight, diabetes mellitus, and a previous TIA conferred a significantly increased 
risk of recurrent stroke in stroke patients. In persons without stroke at the index date, 
hypertension, low HDL cholesterol, current smoking, TIA, and atrial fibrillation were associated 
with an increased risk of stroke. The total PAR for all risk factors combined was similar in people 
with stroke (0.39, 95% CI 0.18; 0.66) compared to those without (0.39, 95% CI 0.24; 0.57). In 
people with stroke main factors attributable to a new stroke were hypertension (PAR 0.22, 95% 
CI 0.06; 0.55), low HDL cholesterol (PAR 0.05, 95% CI 0.01; 0.20), diabetes (PAR 0.06, 95% CI 0.02; 
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0.16), smoking (PAR 0.08, 95% CI 0.004; 0.65) and a previous TIA (PAR 0.06, 95% CI 0.02; 0.16). In 
people without stroke the PARs of a low HDL cholesterol and a previous TIA were similar, the 
PARs of smoking and diabetes were lower, and the PARs of hypertension (PAR 0.30, 95% CI 0.18; 
0.45)) and atrial fibrillation (PAR 0.03, 95% CI 0.01; 0.09) were higher (Table 2).  
Stratified for sex, we found that pre-stroke cardiovascular risk factors had a stronger effect 
on recurrent strokes in women than in men. Diabetes had a significantly stronger effect, and 
hypertension and atrial fibrillation a borderline significantly stronger effect in women than 
men. For diabetes we also found an interaction with stroke in women: diabetes conferred a 
higher risk of a new stroke in women with stroke compared to those without. In total, women 
with stroke had a PAR of 0.59 (95% CI 0.33; 0.81), women without stroke of 0.43 (95% CI 0.27; 
0.60), men with stroke of 0.14 (95% CI 0.04; 0.40) and men without stroke 0.40 (95% CI 0.21; 0.62) 
(Supplementary Table I and II). 
 
Population attributable risk for dementia 
We found no significant associations of pre-stroke cardiovascular risk factors with dementia 
(Table 3). Additionally, the attributable risk of cardiovascular risk factors was low, namely 0.10 
(95% CI 0.001; 0.91) in people with stroke versus 0.09 (95% CI 0.02; 0.37) in those without. 
Although we did not find any statistically significant differences in hazard ratio’s between men 
and women for the risk of dementia, the attributable risk in men with stroke was 0.36 (95% CI 
0.05; 0.84), in men without stroke 0.47 (95% CI 0.19; 0.76), in women with stroke 0.10 (95% CI 
0.00; 0.74) and in women without stroke 0.10 (95% CI 0.01; 0.54). The higher attributable risk in 
men was particularly driven by hypertension (Supplementary Table III and IV). 
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hypertension and atrial fibrillation a borderline significantly stronger effect in women than 
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with stroke had a PAR of 0.59 (95% CI 0.33; 0.81), women without stroke of 0.43 (95% CI 0.27; 
0.60), men with stroke of 0.14 (95% CI 0.04; 0.40) and men without stroke 0.40 (95% CI 0.21; 0.62) 
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(Table 3). Additionally, the attributable risk of cardiovascular risk factors was low, namely 0.10 
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18 
person-year in the first year and 0.04 (95% CI 0.03; 0.04) per person-year in the first ten years. 
Compared to people without stroke, incidence rates in stroke patients were 3.32 (95% CI 2.26; 
4.87) times higher in the first year, particularly due to high rates in the first month. Following, 
incidence rates declined, but remained 1.73 (95% CI 1.38; 2.17) times increased in stroke 
patients versus those without in year 1 to 10 after stroke. This difference was only significant in 
year 1 to 5 (Figure 1). 
Figure 1. Rates of new stroke and dementia in participants with and without stroke at 
baselin   
Age- and sex adjusted incidence rates for a new stroke (upper panels) or dementia (lower 
panels), in the first year (left) or starting one year after baseline (rig t). Dotted lines represent 
95% confidence intervals.  
 
Population attributable risk for recurrent stroke 
Participants with stroke had a worse cardiovascular profile than the participants without stroke, 
more people had hypertension, diabetes, a previous TIA, atrial fibrillation, and more people 
were current smokers (Table 2).  
Only underweight, diabetes mellitus, and a previous TIA conferred a significantly increased 
risk of recurrent stroke in stroke patients. In persons without strok  at the index date, 
hypertension, low HDL cholesterol, current smoking, TIA, and atrial fibrillation were associated 
with n increased risk of stroke. The total PAR for all risk factors combined was similar in people 
with stroke (0.39, 95% CI 0.18; 0.66) compared to those without (0.39, 95% CI 0.24; 0.57). In 
people with stroke main factors attributable to a new stroke were hyp rtension (PAR 0.22, 95% 
CI 0.06; 0.55), low HDL cholesterol (PAR 0.05, 95% CI 0.01; 0.20), diabet s (PAR 0.06, 95% CI 0.02; 
Prestroke vascular pathology and the risk of recurrent stroke and post-stroke dementia 
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0.16), smoking (PAR 0.08, 95% CI 0.004; 0.65) and a previous TIA (PAR 0.06, 95% CI 0.02; 0.16). In 
people without stroke the PARs of a low HDL cholesterol and a previous TIA were similar, the 
PARs of smoking and diabetes were lower, and the PARs of hypertension (PAR 0.30, 95% CI 0.18; 
0.45)) and atrial fibrillation (PAR 0.03, 95% CI 0.01; 0.09) were higher (Table 2).  
Stratified for sex, we found that pre-stroke cardiovascular risk factors had a stronger effect 
on recurrent strokes in women than in men. Diabetes had a significantly stronger effect, and 
hypertension and atrial fibrillation a borderline significantly stronger effect in women than 
men. For diabetes we also found an interaction with stroke in women: diabetes conferred a 
higher risk of a new stroke in women with stroke compared to those without. In total, women 
with stroke had a PAR of .59 (95% CI 0.33; 0.81), women without stroke of 0.43 (95% CI 0.27; 
0.60), men with stroke of 0.14 (95% CI 0.04; 0.40) and men without stroke 0.40 (95% CI 0.21; 0.62) 
(Supplementary Table I and II). 
 
Population attributable risk for dementia 
We found no significant associations of pre-stroke cardiovascular risk factors with dementia 
(Table 3). Additionally, the attributable risk of cardiovascular risk factors was low, namely 0.10 
(95% CI 0.001; 0.91) in people with stroke versus 0.09 (95% CI 0.02; 0.37) in those without. 
Although we did not find any statistically significant differences in hazard ratio’s between men 
and women for the risk of dementia, the attributable risk in men wi h stroke was 0.36 (95% CI 
0.05; 0.84), in men without stroke 0.47 (95% CI 0.19; 0.76), in women with stroke 0.10 (95% CI 
0.00; 0.74) and in women without stroke 0.10 (95% CI 0.01; 0.54). The higher attributable risk in 
men was particularly driven by hypertension (Supplementary Table III and IV). 
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person-year in the first year and 0.04 (95% CI 0.03; 0.04) per person-year in the first ten years. 
Compared to people without stroke, incidence rates in stroke patients were 3.32 (95% CI 2.26; 
4.87) times higher in the first year, particularly due to high rates in the first month. Following, 
incidence rates declined, but remained 1.73 (95% CI 1.38; 2.17) times increased in stroke 
patients versus those without in year 1 to 10 after stroke. This difference was only significant in 
year 1 to 5 (Figure 1). 
Figure 1. Rates of new stroke and dementia in participants with and without stroke at 
baselin   
Age- and sex adjusted incidence rates for a new stroke (upper panels) or dementia (lower 
panels), in the first year (left) or starting one year after baseline (rig t). Dotted lines represent 
95% confidence intervals.  
 
Population attributable risk for recurrent stroke 
Participants with stroke had a worse cardiovascular profile than the participants without stroke, 
more people had hypertension, diabetes, a previous TIA, atrial fibrillation, and more people 
were current smokers (Table 2).  
Only underweight, diabetes mellitus, and a previous TIA conferred a significantly increased 
risk of recurrent stroke in stroke patients. In persons without strok  at the index date, 
hypertension, low HDL cholesterol, current smoking, TIA, and atrial fibrillation were associated 
with n increased risk of stroke. The total PAR for all risk factors combined was similar in people 
with stroke (0.39, 95% CI 0.18; 0.66) compared to those without (0.39, 95% CI 0.24; 0.57). In 
people with stroke main factors attributable to a new stroke were hyp rtension (PAR 0.22, 95% 
CI 0.06; 0.55), low HDL cholesterol (PAR 0.05, 95% CI 0.01; 0.20), diabet s (PAR 0.06, 95% CI 0.02; 
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0.16), smoking (PAR 0.08, 95% CI 0.004; 0.65) and a previous TIA (PAR 0.06, 95% CI 0.02; 0.16). In 
people without stroke the PARs of a low HDL cholesterol and a previous TIA were similar, the 
PARs of smoking and diabetes were lower, and the PARs of hypertension (PAR 0.30, 95% CI 0.18; 
0.45)) and atrial fibrillation (PAR 0.03, 95% CI 0.01; 0.09) were higher (Table 2).  
Stratified for sex, we found that pre-stroke cardiovascular risk factors had a stronger effect 
on recurrent strokes in women than in men. Diabetes had a significantly stronger effect, and 
hypertension and atrial fibrillation a borderline significantly stronger effect in women than 
men. For diabetes we also found an interaction with stroke in women: diabetes conferred a 
higher risk of a new stroke in women with stroke compared to those without. In total, women 
with stroke had a PAR of .59 (95% CI 0.33; 0.81), women without stroke of 0.43 (95% CI 0.27; 
0.60), men with stroke of 0.14 (95% CI 0.04; 0.40) and men without stroke 0.40 (95% CI 0.21; 0.62) 
(Supplementary Table I and II). 
 
Population attributable risk for dementia 
We found no significant associations of pre-stroke cardiovascular risk factors with dementia 
(Table 3). Additionally, the attributable risk of cardiovascular risk factors was low, namely 0.10 
(95% CI 0.001; 0.91) in people with stroke versus 0.09 (95% CI 0.02; 0.37) in those without. 
Although we did not find any statistically significant differences in hazard ratio’s between men 
and women for the risk of dementia, the attributable risk in men wi h stroke was 0.36 (95% CI 
0.05; 0.84), in men without stroke 0.47 (95% CI 0.19; 0.76), in women with stroke 0.10 (95% CI 
0.00; 0.74) and in women without stroke 0.10 (95% CI 0.01; 0.54). The higher attributable risk in 
men was particularly driven by hypertension (Supplementary Table III and IV). 
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Discussion 
 
We found that stroke patients remain on an increased risk of a new stroke and dementia up to 
at least 5 years after the stroke compared to people without stroke. Pre-stroke cardiovascular 
risk factors accounted for a large proportion of recurrent strokes (39%), driven by a particularly 
high proportion in women. In addition, they contributed to 10% of post-stroke dementia cases. 
These proportions were similar for first-ever stroke and dementia in stroke-free participants. 
Established cardiovascular risk factors for recurrent stroke are hypertension, previous 
symptomatic vascular disease, hypercholesterolemia, diabetes mellitus, smoking, and atrial 
fibrillation.10,30,31 Correspondingly, secondary prevention with blood pressure lowering, lipid 
lowering and antithrombotic therapy has shown a beneficial effect in clinical trials.4 Improved 
secondary prevention may explain why the long-term increased risk for a new stroke in stroke 
patients compared to stroke-free participants was only three-times increased in our study, 
compared to four to nine times in studies performed ten to twenty years earlier in time.32,33 A 
three-times increased risk is substantial nevertheless. Previously, we showed that pre-stroke 
cardiovascular risk factors contributed to 27% of deaths after stroke, suggesting that pre-stroke 
pathology plays a large role in the prognosis after stroke.11 In this study, we further expand on 
those findings by showing that pre-stroke cardiovascular risk factors contributed to 39% of 
recurrent strokes. These factors may have caused irreversible damage before the initial stroke 
and thus before secondary prevention started. However, it seems secondary prevention does 
have an effect in men, since the contribution of pre-stroke cardiovascular risk factors in men 
with stroke was smaller compared to those without. So another explanation may be that 
secondary prevention in women is not optimal yet.34 The attributable risk in women with stroke 
was 59% and higher than in stroke-free women. Factors that appeared to be particularly 
important in women were hypertension, smoking, and diabetes mellitus. The PAR is estimated 
based on a combination of prevalence and effect size. Women with stroke had a higher 
prevalence of those factors compared to women without. Additionally, diabetes mellitus even 
conferred a higher risk of a new stroke in women with stroke compared to those without. 
Possible explanations are that diabetes leads to more severe strokes35 or that diabetes leads to 
more lacunar strokes, which are known for their high recurrence rates.36 However, this requires 
further exploration.  
Regarding dementia, incidence rates of previous studies were heterogeneous, due to 
differences in study design, inclusion-, and exclusion criteria.9 Moreover, many studies on post-
stroke dementia were hospital-based and likely to be subject to attrition and selection bias.37,38 
The few available population-based studies determined that stroke increases the risk of 
dementia two-fold.9 We extended these findings by showing that this increased risk remained 
up to five years after stroke. Although post-stroke dementia often has a vascular component,39 
previous studies only identified diabetes mellitus and atrial fibrillation as risk factors.9,40 A bigger 
role was determined for stroke severity and subclinical cerebrovascular disease.9,40 Although we 
expected that those factors might be mediators in the association between pre-stroke risk 
factors and post-stroke dementia, this was unlikely considering the low PAR for pre-stroke 
cardiovascular risk factors we observed. The low PAR might be the consequence of competing 
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risks. Dementia has a long preclinical phase and since pre-stroke cardiovascular risk factors are 
also related to a high risk of dying, people with many risk factors may not survive long enough 
to develop dementia.  
Our findings also underline the importance of the identification of novel modifiable factors 
for both recurrent stroke and dementia. These may include genetic factors, novel biomarkers, 
presence of pre-stroke subclinical vascular disease, or response to treatment.40,41  
Strengths of our study are the population-based setting, the long follow-up, the availability 
of cardiovascular risk factors measured before time of stroke, and the thorough follow-up for 
first-ever stroke, recurrent stroke and dementia. We also acknowledge that several 
considerations need to be taken into account for a proper interpretation of the PAR in our 
study. The PAR is often interpreted as the percentage of cases that can be prevented if risk 
factors under study were to be eliminated. On the one hand, the PAR assumes that risk factors 
are entirely modifiable and preventable and that elimination of the risk factors will completely 
reduce the harmful effect. However, in the real world risk factors may have caused irreversible 
damage over the course of years before start of any preventive treatment, which may thus lead 
to an overestimation of the PAR.42,43 On the other hand, in our study we only estimated the 
effect that removal of a risk factor will have on clinical events after the stroke, while assuming 
that the stroke will still occur. However, in practice removal of a risk factor may also prevent 
stroke itself, irrespective of any clinical events after the stroke.42 In turn, prevention of stroke will 
additionally reduce the burden of post-stroke events. Therefore, the PAR in our study may be 
an underestimate of the actual percentage that can be prevented. A limitation of our study is 
that we were unable to implement the long-term effect of risk factors. This could have led to 
an underestimation of the true attributable risk. Moreover, 6.2% of the population did not visit 
the research center before the stroke, this could have led to selection bias if they were less 
healthy.  
 
In conclusion, patients with stroke suffer at least five years a three-times increased risk of a new 
stroke and an almost doubled risk of dementia compared to people without stroke. Pre-stroke 
cardiovascular risk factors contribute to 39% of recurrent strokes, mainly apparent in women. 
Additionally, they contribute to 10% of post-stroke dementia cases. This emphasizes the need 
of optimizing primary prevention. At the same time, our results encourage exploration of other 
potentially modifiable factors.  
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0.16), smoking (PAR 0.08, 95% CI 0.004; 0. 5) and a previous TIA (PAR 0.06, 95% CI 0.02; 0.16). In 
people without stroke the PARs of a low HDL cholesterol and a previous TIA were similar, the 
PARs of smoking and diabetes were lower, and the PARs of hypertension (PAR 0.30, 95% CI 0.18; 
0.45)) and atrial fibrillation (PAR 0.03, 95% CI 0.01; 0.09) were higher (Table 2).  
Stratified for sex, we found that pre-stroke cardiovascular risk factors had a stronger effect 
on recurrent strokes in women than in men. Diabetes had a significantly stronger effect, and 
hypertension and atrial fibrillation a borderline significantly stronger effect in women than 
men. For diabetes we also found an interaction with stroke in women: diabetes conferred a 
higher risk of a new stroke in women with stroke compared to those without. In total, women 
with stroke had a PAR of 0.59 (95% CI 0.33; 0.81), women without stroke of 0.43 (95% CI 0.27; 
0.60), men with stroke of 0.14 (95% CI 0.04; 0.40) and men without strok  0.40 (95% CI 0.21; 0.62) 
(Supplementary Table I and II). 
 
Population attributable risk for dementia 
We found no significant associations of pre-stroke cardiovascular risk factors with dementia 
(Table 3). Additionally, the attributable risk of cardiovascular risk factors was low, namely 0.10 
(95% CI 0.001; 0.91) in people with stroke versus 0.09 (95% CI 0.02; 0.37) in those without. 
Although we did not find any statistically significant differences in hazard ratio’s between men 
and women for the risk of dementia, the attributable risk in men with strok  was 0.36 (95% CI 
0.05; 0.84), in men without stroke 0.47 (95% CI 0.19; 0.76), in women with stroke 0.10 (95% CI 
0.00; 0.74) and in women without stroke 0.10 (95% CI 0.01; 0.54). The higher attributable risk in 
men was particularly driven by hypertension (Supplementary Table III and IV). 
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0.16), smoking (PAR 0.08, 95% CI 0.004; 0. 5) and a previous TIA (PAR 0.06, 95% CI 0.02; 0.16). In 
people without stroke the PARs of a low HDL cholesterol and a previous TIA were similar, the 
PARs of smoking and diabetes were lower, and the PARs of hypertension (PAR 0.30, 95% CI 0.18; 
0.45)) and atrial fibrillation (PAR 0.03, 95% CI 0.01; 0.09) were higher (Table 2).  
Stratified for sex, we found that pre-stroke cardiovascular risk factors had a stronger effect 
on recurrent strokes in women than in men. Diabetes had a significantly stronger effect, and 
hypertension and atrial fibrillation a borderline significantly stronger effect in women than 
men. For diabetes we also found an interaction with stroke in women: diabetes conferred a 
higher risk of a new stroke in women with stroke compared to those without. In total, women 
with stroke had a PAR of 0.59 (95% CI 0.33; 0.81), women without stroke of 0.43 (95% CI 0.27; 
0.60), men with stroke of 0.14 (95% CI 0.04; 0.40) and men without strok  0.40 (95% CI 0.21; 0.62) 
(Supplementary Table I and II). 
 
Population attributable risk for dementia 
We found no significant associations of pre-stroke cardiovascular risk factors with dementia 
(Table 3). Additionally, the attributable risk of cardiovascular risk factors was low, namely 0.10 
(95% CI 0.001; 0.91) in people with stroke versus 0.09 (95% CI 0.02; 0.37) in those without. 
Although we did not find any statistically significant differences in hazard ratio’s between men 
and women for the risk of dementia, the attributable risk in men with strok  was 0.36 (95% CI 
0.05; 0.84), in men without stroke 0.47 (95% CI 0.19; 0.76), in women with stroke 0.10 (95% CI 
0.00; 0.74) and in women without stroke 0.10 (95% CI 0.01; 0.54). The higher attributable risk in 
men was particularly driven by hypertension (Supplementary Table III and IV). 
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1  
person-year in the first year and 0.04 (95% CI 0.03; 0.04) per person-year in the first ten years. 
Compared to people without stroke, incidence rates in stroke patients were 3.32 (95% CI 2.26; 
4.87) times higher in the first year, particularly due to high rates in the first month. Following, 
incidence rates declined, but remained 1.73 (95% CI 1.38; 2.17) time  increased in stroke 
patients v rsus those without in year 1 to 10 after stroke. This difference was only significant in 
year 1 to 5 (Figure 1). 
Figure 1. Rates of new stroke and dementia in participants with and without stroke at 
baseline  
Age- and sex adjusted incidence rates for a new stroke (upper panels) or dementia (lower 
panels), in the first year (left) or starting one year after baseline (right). Dotted lines represent 
95% confidence intervals.  
 
Population attributable risk for recurrent stroke 
Participants with stroke had a worse cardiovascular profile than the participants without stroke, 
more people had hypertension, diabetes, a previous TIA, atrial fibrillation, and more people 
were current smokers (Table 2).  
Only underweight, diabetes mellitus, and a previous TIA conferred a significa tly increased 
risk of recurrent stroke in stroke patients. In persons without stroke at the index date, 
hypertension, low HDL cholesterol, current smoking, TIA, and atrial fibrillation were associated 
with an increased risk of stroke. The total PAR for all risk factors combined was similar in people 
with stroke (0.39, 95% CI 0.18; 0.66) compared to those without (0.39, 95% CI 0.24; 0.57). In 
people with stroke main factors attributable to a new stroke were hypertension (PAR 0.22, 95% 
CI 0.06; 0.55), low HDL cholesterol (PAR 0.05, 95% CI 0.01; 0.20), diabetes (PAR 0.06, 95% CI 0.02; 
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0.16), smoking (PAR 0.08, 95% CI 0.004; 0.65) and a previous TIA (PAR 0.06, 95% CI 0.02; 0.16). In 
people without stroke the PARs of a low HDL cholesterol and a previous TIA were similar, the 
PARs of smoking and diabetes were lower, and the PARs of hypertension (PAR 0.30, 95% CI 0.18; 
0.45)) and atrial fibrillation (PAR 0.03, 95% CI 0.01; 0.09) were higher (Table 2).  
Stratified for sex, we found that pre-stroke cardiovascular risk factors had a stronger effect 
on recurrent strokes in women than in men. Diabetes had a significantly stronger effect, and 
hypertension and atrial fibrillation a borderline significantly stronger effect in women than 
men. For diabetes we also found an interaction with stroke in women: diabetes conferred a 
higher risk of a new stroke in women with stroke compared to those without. In total, women 
with stroke had a PAR of 0.59 (95% CI 0.33; 0.8 ), women without stroke of 0.43 (95% CI 0.27; 
0.60), men with stroke of 0.14 (95% CI 0.04; 0.40) and men without stroke 0.40 (95% CI 0.21; 0.62) 
(Supplementary Table I and II). 
 
Population attributable risk for dementia 
We found no significant associations of pre-stroke cardiovascular risk factors with dementia 
(Table 3). Additionally, the attributable risk of cardiovascul r risk factors was low, namely 0.10 
(95% CI 0.001; 0.91) in people with stroke versus 0.09 (95% CI 0.02; 0.37) in those without. 
Although we did not find any statistically significant differences in hazard ratio’s between men 
and women for the risk of dementia, the attributable risk in men with stroke was 0.36 (95% CI 
0.05; 0.84), in men without stroke 0.47 (95% CI 0.19; 0.76), in women with stroke 0.10 (95% CI 
0.00; 0.74) and in women without stroke 0.10 (95% CI 0.01; 0.54). The higher attributable risk in 
men was particularly driven by hypertension (Supplementary Table III and IV). 
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person-year in the first year and 0.04 (95% CI 0.03; 0.04) per person-year in the first ten years. 
Compared to people without stroke, incidence rates in stroke patients were 3.32 (95% CI 2.26; 
4.87) times higher in the first year, particularly due to high rates in the first month. Following, 
incidence rates declined, but remained 1.73 (95% CI 1.38; 2.17) time  increased in stroke 
patients v rsus those without in year 1 to 10 after stroke. This difference was only significant in 
year 1 to 5 (Figure 1). 
Figure 1. Rates of new stroke and dementia in participants with and without stroke at 
baseline  
Age- and sex adjusted incidence rates for a new stroke (upper panels) or dementia (lower 
panels), in the first year (left) or starting one year after baseline (right). Dotted lines represent 
95% confidence intervals.  
 
Population attributable risk for recurrent stroke 
Participants with stroke had a worse cardiovascular profile than the participants without stroke, 
more people had hypertension, diabetes, a previous TIA, atrial fibrillation, and more people 
were current smokers (Table 2).  
Only underweight, diabetes mellitus, and a previous TIA conferred a significa tly increased 
risk of recurrent stroke in stroke patients. In persons without stroke at the index date, 
hypertension, low HDL cholesterol, current smoking, TIA, and atrial fibrillation were associated 
with an increased risk of stroke. The total PAR for all risk factors combined was similar in people 
with stroke (0.39, 95% CI 0.18; 0.66) compared to those without (0.39, 95% CI 0.24; 0.57). In 
people with stroke main factors attributable to a new stroke were hypertension (PAR 0.22, 95% 
CI 0.06; 0.55), low HDL cholesterol (PAR 0.05, 95% CI 0.01; 0.20), diabetes (PAR 0.06, 95% CI 0.02; 
Prestroke vascular pathology and the risk of recurrent stroke and post-stroke dementia 
1  
0.16), smoking (PAR 0.08, 95% CI 0.004; 0.65) and a previous TIA (PAR 0.06, 95% CI 0.02; 0.16). In 
people without stroke the PARs of a low HDL cholesterol and a previous TIA were similar, the 
PARs of smoking and diabetes were lower, and the PARs of hypertension (PAR 0.30, 95% CI 0.18; 
0.45)) and atrial fibrillation (PAR 0.03, 95% CI 0.01; 0.09) were higher (Table 2).  
Stratified for sex, we found that pre-stroke cardiovascular risk factors had a stronger effect 
on recurrent strokes in women than in men. Diabetes had a significantly stronger effect, and 
hypertension and atrial fibrillation a borderline significantly stronger effect in women than 
men. For diabetes we also found an interaction with stroke in women: diabetes conferred a 
higher risk of a new stroke in women with stroke compared to those without. In total, women 
with stroke had a PAR of 0.59 (95% CI 0.33; 0.8 ), women without stroke of 0.43 (95% CI 0.27; 
0.60), men with stroke of 0.14 (95% CI 0.04; 0.40) and men without stroke 0.40 (95% CI 0.21; 0.62) 
(Supplementary Table I and II). 
 
Population attributable risk for dementia 
We found no significant associations of pre-stroke cardiovascular risk factors with dementia 
(Table 3). Additionally, the attributable risk of cardiovascul r risk factors was low, namely 0.10 
(95% CI 0.001; 0.91) in people with stroke versus 0.09 (95% CI 0.02; 0.37) in those without. 
Although we did not find any statistically significant differences in hazard ratio’s between men 
and women for the risk of dementia, the attributable risk in men with stroke was 0.36 (95% CI 
0.05; 0.84), in men without stroke 0.47 (95% CI 0.19; 0.76), in women with stroke 0.10 (95% CI 
0.00; 0.74) and in women without stroke 0.10 (95% CI 0.01; 0.54). The higher attributable risk in 
men was particularly driven by hypertension (Supplementary Table III and IV). 
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person-year in the first year and 0.04 (95% CI 0.03; 0.04) per person-year in the first ten years. 
Compared to people without stroke, incidence rates in stroke patients were 3.32 (95% CI 2.26; 
4.87) times higher in the first year, particularly due to high rates in the first month. Following, 
incidence rates declined, but remained 1.73 (95% CI 1.38; 2.17) times increased in stroke 
patients versus those without in year 1 to 10 after stroke. This difference was only significant in 
year 1 to 5 (Figure 1). 
Figure 1. Rates of new stroke and dementia in participants with and without stroke at 
baseline  
Age- and sex adjusted incidence rates for a new stroke (upper panels) or dementia (lower 
panels), in the first year (left) or starting one year after b seline (right). Dotted lines represent 
95% confidence intervals.  
 
Population attributable risk for recurrent stroke 
Participants with stroke had a worse cardiovascular profile than the participants without stroke, 
more people had hypertension, diabetes, a previous TIA, atrial fibrillation, a d more people 
were current smokers (Table 2).  
Only underweight, diabetes mellitus, and a previous TIA conferred a sig ificantly increased 
risk of recurrent stroke in stroke patients. In persons without stroke at the index date, 
hypertension, low HDL cholesterol, current smoking, TIA, and atrial fibrillation were associated 
with an increased risk of stroke. The total PAR for all risk factors co bined was similar in people 
with stroke (0.39, 95% CI 0.18; 0.66) compared to those without (0.39, 95% CI 0.24; 0.57). In 
people with stroke main factors attributable to a new stroke were hypertension (PAR 0.22, 95% 
CI 0.06; 0.55), low HDL cholesterol (PAR 0.05, 95% CI 0.01; 0.20), diab tes (PAR 0.06, 95% CI 0.02; 
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person-year in the first year and 0.04 (95% CI 0.03; 0.04) per person-year in the first ten years. 
Compared to people without stroke, incidence rates in stroke patients were 3.32 (95% CI 2.26; 
4.87) times higher in the first year, particularly due to high rates in the first month. Following, 
incidence rates declined, but remained 1.73 (95% CI 1.38; 2.17) times increased in stroke 
patients versus those without in year 1 to 10 after stroke. This difference was only significant in 
year 1 to 5 (Figure 1). 
Figure 1. Rates of new stroke and dementia in participants with and without stroke at 
baseline  
Age- and sex adjusted incidence rates for a new stroke (upper panels) or dementia (lower 
panels), in the first year (left) or starting one year after b seline (right). Dotted lines represent 
95% confidence intervals.  
 
Population attributable risk for recurrent stroke 
Participants with stroke had a worse cardiovascular profile than the participants without stroke, 
more people had hypertension, diabetes, a previous TIA, atrial fibrillation, a d more people 
were current smokers (Table 2).  
Only underweight, diabetes mellitus, and a previous TIA conferred a sig ificantly increased 
risk of recurrent stroke in stroke patients. In persons without stroke at the index date, 
hypertension, low HDL cholesterol, current smoking, TIA, and atrial fibrillation were associated 
with an increased risk of stroke. The total PAR for all risk factors co bined was similar in people 
with stroke (0.39, 95% CI 0.18; 0.66) compared to those without (0.39, 95% CI 0.24; 0.57). In 
people with stroke main factors attributable to a new stroke were hypertension (PAR 0.22, 95% 
CI 0.06; 0.55), low HDL cholesterol (PAR 0.05, 95% CI 0.01; 0.20), diab tes (PAR 0.06, 95% CI 0.02; 
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Abstract 
 
Background and purpose 
Higher education is associated with a lower risk of dementia, possibly because of a higher 
tolerance to subclinical neurodegenerative pathology. Whether higher education also protects 
against dementia after clinical stroke or transient ischemic attack (TIA) remains unknown. 
 
Methods  
Within the population-based Rotterdam Study, 12,561 participants free of stroke, TIA, and 
dementia were followed for occurrence of stroke, TIA and dementia. Across the levels of 
education, associations of incident stroke or TIA with subsequent development of dementia, 
and differences in cognitive decline following stroke or TIA, were investigated. 
 
Results 
During 124,862 person-years, 1,463 persons suffered a stroke or TIA, 1,158 persons developed 
dementia, of whom 186 developed dementia after stroke or TIA. Risk of dementia after a stroke 
or TIA compared to no stroke or TIA, was highest in the low education category, HR 1.46 (95% 
CI 1.18; 1.81), followed by intermediate education, HR 1.36 (95% CI 1.03; 1.81). No significant 
association was observed in high education category, HR 0.62 (95% CI 0.25; 1.54). In gender 
stratified analyses, decrease in risk of dementia with increasing education was significant only 
in men.  
 
Conclusion 
Higher education is associated with a lower risk of dementia after stroke or TIA, particularly in 
men, which might be explained by a higher cognitive reserve. 
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Introduction 
 
Higher education is associated with a lower risk of dementia, which is thought to be explained 
by a higher cognitive reserve.1,2 The cognitive reserve hypothesis postulates that people with 
a higher reserve can tolerate more neurodegenerative pathology and maintain brain function 
for longer than people with low reserve, before the damage manifests clinically as dementia.3-
5 In the context of Alzheimer’s disease, people with higher cognitive reserve can have more 
senile plaques and amyloid- β deposits before the disease manifests clinically.6-9 
Although vascular disease is also an important risk factor for dementia including 
Alzheimer’s disease,10 it is less known if people with higher education, and thus more cognitive 
reserve, can also tolerate more cerebrovascular damage before dementia occurs. Evidence 
does suggest, however, that subclinical vascular lesions such as white matter lesions11 or silent 
brain infarcts12 result in less cognitive decline in people with higher education. Since clinical 
cerebrovascular events such as stroke and transient ischemic attack (TIA) are related to more 
tissue damage than silent lesions,13 it remains to be established whether higher education also 
protects against dementia after clinical events. More importantly, stroke and TIA have a high 
clinical impact and may lead to considerable morbidity, which is further aggravated by 
sequelae like dementia.14,15 Hence, identification of (modifiable) factors that act as protectors 
against dementia following a stroke or TIA is of major public health and clinical importance. 
Finally, given the differences in risk factors,16 education categories,17 and incidence of stroke 
and dementia in men and women,18,19 the association between stroke or TIA and consequent 
dementia across education categories needs to be explored for sex differences.   
Therefore, in this population-based study we investigated whether educational level used 
as a marker of cognitive reserve, is associated with a lower risk of dementia after a stroke or TIA. 
We also examined differences in cognitive decline after a stroke or TIA across levels of 
education. 
 
Materials and Methods 
 
Setting and study population 
This study was part of the population-based Rotterdam Study.20 In 1990, 7,983 persons aged 55 
years and older were recruited. In 2000, the cohort was expanded by 3,011 persons aged 55 
and older, and in 2006 in a second expansion wave, an additional 3,932 persons aged 45 and 
older were added. Of these total 14,926 participants, 527 with prevalent dementia, and 902 
with insufficient baseline information for dementia or no consent for the follow-up of stroke, 
TIA or dementia were excluded. We also excluded 354 persons with prevalent stroke, 324 with 
prevalent TIA, and 258 with missing education information, resulting in 12,561 participants 
eligible for the analyses of incident dementia.  
For the analyses of cognition, only participants who suffered a stroke or TIA between the 
two follow-up rounds in 2004-2008 and 2009-2013 were eligible, as these rounds comprised 
the most comprehensive cognitive test battery. In these examination rounds, 7,039 persons 
participated, of which 34 participants with no consent for collection of follow-up data, 435 
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participants with prevalent stroke or TIA at the first test date, 3 participants with prevalent 
dementia, 80 participants with insufficient information for dementia at the first test date, and 
83 with missing data on education were excluded. Of the remaining 6,404 participants, 5,588 
had at least one cognitive test in both follow-up rounds. 205 of these participants suffered a 
stroke or TIA between the two follow-up rounds and were therefore eligible for analyses. 
The Rotterdam Study is approved by the Medical Ethics Committee of the Erasmus MC and 
by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the “Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. A written informed 
consent was obtained from all participants. 
 
Educational level as a measure of cognitive reserve  
Educational level as marker of cognitive reserve can be measured based on years of education 
or degree of literacy. We used the latter since it measures educational attainment more directly 
and might therefore be a better marker of cognitive reserve.21 Participants were classified as 
having low (primary, unfinished secondary, and lower vocational), intermediate (secondary or 
intermediate vocational), or high education (higher vocational or university).  
 
Assessment of stroke and TIA 
At baseline, history of stroke and TIA was assessed using home interviews and verified using 
medical records. From baseline onwards, participants were continuously followed-up for 
occurrence of stroke and TIA through a computerized linkage between the study database and 
medical records of general practitioners (GPs). This data linkage system is highly efficient in the 
Dutch situation where the GPs receive all medical information about their patients if they 
contact any medical caregiver or professional, including specialists. Additionally, nursing home 
physicians’ files and files from GPs of participants that moved out of the study area were 
checked on a regular basis. Information from GPs and hospital records was collected from 
participants with a potential stroke or TIA. Research physicians reviewed the information and 
an experienced vascular neurologist verified the strokes according to World Health 
Organization criteria.22,23 We defined TIAs as temporary attacks with presence of focal 
symptoms, which are attributable to dysfunction of one arterial territory of the brain.24 Follow-
up for stroke and TIA was complete until 2013 for 98.5% of potential person-years.25 
 
Assessment of dementia 
Participants were screened for dementia at baseline and follow-up examinations using a three-
step protocol.26 First, screening was done using the Mini-Mental State Examination (MMSE)27 
and the Geriatric Mental Schedule (GMS) organic level. Second, screen-positives (MMSE < 26 
or GMS organic level > 0) subsequently underwent an examination and informant interview 
with the Cambridge Examination for Mental Disorders in the Elderly (CAMDEX). Participants 
who were suspected of having dementia, underwent if necessary, further neuropsychological 
testing. Additionally, the total cohort was continuously monitored for dementia through 
computerized linkage between the study database and digitized medical records from GPs and 
the Regional Institute for Outpatient Mental Health Care. Third, a consensus panel led by a 
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neurologist decided on the final diagnosis in accordance with standard criteria using the DSM-
III-R criteria for dementia, the NINCDS-ADRDA for Alzheimer disease,28 and the NINCDS-AIREN 
criteria for vascular dementia.29 Follow-up for dementia was complete until 2013 for 98.4% of 
potential person-years.  
 
Cognitive tests 
From 2004-2008 and 2009-2013, participants underwent extensive cognitive testing. Executive 
function was assessed by the Stroop test (interference task) which tests attention and 
concentration, Letter-Digit Substitution Task which tests processing speed, and Verbal Fluency 
Test which assesses verbal fluency. Memory was assessed by the 15-Word verbal Learning test 
including both immediate and delayed recall. Fine motor skills and coordination was assessed 
by the Purdue pegboard test for both hands.30 A higher score indicates a better cognitive 
performance for all tests, except the Stroop test in which a higher score indicates a worse 
performance as it measures time to complete the task. 
 
Covariates 
Smoking habits and medication use were assessed during the home interview. Participants 
were categorized into current, former and never smokers. Body mass index was calculated as 
weight in kilograms/height in meters squared. Total cholesterol and high-density lipoprotein 
cholesterol were measured in serum in mmol/L. Blood pressure was measured twice at the 
right arm in sitting position at the research center and average of two blood pressure readings 
was used. Diabetes mellitus type 2 was diagnosed as fasting blood glucose ≥ 7.00 mmol/L, or 
use of anti-diabetic medication evaluated by interview and pharmacy records.31 Cognitive 
score was assessed using the Mini-Mental State Examination.27 Since the study population 
included 3 cohorts from the Rotterdam Study, cohort was also used as a covariate. 
 
Statistical analyses  
We examined the risk of dementia in people with stroke or TIA as compared to people without 
stroke or TIA using Cox proportional hazard models. Adherence to the proportional hazards 
assumption was tested by plotting smoothed Schoenfeld residuals against time; no violations 
of the assumption were identified. Stroke or TIA was used as time varying exposure, which took 
into account the incident cases of stroke or TIA as they occurred during follow-up. Participants 
were censored at date of dementia, date of death, or last date of follow-up, whichever came 
first. Subsequently, we examined this association across levels of education by stratifying on 
educational level as well as by including an interaction term. In secondary analyses, we 
examined this association in men and women separately since levels of education differ 
between older men and women, as well as their risk factors for stroke.16  
Subsequently, we tested whether education is associated with change in cognitive test 
scores after a stroke or TIA using linear regression models. This was conducted in a subgroup 
of participants with stroke or TIA, for which cognitive test scores were available both before 
and after the stroke or TIA. Using low education level as the reference, we first examined the 
association of education with cognitive test scores before stroke or TIA. Second, we examined 
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neurologist decided on the final diagnosis in accordance with standard criteria using the DSM-
III-R criteria for dementia, the NINCDS-ADRDA for Alzheimer disease,28 and the NINCDS-AIREN 
criteria for vascular dementia.29 Follow-up for dementia was complete until 2013 for 98.4% of 
potential person-years.  
 
Cognitive tests 
From 2004-2008 and 2009-2013, participants underwent extensive cognitive testing. Executive 
function was assessed by the Stroop test (interference task) which tests attention and 
concentration, Letter-Digit Substitution Task which tests processing speed, and Verbal Fluency 
Test which assesses verbal fluency. Memory was assessed by the 15-Word verbal Learning test 
including both immediate and delayed recall. Fine motor skills and coordination was assessed 
by the Purdue pegboard test for both hands.30 A higher score indicates a better cognitive 
performance for all tests, except the Stroop test in which a higher score indicates a worse 
performance as it measures time to complete the task. 
 
Covariates 
Smoking habits and medication use were assessed during the home interview. Participants 
were categorized into current, former and never smokers. Body mass index was calculated as 
weight in kilograms/height in meters squared. Total cholesterol and high-density lipoprotein 
cholesterol were measured in serum in mmol/L. Blood pressure was measured twice at the 
right arm in sitting position at the research center and average of two blood pressure readings 
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use of anti-diabetic medication evaluated by interview and pharmacy records.31 Cognitive 
score was assessed using the Mini-Mental State Examination.27 Since the study population 
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Statistical analyses  
We examined the risk of dementia in people with stroke or TIA as compared to people without 
stroke or TIA using Cox proportional hazard models. Adherence to the proportional hazards 
assumption was tested by plotting smoothed Schoenfeld residuals against time; no violations 
of the assumption were identified. Stroke or TIA was used as time varying exposure, which took 
into account the incident cases of stroke or TIA as they occurred during follow-up. Participants 
were censored at date of dementia, date of death, or last date of follow-up, whichever came 
first. Subsequently, we examined this association across levels of education by stratifying on 
educational level as well as by including an interaction term. In secondary analyses, we 
examined this association in men and women separately since levels of education differ 
between older men and women, as well as their risk factors for stroke.16  
Subsequently, we tested whether education is associated with change in cognitive test 
scores after a stroke or TIA using linear regression models. This was conducted in a subgroup 
of participants with stroke or TIA, for which cognitive test scores were available both before 
and after the stroke or TIA. Using low education level as the reference, we first examined the 
association of education with cognitive test scores before stroke or TIA. Second, we examined 
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the association of education with cognitive test scores after stroke or TIA. Third, the association 
of education with the change in cognitive tests scores after stroke or TIA was examined. This 
was tested by performing linear regression of education with cognitive test scores after stroke 
or TIA, adjusting for the test score before stroke or TIA. In these analyses, an interaction between 
cognitive performance and sex was also tested.  
Finally, we tested cognitive decline in persons with a stroke or TIA altogether, as compared 
to persons without a stroke or TIA, across levels of education. 
As sensitivity analyses, we repeated the dementia analyses combining the intermediate 
and high education categories. 
For all analyses, two models were fitted. Model 1 was adjusted for age and sex only (where 
applicable). Model 2 was additionally adjusted for education level (where applicable), body 
mass index, smoking, total and high-density lipoprotein cholesterol, systolic and diastolic blood 
pressure, lipid- and blood pressure-lowering medication, diabetes mellitus type 2, MMSE, and 
study cohort. The analyses of change in cognition were additionally adjusted for time between 
the two cognitive examinations. The dementia analyses were adjusted for covariates using 
their baseline values, while cognition analyses were adjusted using the values of covariates 
from the first visit of cognition assessment. Missing values on covariates (< 6%) were handled 
by multiple imputations. 
Data were analyzed using the Stata Software Version 13 (StataCorp, College Station, TX, 
USA) and IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
This study included 12,561 dementia-, TIA-, and stroke-free participants at baseline. Table 1 
summarizes baseline characteristics of the study population. People with higher education 
were younger and more frequently men. During a mean follow-up of 9.9 ± 5.2 years, 1,463 
persons suffered a stroke or TIA and 1,158 persons were diagnosed with dementia. Of these 
1,158, 186 persons developed dementia after a stroke or TIA. 
Differences in baseline characteristics of persons excluded and those included in the 
analyses are summarized in Supplementary Table I. 
 
Of the total 1,463 stroke cases or TIAs, the low education category had 449 (8.5%) stroke 
cases and 300 (5.7%) TIAs. The intermediate education category suffered 331 (6.2%) strokes and 
245 (4.6%) TIAs, whereas the high education category had 64 (3.3%) stroke cases and 74 (3.8%) 
TIAs. 
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Table 1. Baseline characteristics of the study population 
  Levels of education 
  Low  Intermediate  High 
Characteristics  N=5,299  N=5,342  N=1,920 
Age, years  67.8 (9.9)bc  63.3 (8.8)ac  60.0 (8.2)ab 
Women  3754 (70.8)bc  2838 (53.1)ac  735 (38.3)ab 
Study cohort       
First cohort  3463 (65.4)bc  2402 (45.0)ac  532 (27.7)ab 
Second cohort  910 (17.2)bc  1344 (25.2)ac  470 (24.5)ab 
Third cohort  926 (17.5)bc  1596 (29.9)ac  918 (47.8)ab 
Body mass index, kg/m2  27.2 (4.2)bc  26.8 (4.1)ac  26.5 (3.9)ab 
Smoking       
Never  1,993 (37.9)c  1,558 (29.3)c  539 (28.1)ab 
Former  2,018 (38.4)bc  2,459 (46.2)a  950 (49.6)a 
Current   1,247 (23.7)bc  1,301 (24.5)ac  428 (22.3)ab 
Total cholesterol, mmol/L  6.4 (1.3)bc  6.1 (1.2)ac  5.8 (1.2)ab 
High-density lipoprotein 
cholesterol, mmol/L 
 1.4 (0.4)bc  1.4 (0.4)ac  1.4 (0.4)ab 
Lipid lowering medication  409 (7.7)  556 (10.4)  222 (11.6) 
Systolic blood pressure, 
mmHg 
 139.8 (22.2)  137.3 (20.9)  135.3 (21.1) 
Diastolic blood pressure, 
mmHg 
 76.0 (12.0)bc  78.0 (11.6)ac  79.8 (11.7)ab 
Blood pressure lowering 
medication 
 1,313 (24.8)c  1,131 (21.2)  350 (18.3)a 
Mini Mental State 
Examination, points 
 27.2 (2.1)bc  28.2 (1.5)ac  28.6 (1.4)ab 
Diabetes mellitus type 2  417 (8.6)  390 (7.7)  107 (5.8) 
Abbreviations: N = number of persons included in study. 
Values are means (standard deviation) or counts (percentage). 
a Significantly different from people with low education (p<0.05), after age and sex adjustment - if applicable. 
b Significantly different from people with intermediate education (p<0.05), after age and sex adjustment - if 
applicable. 
c Significantly different from people with high education (p<0.05), after age and sex adjustment - if applicable. 
 
People with a stroke or TIA had an increased risk of dementia compared to participants 
without stroke or TIA (multivariable adjusted hazard ratio (HR) 1.42 (95% CI 1.20; 1.67)). In 
analyses stratified for education, this risk was highest in persons with low education, HR 1.46 
(95% CI 1.18; 1.81), followed by those with intermediate education, HR 1.36 (95% CI 1.03; 1.81). 
In the high education group, people with a stroke or TIA did not have an increased risk of 
dementia compared to people without a stroke or TIA, HR 0.62 (95% CI 0.25; 1.54) (Table 2). 
Stratification by gender showed a similar pattern of associations, which was more pronounced 
in men than in women (Table 3). Interaction testing of educational level with stroke or TIA on 
the risk of dementia yielded p-value 0.65 in the overall population, 0.05 in men, and 0.82 in 
women. 
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the association of education with cognitive test scores after stroke or TIA. Third, the association 
of education with the change in cognitive tests scores after stroke or TIA was examined. This 
was tested by performing linear regression of education with cognitive test scores after stroke 
or TIA, adjusting for the test score before stroke or TIA. In these analyses, an interaction between 
cognitive performance and sex was also tested.  
Finally, we tested cognitive decline in persons with a stroke or TIA altogether, as compared 
to persons without a stroke or TIA, across levels of education. 
As sensitivity analyses, we repeated the dementia analyses combining the intermediate 
and high education categories. 
For all analyses, two models were fitted. Model 1 was adjusted for age and sex only (where 
applicable). Model 2 was additionally adjusted for education level (where applicable), body 
mass index, smoking, total and high-density lipoprotein cholesterol, systolic and diastolic blood 
pressure, lipid- and blood pressure-lowering medication, diabetes mellitus type 2, MMSE, and 
study cohort. The analyses of change in cognition were additionally adjusted for time between 
the two cognitive examinations. The dementia analyses were adjusted for covariates using 
their baseline values, while cognition analyses were adjusted using the values of covariates 
from the first visit of cognition assessment. Missing values on covariates (< 6%) were handled 
by multiple imputations. 
Data were analyzed using the Stata Software Version 13 (StataCorp, College Station, TX, 
USA) and IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
Results 
 
This study included 12,561 dementia-, TIA-, and stroke-free participants at baseline. Table 1 
summarizes baseline characteristics of the study population. People with higher education 
were younger and more frequently men. During a mean follow-up of 9.9 ± 5.2 years, 1,463 
persons suffered a stroke or TIA and 1,158 persons were diagnosed with dementia. Of these 
1,158, 186 persons developed dementia after a stroke or TIA. 
Differences in baseline characteristics of persons excluded and those included in the 
analyses are summarized in Supplementary Table I. 
 
Of the total 1,463 stroke cases or TIAs, the low education category had 449 (8.5%) stroke 
cases and 300 (5.7%) TIAs. The intermediate education category suffered 331 (6.2%) strokes and 
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People with a stroke or TIA had an increased risk of dementia compared to participants 
without stroke or TIA (multivariable adjusted hazard ratio (HR) 1.42 (95% CI 1.20; 1.67)). In 
analyses stratified for education, this risk was highest in persons with low education, HR 1.46 
(95% CI 1.18; 1.81), followed by those with intermediate education, HR 1.36 (95% CI 1.03; 1.81). 
In the high education group, people with a stroke or TIA did not have an increased risk of 
dementia compared to people without a stroke or TIA, HR 0.62 (95% CI 0.25; 1.54) (Table 2). 
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Table 2. Risk of dementia after stroke or TIA by levels of education 
 Dementia 
   Model 1 Model 2 
 n/Na n/Nb HR (95% CI) HR (95% CI) 
Total population 1,158/12,561 186/1,463 1.40 (1.19; 1.65) 1.42 (1.20; 1.67) 
Strata of education     
Low education 732/5,299 112/749c 1.47 (1.19; 1.81) 1.46 (1.18; 1.81) 
Intermediate education 364/5,342 68/576c 1.38 (1.04; 1.82) 1.36 (1.03; 1.81) 
High education 62/1,920 6/138c 0.74 (0.31; 1.77) 0.62 (0.25; 1.54) 
     
p-value for interactiond   0.65 0.65 
Abbreviations: TIA = transient ischemic attack. 
Values are hazard ratios with 95% confidence intervals. 
Model 1: adjusted for age and sex. 
Model 2: adjusted for age, sex, education (where applicable), study cohort, Mini-Mental state Examination score, 
body mass index, smoking, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering medication use, 
systolic blood pressure, diastolic blood pressure, blood pressure-lowering medication use, and diabetes mellitus 
type 2. 
a n/N = number of dementia cases/total number of participants at risk for dementia. 
b n/N = number of dementia cases after stroke or TIA/total number of stroke or TIA. 
c Low education = 300 TIAs, 449 strokes; Intermediate education = 245 TIAs, 331 strokes; High education = 64 
TIAs, 74 strokes. 
d Interaction between presence of stroke or TIA and educational level for the risk of dementia. 
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Table 1. Baseline characteristics of the study population 
  Levels of education 
  Low  Intermediate  High 
Characteristics  N=5,299  N=5,342  N=1,920 
Age, years  67.8 (9.9)bc  63.3 (8.8)ac  60.0 (8.2)ab 
Women  3754 (70.8)bc  2838 (53.1)ac  735 (38.3)ab 
Study cohort       
First cohort  3463 (65.4)bc  2402 (45.0)ac  532 (27.7)ab 
Second cohort  910 (17.2)bc  1344 (25.2)ac  470 (24.5)ab 
Third cohort  926 (17.5)bc  1596 (29.9)ac  918 (47.8)ab 
Body mass index, kg/m2  27.2 (4.2)bc  26.8 (4.1)ac  26.5 (3.9)ab 
Smoking       
Never  1,993 (37.9)c  1,558 (29.3)c  539 (28.1)ab 
Former  2,018 (38.4)bc  2,459 (46.2)a  950 (49.6)a 
Current   1,247 (23.7)bc  1,301 (24.5)ac  428 (22.3)ab 
Total cholesterol, mmol/L  6.4 (1.3)bc  6.1 (1.2)ac  5.8 (1.2)ab 
High-density lipoprotein 
cholesterol, mmol/L 
 1.4 (0.4)bc  1.4 (0.4)ac  1.4 (0.4)ab 
Lipid lowering medication  409 (7.7)  556 (10.4)  222 (11.6) 
Systolic blood pressure, 
mmHg 
 139.8 (22.2)  137.3 (20.9)  135.3 (21.1) 
Diastolic blood pressure, 
mmHg 
 76.0 (12.0)bc  78.0 (11.6)ac  79.8 (11.7)ab 
Blood pressure lowering 
medication 
 1,313 (24.8)c  1,131 (21.2)  350 (18.3)a 
Mini Mental State 
Examination, points 
 27.2 (2.1)bc  28.2 (1.5)ac  28.6 (1.4)ab 
Diabetes mellitus type 2  417 (8.6)  390 (7.7)  107 (5.8) 
Abbreviations: N = number of persons included in study. 
Values are means (standard deviation) or counts (percentage). 
a Significantly different from people with low education (p<0.05), after age and sex adjustment - if applicable. 
b Significantly different from people with intermediate education (p<0.05), after age and sex adjustment - if 
applicable. 
c Significantly different from people with high education (p<0.05), after age and sex adjustment - if applicable. 
 
People with a stroke or TIA had an increased risk of dementia compared to participants 
without stroke or TIA (multivariable adjusted hazard ratio (HR) 1.42 (95% CI 1.20; 1.67)). In 
analyses stratified for education, this risk was highest in persons with low education, HR 1.46 
(95% CI 1.18; 1.81), followed by those with intermediat  education, HR 1.36 (95% CI 1.03; 1.81). 
In the high education group, people with a stroke or TIA did not have an increased risk of 
dementia compared to people without a stroke or TIA, HR 0.62 (95% CI 0.25; 1.54) (Table 2). 
Stratification by gender showed a similar pattern of associations, which was more pronounced 
in men than in women (Table 3). Interaction testing of educational level with stroke or TIA on 
the risk of dementia yielded p-value 0.65 in the overall population, 0.05 in men, and 0.82 in 
women. 
 
 
5Chapter 5.4 
238 
Table 2. Risk of dementia after stroke or TIA by levels of education 
 Dementia 
   Model 1 Model 2 
 n/Na n/Nb HR (95% CI) HR (95% CI) 
Total population 1,158/12,561 186/1,463 1.40 (1.19; 1.65) 1.42 (1.20; 1.67) 
Strata of education     
Low education 732/5,299 112/749c 1.47 (1.19; 1.81) 1.46 (1.18; 1.81) 
Intermediate education 364/5,342 68/576c 1.38 (1.04; 1.82) 1.36 (1.03; 1.81) 
High education 62/1,920 6/138c 0.74 (0.31; 1.77) 0.62 (0.25; 1.54) 
     
p-value for interactiond   0.65 0.65 
Abbreviations: TIA = transient ischemic attack. 
Values are hazard ratios with 95% confidence intervals. 
Model 1: adjusted for age and sex. 
Model 2: adjusted for age, sex, education (where applicable), study cohort, Mini-Mental state Examination score, 
body mass index, smoking, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering medication use, 
systolic blood pressure, diastolic blood pressure, blood pressure-lowering medication use, and diabetes mellitus 
type 2. 
a n/N = number of dementia cases/total number of participants at risk for dementia. 
b n/N = number of dementia cases after stroke or TIA/total number of stroke or TIA. 
c Low education = 300 TIAs, 449 strokes; Intermediate education = 245 TIAs, 331 strokes; High education = 64 
TIAs, 74 strokes. 
d Interaction between presence of stroke or TIA and educational level for the risk of dementia. 
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Table 1. Baseline characteristics of the study population 
  Levels of education 
  Low  Intermediate  High 
Characteristics  N=5,299  N=5,342  N=1,920 
Age, years  67.8 (9.9)bc  63.3 (8.8)ac  60.0 (8.2)ab 
Women  3754 (70.8)bc  2838 (53.1)ac  735 (38.3)ab 
Study cohort       
First cohort  3463 (65.4)bc  2402 (45.0)ac  532 (27.7)ab 
Second cohort  910 (17.2)bc  1344 (25.2)ac  470 (24.5)ab 
Third cohort  926 (17.5)bc  1596 (29.9)ac  918 (47.8)ab 
Body mass index, kg/m2  27.2 (4.2)bc  26.8 (4.1)ac  26.5 (3.9)ab 
Smoking       
Never  1,993 (37.9)c  1,558 (29.3)c  539 (28.1)ab 
Former  2,018 (38.4)bc  2,459 (46.2)a  950 (49.6)a 
Current   1,247 (23.7)bc  1,301 (24.5)ac  428 (22.3)ab 
Total cholesterol, mmol/L  6.4 (1.3)bc  6.1 (1.2)ac  5.8 (1.2)ab 
High-density lipoprotein 
cholesterol, mmol/L 
 1.4 (0.4)bc  1.4 (0.4)ac  1.4 (0.4)ab 
Lipid lowering medication  409 (7.7)  556 (10.4)  222 (11.6) 
Systolic blood pressure, 
mmHg 
 139.8 (22.2)  137.3 (20.9)  135.3 (21.1) 
Diastolic blood pressure, 
mmHg 
 76.0 (12.0)bc  78.0 (11.6)ac  79.8 (11.7)ab 
Blood pressure lowering 
medication 
 1,313 (24.8)c  1,131 (21.2)  350 (18.3)a 
Mini Mental State 
Examination, points 
 27.2 (2.1)bc  28.2 (1.5)ac  28.6 (1.4)ab 
Diabetes mellitus type 2  417 (8.6)  390 (7.7)  107 (5.8) 
Abbreviations: N = number of persons included in study. 
Values are means (standard deviation) or counts (percentage). 
a Significantly different from people with low education (p<0.05), after age and sex adjustment - if applicable. 
b Significantly different from people with intermediate education (p<0.05), after age and sex adjustment - if 
applicable. 
c Significantly different from people with high education (p<0.05), after age and sex adjustment - if applicable. 
 
People with a stroke or TIA had an increased risk of dementia compared to participants 
without stroke or TIA (multivariable adjusted hazard ratio (HR) 1.42 (95% CI 1.20; 1.67)). In 
analyses stratified for education, this risk was highest in persons with low education, HR 1.46 
(95% CI 1.18; 1.81), followed by those with intermediat  education, HR 1.36 (95% CI 1.03; 1.81). 
In the high education group, people with a stroke or TIA did not have an increased risk of 
dementia compared to people without a stroke or TIA, HR 0.62 (95% CI 0.25; 1.54) (Table 2). 
Stratification by gender showed a similar pattern of associations, which was more pronounced 
in men than in women (Table 3). Interaction testing of educational level with stroke or TIA on 
the risk of dementia yielded p-value 0.65 in the overall population, 0.05 in men, and 0.82 in 
women. 
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People with high education scored better on 15-Word verbal learning test (both immediate 
and delayed recall), Verbal fluency test, and Letter Digit Substitution task both before and after 
stroke or TIA (Table 4). When we studied the change in cognitive test scores from before to 
after stroke or TIA, we found that that people with high education declined less in delayed 
recall compared to people with low education, β 1.33 (95% CI 0.24; 2.43). Effect sizes of the 
Stroop interference task and Verbal fluency test also suggested a lower decline in the higher 
education group, although only borderline significant. We did not observe an interaction 
between cognitive performance and sex, which is why we did not stratify on sex in these 
analyses. 
When comparing cognitive decline in those with a stroke or TIA to those without, we found 
that people with a stroke or TIA had a stronger decline on the Stroop test, immediate recall, 
and delayed recall than people without stroke or TIA in low and intermediate education 
categories (Supplementary Table II). This difference was not observed in the high education 
category. However, interaction testing of educational level with stroke or TIA on cognitive 
decline only gave a borderline significant interaction for the Stroop test (p=0.08). 
In the sensitivity analyses for risk of dementia, our results did not change after combining 
the intermediate and high education categories (data not shown). 
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Table 1. Baseline characteristics of the study population 
  Levels of education 
  Low  Intermediate  High 
Characteristics  N=5,299  N=5,342  N= ,920 
Age, years  67.8 (9.9)bc  63.3 (8.8)ac  60.0 (8.2)ab 
Women  3754 (70.8)bc  2838 (53.1)ac  735 (38.3)ab 
Study cohort       
First cohort  3463 (65.4)bc  2402 (45.0)ac  532 (27.7)ab 
Second cohort  910 (17.2)bc  1344 (25.2)ac  470 (24.5)ab 
Third cohort  926 (17.5)bc  1596 (29.9)ac  918 (47.8)ab 
Body mass index, kg/m2  27.2 (4.2)bc  26.8 (4.1)ac  26.5 (3.9)ab 
Smoking       
Never  1,993 (37.9 c  1,558 (29.3)c  539 (28.1)ab 
Former  2,018 (38.4)bc  2,459 (46.2)a  950 (49.6)a 
Current   1,247 (23.7)bc  1,301 (24.5)ac  428 (22.3)ab 
Total cholesterol, mmol/L  6.4 (1.3)bc  6.1 (1.2)ac  5.8 (1.2)ab 
High-density lipoprotein 
cholesterol, mmol/L 
 1.4 (0.4)bc  1.4 (0.4)ac  1.4 (0.4)ab 
Lipid lowering medication  409 (7.7)  556 (10.4)  222 (11.6) 
Systolic blood pressure, 
mmHg 
 139.8 (22.2)  137.3 (20.9)  135.3 (21.1) 
Diastolic blood pressure, 
mmHg 
 76.0 (12.0)bc  78.0 (11.6)ac  79.8 (11.7)ab 
Blood pressure lowering 
medication 
 1,313 (24.8)c  1,131 (21.2)  350 (18.3)a 
Mini Mental State 
Examination, points 
 27.2 (2.1)bc  28.2 (1.5)ac  28.6 (1.4)ab 
Diabetes mellitus type 2  417 (8.6)  390 (7.7)  107 (5.8) 
Abbreviations: N = number of persons included in study. 
Values are means (standard deviation) or counts (percentage). 
a Significantly different from people with low education (p<0.05), after age and sex adjustment - if applicable. 
b Significantly different from people with intermediate education (p<0.05), after age and sex adjustment - if 
applicable. 
c Significantly different from people with high education (p<0.05), after age and sex adjust ent - if applicable. 
 
People with a stroke or TIA had an increased risk of dementia compared to participants 
without stroke or TIA (multivariable adjusted hazard ratio (HR) 1.42 (95% CI 1.20; 1.67)). In 
analyses stratified for education, this risk was highest in persons with low education, HR 1.46 
(95% CI 1.18; 1.81), followed by those with intermediate education, HR 1.36 (95% CI 1.03; 1.81). 
In the high education group, people with a stroke or TIA did not have an increased risk of 
dementia compared to people without a stroke or TIA, HR 0.62 (95% CI 0.25; 1.54) (Table 2). 
Stratification by gender showed a similar pattern of associations, which was more pronounced 
in men than in women (Table 3). Interaction testing of educational level with stroke or TIA on 
the risk of dementia yielded p-value 0.65 in the overall population, 0.05 in men, and 0.82 in 
women. 
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People with high education scored better on 15-Word verbal learning test (both immediate 
and delayed recall), Verbal fluency test, and Letter Digit Substitution task both before and after 
stroke or TIA (Table 4). When we studied the change in cognitive test scores from before to 
after stroke or TIA, we found that that people with high education declined less in delayed 
recall compared to people with low education, β 1.33 (95% CI 0.24; 2.43). Effect sizes of the 
Stroop interference task and Verbal fluency test also suggested a lower decline in the higher 
education group, although only borderline significant. We did not observe an interaction 
between cognitive performance and sex, which is why we did not stratify on sex in these 
analyses. 
When comparing cognitive decline in those with a stroke or TIA to those without, we found 
that people with a stroke or TIA had a stronger decline on the Stroop test, immediate recall, 
and delayed recall than people without stroke or TIA in low and intermediate education 
categories (Supplementary Table II). This difference was not observed in the high education 
category. However, interaction testing of educational level with stroke or TIA on cognitive 
decline only gave a borderline significant interaction for the Stroop test (p=0.08). 
In the sensitivity analyses for risk of dementia, our results did not change after combining 
the intermediate and high education categories (data not shown). 
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Table 1. Baseline characteristics of the study population 
  Levels of education 
  Low  Intermediate  High 
Characteristics  N=5,299  N=5,342  N= ,920 
Age, years  67.8 (9.9)bc  63.3 (8.8)ac  60.0 (8.2)ab 
Women  3754 (70.8)bc  2838 (53.1)ac  735 (38.3)ab 
Study cohort       
First cohort  3463 (65.4)bc  2402 (45.0)ac  532 (27.7)ab 
Second cohort  910 (17.2)bc  1344 (25.2)ac  470 (24.5)ab 
Third cohort  926 (17.5)bc  1596 (29.9)ac  918 (47.8)ab 
Body mass index, kg/m2  27.2 (4.2)bc  26.8 (4.1)ac  26.5 (3.9)ab 
Smoking       
Never  1,993 (37.9 c  1,558 (29.3)c  539 (28.1)ab 
Former  2,018 (38.4)bc  2,459 (46.2)a  950 (49.6)a 
Current   1,247 (23.7)bc  1,301 (24.5)ac  428 (22.3)ab 
Total cholesterol, mmol/L  6.4 (1.3)bc  6.1 (1.2)ac  5.8 (1.2)ab 
High-density lipoprotein 
cholesterol, mmol/L 
 1.4 (0.4)bc  1.4 (0.4)ac  1.4 (0.4)ab 
Lipid lowering medication  409 (7.7)  556 (10.4)  222 (11.6) 
Systolic blood pressure, 
mmHg 
 139.8 (22.2)  137.3 (20.9)  135.3 (21.1) 
Diastolic blood pressure, 
mmHg 
 76.0 (12.0)bc  78.0 (11.6)ac  79.8 (11.7)ab 
Blood pressure lowering 
medication 
 1,313 (24.8)c  1,131 (21.2)  350 (18.3)a 
Mini Mental State 
Examination, points 
 27.2 (2.1)bc  28.2 (1.5)ac  28.6 (1.4)ab 
Diabetes mellitus type 2  417 (8.6)  390 (7.7)  107 (5.8) 
Abbreviations: N = number of persons included in study. 
Values are means (standard deviation) or counts (percentage). 
a Significantly different from people with low education (p<0.05), after age and sex adjustment - if applicable. 
b Significantly different from people with intermediate education (p<0.05), after age and sex adjustment - if 
applicable. 
c Significantly different from people with high education (p<0.05), after age and sex adjust ent - if applicable. 
 
People with a stroke or TIA had an increased risk of dementia compared to participants 
without stroke or TIA (multivariable adjusted hazard ratio (HR) 1.42 (95% CI 1.20; 1.67)). In 
analyses stratified for education, this risk was highest in persons with low education, HR 1.46 
(95% CI 1.18; 1.81), followed by those with intermediate education, HR 1.36 (95% CI 1.03; 1.81). 
In the high education group, people with a stroke or TIA did not have an increased risk of 
dementia compared to people without a stroke or TIA, HR 0.62 (95% CI 0.25; 1.54) (Table 2). 
Stratification by gender showed a similar pattern of associations, which was more pronounced 
in men than in women (Table 3). Interaction testing of educational level with stroke or TIA on 
the risk of dementia yielded p-value 0.65 in the overall population, 0.05 in men, and 0.82 in 
women. 
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Discussion 
 
This population-based study showed that stroke or TIA increased the risk of subsequent 
dementia in persons with low and intermediate education, but not in persons with high 
education. Additionally, as compared to people with low education, those with high education 
not only scored better on cognitive tests both before and after stroke or TIA, but also declined 
less in memory and executive function after a stroke or TIA.  
It is known that people with stroke or TIA have an increased risk of dementia compared to 
those without stroke or TIA,24,32 but we showed that this effect was dependent upon the level 
of education.  
Previously, clinical studies have identified low education as a risk factor for dementia in 
patients with stroke, but because of the clinical setting, a comparison to risk of dementia in 
persons without stroke was lacking.15,33-35 It is specifically this comparison with persons without 
stroke that provides evidence for higher education to be protective against post-stroke 
dementia. Therefore, a major novelty of our study is that we were able to make this comparison, 
and importantly showed that in persons with high education, stroke or TIA did not increase the 
risk of dementia. This differing effect across levels of education has two major probable 
explanations.  
One likely explanation is the cognitive reserve, which is an established concept and has 
been shown to protect against Alzheimer pathology. Cognitive reserve is thought to be built 
by cognitively enduring activities such as education and occupation complexity. Our results 
are novel as they demonstrate the protective role of cognitive reserve against clinical 
cerebrovascular pathology. Perhaps people with higher education, and consequently higher 
cognitive reserve are more resilient to the damage caused by a stroke or TIA either due to better 
efficiency, or more capacity or flexibility of brain networks already present before the damage 
(neural reserve), or because of better compensation for the damage (neural compensation). 
Neural compensation pertains to the ability of persons with higher cognitive reserve, to form 
collateral networks in the brain, when the usual neuronal networks are compromised by the 
vascular damage.4,36,37 Studies have suggested that cognitively stimulating activities, which are 
mostly experienced during education, not only promote neurogenesis, but also upregulate 
Brain Derived Neurotrophic Factor (BDNF) which in turn promotes plasticity.3,37  
However, an alternative explanation is that people with higher education have a more 
favorable environment including a healthier lifestyle, better compliance to treatment, and 
better access to healthcare. Such a favorable environment might lead to less severe strokes, 
perhaps better detection of less severe strokes, and more importantly, early hospitalization and 
thus fewer complications after stroke. In our study, we adjusted for the potential cardiovascular 
risk factors. Although associations did not change meaningfully, these adjustments might not 
fully address every aspect of a favorable environment as pointed out above. This was also 
reflected in our data, as we found relatively fewer strokes compared to TIAs with increasing 
educational level. 
In analyses stratified on gender, we found that the decrease in the risk of dementia after a 
stroke or TIA with increasing education was only significant in men. This suggests a stronger 
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protective effect of cognitive reserve against dementia following stroke in men. However, only 
few women had dementia after a stroke or TIA in the high education group, which could have 
affected our power, and might explain the findings. For both men and women, we did not 
observe a higher risk in the high education category. Alternatively, perhaps in women from 
older generation birth cohorts, education is less representative of their cognitive reserve than 
in men, particularly for West-European populations. In our study, many women were born in a 
period when girls were not equally encouraged for education as boys, and often only 
completed limited years of education, which was not reflective of their potential. Instead, they 
quit school to work at home. Therefore, in this group, educational level might not be the best 
proxy for cognitive reserve and thus obscured any associations in women. The time spent on 
leisure activities including social, physical and recreational activities might have been a better 
proxy for cognitive reserve, but we did not have that information in our study. 
The finding in our study of less cognitive decline in the high education category in people 
with stroke or TIA further supports the role of cognitive reserve. Unlike previous studies which 
only had information on cognitive decline after stroke or TIA,34,35 we had cognition assessments 
both before and after the stroke or TIA. This allowed to demonstrate that the impact of a stroke 
or TIA on executive function and memory was smaller in people with high education, 
suggesting that persons with higher education not only have a better cognition in the first 
place, they can also adapt better to the cerebrovascular damage, indicating cognitive reserve.  
Strengths of this study include a large population-based sample representative of different 
levels of education, a long and robust follow-up of incident TIA, stroke, and dementia, and the 
availability of cognitive tests before and after stroke or TIA. However there are certain 
limitations. First, only education as a measure of cognitive reserve was available. Activities in 
later life, such as occupational complexity or leisure activities including recreation, physical and 
social engagements could not be taken into account, which might be important particularly in 
older adults. Education might also reflect a better socio-economic status and thus a better 
access to healthcare. Nevertheless, these other markers of cognitive reserve might have the 
same limitations as the educational level, and education remains the most used measure of 
cognitive reserve in existing literature.36,38 Second, we could not adjust for brain reserve in our 
study, since brain volumes were not available in this population. This might have led to an 
overestimation of results, as the observed associations could partly be explained by brain 
reserve. Another limitation is that we did not have information about the severity of stroke. It is 
possible that people with higher education had less severe strokes leading to less brain 
damage and therefore a smaller risk of dementia. Third, we did not have enough cases of 
dementia in the high education category for women and therefore the effect estimates might 
be underpowered. Finally, complete cognitive testing was available in a subgroup of our study 
population only, therefore the results might be influenced by selection. Since people with 
severe strokes primarily stop attending the research center, our results are only applicable to 
those with less severe stroke or TIA. 
In conclusion, these results suggest that higher education is associated with a lower risk of 
dementia after cerebrovascular events, particularly in men. Future studies should explore the 
mechanisms underlying this protective effect as well as investigate whether improvement of 
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Discussion 
 
This population-based study showed that stroke or TIA increased the risk of subsequent 
dementia in persons with low and intermediate education, but not in persons with high 
education. Additionally, as compared to people with low education, those with high education 
not only scored better on cognitive tests both before and after stroke or TIA, but also declined 
less in memory and executive function after a stroke or TIA.  
It is known that people with stroke or TIA have an increased risk of dementia compared to 
those without stroke or TIA,24,32 but we showed that this effect was dependent upon the level 
of education.  
Previously, clinical studies have identified low education as a risk factor for dementia in 
patients with stroke, but because of the clinical setting, a comparison to risk of dementia in 
persons without stroke was lacking.15,33-35 It is specifically this comparison with persons without 
stroke that provides evidence for higher education to be protective against post-stroke 
dementia. Therefore, a major novelty of our study is that we were able to make this comparison, 
and importantly showed that in persons with high education, stroke or TIA did not increase the 
risk of dementia. This differing effect across levels of education has two major probable 
explanations.  
One likely explanation is the cognitive reserve, which is an established concept and has 
been shown to protect against Alzheimer pathology. Cognitive reserve is thought to be built 
by cognitively enduring activities such as education and occupation complexity. Our results 
are novel as they demonstrate the protective role of cognitive reserve against clinical 
cerebrovascular pathology. Perhaps people with higher education, and consequently higher 
cognitive reserve are more resilient to the damage caused by a stroke or TIA either due to better 
efficiency, or more capacity or flexibility of brain networks already present before the damage 
(neural reserve), or because of better compensation for the damage (neural compensation). 
Neural compensation pertains to the ability of persons with higher cognitive reserve, to form 
collateral networks in the brain, when the usual neuronal networks are compromised by the 
vascular damage.4,36,37 Studies have suggested that cognitively stimulating activities, which are 
mostly experienced during education, not only promote neurogenesis, but also upregulate 
Brain Derived Neurotrophic Factor (BDNF) which in turn promotes plasticity.3,37  
However, an alternative explanation is that people with higher education have a more 
favorable environment including a healthier lifestyle, better compliance to treatment, and 
better access to healthcare. Such a favorable environment might lead to less severe strokes, 
perhaps better detection of less severe strokes, and more importantly, early hospitalization and 
thus fewer complications after stroke. In our study, we adjusted for the potential cardiovascular 
risk factors. Although associations did not change meaningfully, these adjustments might not 
fully address every aspect of a favorable environment as pointed out above. This was also 
reflected in our data, as we found relatively fewer strokes compared to TIAs with increasing 
educational level. 
In analyses stratified on gender, we found that the decrease in the risk of dementia after a 
stroke or TIA with increasing education was only significant in men. This suggests a stronger 
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protective effect of cognitive reserve against dementia following stroke in men. However, only 
few women had dementia after a stroke or TIA in the high education group, which could have 
affected our power, and might explain the findings. For both men and women, we did not 
observe a higher risk in the high education category. Alternatively, perhaps in women from 
older generation birth cohorts, education is less representative of their cognitive reserve than 
in men, particularly for West-European populations. In our study, many women were born in a 
period when girls were not equally encouraged for education as boys, and often only 
completed limited years of education, which was not reflective of their potential. Instead, they 
quit school to work at home. Therefore, in this group, educational level might not be the best 
proxy for cognitive reserve and thus obscured any associations in women. The time spent on 
leisure activities including social, physical and recreational activities might have been a better 
proxy for cognitive reserve, but we did not have that information in our study. 
The finding in our study of less cognitive decline in the high education category in people 
with stroke or TIA further supports the role of cognitive reserve. Unlike previous studies which 
only had information on cognitive decline after stroke or TIA,34,35 we had cognition assessments 
both before and after the stroke or TIA. This allowed to demonstrate that the impact of a stroke 
or TIA on executive function and memory was smaller in people with high education, 
suggesting that persons with higher education not only have a better cognition in the first 
place, they can also adapt better to the cerebrovascular damage, indicating cognitive reserve.  
Strengths of this study include a large population-based sample representative of different 
levels of education, a long and robust follow-up of incident TIA, stroke, and dementia, and the 
availability of cognitive tests before and after stroke or TIA. However there are certain 
limitations. First, only education as a measure of cognitive reserve was available. Activities in 
later life, such as occupational complexity or leisure activities including recreation, physical and 
social engagements could not be taken into account, which might be important particularly in 
older adults. Education might also reflect a better socio-economic status and thus a better 
access to healthcare. Nevertheless, these other markers of cognitive reserve might have the 
same limitations as the educational level, and education remains the most used measure of 
cognitive reserve in existing literature.36,38 Second, we could not adjust for brain reserve in our 
study, since brain volumes were not available in this population. This might have led to an 
overestimation of results, as the observed associations could partly be explained by brain 
reserve. Another limitation is that we did not have information about the severity of stroke. It is 
possible that people with higher education had less severe strokes leading to less brain 
damage and therefore a smaller risk of dementia. Third, we did not have enough cases of 
dementia in the high education category for women and therefore the effect estimates might 
be underpowered. Finally, complete cognitive testing was available in a subgroup of our study 
population only, therefore the results might be influenced by selection. Since people with 
severe strokes primarily stop attending the research center, our results are only applicable to 
those with less severe stroke or TIA. 
In conclusion, these results suggest that higher education is associated with a lower risk of 
dementia after cerebrovascular events, particularly in men. Future studies should explore the 
mechanisms underlying this protective effect as well as investigate whether improvement of 
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cognitive reserve later in life, for instance using cognitively stimulating activities, might delay 
or prevent dementia in stroke patients. 
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Supplementary information 
 
Supplementary Table I. Comparison of baseline characteristics of participants included and not included 
in the analyses 
 Participants 
 Excluded Included in 
dementia 
analyses 
Included in 
cognition 
analyses 
Not included in 
cognition 
analyses 
Characteristics N=2,364 N=12,561 5,588 6,973 
Age, years 72.8 (12.3) 64.7 (9.6)a 63.1 (8.8)b 72.6 (11.0) 
Women 1,496 (63.3) 7,327 (58.3)a 3,219 (57.6) 4,108 (58.9) 
Body mass index, kg/m2 26.6 (4.2) 26.9 (4.1)a 27.7 (4.2) 27.6 (4.5) 
Smoking     
Never 730 (36.1) 4,090 (32.7)a 1,614 (29.2) 943 (27.7) 
Former 745 (36.9) 5,428 (43.4)a 2,851 (51.6) 1,753 (51.5) 
Current  545 (27.0) 2,976 (23.8)a 1,064 (19.2) 705 (20.7) 
Total cholesterol, mmol/L 6.0 (1.3) 6.2 (1.2)a 5.6 (1.0)b 5.5 (1.0) 
High-density lipoprotein 
cholesterol, mmol/L 
1.3 (0.4) 1.4 (0.4)a 1.4 (0.4) 1.4 (0.4) 
Lipid lowering medication 245 (10.5) 1,187 (9.4)a 1,185 (21.3) 765 (22.1) 
Systolic blood pressure, mmHg 141.6 (23.3) 138.0 (21.5)a 139.6 (20.6)b 149.2 (23.7) 
Diastolic blood pressure, 
mmHg 
75.8 (13.1) 77.4 (11.8)a 81.4 (10.7)b 80.1 (11.9) 
Blood pressure lowering 
medication 
609 (25.9) 2,794 (22.3)a 1,426 (25.5)b 1,293 (18.5) 
Mini Mental State Examination, 
points 
24.1 (5.8) 27.8 (1.8)a 28.1 (1.7)b 26.9 (3.1) 
Diabetes mellitus type 2 236 (11.4) 753 (6.0)a 525 (9.5)b 1,191 (30.1) 
Values are means (standard deviation) or counts (percentage). 
a Significantly different (P-value<0.05) from persons in the excluded group. 
b Significantly different from the group not included in the cognition analysis. 
  
5Chapter 5.4 
246 
24. Bos MJ, van Rijn MJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Incidence and prognosis of 
transient neurological attacks. JAMA. 2007;298(24):2877-2885. 
25. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 
2002;359(9314):1309-1310. 
26. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence 
declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 
2012;78(19):1456-1463. 
27. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive 
state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. 
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's 
disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and 
Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. 
29. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. 
Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250-260. 
30. Hoogendam YY, Hofman A, van der Geest JN, van der Lugt A, Ikram MA. Patterns of cognitive function 
in aging: the Rotterdam Study. Eur J Epidemiol. 2014;29(2):133-140. 
31. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its 
complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO 
consultation. Diabet Med. 1998;15(7):539-553. 
32. Savva GM, Stephan BC, Alzheimer's Society Vascular Dementia Systematic Review G. Epidemiological 
studies of the effect of stroke on incident dementia: a systematic review. Stroke. 2010;41(1):e41-46. 
33. Jacquin A, Binquet C, Rouaud O, et al. Post-stroke cognitive impairment: high prevalence and 
determining factors in a cohort of mild stroke. J Alzheimers Dis. 2014;40(4):1029-1038. 
34. Ojala-Oksala J, Jokinen H, Kopsi V, et al. Educational history is an independent predictor of cognitive 
deficits and long-term survival in postacute patients with mild to moderate ischemic stroke. Stroke. 
2012;43(11):2931-2935. 
35. Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz LM, Koschera A. Progression of cognitive impairment 
in stroke patients. Neurology. 2004;63(9):1618-1623. 
36. Harrison SL, Sajjad A, Bramer WM, Ikram MA, Tiemeier H, Stephan BC. Exploring strategies to 
operationalize cognitive reserve: A systematic review of reviews. J Clin Exp Neuropsychol. 
2015;37(3):253-264. 
37. Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):2015-2028. 
38. Valenzuela MJ. Brain reserve and the prevention of dementia. Curr Opin Psychiatry. 2008;21(3):296-
302. 
  
Higher education is associated with a lower risk of dementia after a stroke or TIA 
247 
Supplementary information 
 
Supplementary Table I. Comparison of baseline characteristics of participants included and not included 
in the analyses 
 Participants 
 Excluded Included in 
dementia 
analyses 
Included in 
cognition 
analyses 
Not included in 
cognition 
analyses 
Characteristics N=2,364 N=12,561 5,588 6,973 
Age, years 72.8 (12.3) 64.7 (9.6)a 63.1 (8.8)b 72.6 (11.0) 
Women 1,496 (63.3) 7,327 (58.3)a 3,219 (57.6) 4,108 (58.9) 
Body mass index, kg/m2 26.6 (4.2) 26.9 (4.1)a 27.7 (4.2) 27.6 (4.5) 
Smoking     
Never 730 (36.1) 4,090 (32.7)a 1,614 (29.2) 943 (27.7) 
Former 745 (36.9) 5,428 (43.4)a 2,851 (51.6) 1,753 (51.5) 
Current  545 (27.0) 2,976 (23.8)a 1,064 (19.2) 705 (20.7) 
Total cholesterol, mmol/L 6.0 (1.3) 6.2 (1.2)a 5.6 (1.0)b 5.5 (1.0) 
High-density lipoprotein 
cholesterol, mmol/L 
1.3 (0.4) 1.4 (0.4)a 1.4 (0.4) 1.4 (0.4) 
Lipid lowering medication 245 (10.5) 1,187 (9.4)a 1,185 (21.3) 765 (22.1) 
Systolic blood pressure, mmHg 141.6 (23.3) 138.0 (21.5)a 139.6 (20.6)b 149.2 (23.7) 
Diastolic blood pressure, 
mmHg 
75.8 (13.1) 77.4 (11.8)a 81.4 (10.7)b 80.1 (11.9) 
Blood pressure lowering 
medication 
609 (25.9) 2,794 (22.3)a 1,426 (25.5)b 1,293 (18.5) 
Mini Mental State Examination, 
points 
24.1 (5.8) 27.8 (1.8)a 28.1 (1.7)b 26.9 (3.1) 
Diabetes mellitus type 2 236 (11.4) 753 (6.0)a 525 (9.5)b 1,191 (30.1) 
Values are means (standard deviation) or counts (percentage). 
a Significantly different (P-value<0.05) from persons in the excluded group. 
b Significantly different from the group not included in the cognition analysis. 
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It has been estimated that 50-90% of strokes are attributable to known risk factors.1,2 Despite 
implementation of such risk factors in prevention guidelines,3 the incidence and mortality of 
stroke remains high.4,5 The search for new factors and a better understanding of the 
pathophysiological pathways is therefore still of major importance. This thesis combined 
studies into determinants of stroke and stroke outcomes, focusing on emerging markers within 
known pathophysiological pathways. All studies were performed within the population-based 
Rotterdam Study.6  
In the following chapter I will first discuss the main findings of my thesis in the context of 
the current literature, before discussing some methodological considerations. Finally, I will 
translate the results into clinical practice and will provide suggestions for future research within 
the field of stroke. 
 
Main findings 
 
Subclinical cardiac disease increases the risk of stroke 
One major aim of my thesis was to examine early risk factors or markers for stroke, within 
categories of known pathophysiology. I first examined markers of subclinical cardiac disease. 
The clinical cardiac diseases atrial fibrillation, heart failure, and myocardial infarction have all 
been related to stroke.7-9 However, abnormalities in the heart can be present before they 
become clinically apparent.10-12 Previous echocardiographic studies detected structural 
abnormalities, e.g. left ventricular hypertrophy or atrial enlargement,13-16 or a decreased cardiac 
function in people free of clinical cardiac disease.10-12 Many structural measures of the heart 
have been related to stroke before, of which left ventricular hypertrophy appeared to be most 
important.13-16 However, cardiac function may provide additional information.17 In Chapter 2.1, 
I showed that in people without clinical cardiac disease, a diminished systolic and diastolic 
function of the heart as measured by echocardiography was related to an increased risk of 
stroke. These associations were independent of atrial diameter and left ventricular mass, a 
marker of left ventricular hypertrophy (data not shown), and suggest that detecting early 
cardiac dysfunction may add to the identification of people at high risk of stroke. Future studies 
should investigate whether presence of a diminished cardiac function contributes to stroke 
prediction.  
Since echocardiography is time-consuming, this may not be the best screening method 
for cardiac function in prediction studies, particularly if population-based. This raised my 
interest in the association between a laboratory marker of cardiac dysfunction and the risk of 
stroke. N-terminal pro-B-type natriuretic peptide NT-proBNP is a cardiac marker that is excreted 
in response of ventricular wall stress.18,19 Similar to echocardiographic values, it may reveal 
cardiac dysfunction even in the absence of clinical cardiac disease.20 In Chapter 2.2, I examined 
the association of N-terminal pro-B-type natriuretic peptide and the risk of stroke. NT-proBNP 
related to an increased risk of both ischemic and hemorrhagic stroke. Even after censoring for 
incident cardiac disease, the associations remained. The association between NT-proBNP and 
stroke was known from previous studies.21-25 Our results further enhance this relation by 
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showing that it can serve as a marker for stroke risk even in a very early phase, namely in people 
without clinical cardiac disease.  
I hypothesized that associations described above may be the consequence of 
cardioembolism26 or cerebral hypoperfusion.27 However, part of the association may also be 
driven by shared etiology, which I will discuss later in further detail.  
 
Novel markers of large and small vessel disease and the risk of stroke 
The search for preclinical markers was continued in Chapter 3. In this chapter, I focused on 
markers of the two other major etiologies of stroke besides cardiac disease, i.e. large and small 
vessel disease. Large vessel disease, or atherosclerosis, starts with lipid depositions in the artery 
wall, followed by an inflammatory response, accumulation of fibrous elements and arterial 
calcification.28,29 Small vessel disease has a similar pathophysiology. Infiltration of inflammatory 
cells and lipid depositions damage the smaller arterioles, also known as arteriolosclerosis. In 
addition, small vessels can get damaged due to cerebral amyloid angiopathy (CAA).30,31 
 
Atherosclerosis can be detected from the aortic arch up to the brain using CT, MRI, or 
ultrasonography32 and the burden may differ across vessel beds.33 For stroke, presence of 
asymptomatic extracranial carotid stenosis has gained a lot of attention as risk factor,3,34,35 but 
studies in Asian and African populations revealed that intracranial atherosclerosis, even closer 
to the brain, might be more useful in the preclinical phase.36 I explored in Chapter 3.1 whether 
these results can be extrapolated to a white population, especially as Asian and African 
populations have disproportionally higher rates of intracranial atherosclerosis than white 
populations.36 Intracranial carotid artery calcification on CT was used as proxy for intracranial 
atherosclerosis. Around 80% of the participants in our study had some calcification in the 
intracranial carotid artery. This increased the risk of stroke four-fold and played a role in up to 
75% of all strokes. Importantly, this study underlines the value of the location of atherosclerosis 
for the risk of stroke. As expected, atherosclerosis closer to the brain was associated with a 
higher risk of stroke. Yet, this does not necessarily imply that markers close to the brain provide 
less information about systemic vascular damage. For example, in Chapter 3.2 I found that 
vasomotor reactivity, a marker for cerebral autoregulation measured in the medial cerebral 
artery,37 was associated with an increased risk of mortality independent from stroke. This 
suggests that an impaired vasomotor reactivity reflects a more systemic dysfunction of the 
vascular system rather than a local dysfunction in the brain. 
 
Subclinical small vessel disease can be visible on MRI as white matter lesions, lacunar infarcts, 
and microbleeds.30,31 Silent lacunar infarcts and white matter lesions are known to increase the 
risk of stroke.38-41 Microbleeds increased the risk of a recurrent stroke in people who already 
suffered a stroke,42 but whether these results can be extended to the general population was 
still unclear. Chapter 3.3 showed that presence of microbleeds increased the risk of both 
ischemic and hemorrhagic stroke, even independent of white matter lesions and lacunes. This 
means these lesions might also be a good marker for subclinical cerebrovascular pathology in 
the general population. 
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It has been estimated that 50-90% of strokes are attributable to known risk factors.1,2 Despite 
implementation of such risk factors in prevention guidelines,3 the incidence and mortality of 
stroke remains high.4,5 The search for new factors and a better understanding of the 
pathophysiological pathways is therefore still of major importance. This thesis combined 
studies into determinants of stroke and stroke outcomes, focusing on emerging markers within 
known pathophysiological pathways. All studies were performed within the population-based 
Rotterdam Study.6  
In the following chapter I will first discuss the main findings of my thesis in the context of 
the current literature, before discussing some methodological considerations. Finally, I will 
translate the results into clinical practice and will provide suggestions for future research within 
the field of stroke. 
 
Main findings 
 
Subclinical cardiac disease increases the risk of stroke 
One major aim of my thesis was to examine early risk factors or markers for stroke, within 
categories of known pathophysiology. I first examined markers of subclinical cardiac disease. 
The clinical cardiac diseases atrial fibrillation, heart failure, and myocardial infarction have all 
been related to stroke.7-9 However, abnormalities in the heart can be present before they 
become clinically apparent.10-12 Previous echocardiographic studies detected structural 
abnormalities, e.g. left ventricular hypertrophy or atrial enlargement,13-16 or a decreased cardiac 
function in people free of clinical cardiac disease.10-12 Many structural measures of the heart 
have been related to stroke before, of which left ventricular hypertrophy appeared to be most 
important.13-16 However, cardiac function may provide additional information.17 In Chapter 2.1, 
I showed that in people without clinical cardiac disease, a diminished systolic and diastolic 
function of the heart as measured by echocardiography was related to an increased risk of 
stroke. These associations were independent of atrial diameter and left ventricular mass, a 
marker of left ventricular hypertrophy (data not shown), and suggest that detecting early 
cardiac dysfunction may add to the identification of people at high risk of stroke. Future studies 
should investigate whether presence of a diminished cardiac function contributes to stroke 
prediction.  
Since echocardiography is time-consuming, this may not be the best screening method 
for cardiac function in prediction studies, particularly if population-based. This raised my 
interest in the association between a laboratory marker of cardiac dysfunction and the risk of 
stroke. N-terminal pro-B-type natriuretic peptide NT-proBNP is a cardiac marker that is excreted 
in response of ventricular wall stress.18,19 Similar to echocardiographic values, it may reveal 
cardiac dysfunction even in the absence of clinical cardiac disease.20 In Chapter 2.2, I examined 
the association of N-terminal pro-B-type natriuretic peptide and the risk of stroke. NT-proBNP 
related to an increased risk of both ischemic and hemorrhagic stroke. Even after censoring for 
incident cardiac disease, the associations remained. The association between NT-proBNP and 
stroke was known from previous studies.21-25 Our results further enhance this relation by 
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showing that it can serve as a marker for stroke risk even in a very early phase, namely in people 
without clinical cardiac disease.  
I hypothesized that associations described above may be the consequence of 
cardioembolism26 or cerebral hypoperfusion.27 However, part of the association may also be 
driven by shared etiology, which I will discuss later in further detail.  
 
Novel markers of large and small vessel disease and the risk of stroke 
The search for preclinical markers was continued in Chapter 3. In this chapter, I focused on 
markers of the two other major etiologies of stroke besides cardiac disease, i.e. large and small 
vessel disease. Large vessel disease, or atherosclerosis, starts with lipid depositions in the artery 
wall, followed by an inflammatory response, accumulation of fibrous elements and arterial 
calcification.28,29 Small vessel disease has a similar pathophysiology. Infiltration of inflammatory 
cells and lipid depositions damage the smaller arterioles, also known as arteriolosclerosis. In 
addition, small vessels can get damaged due to cerebral amyloid angiopathy (CAA).30,31 
 
Atherosclerosis can be detected from the aortic arch up to the brain using CT, MRI, or 
ultrasonography32 and the burden may differ across vessel beds.33 For stroke, presence of 
asymptomatic extracranial carotid stenosis has gained a lot of attention as risk factor,3,34,35 but 
studies in Asian and African populations revealed that intracranial atherosclerosis, even closer 
to the brain, might be more useful in the preclinical phase.36 I explored in Chapter 3.1 whether 
these results can be extrapolated to a white population, especially as Asian and African 
populations have disproportionally higher rates of intracranial atherosclerosis than white 
populations.36 Intracranial carotid artery calcification on CT was used as proxy for intracranial 
atherosclerosis. Around 80% of the participants in our study had some calcification in the 
intracranial carotid artery. This increased the risk of stroke four-fold and played a role in up to 
75% of all strokes. Importantly, this study underlines the value of the location of atherosclerosis 
for the risk of stroke. As expected, atherosclerosis closer to the brain was associated with a 
higher risk of stroke. Yet, this does not necessarily imply that markers close to the brain provide 
less information about systemic vascular damage. For example, in Chapter 3.2 I found that 
vasomotor reactivity, a marker for cerebral autoregulation measured in the medial cerebral 
artery,37 was associated with an increased risk of mortality independent from stroke. This 
suggests that an impaired vasomotor reactivity reflects a more systemic dysfunction of the 
vascular system rather than a local dysfunction in the brain. 
 
Subclinical small vessel disease can be visible on MRI as white matter lesions, lacunar infarcts, 
and microbleeds.30,31 Silent lacunar infarcts and white matter lesions are known to increase the 
risk of stroke.38-41 Microbleeds increased the risk of a recurrent stroke in people who already 
suffered a stroke,42 but whether these results can be extended to the general population was 
still unclear. Chapter 3.3 showed that presence of microbleeds increased the risk of both 
ischemic and hemorrhagic stroke, even independent of white matter lesions and lacunes. This 
means these lesions might also be a good marker for subclinical cerebrovascular pathology in 
the general population. 
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Together, these results show that emerging markers of large and small vessel disease may 
help to identify people at high risk of stroke. Another question is whether large and small vessel 
disease are independent pathways leading to stroke. Given that large and small vessel disease 
are associated with different subtypes of stroke, i.e. cortical versus lacunar, large and small 
vessel disease are currently considered to be separate etiological mechanisms.43 However, in 
Chapter 3.4 I showed that different markers of vessel disease may interact in their risk of stroke. 
For example, I found that the risk of stroke and TIA was only increased in people with a 
combination of impaired brain perfusion and large retinal venules. Large retinal vessels reflect 
small vessel disease,44,45 whereas a low cerebral blood flow may reflect large vessel disease.46 
This suggests that instead of focusing on one etiological cause, the possibility of overlapping 
causes should be considered. I hypothesized that cerebral autoregulation may compensate for 
a diminished perfusion. In people with small vessel disease this mechanism may be impaired. 
In reverse, a high perfusion may compensate for a diminished autoregulation. This may also 
explain why I did not observe an association between vasomotor reactivity and stroke in 
Chapter 3.2. Vasomotor reactivity may only associate with stroke in combination with a low 
perfusion. Another explanation for the interaction I observed may be that small vessel disease 
only relates to stroke if it is severe enough to lead to a lower blood flow demand.47  
 
The last paragraph of this chapter focused on hypertension, which is a major modifiable 
vascular risk factor for stroke,1,2 possibly because it relates to both large and small vessel 
disease.31,36 It is known that treatment of hypertension has had a major preventative effect on 
stroke,3,48 but this only targets high levels of blood pressure.49-52 Yet, in Chapter 3.5 I showed 
that the risk of stroke may be further influenced by long-term trajectories of blood pressure. Of 
particular interest was the finding that the trajectory with a normal blood pressure at middle 
age, but a steep increase afterwards, had a high risk of stroke and death compared to the 
trajectory with normal blood pressure at middle age and a more gradual increase. This risk was 
equally high compared to the trajectory characterized by a high blood pressure at middle age 
and beyond. The trajectory characterized by a moderate blood pressure at middle age and 
beyond only had an increased risk of stroke. This raises the question whether the temporal 
course of blood pressure should also be taken into account when deciding about treatment, 
especially since the trajectory with a steep increase appeared to be undertreated. Limitations 
in the use of trajectories, e.g. concomitant time frames, hampered me in the ability to answer 
this causal and treatment question. However, the results do emphasize that future studies 
examining the impact of increasing blood pressure are of major interest.  
 
Non-cardiovascular disorders and their risk of stroke 
In Chapter 4, I moved from markers that reflect the pathophysiology of stroke towards non-
cardiovascular diseases for which recently it has been suggested they might influence the 
cardiovascular system. Specifically, I focused on the relation of COPD and anxiety with 
stroke.54,55  
COPD possibly relates to stroke through systemic inflammation resulting in 
atherosclerosis.53 COPD is characterized by an inflammatory response of the lungs to noxious 
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particles or gases,54 which may extend systemically.53 Some previous studies did find 
associations with stroke,55-59 but were hampered by a cross-sectional design and limited 
assessment of confounders such as smoking. In Chapter 4.1, I observed associations between 
COPD and both ischemic and hemorrhagic stroke, which strongly attenuated after adjustment 
for smoking. However, risks remained for certain subtypes of stroke, namely the cortical and 
atherosclerotic strokes. Adjustment for CRP did not have an effect, which suggests a minor role 
for inflammation. Furthermore, I found an increased risk of stroke following severe 
exacerbations, which could be the consequence of acute inflammation or hypoperfusion.60 I 
therefore concluded that smoking particularly explains the association between COPD and 
stroke, but people with COPD may be extra vulnerable for certain subtypes of stroke and as 
well as for stroke following exacerbations.  
Anxiety activates the hypothalamic-pituitary-adrenal axis and sympathetic nervous 
system.61 This could damage the endothelial system and contribute to stroke. However, 
previous studies were inconsistent on whether anxiety relates to stroke.62,63 I therefore used 
measures of both anxiety symptoms and anxiety disorders to relate to stroke. In chapter 4.2, I 
found no association between anxiety and stroke. Discrepancies between mine and other 
studies may be explained by different scores to assess anxiety. It is difficult to disentangle 
anxiety symptoms from depressive and stress symptoms, which are both disorders that have 
previously been related to stroke.64,65 Furthermore, our study pointed towards the importance 
of a long follow-up. I did find an effect in the short-term, but this is likely to be explained by 
reversed causality. People might become anxious when they notice their health is 
deteriorating. The short-term increased risk of stroke is a spurious effect due to the increased 
health.  
The studies described above underline the importance of a complete set of confounders, 
a large follow-up, and a detailed exposure assessment to explore the risk of non-cardiovascular 
disorders with stroke. Spurious effects may occur due to confounding, reverse causality, or 
misclassification. 
 
Challenges after stroke 
Having examined the determinants of stroke, I continued studying problems in stroke 
recognition and determinants of stroke outcome. When a stroke occurs, patients need to be 
hospitalized immediately for a rapid assessment of the main subtype, i.e. ischemic or 
hemorrhagic. Ischemic strokes are treated with intravenous thrombolysis and, in case of a 
proximal artery occlusion, by intra-arterial mechanical thrombectomy.66-68 Recognizing a stroke 
is therefore of utmost importance. Elderly themselves, however, often experience difficulty 
recognizing symptoms of stroke.69,70 This might be even more difficult for some right 
hemispheric strokes, as these can lead to vague symptoms such as neglect, spatial 
disorientation or anosognosia.71 Previous studies noticed fewer right-sided than left-sided 
strokes and suggested this could either be due to the aforementioned recognition problems 
or due to an actual lower frequency of right-sided strokes, for instance as a consequence of 
differences in anatomy.72-74 To explain this difference, I compared in Chapter 5.1 clinical strokes 
to infarcts on MRI. I detected more left-sided than right-sided clinical strokes, but an equal 
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Together, these results show that emerging markers of large and small vessel disease may 
help to identify people at high risk of stroke. Another question is whether large and small vessel 
disease are independent pathways leading to stroke. Given that large and small vessel disease 
are associated with different subtypes of stroke, i.e. cortical versus lacunar, large and small 
vessel disease are currently considered to be separate etiological mechanisms.43 However, in 
Chapter 3.4 I showed that different markers of vessel disease may interact in their risk of stroke. 
For example, I found that the risk of stroke and TIA was only increased in people with a 
combination of impaired brain perfusion and large retinal venules. Large retinal vessels reflect 
small vessel disease,44,45 whereas a low cerebral blood flow may reflect large vessel disease.46 
This suggests that instead of focusing on one etiological cause, the possibility of overlapping 
causes should be considered. I hypothesized that cerebral autoregulation may compensate for 
a diminished perfusion. In people with small vessel disease this mechanism may be impaired. 
In reverse, a high perfusion may compensate for a diminished autoregulation. This may also 
explain why I did not observe an association between vasomotor reactivity and stroke in 
Chapter 3.2. Vasomotor reactivity may only associate with stroke in combination with a low 
perfusion. Another explanation for the interaction I observed may be that small vessel disease 
only relates to stroke if it is severe enough to lead to a lower blood flow demand.47  
 
The last paragraph of this chapter focused on hypertension, which is a major modifiable 
vascular risk factor for stroke,1,2 possibly because it relates to both large and small vessel 
disease.31,36 It is known that treatment of hypertension has had a major preventative effect on 
stroke,3,48 but this only targets high levels of blood pressure.49-52 Yet, in Chapter 3.5 I showed 
that the risk of stroke may be further influenced by long-term trajectories of blood pressure. Of 
particular interest was the finding that the trajectory with a normal blood pressure at middle 
age, but a steep increase afterwards, had a high risk of stroke and death compared to the 
trajectory with normal blood pressure at middle age and a more gradual increase. This risk was 
equally high compared to the trajectory characterized by a high blood pressure at middle age 
and beyond. The trajectory characterized by a moderate blood pressure at middle age and 
beyond only had an increased risk of stroke. This raises the question whether the temporal 
course of blood pressure should also be taken into account when deciding about treatment, 
especially since the trajectory with a steep increase appeared to be undertreated. Limitations 
in the use of trajectories, e.g. concomitant time frames, hampered me in the ability to answer 
this causal and treatment question. However, the results do emphasize that future studies 
examining the impact of increasing blood pressure are of major interest.  
 
Non-cardiovascular disorders and their risk of stroke 
In Chapter 4, I moved from markers that reflect the pathophysiology of stroke towards non-
cardiovascular diseases for which recently it has been suggested they might influence the 
cardiovascular system. Specifically, I focused on the relation of COPD and anxiety with 
stroke.54,55  
COPD possibly relates to stroke through systemic inflammation resulting in 
atherosclerosis.53 COPD is characterized by an inflammatory response of the lungs to noxious 
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particles or gases,54 which may extend systemically.53 Some previous studies did find 
associations with stroke,55-59 but were hampered by a cross-sectional design and limited 
assessment of confounders such as smoking. In Chapter 4.1, I observed associations between 
COPD and both ischemic and hemorrhagic stroke, which strongly attenuated after adjustment 
for smoking. However, risks remained for certain subtypes of stroke, namely the cortical and 
atherosclerotic strokes. Adjustment for CRP did not have an effect, which suggests a minor role 
for inflammation. Furthermore, I found an increased risk of stroke following severe 
exacerbations, which could be the consequence of acute inflammation or hypoperfusion.60 I 
therefore concluded that smoking particularly explains the association between COPD and 
stroke, but people with COPD may be extra vulnerable for certain subtypes of stroke and as 
well as for stroke following exacerbations.  
Anxiety activates the hypothalamic-pituitary-adrenal axis and sympathetic nervous 
system.61 This could damage the endothelial system and contribute to stroke. However, 
previous studies were inconsistent on whether anxiety relates to stroke.62,63 I therefore used 
measures of both anxiety symptoms and anxiety disorders to relate to stroke. In chapter 4.2, I 
found no association between anxiety and stroke. Discrepancies between mine and other 
studies may be explained by different scores to assess anxiety. It is difficult to disentangle 
anxiety symptoms from depressive and stress symptoms, which are both disorders that have 
previously been related to stroke.64,65 Furthermore, our study pointed towards the importance 
of a long follow-up. I did find an effect in the short-term, but this is likely to be explained by 
reversed causality. People might become anxious when they notice their health is 
deteriorating. The short-term increased risk of stroke is a spurious effect due to the increased 
health.  
The studies described above underline the importance of a complete set of confounders, 
a large follow-up, and a detailed exposure assessment to explore the risk of non-cardiovascular 
disorders with stroke. Spurious effects may occur due to confounding, reverse causality, or 
misclassification. 
 
Challenges after stroke 
Having examined the determinants of stroke, I continued studying problems in stroke 
recognition and determinants of stroke outcome. When a stroke occurs, patients need to be 
hospitalized immediately for a rapid assessment of the main subtype, i.e. ischemic or 
hemorrhagic. Ischemic strokes are treated with intravenous thrombolysis and, in case of a 
proximal artery occlusion, by intra-arterial mechanical thrombectomy.66-68 Recognizing a stroke 
is therefore of utmost importance. Elderly themselves, however, often experience difficulty 
recognizing symptoms of stroke.69,70 This might be even more difficult for some right 
hemispheric strokes, as these can lead to vague symptoms such as neglect, spatial 
disorientation or anosognosia.71 Previous studies noticed fewer right-sided than left-sided 
strokes and suggested this could either be due to the aforementioned recognition problems 
or due to an actual lower frequency of right-sided strokes, for instance as a consequence of 
differences in anatomy.72-74 To explain this difference, I compared in Chapter 5.1 clinical strokes 
to infarcts on MRI. I detected more left-sided than right-sided clinical strokes, but an equal 
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distribution of MRI infarcts in both hemispheres, suggesting that the difference has to do with 
recognition: right-sided strokes are more prone to be overlooked.  
 
As soon as the stroke is recognized, specified, and treated, patients are admitted to the stroke 
unit.66 Although improvement in stroke treatment has strongly improved functional outcome, 
improved stroke fatality and ageing of the population have increased the number of people 
who live with the long-term consequences after stroke, such as recurrent stroke, dementia, and 
death.4,67,68,75-78 The current approach to reduce these events is aggressive cardiovascular risk 
management, initiated directly after the diagnosis of stroke.79 However, in Chapter 5.2 and 5.3, 
I observed that pre-stroke cardiovascular risk factors contributed to 27% of deaths, 39% of 
recurrent strokes, and 10% of dementia cases after stroke. This suggests that prevention of 
consequences after stroke should preferably start before stroke. At time of secondary 
prevention, irreversible damage contributing to the consequences may have already occurred. 
Compared to previous studies on stroke prognosis,77,80-84 I had the advantage of being able to 
compare the results in the stroke patients with those in a stroke-free reference population. Risks 
of death, recurrent stroke, and dementia were 1.7 to 3 times higher in the stroke patients 
compared with the reference population. In the reference population, however, cardiovascular 
risk factors contributed to a similar amount of adverse events, suggesting that these factors 
cannot fully explain the increased risk in stroke patients. Therefore, further research into other 
factors is required. Subclinical large or small vessel disease may play a role, or inflammation, 
thrombosis, or cardiac dysfunction,85,86 but I did not yet have enough power to reliably 
investigate this.  
Education was not included in Chapter 5.2 and 5.3, since it is a non-cardiovascular marker 
and the potential to modify its effect is still unclear. Education may however have an additional 
effect on dementia after stroke, being a proposed marker of cognitive reserve.87 Cognitive 
reserve represents the ability of the brain to tolerate brain damage, in which people with higher 
reserve can handle more damage before it becomes apparent as dementia.88,89 In Chapter 5.4, 
I detected that higher education was associated with a lower risk of dementia after a stroke or 
TIA, particularly in men. This suggests that cognitive reserve might protect against dementia 
after a stroke or TIA. 
 
Methodological considerations 
My study was conducted within the framework of the prospective population-based 
Rotterdam Study.6 Benefits of this study are the large study population, currently consisting of 
14,926 participants aged 45 years and over, the availability of a large variety of exposures and 
the thorough collection of follow-up information. The Rotterdam Study has a thorough case 
finding for many diseases, including stroke and TIA, but also heart diseases, COPD, and COPD 
exacerbations.90-94 This allowed me to examine the association of cardiac dysfunction and 
stroke independent from heart disease, and even to examine the risk of stroke after a COPD 
exacerbation.  
Common biases in observational studies are selection bias, information bias, and 
confounding. These have been minimized by limiting the loss-to-follow-up, a thorough search 
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for outcomes blinded from the exposure, and adjustment for many known confounders. Still, 
some biases may have affected results of studies presented in this thesis to some extent as 
described in the following paragraphs. 
 
Healthy volunteer effect 
The healthy volunteer effect is a form of selection bias that may have affected my results since 
participation in the Rotterdam Study is voluntary.95,96 In order to assess many of the markers 
used in my thesis, subjects needed to attend the research center. People who were older, less 
educated, and had more cardiovascular risk factors were less likely to attend.95  Participation 
rates were, however, still high and as non-participants were often people at highest risk, the 
healthy volunteer effect was likely to result only in a slight underestimation of the effect if it 
had any effect at all. 
In the studies that required post-stroke visits, the healthy volunteer effect was stronger. 
After all, people with severe stroke are unlikely to visit the study center. My finding that 
cognitive decline after stroke or TIA is smaller in those with high compared to low education 
in the cognitive reserve study, can therefore only be generalized to people with minor strokes 
or TIA. Similarly, it has to be considered that in the study about recognition of left- and right-
sided strokes, people with severe stroke did not undergo an MRI scan. If left-sided strokes are 
more severe, this may explain why I found fewer left-sided infarcts on MRI than left-sided 
strokes in the total population. However, symptomatic infarcts were also more often left-sided 
compared to the silent infarcts in the MRI population, although not significantly, suggesting 
that results were robust. Yet, also these results may be less generalizable to people with severe 
stroke.  
The healthy volunteer effect is unlikely to have affected the results of the studies on stroke 
prognosis. The ascertainment of follow-up information through medical records continued 
also in participants who terminated their visits to the study center. My results even seem to be 
more valid and generalizable than those of previous studies, especially with respect to post-
stroke dementia. The population-based design and the continuous follow-up through medical 
records avoided selection bias and attrition that may have been present in the previous 
hospital-based studies that often did require a visit after stroke.77,97,98  
 
Misclassification of stroke subtypes 
Within the Rotterdam Study, participants are continuously monitored for occurrence of stroke 
using automated data-linkage of general practitioner files with the stroke database.90 
Additionally, medical records from people who moved out of the study area or moved to 
nursing homes are checked on a regular basis. Further data is obtained from hospital records. 
Potential events identified by medical records are reviewed by research physicians. The 
diagnosis is based on WHO criteria,99 and an experienced vascular neurologist verifies each 
diagnosis.90 This approach does not rely on participants’ memory and therefore prevents recall 
bias. Additionally, the availability of hospital records limits misclassification. Yet, some 
information bias is still present in the subclassification of stroke. Classification into ischemic and 
hemorrhagic is based on neuroimaging reports. Strokes are classified as unspecified if no 
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distribution of MRI infarcts in both hemispheres, suggesting that the difference has to do with 
recognition: right-sided strokes are more prone to be overlooked.  
 
As soon as the stroke is recognized, specified, and treated, patients are admitted to the stroke 
unit.66 Although improvement in stroke treatment has strongly improved functional outcome, 
improved stroke fatality and ageing of the population have increased the number of people 
who live with the long-term consequences after stroke, such as recurrent stroke, dementia, and 
death.4,67,68,75-78 The current approach to reduce these events is aggressive cardiovascular risk 
management, initiated directly after the diagnosis of stroke.79 However, in Chapter 5.2 and 5.3, 
I observed that pre-stroke cardiovascular risk factors contributed to 27% of deaths, 39% of 
recurrent strokes, and 10% of dementia cases after stroke. This suggests that prevention of 
consequences after stroke should preferably start before stroke. At time of secondary 
prevention, irreversible damage contributing to the consequences may have already occurred. 
Compared to previous studies on stroke prognosis,77,80-84 I had the advantage of being able to 
compare the results in the stroke patients with those in a stroke-free reference population. Risks 
of death, recurrent stroke, and dementia were 1.7 to 3 times higher in the stroke patients 
compared with the reference population. In the reference population, however, cardiovascular 
risk factors contributed to a similar amount of adverse events, suggesting that these factors 
cannot fully explain the increased risk in stroke patients. Therefore, further research into other 
factors is required. Subclinical large or small vessel disease may play a role, or inflammation, 
thrombosis, or cardiac dysfunction,85,86 but I did not yet have enough power to reliably 
investigate this.  
Education was not included in Chapter 5.2 and 5.3, since it is a non-cardiovascular marker 
and the potential to modify its effect is still unclear. Education may however have an additional 
effect on dementia after stroke, being a proposed marker of cognitive reserve.87 Cognitive 
reserve represents the ability of the brain to tolerate brain damage, in which people with higher 
reserve can handle more damage before it becomes apparent as dementia.88,89 In Chapter 5.4, 
I detected that higher education was associated with a lower risk of dementia after a stroke or 
TIA, particularly in men. This suggests that cognitive reserve might protect against dementia 
after a stroke or TIA. 
 
Methodological considerations 
My study was conducted within the framework of the prospective population-based 
Rotterdam Study.6 Benefits of this study are the large study population, currently consisting of 
14,926 participants aged 45 years and over, the availability of a large variety of exposures and 
the thorough collection of follow-up information. The Rotterdam Study has a thorough case 
finding for many diseases, including stroke and TIA, but also heart diseases, COPD, and COPD 
exacerbations.90-94 This allowed me to examine the association of cardiac dysfunction and 
stroke independent from heart disease, and even to examine the risk of stroke after a COPD 
exacerbation.  
Common biases in observational studies are selection bias, information bias, and 
confounding. These have been minimized by limiting the loss-to-follow-up, a thorough search 
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for outcomes blinded from the exposure, and adjustment for many known confounders. Still, 
some biases may have affected results of studies presented in this thesis to some extent as 
described in the following paragraphs. 
 
Healthy volunteer effect 
The healthy volunteer effect is a form of selection bias that may have affected my results since 
participation in the Rotterdam Study is voluntary.95,96 In order to assess many of the markers 
used in my thesis, subjects needed to attend the research center. People who were older, less 
educated, and had more cardiovascular risk factors were less likely to attend.95  Participation 
rates were, however, still high and as non-participants were often people at highest risk, the 
healthy volunteer effect was likely to result only in a slight underestimation of the effect if it 
had any effect at all. 
In the studies that required post-stroke visits, the healthy volunteer effect was stronger. 
After all, people with severe stroke are unlikely to visit the study center. My finding that 
cognitive decline after stroke or TIA is smaller in those with high compared to low education 
in the cognitive reserve study, can therefore only be generalized to people with minor strokes 
or TIA. Similarly, it has to be considered that in the study about recognition of left- and right-
sided strokes, people with severe stroke did not undergo an MRI scan. If left-sided strokes are 
more severe, this may explain why I found fewer left-sided infarcts on MRI than left-sided 
strokes in the total population. However, symptomatic infarcts were also more often left-sided 
compared to the silent infarcts in the MRI population, although not significantly, suggesting 
that results were robust. Yet, also these results may be less generalizable to people with severe 
stroke.  
The healthy volunteer effect is unlikely to have affected the results of the studies on stroke 
prognosis. The ascertainment of follow-up information through medical records continued 
also in participants who terminated their visits to the study center. My results even seem to be 
more valid and generalizable than those of previous studies, especially with respect to post-
stroke dementia. The population-based design and the continuous follow-up through medical 
records avoided selection bias and attrition that may have been present in the previous 
hospital-based studies that often did require a visit after stroke.77,97,98  
 
Misclassification of stroke subtypes 
Within the Rotterdam Study, participants are continuously monitored for occurrence of stroke 
using automated data-linkage of general practitioner files with the stroke database.90 
Additionally, medical records from people who moved out of the study area or moved to 
nursing homes are checked on a regular basis. Further data is obtained from hospital records. 
Potential events identified by medical records are reviewed by research physicians. The 
diagnosis is based on WHO criteria,99 and an experienced vascular neurologist verifies each 
diagnosis.90 This approach does not rely on participants’ memory and therefore prevents recall 
bias. Additionally, the availability of hospital records limits misclassification. Yet, some 
information bias is still present in the subclassification of stroke. Classification into ischemic and 
hemorrhagic is based on neuroimaging reports. Strokes are classified as unspecified if no 
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neuroimaging is performed.90 Since we also collected stroke data of people who were not 
admitted to the hospital, our study population contains a relatively large percentage of 
unspecified strokes (33%). People with unspecified strokes were on average older and had 
more risk factors and comorbidities compared to people with ischemic or hemorrhagic stroke. 
The consequences of this misclassification have been extensively described in a previous 
thesis.100 Misclassification may be differential, which means it can lead to both over and 
underestimation of the estimates of ischemic and hemorrhagic stroke. In the studies about 
echocardiography and anxiety and stroke, associations with unspecified strokes were in 
general stronger compared to the other subtypes. This suggests that this misclassification led 
to underestimation of the effects with ischemic and hemorrhagic stroke. In contrast, NT-
proBNP and COPD had a weaker association with unspecified strokes compared to other 
subtypes, suggesting that this misclassification led to an overestimation of the result with 
ischemic stroke. This implies that subtype analyses have to be interpreted with caution. 
However, in all studies even reclassifying all unspecified strokes as ischemic did not materially 
change the effects with ischemic stroke, suggesting our results were robust. Moreover, since 
an increasing number of people is now referred, this source of misclassification has reduced 
over time. Over the past 20 years it dropped from 40.5% in 1994 to just 8.0% in 2013 (Figure 1). 
  
 
       Figure 1. Trends in stroke subtypes per calendar year 
 
Even at a high age (90+) the frequency of unspecified strokes decreased from 75.0% in 1994-
1999 to 34.5% in 2009-2014 (Figure 2). Therefore, the misclassification had a smaller role in 
studies with a later baseline visit; e.g. the studies in which I related ICAC and microbleeds to 
stroke. 
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Figure 2. Trends in stroke subtypes per age category 
Trends in 1994-1999 (left) and 2009-2014 (right). 
 
Misclassification between TIA and stroke 
The definition of TIA suggests it leaves no permanent damage in the form of an infarct.101,102 
However, evidence is increasing that some TIA do leave (subtle) neurological damage.103 
Furthermore, studies using MRI revealed that many events classified as TIA do appear as infarct 
on later scans.104 They are actually strokes misclassified as TIA. To measure the extent of this 
misclassification in our study, I compared the results of clinical TIA to MRI infarcts (Box 1). My 
results suggest that approximately 15% of TIA is misclassified. This misclassification may be 
differential if people with more risk factors are more prone to get an MRI after their TIA. 
However, in most cases a CT was performed that showed no abnormalities. Misclassification is 
therefore likely to be non-differential. Even if this had any effect, it would be a dilution. 
 
Box 1. Misclassification between TIA and stroke 
Of the 5081 participants with an MRI scan,105 225 had one or more prevalent TIA. Participants who also 
experienced a stroke before the scan date (n=35) or who only had vertebrobasilar TIA or a TIA with unknown 
location, were excluded (n=57). This left 115 participants with left- or right-sided TIA for analysis. 64 people 
had one or more left-sided TIA, 57 one or more right-sided TIA. 
Of the 64 participants with a left-sided TIA, eight (12.5%) had a left-sided infarct on the MRI scan, and of 
the 57 participants with a right-sided TIA, eleven (19.3%) had a right-sided infarct on the MRI scan. Assuming 
that the infarct on MRI coincides temporarily with the TIA, this suggests that approximately 15% of TIA is 
misclassified. This percentage is lower than what was found in previous studies. Those studies found that 
44% of TIAs lead to diffusion abnormalities.106 This may be explained by a previous finding that only half of 
TIAs with diffusion abnormalities appear as infarcts on later scans.107 
 
Immortal time bias 
Immortal time is defined as a period of follow-up during which the outcome cannot occur.108 
This is present in studies that relate incident events to an outcome, in this thesis the study that 
related COPD to stroke and the studies that related pre-stroke risk factors to consequences 
after stroke. In the first study, the time between baseline and COPD was immortal time, in the 
last studies the time between baseline and stroke. People could not get a stroke before start of 
COPD and could not suffer from stroke consequences before they had the stroke. When 
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comparing exposed people (with incident event) to unexposed people (without incident 
event), it has to be considered that people were unexposed during this immortal time. 
Immortal time bias is introduced if this period is misclassified as exposed (information bias), or 
if it is excluded (selection bias) (Figure 3). In both cases, this will lead to an underestimation of 
the effect. It results in a spuriously high rate of cases among the unexposed, since a large period 
of unexposed time is missed or even misclassified.108,109  
This form of bias can be solved in several ways (Figure 4). The first is to use a time-
dependent analysis. This analysis attributes the unexposed time to the unexposed. I used this 
analysis in the study on COPD and stroke. A limitation is that COPD does not have a clear start. 
Using this method, the latent period will be classified as unexposed.  
 
Figure 3. Bias due to immortal time 
Immortal time bias introduced when the immortal time is misclassified (top) or when the immortal time is 
excluded (bottom). Adapted from Levesque et al.108 
 
A time-dependent analysis was unfeasible for our analysis on stroke prognosis, since my 
interest was not in the effect of stroke itself, but in the effect of pre-stroke factors. I therefore 
used a second solution, which is to include only survivors of the immortal person-time in both 
the exposed and unexposed groups.108 This was done by randomly matching unexposed 
stroke-free participants to the stroke cases at the date of the incident stroke (index date). It 
prevents immortal person-time bias by taking only survivors until the index date.108 This 
approach allowed me to use cardiovascular risk factors measured at approximately the same 
time before the index date in the exposed and unexposed.  
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Figure 4. Solutions to immortal time bias  
Top: use of a time-dependent analysis in which immortal time is classified as unexposed (as in actual 
situation). Bottom: exclude immortal time in both exposed and unexposed, for instance by using a nested 
matched cohort. Adapted from Levesque et al.108 
 
Residual confounding 
To prevent confounding, all analyses described in this thesis have been adjusted for a set of 
known confounding factors. However, some considerations need to be taken into account. I 
mostly adjusted for confounders that were measured once (at baseline), and which might not 
be representative for the life-long exposure. The markers for subclinical cardiovascular disease 
tested in this thesis may be better markers of life-long exposure to cardiovascular risk factors 
than the single measured risk factors I adjusted for. Therefore, although adjustment for 
cardiovascular risk factors did not change the effect, a shared etiology may still be a plausible 
explanation for their association with stroke. On the other hand, the markers may be mediators 
in the association between cardiovascular risk factors and stroke. Additionally, in the analysis 
with COPD and stroke and in the analysis with stroke prognosis, changes in therapy during 
follow-up may have affected the result. At time of COPD and at time of stroke, participants are 
expected to be more intensively treated. This may have given an underestimation of the effect. 
Another issue is that adjustment leads to overadjustment if the factors are in the causal 
pathway. Therefore, I always compared multivariable adjusted results to a basic model, which 
only adjusts for age and sex. Improving methods of mediation analysis may facilitate detecting 
whether factors function as confounders or mediators of an association.110  
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Population attributable risk 
In the study relating ICAC to stroke and in the studies that related pre-stroke cardiovascular risk 
factors to consequences after stroke, I used the population attributable risk (PAR) to describe 
what proportion of events is attributable to the exposure or combination of exposures. The 
PAR requires that associations are causal. A cause is defined as a “an antecedent event, 
condition or characteristic that was necessary for the occurrence of the disease at the moment 
it occurred, given that other conditions are fixed”.96 In other words, the event would not have 
occurred if this antecedent, condition, or characteristic was absent.96 However, most diseases 
have multiple causes, i.e. they are multifactorial. This includes stroke.3 The disease would be 
absent if either one of the causes is absent. This interaction between causes means that just 
adding up individual PARs would lead to an overestimation of the proportion of events that 
can be prevented. To reduce this effect we used adjusted PARs in our analyses. Still, some 
considerations need to be addressed. The PAR assumes that risk factors can be completely 
avoided and that the harmful effect disappears in an instant after removing the risk factor, 
which is generally false.1,111 It is often possible to modify a risk factor, but not to avoid it 
altogether. For the relationship between ICAC and stroke it is not even clear whether, or to 
what extent, the calcification is modifiable.112 Additionally, if one cause is eliminated, another 
set of causes may result in the event. This may lead to an overestimation of the PAR. In contrast, 
PARs with respect to pre-stroke risk factors may also be underestimated. I calculated the PAR 
of consequences after stroke assuming that the stroke would still occur. However, a more 
aggressive management of pre-stroke risk factors will also prevent the first-ever stroke and 
additionally reduce the burden of post-stroke consequences. A final consideration is that even 
if many events can be attributed to a single cause, for example, we estimated that 75% of 
strokes is attributable to ICAC, 100% of events can be attributable to other, possibly unknown 
causes. Such causes may interact with the already known factors.96 Therefore, the search for 
new factors needs to be continued until all strokes and consequences of stroke are eliminated.  
 
Clinical implications and future directions 
 
Prevention of stroke 
In my thesis, I identified several markers of subclinical cardiac dysfunction, large vessel disease, 
and small vessel disease to stroke. Being able to use this information for prevention strategies 
is of major clinical interest, since it may reduce the burden of stroke. There are two ways in 
which the detected factors may improve stroke prevention. Firstly, risk factors may be a direct 
target for prevention. Secondly, risk factors may identify people at high risk of stroke that 
benefit from more aggressive preventive management. In the following paragraphs, I will first 
discuss the potential use of our identified factors for prevention, followed by the use of these 
factors for stroke prediction. 
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Potential targets for prevention 
Requisites for a marker to be a direct target for stroke prevention are that the factor is causally 
related to stroke and that it is modifiable. Three factors described in this thesis may fulfill this 
requirement, namely a steep blood pressure increase, cardiac dysfunction, and ICAC. 
The study in which I related blood pressure trajectories to stroke raised the question 
whether blood pressure management can be improved if people with fast increasing blood 
pressure are treated irrespective of their blood pressure level. The trajectory with a steep 
increase was associated with a high risk of stroke and death. Since blood pressure is highly 
treatable and the class characterized by a steep increase had limited use of blood pressure 
lowering medication, the occurrence of a steep increase may be a potential target for 
prevention. However, the increased risk in this trajectory may also be the consequence of 
several non-causal explanations, e.g. limited access to health care, difference in health 
behaviors, and competing risks. Future studies should therefore determine the etiologic 
significance of this finding. This can subsequently allow for examination of the potential for 
prevention. 
The same applies to cardiac dysfunction. Cardiac dysfunction may causally relate to stroke 
through cardioembolism26 or cerebral hypoperfusion.27 However, shared etiology may also play 
a role. Although associations in our studies remained after adjustment for cardiovascular risk 
factors, subclinical cardiac dysfunction may better reflect the long-term strain of cardiovascular 
risk factors on the heart than a single measurement of those risk factors. Before it is possible to 
examine the preventive potential, we need to be confident about the causal effect. 
Importantly, if the association is caused by cardioembolism, people may need to be treated 
with oral anticoagulants.113 
The finding that 75% of strokes can be attributed to intracranial carotid atherosclerosis 
arouses interest in whether ICAC can be a target for prevention. It might be that the plaques 
themselves cause stroke, since they are a source of emboli. On the other hand, ICAC may also 
reflect atherosclerosis in other vessels of the brain. Furthermore, it is unclear whether this can 
be a direct target for treatment. So far, intensive medical management with antiplatelet 
therapy, intensive management of vascular risk factors, and life-style modification appear to 
outweigh the effect of stenting in symptomatic intracranial stenosis.112,114 Whether similar 
aggressive management can be beneficial in an asymptomatic population with ICAC needs to 
be further explored.  
 
Potential markers for stroke prediction 
Markers that cannot be a direct target for prevention, may still be helpful for stroke prediction. 
To determine whether a marker is useful for stroke prediction, the incremental predictive value 
of this new marker above known markers needs to be investigated. The detected markers of 
cardiac disease, large vessel disease, and small vessel disease should for instance be added to 
risk assessment tools such as the Framingham Stroke Profile, Qstroke, or the Stroke 
RiskometerTM.115-117 Even if they improve prediction, it remains to be seen if CT, 
echocardiography, and MRI are feasible screening tools. Their costs are high and CT gives 
radiation exposure. A laboratory marker, such as NT-proBNP, is easier to use for screening 
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purposes and has therefore been tested. It appears to improve prediction of stroke and 
coronary heart disease.24,118 Another question is what therapy should be initiated in people at 
high risk of stroke. Detection of a high risk population is only useful if there are methods to 
reduce their risk. Treatment of risk factors such as hypertension, hypercholesterolemia, and 
diabetes is well accepted and has proven to be effective.3 However, the treatment with aspirin 
in people without a cardiovascular event remains subject of discussion.3,119,120 So far, trials with 
people without cardiovascular disease only showed a modest reduction in total cardiovascular 
events, but not of stroke or cardiovascular deaths.3,119,120 Guidelines therefore suggest that use 
of aspirin may be reasonable in people with sufficiently high risk, but especially for prevention 
of cardiac disease.3 However, when prediction of stroke improves, the detection of high risk 
groups will become more accurate, which could lead to better trial results also for stroke. 
 
Primary prevention to reduce the consequences after stroke 
A better prevention of stroke will subsequently prevent its consequences, but in this paragraph 
I will further discuss the possibilities for prevention by translating our results on stroke 
prognosis into clinical practice. The three principle strategies in secondary prevention are 
lowering of blood pressure, statin therapy, and antiplatelet therapy (or oral anticoagulants in 
selected patients), with the aim to reduce the increased vascular risk after stroke.121 My main 
message from Chapter 5.2 and 5.3 was, however, that secondary prevention may be 
insufficient to prevent all adverse consequences after stroke, since pre-stroke cardiovascular 
risk factors already largely contribute to the adverse prognosis after stroke. Primary prevention 
is necessary to reduce these consequences. Risk factors important for prognosis were 
hypertension, diabetes, and smoking, and for mortality also atrial fibrillation. Since attacking 
these factors is already a goal of primary prevention,3 this raises the question whether and how 
this can be further improved. Room for further improvement may be in the awareness of risk 
factors and the adherence to treatment and lifestyle changes. Many people are never tested 
for cardiovascular risk factors and therefore may be unaware of their cardiovascular risk.3,122 
Furthermore, of those who are aware of their risk factors, only half adheres to the therapy 
prescribed.123,124 Poor awareness and adherence is a major risk factor for stroke and possibly of 
the consequences after stroke.125 Prevention programs should therefore further improve and 
test all people above a certain age (e.g. 50 years) for risk factors.3 Furthermore, more awareness 
among the general population of their cardiovascular risk and its consequences is necessary.3 
Our finding that these factors also influence the consequences of stroke may be a further 
incentive for people to keep using their medication.  
Cognitive reserve is another factor that may be a target for prevention of dementia after 
stroke besides the cardiovascular risk factors. Higher education, occupation, learning another 
language and playing a musical instrument have all been related to a higher cognitive 
reserve.126-128 However, people engaging in these activities may also have a healthier lifestyle 
with fewer risk factors compared to people who do not. This may result in fewer severe strokes 
and consequently a lower risk of dementia. Future studies should determine whether cognitive 
reserve can be enhanced and consequently prevent dementia after stroke.  
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Novel risk factors for the prognosis after stroke 
Although 10-39% of the consequences after stroke could be attributed to pre-stroke risk 
factors, an even larger part of the consequences remained unexplained. This encourages 
further study of novel risk factors. Other pre-stroke markers that are potentially useful to define 
the risk of adverse events after stroke are genetic markers, imaging markers of large and small 
vessel disease85 and biomarkers of inflammation, thrombosis, or cardiac dysfunction.86 As 
described previously, such factors may not be direct targets for prevention, but may identify 
those people who need more aggressive therapy.  
Studying risk factors for stroke severity is another approach to detect factors that relate to 
adverse events after stroke. Factors that increase the severity of stroke, may subsequently 
increase the risk of its consequences.129 Population-based studies are required to properly 
investigate these risks, since they measure risk factors before stroke occurs. However, these 
studies often need to assess stroke severity retrospectively based on medical records. Medical 
records often lack specific information on symptoms, and unfortunately still rarely mention the 
NIH Stroke Scale (NIHSS) score, a well-validated score for severity.130,131 Still, since symptoms that 
are not described are usually absent, the score appears to be reliable even if retrospectively 
assessed using medical records.132 The value of the information is therefore likely to outweigh 
the small risk of misclassification.  
 
Directions for future stroke research 
A main question for future stroke research is why even though many of its risk factors are 
known stroke remains such a major health problem.1,2 Could it be that prevention starts too 
late? What part is caused by a poor compliance with preventive measures? Do we require novel 
preventive therapies? Novel research should define the proportion of events that occurs due 
to undertreatment, for instance as a consequence of low adherence to or unawareness of the 
condition or guidelines. Research into risk factors should also be continued. We particularly 
need to be able to detect abnormalities within the pathophysiological pathway earlier in time. 
Although factors like NT-proBNP and ICAC are subclinical, they may appear relatively late, 
reflecting the life-time exposure of risk factors. Knowing the starting point of abnormalities may 
further inform about the moment prevention should be initiated. To do so, imaging is of value, 
possibly at a younger starting age. Research into genetics and metabolomics could also add 
information,133-135 especially if this further focuses on specific pathways, such as large or small 
vessel disease.136 Finally, the use of longitudinal data is likely to be of additional value. Similarly 
to the long-term pattern of blood pressure, change over time in markers of cardiac dysfunction, 
cerebral small vessel disease and large vessel disease may enhance the understanding of stroke 
occurrence. 
 
Concluding remarks 
 
The scientific discoveries described in my thesis provide a useful insight in the relationship 
between subclinical pathology and stroke and hence may provide the basis for future studies 
that examine the value of these markers for stroke prediction. Furthermore, they reveal the 
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importance of pre-stroke risk factors to reduce the consequences after stroke. Although the 
knowledge on stroke is rapidly expanding, the solution to prevent all strokes is still a long way 
off. Hopefully, my results will inspire novel research and bring us a step further towards a better 
prevention of stroke and its consequences. More research remains necessary to determine 
when to start with prevention, how to interfere with the subclinical pathways leading to stroke 
and whether it is possible overturn this subclinical process. 
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Summary 
 
Despite knowledge on many risk factors, stroke remains the second leading cause of death and 
a major cause of disability. Further improvement of stroke prevention is therefore essential. This 
may be achieved by early intervention in the process that leads to stroke, which requires a 
thorough knowledge on the pathophysiology of stroke. Cardiac abnormalities, as well as large 
and small vessel disease evolve silently for years before suddenly blocking a vessel to the brain, 
which causes a stroke. Imaging and laboratory markers that can identify this preclinical damage 
are emerging. Studying their relation with stroke may help us to understand the 
pathophysiology of stroke and to detect people at high risk of stroke and may inspire us to find 
novel options for prevention. Additionally, a better insight in the adverse consequences of 
stroke is mandatory, since these further increase the burden of stroke. Possible consequences 
not only include recurrent stroke and dementia, but also death. Since they often have a vascular 
background and vascular pathology already accumulates years before the stroke, pre-stroke 
cardiovascular risk factors might predispose to these clinical adverse events after stroke. 
Therefore, my thesis had the following aims: First, to detect novel determinants of stroke, 
mainly focused on the cardiovascular system. Second, to detect pre-stroke risk factors for the 
long-term consequences after stroke. All studies were embedded in the Rotterdam Study, a 
population-based cohort study currently consisting of 14,926 participants aged 45 years and 
over. 
 
Chapter 2 focused on subclinical markers of cardiac disease and their relation with stroke. 
People without cardiac disease may have abnormalities of the heart. To determine the 
association between subclinical cardiac disease and stroke, I used echocardiographic values of 
people without clinical cardiac disease in Chapter 2.1. I detected that both a diminished 
systolic and diastolic function were related to an increased risk of stroke, even though these 
values were not severe enough to diagnose participants with heart failure. The relation 
between subclinical cardiac dysfunction and stroke was further emphasized by my findings in 
Chapter 2.2. A higher N-terminal pro-B-type natriuretic peptide (NT-proBNP), which reflects 
increased ventricular wall stress of the heart, was related to an increased risk of stroke and 
transient ischemic attack (TIA), even in people without cardiac disease before their stroke or 
TIA. Results of these two studies suggest that cardiac dysfunction measured by 
echocardiography and by NT-proBNP can serve as an early marker for stroke.  
In Chapter 3 the search for subclinical markers continued, with focus on two other etiologic 
pathways for stroke, i.e. large and small vessel disease. Intracranial carotid artery calcification 
(ICAC) is a large vessel disease marker of interest for stroke, since it is a proxy for atherosclerosis 
in the intracranial vessels. In Chapter 3.1, I used CT-scans to show that presence of ICAC 
increased the risk of stroke four-fold and contributed to 75% of strokes. Interestingly, ICAC had 
a stronger association with stroke compared to values of atherosclerosis further from the brain, 
suggesting that the location of atherosclerosis is important. Another vascular marker close to 
the brain is vasomotor reactivity. It is measured in the medial cerebral artery and reflects 
cerebral autoregulation. Despite the close relation to the brain, I observed in Chapter 3.2 that 
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this marker was only associated with mortality, and not with stroke, suggesting that a 
diminished vasomotor reactivity reflects a more systemic instead of local dysfunction of the 
vascular system.  
A small vessel disease marker that raised my interest was presence of microbleeds. Previous 
studies showed that silent lacunar infarcts and white matter lesions, which are other markers 
of small vessel disease, relate to an increased risk of ischemic stroke. In Chapter 3.3, I showed 
that microbleeds relate to an increased risk of both ischemic and hemorrhagic stroke. These 
results were independent of lacunar infarcts and white matter lesions, suggesting microbleeds 
may be a useful marker of subclinical cerebrovascular pathology in the general population.  
Having studied several large and small vessel disease markers, my next step was to examine 
whether large and small vessel disease reflect separate etiologies of stroke. This is a common 
assumption since they are associated with different stroke subtypes, namely cortical versus 
lacunar. In Chapter 3.4, I question this assumption, since the risk of stroke and TIA was only 
increased in people with a combination of impaired brain perfusion and large retinal venules. 
Since impaired brain perfusion is a possible marker of large vessel disease, and large retinal 
venules of small vessel disease, this suggests that pathophysiological mechanisms may overlap 
and interact. This, however, needs further exploration. Severe small-vessel disease can also 
induce a lower blood flow, which is another explanation for the higher risk of stroke in people 
who have both. 
The final part of this chapter (Chapter 3.5) focused on blood pressure, which is a major risk 
factor for stroke, possibly through its effect on large and small vessel disease. I examined the 
association of long-term trajectories of systolic blood pressure with stroke and death. Current 
treatment guidelines only target high levels of blood pressure, whereas trajectories may 
provide additional information. I observed that not only levels, but also trajectories of blood 
pressure are associated with the risk of stroke and mortality. Of particular interest was my 
finding that the trajectory characterized by a steep increase in blood pressure was associated 
with a high risk of stroke and death. This is potentially important for preventive strategies. 
 
Chapter 4 described the association between two primarily non-cardiovascular diseases and 
stroke, namely COPD and anxiety. Both diseases may affect the cardiovascular system, which 
suggests they potentially relate to stroke. A connection was indeed found in Chapter 4.1. 
COPD was associated with an increased risk of stroke, both ischemic and hemorrhagic. This was 
mainly the consequence of a shared etiology of smoking, but for atherosclerotic subtypes of 
stroke there may also be a direct causal effect. Furthermore, I detected people were at high risk 
of stroke following severe exacerbations. In Chapter 4.2, I assessed that neither anxiety 
symptoms nor anxiety disorders were related to stroke. Anxiety symptoms were only related 
to an increased risk of stroke in the short-term, which may reflect reverse causality. People may 
experience a deteriorating health in the years preceding stroke and become anxious in 
response.  
 
Chapter 5 was dedicated to challenges after stroke. Chapter 5.1 was inspired by studies that 
noticed a higher frequency of left-sided strokes compared to right-sided strokes. I investigated 
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pressure are associated with the risk of stroke and mortality. Of particular interest was my 
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Chapter 4 described the association between two primarily non-cardiovascular diseases and 
stroke, namely COPD and anxiety. Both diseases may affect the cardiovascular system, which 
suggests they potentially relate to stroke. A connection was indeed found in Chapter 4.1. 
COPD was associated with an increased risk of stroke, both ischemic and hemorrhagic. This was 
mainly the consequence of a shared etiology of smoking, but for atherosclerotic subtypes of 
stroke there may also be a direct causal effect. Furthermore, I detected people were at high risk 
of stroke following severe exacerbations. In Chapter 4.2, I assessed that neither anxiety 
symptoms nor anxiety disorders were related to stroke. Anxiety symptoms were only related 
to an increased risk of stroke in the short-term, which may reflect reverse causality. People may 
experience a deteriorating health in the years preceding stroke and become anxious in 
response.  
 
Chapter 5 was dedicated to challenges after stroke. Chapter 5.1 was inspired by studies that 
noticed a higher frequency of left-sided strokes compared to right-sided strokes. I investigated 
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whether this was the consequence of a better recognition of left-sided strokes or whether left-
sided infarcts actually occur more often. I compared the left-right sided distribution of clinical 
strokes and TIA to the distribution of infarcts on MRI. My finding that clinical strokes and TIA are 
more frequently left-sided than right-sided, and that infarcts on MRI are more evenly 
distributed, suggests that right-sided strokes are more prone to be overlooked.  
In the remaining paragraphs of Chapter 5, I aimed to examine the association between 
pre-stroke risk factors and consequences after stroke. In Chapter 5.2 and 5.3, I detected that 
pre-stroke cardiovascular risk factors contribute to 27% of deaths, 39% of recurrent strokes, and 
10% of dementia cases after stroke. This suggests that secondary prevention may be initiated 
too late to prevent these events and underlines the importance of primary prevention from 
another perspective. Since pre-stroke cardiovascular risk factors could not fully explain the 
higher risk of stroke, dementia, and death people in people with stroke, results of this chapter 
also encourage research into novel risk factors for adverse events after stroke. One novel risk 
factor for dementia after stroke or TIA may be a low cognitive reserve. Cognitive reserve reflects 
someone’s ability to cope with brain pathology. In Chapter 5.4, I related education, a proposed 
marker of cognitive reserve, with dementia after a stroke or TIA. I detected that people, 
particularly men, with higher education had a lower risk of dementia after stroke compared to 
people with low education. I therefore concluded that cognitive reserve might protect against 
dementia after stroke or TIA.  
 
In Chapter 6, I reviewed the main findings of my thesis in light of previous literature, discussed 
methodological issues, and translated the findings into potential clinical implications. To 
summarize, I found that subclinical pathology in the heart, large vessels, and small vessels all 
relate to an increased risk of stroke. This should form the basis for future studies into the 
predictive value of these markers. Additionally, I underlined the importance of an early start of 
prevention, since pathology is present early in time and even contributes to the adverse 
consequences after stroke. Future studies should continue the search for early abnormalities 
and their change over time, which hopefully will eventually give us the opportunity to slow 
down or stop their further deterioration towards stroke.  
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Samenvatting 
 
Ondanks dat veel risicofactoren al bekend zijn, blijft de beroerte de op één na meest 
voorkomende doodsoorzaak en een belangrijke oorzaak van invaliditeit. Een verdere 
verbetering van beroertepreventie is dan ook van groot belang. Dit kan bereikt worden door 
vroeg in te grijpen in het proces dat leidt tot een beroerte, wat een grondige kennis over de 
pathofysiologie van beroertes vereist. Hartafwijkingen en macro- en microvasculaire schade 
hebben vaak een lange onopvallende aanloop, voordat ze plots een bloedvat in de hersenen 
blokkeren en zo een beroerte veroorzaken. Met nieuwe imaging- en laboratoriummarkers kan 
deze subklinische schade steeds beter in beeld gebracht worden. Het bestuderen van de 
relatie tussen zulke markers en beroertes kan ons verder helpen de pathofysiologie van 
beroertes te begrijpen, mensen met een hoog risico op beroertes te detecteren en ideeën voor 
preventie op te doen. Daarnaast is het van belang om een beter inzicht te krijgen in de 
schadelijke gevolgen van beroertes. Deze omvatten een recidief beroerte, dementie en 
overlijden en hebben vaak een vasculaire oorzaak. Gezien de geleidelijke toename van 
vasculaire pathologie in de periode voor de beroerte, is het mogelijk dat cardiovasculaire 
risicofactoren die al aanwezig waren voor de beroerte, bijdragen aan deze schadelijke 
gevolgen van beroertes. 
De doelen van mijn proefschrift waren daarom als volgt: ten eerste, het ontdekken van 
nieuwe determinanten van beroertes, met een focus op het cardiovasculaire systeem. Ten 
tweede, het ontdekken van risicofactoren aanwezig vóór de beroerte die bijdragen aan de 
gevolgen na een beroerte. Alle studies waren onderdeel van de Rotterdam Studie (ERGO 
onderzoek). Dit is een langlopende cohortstudie die inmiddels bestaat uit 14.926 deelnemers 
van 45 jaar en ouder. 
 
Hoofdstuk 2 is gericht op subklinische markers van hartziekten en hun relatie met beroertes. 
Mensen zonder hartziekten kunnen namelijk al hartafwijkingen hebben. Om de associatie 
tussen subklinische hartziekte en beroertes te onderzoeken, gebruikte ik in Hoofdstuk 2.1 
echocardiografische waarden van mensen zonder klinische hartziekten. Ik ontdekte dat zowel 
een verminderde systolische als een verminderde diastolische functie gerelateerd was aan een 
verhoogd risico op beroertes, zelfs ondanks dat deze waarden niet ernstig genoeg waren voor 
de diagnose hartfalen. De relatie tussen een subklinisch verminderde hartfunctie en beroertes 
werd verder ondersteund door mijn bevindingen in Hoofdstuk 2.2. Een hogere NT-proBNP 
waarde, wat betekent dat het hart zwaarder belast wordt, was gerelateerd aan een verhoogd 
risico op beroertes en TIA’s, zelfs in mensen die nooit een hartziekte hadden gehad. 
Bovenstaande studies laten zien dat een verminderde hartfunctie gemeten met 
echocardiografie of met NT-proBNP gebruikt kan worden als vroege marker voor beroertes.  
In Hoofdstuk 3 vervolgde ik de zoektocht naar subklinische markers, met een focus op 
twee andere etiologische routes voor beroertes, namelijk macro- en microvasculaire schade. 
Verkalking in de intracraniële arteriën is een macrovasculaire risicofactor die vanwege zijn 
locatie interessant is voor beroertes. In Hoofdstuk 3.1 vond ik dat verkalking in de intracraniële 
arteriën, gemeten op CT-scans, het risico op beroertes verviervoudigde en dat het bijdroeg aan 
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Verkalking in de intracraniële arteriën is een macrovasculaire risicofactor die vanwege zijn 
locatie interessant is voor beroertes. In Hoofdstuk 3.1 vond ik dat verkalking in de intracraniële 
arteriën, gemeten op CT-scans, het risico op beroertes verviervoudigde en dat het bijdroeg aan 
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75% van de beroertes. Een andere interessante bevinding was dat intracraniële atherosclerose 
een sterkere relatie had met beroertes dan atherosclerose verder weg van de hersenen. Dit 
suggereert dat de locatie van atherosclerose van belang is. Een andere vasculaire marker 
dichtbij de hersenen is de reactiviteit van de cerebrale vaten. Dit wordt gemeten in de arteria 
cerebri media en is een reflectie van de cerebrale autoregulatie. Ondanks dat deze marker 
vlakbij de hersenen gemeten wordt, vonden we in Hoofdstuk 3.2 alleen een relatie met 
overlijden en niet met beroertes. Dit suggereert dat een verminderde reactiviteit van de 
cerebrale vaten meer een systemisch dan een lokale verminderde functie van het vaatsysteem 
weergeeft.  
De microvasculaire marker waar ik geïnteresseerd in was, was de aanwezigheid van 
microbloedingen. Het is bekend dat andere markers van microvasculaire schade, zoals stille 
lacunaire infarcten en witte stof afwijkingen, gerelateerd zijn aan een verhoogd risico op 
herseninfarcten. In Hoofdstuk 3.3 liet ik zien dat microbloedingen een verhoogd risico op 
zowel herseninfarcten als hersenbloedingen geven. Deze resultaten waren onafhankelijk van 
de aanwezigheid van lacunaire infarcten of witte stof afwijkingen, wat suggereert dat 
microbloedingen een bruikbare marker voor subklinische microvasculaire schade kunnen zijn 
in de algemene populatie. 
Na het bestuderen van markers voor macro- en microvasculaire schade, was mijn volgende 
stap om te onderzoeken of macro- en microvasculaire schade elkaars risico op beroertes 
versterken. Er wordt vaak gedacht dat het verschillende etiologische routes zijn, aangezien ze 
geassocieerd zijn met verschillende subtypes van beroertes, namelijk corticaal versus lacunair. 
Ik trek deze assumptie in twijfel in Hoofdstuk 3.4, aangezien het risico op beroertes en TIA’s 
alleen verhoogd was in mensen met een combinatie van een verminderde breinperfusie en 
verwijde retinavenen. Een verminderde breinperfusie is een mogelijke marker van 
macrovasculaire schade en wijde retinavenen van microvasculaire schade. Dit suggereert dat 
verschillende pathofysiologische mechanismen elkaar overlappen en versterken. Hier is nog 
wel extra onderzoek voor nodig. Microvasculaire schade kan namelijk ook een verminderde 
breinperfusie veroorzaken. Dit is een mogelijke andere verklaring voor waarom mensen met 
beide afwijkingen een verhoogd risico op beroertes hebben. 
Het laatste deel van dit hoofdstuk (Hoofdstuk 3.5) richtte zich op bloeddruk, een 
belangrijke risicofactor voor beroertes, waarschijnlijk door zijn effect op zowel macro- als 
microvasculaire schade. Ik onderzocht de associatie tussen het lange termijn verloop van 
systolische bloeddruk en beroertes en overlijden. Huidige richtlijnen voor de behandeling van 
te hoge bloeddruk richten zich nu alleen nog maar op de hoogte van de bloeddruk, terwijl het 
verloop in de tijd extra informatie kan geven. Ik vond dat niet alleen de hoogte, maar ook het 
verloop van bloeddruk in de tijd geassocieerd was met het risico op beroertes en overlijden. 
Een belangrijke bevinding was dat de groep met een sterke toename in bloeddruk een 
verhoogd risico op beroertes en overlijden had, zelfs op het moment dat de bloeddruk zelf nog 
niet sterk verhoogd was. Dit is mogelijk van belang voor preventiestrategieën.  
 
Hoofdstuk 4 beschrijft de associatie tussen twee niet-cardiovasculaire ziekten en beroertes, 
namelijk COPD en angst. Voor beiden is gesuggereerd dat ze het cardiovasculaire systeem 
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beïnvloeden, wat mogelijk een verhoogd risico op beroertes geeft. In Hoofdstuk 4.1 vond ik 
dat aanwezigheid van COPD inderdaad het risico op beroertes verhoogt, zowel het risico op 
herseninfarcten als hersenbloedingen. Dit kwam met name door het gedeelde effect van roken 
op zowel COPD als beroertes, maar mogelijk is er ook een causaal verband tussen COPD en 
beroertes van het atherosclerotische subtype. Daarnaast vond ik dat COPD patiënten een 
verhoogd risico op beroertes hadden na een ernstige exacerbatie. In Hoofdstuk 4.2 stelde ik 
vast dat angstsymptomen en angststoornissen beiden niet gerelateerd waren aan een 
verhoogd risico op beroertes. Angstsymptomen waren alleen gerelateerd aan een verhoogd 
risico op beroertes op de korte termijn. Dit komt mogelijk doordat mensen in de jaren voor 
hun beroerte achteruitgaan in hun gezondheid en daar angstig van worden.  
 
Hoofdstuk 5 was gericht op problemen na de beroertes. Inspiratie voor Hoofdstuk 5.1 kwam 
van studies die opmerkten dat linkszijdige beroertes vaker voorkomen dan rechtszijdige 
beroertes. Ik onderzocht of dit het gevolg was van een betere herkenning van linkszijdige 
beroertes of van het werkelijk vaker optreden van linkszijdige infarcten. Ik vergeleek de links- 
versus rechtszijdige distributie van klinische beroertes en TIA’s met de distributie van infarcten 
op MRI. Ik vond dat klinische beroertes en TIA’s vaker linkszijdig waren dan rechtszijdig, maar 
dat dit verschil voor infarcten op MRI significant kleiner was. Hieruit concludeerde ik dat 
rechtszijdige beroertes vaker over het hoofd worden gezien.  
In de laatste paragrafen van Hoofdstuk 5 onderzocht ik de associatie tussen risicofactoren 
aanwezig voor de beroerte en de gevolgen na de beroerte. In Hoofdstuk 5.2 en 5.3 vond ik 
dat cardiovasculaire risicofactoren gemeten voor de beroerte bijdroegen aan 27% van de 
overlijdens, aan 39% van de recidief beroertes en aan 10% van de dementiegevallen na de 
beroerte. Dit suggereert dat secundaire preventie te laat komt om deze gevolgen te 
voorkomen en laat vanuit een ander perspectief zien dat primaire preventie zeer belangrijk is. 
Aangezien de risicofactoren gemeten voor de beroerte niet volledig het verhoogde risico op 
recidief beroertes, dementie en overlijden in patiënten met beroertes konden verklaren, 
moedigen de resultaten in deze hoofdstukken ook aan om extra onderzoek te doen naar 
risicofactoren voor schadelijke gevolgen van beroertes. Eén nieuwe risicofactor voor dementie 
na een beroerte of TIA is mogelijk een lage cognitieve reserve. Iemands cognitieve reserve 
weerspiegelt zijn vermogen om hersenschade op te vangen. In Hoofdstuk 5.4 relateerde ik 
onderwijs, een mogelijke marker van cognitieve reserve, met dementie na een beroerte of TIA. 
Ik vond dat mensen, voornamelijk mannen, die hoger onderwijs hadden genoten een lager 
risico hadden op dementie na een beroerte vergeleken met mensen die lager onderwijs 
hadden gehad. Ik concludeerde hieruit dat cognitieve reserve mogelijk beschermt tegen 
dementie na een beroerte of TIA. 
 
In Hoofdstuk 6 bediscussieerde ik de belangrijkste bevindingen van mijn proefschrift, de 
methodologische problemen en de potentiële klinische implicaties van mijn bevindingen. 
Samenvattend vond ik dat zowel subklinische schade in het hart, als in de grote en kleine vaten 
gerelateerd was aan een verhoogd risico op beroertes. Dit kan de basis vormen voor 
toekomstige studies naar de voorspellende waarde van deze markers. Daarnaast onderstreepte 
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ik het belang van een vroege start van primaire preventie, aangezien pathologie vaak al vroeg 
aanwezig is en zelfs bijdraagt aan de schadelijke gevolgen na de beroerte. Toekomstige studies 
zullen de zoektocht naar vroegtijdige afwijkingen en hun verloop in de tijd moeten 
continueren. Hopelijk geeft dat ons uiteindelijk de mogelijkheid om hun voortschrijding 
richting een beroerte te voorkomen.  
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Dankwoord 
Dit proefschrift is mede tot stand gekomen dankzij de hulp en steun van vele anderen. Ik wil 
iedereen daar hartelijk voor bedanken. Een aantal mensen wil ik in het bijzonder noemen. 
  
Allereerst mijn promotoren, professor Bert Hofman en professor Peter Koudstaal. Beste Bert, 
hartelijk dank dat deel uit mocht maken van de beroemde Rotterdam Study. Beste Peter, ik 
weet nog als de dag van gisteren dat ik je enthousiaste telefoontje kreeg, met daarin de vraag 
of ik geïnteresseerd was in dit onderzoek. Ik hoefde geen moment te twijfelen. Tijdens het 
onderzoek heb ik je enthousiasme en je scherpe klinische blik altijd erg gewaardeerd. Ik hoop 
dat ik ook in de kliniek nog veel van je zal leren. 
  
Dr. Arfan Ikram, waarschijnlijk al bijna professor Arfan Ikram. Als copromotor was jij mijn 
dagelijkse begeleider en ik heb erg veel van je mogen leren. Ik bewonder je epidemiologische 
kennis en je manier van schrijven. Jij weet altijd in een artikel elk woord op de juiste plek te 
zetten. Dit heeft me enorm geholpen mijn kennis en manier van schrijven te verbeteren. Ik 
hoop nog vaker met je samen te werken en anders zie ik je vast nog eens op de fiets op de 
Erasmusbrug. 
  
Daarnaast wil ik de leden van de kleine promotiecommissie bedanken, professor Geert Jan 
Biessels, professor Diederik Dippel en dr. Meike Vernooij. Hartelijk dank dat jullie de tijd wilden 
nemen om mijn proefschrift kritisch door te nemen. Beste Geert Jan, nadat je me de eerste 
stapjes in de wetenschappelijke wereld hebt laten zetten ben ik blij dat je nu ook deel wil 
uitmaken van mijn volgende wetenschappelijke stap. Beste Diederik, als leider van de 
befaamde MrClean study ben ik vereerd dat je deel wil uitmaken van deze commissie. Ik hoop 
ook in de kliniek nog veel van je stroke kennis te leren. Beste Meike, je heldere opmerkingen 
tijdens de groepsmeetings zorgden vaak voor nieuwe ideeën. Dank je wel daarvoor.  
  
De manuscripten in dit proefschrift waren er ook niet geweest zonder de medewerking van 
alle coauteurs. Hartelijk dank voor jullie waardevolle feedback. Beste Maarten, Michiel, Maryam 
en Lies, dank voor jullie hulp en waardevolle inzichten. Beste Oscar Franco, Henning Tiemeier, 
Bruno Stricker en Guy Brusselle. Dankzij jullie commentaar heb ik ook wat van jullie kennis mee 
kunnen krijgen. Hartelijk dank daarvoor. 
  
Het belangrijkste onderdeel van de Rotterdam Study / het ERGO onderzoek, zijn echter de 
deelnemers. Zonder hen hadden we nooit zoveel data gehad om dit onderzoek te kunnen 
doen. Ik wil hen bij dezen bedanken voor al hun inzet. Daarnaast wil ik Anneke Korving, de FUP-
sters en alle andere medewerkers van het ERGO-centrum bedanken. Ik voelde me altijd welkom 
tijdens de uitschrijf- of CAMDEX-diensten.  
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Een speciaal woord van dank ook voor Jolande en Frank. Dankzij jullie supersnelle acties lukte 
het ons meermalen om snel een nieuw up-to-date stroke bestand af te krijgen, jullie verdienen 
nog veel meer stroopwafels! Beste Gabriëlle, bedankt voor al je hulp als er iets geregeld moest 
worden. Beste Nano, bedankt voor het oplossen van alle computerproblemen. 
  
Het doen van onderzoek was echter nooit zo leuk geworden zonder alle gezelligheid van de 
collega-promovendi in de neuro-epi groep, of dit nu was tijdens meetings, uitjes, lunches of 
overlegmomentjes op de kamers. Ana, Ayesha, Ben, Daniel, Frank, Hazel, Hieab, Hoyan, Jasper, 
Jory, Liselotte, Liz, Lotte, Renée, Rens, Saira, Saloua, Sanaz, Sirwan, Sonja, Sven, Tavia, Unal en 
Vincent, hartelijk dank daarvoor!  
Renée, jij ving me op de eerste dag en leerde mij de kneepjes van het vak tijdens het 
schrijven van het eerste artikel. Ik heb veel je zorgvuldigheid en perfectionisme geleerd en ben 
blij dat we nog meer samen hebben geschreven en nu opnieuw collega’s zijn. Saloua, ik heb 
veel plezier gehad tijdens de stroke congressen samen met jou en vind het fijn om nu ook weer 
in de kliniek met je samen te werken.  
Rens, Frank en Sirwan, ik kijk ernaar uit dat jullie opnieuw collega’s worden bij de neuro. 
Rens, we hebben samen de frustraties van het schrijven van een hoofdstuk gedeeld, maar het 
lijkt erop dat we het boek binnenkort in de kast zullen hebben staan! Frank, je enthousiasme 
heeft me nog op veel nieuwe ideeën gebracht. Ik hoop dat het nog lukt te schrijven over 
atriumfibrilleren en over de ernst van de beroertes.  
Vincent, hartelijk dank voor je hulp als bij statistische vraagstukken, fijn dat je ook na je 
promotie nog af en toe langs kwam. Daniel, fijn dat ik mocht meewerken aan het ICAC artikel 
en dank dat je je kennis bent blijven delen door na je promotie terug te komen als postdoc. 
Sonja, thank you for all your useful methodological advice for the trajectory paper. Hazel, je 
vriendelijkheid en spontaniteit zorgden ervoor dat ik graag bij je binnen viel om even bij te 
praten. Lotte en Sanaz, ook bij jullie kon ik altijd gezelligheid vinden. Unal, succes met het 
oppakken van de strokes, wees er zuinig op.  
Het meest heb ik in deze jaren echter opgetrokken met mijn kamergenootjes Saira, Jory en 
Hoyan. Saira, both a bit silent, but hard workers, we almost directly became friends. We shared 
the ups and downs of doing research, the frustrations of rejected articles and statistical 
programs that didn’t want to run, but also the joy of a publication. I really enjoyed working 
together and hope I will see you soon!  Jory, natuurlijk hadden we ook iemand nodig voor de 
sfeer in de kamer. Ik kon altijd bij je terecht om te kletsen over meer of minder belangrijke 
zaken. Laten we daarmee doorgaan. Hoyan, jij kwam er in mijn laatste jaar bij. Je vrolijkheid, 
spontaniteit en koekjes waren erg fijn tijdens de afronding van mijn promotie. Ik ben blij dat je 
mijn paranimf wil zijn! 
  
Ook mijn nieuwe collega’s bij de neurologie wil ik hartelijk danken voor hun warme ontvangst. 
Ik hoop ook met jullie een mooie tijd tegemoet te gaan. 
  
Dankwoord 
289 
De beste ontspanning tijdens mijn promotieonderzoek was het spelen van muziek. Ik ging dan 
ook met veel plezier elke woensdagavond klarinetten. Tirza, Sandra, Hélène, Antoinette, Marjan, 
Adri, Eline, Marjolein, Evalien en Coen, hartelijk dank voor de gezelligheid. En ik denk dat muziek 
maken ook nog eens heel goed is voor onze hersenen! 
  
Lieve vriendinnen: Susanne, Margreet en Ilse. Hoe lastig het ook is om met z’n vieren af te 
spreken, het is altijd weer gezellig als vanouds als we samen zijn. Laten we nu maar vast een 
nieuwe datum plannen. 
Lieve Tamara, al vriendinnen sinds we samen bij Luctor zwommen. Jammer dat we elkaar 
door de afstand niet zo vaak meer kunnen zien. Ik moet toch maar vaker teruggaan naar 
Zeeland. 
  
En dan, niet te vergeten, mijn familie.  
Lieve opa en oma, ik denk dat er maar weinig opa’s en oma’s zo betrokken zijn als jullie. 
Wat mooi dat we elke week kunnen skypen, al is het natuurlijk fijner om elkaar in Yerseke te 
zien. Ik waardeer het erg dat jullie nog steeds zo goed op de hoogte zijn van wat ik allemaal 
doe en mij daar altijd in blijven steunen. 
Lieve broers, Jim en Jorg, allebei ook in het wetenschappelijke wereldje weten jullie precies 
wat promoveren inhoudt. Hopelijk komt er ooit nog een Portegies, Portegies, Portegies et al. 
artikel. Dank voor jullie hulp bij wiskundige vragen en dank voor onze chatpartijen als ik soms 
wat aandacht nodig had. Jorg, fijn dat je op deze speciale dag als paranimf naast me wil staan. 
Lieve Mei Li, inmiddels ook alweer heel wat jaar deel van onze familie. Dank voor de vrolijkheid 
en energie die je altijd meebrengt. Lieve kleine Jason, een moment contact met jou zorgt altijd 
voor een lach op mijn gezicht. 
Lieve pa en ma, ik had dit alles niet kunnen bereiken zonder jullie. Het zal soms misschien 
lastig zijn, drie ambitieuze kinderen, allemaal weg uit Zeeland. Toch staan jullie altijd voor ons 
klaar. Zie als voorbeeld de opmaak van dit proefschrift, waarvoor jullie meermalen naar 
Rotterdam zijn gekomen. En wat blijf ik het gezellig vinden om met het hele gezin in 
Middelburg te zijn. Ik kan jullie niet genoeg bedanken voor al jullie steun, liefde en grenzeloze 
vertrouwen.  
  
Lieve Quint, vanaf het moment dat ik jou leerde kennen, ging mijn promotie in een 
stroomversnelling. Jouw enthousiasme voor onderzoek doen is aanstekelijk. Maar bovenal, jij 
maakt me gelukkig, elke dag opnieuw.  
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